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Abstract 
Keratoconus (KC) is a non-inflammatory, progressive thinning of the 
cornea resulting in a conically shaped protrusion. Its incidence in the 
population is 1/2000. There are known environmental causes, but familial 
aggregation, bilateralism and twin studies point to a genetic component, 
which is poorly understood. This project aims to identify these genetic 
causes by studying a cohort of familial cases and KC and wild type (WT) 
corneal tissue. 
The family cohort consisted of 15 multiplex recessive KC families 
from consanguineous and endogamous ethnic backgrounds. DNA from at 
least one family member was subjected to autozygosity mapping and whole 
exome sequencing (WES). Tissue from 6 sporadic KC and 5 WT corneas 
was analysed by RNA-seq. Genomic DNA from the 6 KC patients who 
donated their corneas was also subjected to WES. 
Autozygosity mapping and WES did not identify clear pathogenic 
alleles, though WES alone yielded long lists of variants segregating in 
families. An underpowered enrichment test on the WES results also yielded 
lists of variants potentially implicated in KC. RNA-seq generated a 
transcriptome profile of the normal anterior human cornea, and highlighted 
putative new cornea-specific transcripts. The differential expression (DE) 
data between KC/WT corneas generated lists of significantly DE genes. The 
combination of all these analyses identified 5 genes, FLNB, ITGB4, 
KIAA0100, LAMA5 and PCDH1, harbouring coding variants that 
cosegregated with KC in the families, enriched in variation in the cohort and 
significantly down-regulated in KC corneas. These are now strong 
candidates to harbour variants increasing susceptibility to KC. 
The work describe shows that recessive alleles of large effect are 
either rare or non-existent in the cohort studied, suggesting that KC is 
indeed a genetically complex disease. Combining the datasets highlights 
variants in 5 large structural proteins requiring further analysis to confirm 
their involvement in KC pathogenesis. 
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1 General Introduction 
1.1 The Human Eye  
The eye is the sensory organ for vision. Its role in collecting and focusing the 
light onto specialized cells, which convert photons into neural signals, means 
that the eye is an exquisitely complicated organ. Vision is important for 
modern independent living and has also been subject to strong selection for 
the survival of many animal species, including humans, throughout their 
evolution. 
 
The human eye is composed of three main layers (Figure 1-1) (reviewed by 
(Willoughby et al., 2010). The outer layer comprises the cornea and the 
sclera; the middle layer is composed of the iris, the ciliary body and the 
choroid; and finally the inner layer of the eye consists of the retina. The optic 
nerve, part of the optical apparatus, consists of a bundle of nerve fibres 
extending to the visual cortex of the brain. The aqueous humour, the 
vitreous and the lens are the three transparent structures that make part of 
the visual system and are surrounded by the ocular layers (Justice, 1946). 
Figure 1-1 is adopted from National Cancer Institute - part of the National 
Institutes of Health – and shows the lateral view of the human eye, while 
depicting the three layers of the eye. 
 
Good vision relies on the passage of refracted light rays through a clear and 
transparent cornea. The cornea also provides approximately two thirds of 
the focussing power, while the lens acts as a fine focus to form an image on 
the retina. Once the image hits the retina, light is converted by the retinal 
photoreceptors into electrical impulses that get transmitted to the brain 
through the optic nerve.  
 
 


















1.2 The Human Cornea 
1.2.1 Structure and function of the adult cornea 
The cornea is an avascular, transparent dome covering the anterior part of 
the human eyeball. A healthy human cornea will have a diameter, or white-
to-white distance, in the average adult (18-45 years old) of 11.65±0.36 mm. 
This figure is slightly higher in males than in females and decreases with age 
(Gharaee et al., 2014). The human cornea is 0.5 – 0.6 mm thick in the centre 
and slightly increases in thickness at the periphery (DelMonte and Kim, 
2011). Along with the tear film, the cornea represents the main and the most 
refractive component of the ocular system (Maurice, 1957) accounting for 
approximately 2/3rd of the refractive power of the eye (DelMonte and Kim, 
2011). Since it represents the first barrier of the eye, it is known to protect 
Figure 1-1: Schematic illustration showing lateral view of the human 
eye.  Diagram showing all the major different parts of the eye. It depicts the 
cornea and the sclera in the anterior part of the eye, then the iris, the choroid 
and the ciliary body in the middle part of the eye, and the retina constituting 
the inner layer of the eye; as well as the three transparent layers: the 
aqueous, the lens and the vitreous gel.  (Free Source: National Cancer 
Institute). 
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the eye against infections and structural damage and to maintain mechanical 
strength. It is also characterized by its unique optical properties, with its 
ability to refract light while also absorbing the major part of the incoming 
ultraviolet (UV) radiation entering the optical system (Ringvold, 1998). The 
cornea represents one of the most sensitive tissues of the body due to 
heavy innervation via the rich sub-basal nerve plexus beneath the basal 










The human cornea is organized into five layers; three cellular (epithelium, 
stroma and endothelium) and two interface layers (Bowman and Descemet 
membranes)  (Figure 1-2).  
 
The outer epithelium is derived embryologically at around 5 to 6 weeks of 
gestation from surface ectoderm (Vasileva, 1957, DelMonte and Kim, 2011). 
It is a non-keratinized, stratified, squamous epithelium representing 10% 
(40-50 µm) of the corneal thickness. It is composed of 4-6 cell layers. These 
consist of superficial flat polygonal cells for 2-3 layers that lie in direct 
contact with the tear film on the corneal surface, and then less flat, wing cells 
or suprabasal cells for another 2-3 layers followed by a single cell layer of 
basal columnar cells (20 µm tall). The basal columnar cells are attached to 
the basement membrane by a hemidesmosomal system for enhanced 
Figure 1-2: Schematic diagram depicting the human corneal layers. 
k stands for keratocytes. (Millodot: Dictionary of Optometry and Visual 
Science, 7th edition. © 2009 Butterworth-Heinemann http://medical-
dictionary.thefreedictionary.com/cornea). 
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adherence to the underlying corneal layers. The outer epithelium is covered 
by a tear film and is responsible for protecting the rest of the eye from debris 
and bacteria, smoothing out corneal surface micro-irregularities and 
contributing to the refractive power of the cornea (DelMonte and Kim, 2011).  
 
The anterior limiting lamella, also known as Bowman’s layer is localized 
beneath the basement membrane of the epithelium and just anterior to the 
stroma. It is attached to the stroma and often considered as a simple 
extension of this layer (Komai and Ushiki, 1991). The Bowman’s layer is a 
15µm thick acellular membrane that helps the cornea maintain its shape. It 
consists of collagen fibres of types I, V, VI, XII and XXIV that run in various 
directions (Ihanamaki et al., 2004).  
 
The stroma originates from the migrating neural crest cells during the 7th 
week of gestation. It comprises a series of collagen-rich lamellae and a 
keratocyte matrix, and constitutes about 80-85% of the corneal thickness. 
This layer consists mainly of water, collagen (types I, III, V, VI, XII, XIII and 
XXIV), salts, proteoglycans and proteins (Ihanamaki et al., 2004). The 
stroma provides the mechanical strength of the cornea, mainly through its 
collagen fibrils. The main type of collagens found in the stroma are types I 
and V which are arranged in long, thin, flat bundles called fibrils that run 
parallel to one another to form sheets called lamellae (Fini and Stramer, 
2005). The lamellae run along the cornea from one side to the other (Figure 
1-3) (Mathew et al., 2008). The precise organization of collagen and 
extracellular matrix (ECM) in the stroma provides the cornea with its 
transparency (Hassell and Birk, 2010). The keratocytes provide stromal 
homeostasis to allow optimal light refraction and transparency by 
maintaining the synthesis of ECM molecules including crystallins, collagens, 
proteoglycans and matrix metalloproteinases (Jester et al., 1999). 
 










Pre-Descemet’s layer (also called Dua’s layer) is an acellular layer about 
10.1±3.60 µm in thickness (Figure 1-4) (Dua et al., 2013). It is composed of 
collagen types I, IV and VI. The Dua’s layer is made of 5 to 8 thin lamellae 
for which the structure seems more compact than the adjacent anterior deep 












The posterior limiting lamella, also known as Descemet’s membrane, is a 
strong non-cellular layer located under the stroma and loosely attached to it. 
Figure 1-3: Collagen fibrils in lamellae in paracentral region of the stroma. 
Scanning electron micrograph shows interweaving lamellae running in different 
directions. The arrowhead shows a small lamellae sheet crossing another 
lamellae (Reused from (Radner et al., 1998) by the permission of Elsevier Copy 
Right Clearance Centre, License number: 3771890898791). 
Figure 1-4: Transmission electron micrograph showing Dua’s layer (DL) and 
Descemet’s membrane (DM). Part of an endothelial cell (EC) is shown posterior 
to DM. DL is located in the anterior part of DM and is seen to be made of multiple 
thin layer. (Reused from (Dua et al., 2013) by the permission of Elsevier Copy 
Right Clearance Centre, License number: 3764670382072). 
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Descemet’s membrane measures a mean of 10.97±2.36 µm of thickness in 
the adult cornea (Dua et al., 2013). It is composed of collagen types IV, VI 
and VIII (Ihanamaki et al., 2004). Descemet’s membrane is divided into two 
distinct parts: the anterior part adjacent to the stroma, is secreted by the 
underlying endothelial cells at the 8th week in utero (in the womb) and 
represents around 3µm of thickness of a highly organised collagen structure. 
The posterior part, adjacent to the endothelium, has a vague and undefined 
ultrastructural texture compared to the anterior part, and is secreted after 
birth (DelMonte and Kim, 2011). 
 
The endothelium is the innermost corneal cell layer. It is a monocellular layer 
that is responsible for maintaining tissue integrity and corneal deturgescence 
by retaining the balance of fluids. As the endothelium ages, it undergoes a 
decrease in cell density and change in topography. The cells, which are 
10µm thick at birth, start to flatten becoming 4µm thick at adulthood (Watsky 
et al., 1989).  
 
The strength and power of corneal refractive performance is determined by 
the curvature of the cornea, which can be measured by Keratometry (K). K-
readings can be retrieved using a corneal topographer and the anterior 
segment imaging can be achieved using an optical coherence tomography 
(OCT) device or an anterior segment optical coherence tomography (AS-
OCT) imager.  
 
The normal corneal mean horizontal K-readings measured by AS-OCT for 
adult corneas of 32 years old mean age are 43 ±1.73 D (where D, the 
Diopter, is the unit of K-readings describing the refractive power of the 




- 7 - 
 
1.3 Diseases of the Cornea 
Being the first light barrier, the cornea serves not only to refract the light to 
the lens then the retina, but also as a filter, screening out the most damaging 
UV light and thus preventing lens and retina UV radiation injury. The cornea 
also serves as a shield to protect the rest of the eye from dust and bacteria. 
It follows a systematic mechanism of wound healing, allowing it to cope with 
minor injuries and abrasions (Maycock and Marshall, 2014). Thus corneal 
clarity and transparency is essential for its main function and any damage in 
its structure and/or composition can lead to a vision disturbance.  
 
The cornea can be affected by a variety of corneal diseases arising from 
infections, inherited degenerations or ectasias. This last group, which 
includes Keratoconus, have varying degrees of genetic and environmental 
causes of disease and include some conditions for which the cause is 
unknown.   
 
1.3.1 Infectious diseases 
Infectious conditions include keratitis (Ong and Corbett, 2015), ocular herpes 
(Zhu and Zhu, 2014) and herpes zoster (Shingles) (Shaikh and Ta, 2002). 
Microbial keratitis is the most common form of keratitis accounting for 55-
65% of cases (Dart et al., 1991, Toshida et al., 2007). The common cause of 
microbial keratitis is bacterial infection. This can be the result of infection by 
Pseudomonas, Serratia marcescens, Enterobacteriaceae and 
Mycobacterium, all belonging to the Gram-negative bacteria and 
Staphylococcus and Streptococcus species and Nocardia, belonging to the 
Gram-positive bacteria (Keay et al., 2006, Dart et al., 2008, Shah et al., 
2011).  Fungal keratitis is another cause for microbial keratitis and is caused 
by filamentary fungi such as Fusarium, Aspergillus and microsporidia, or by 
yeast Candida (Srinivasan et al., 1997, Basak et al., 2005, Sharma et al., 
2007, Loh et al., 2009). Additionally, Acanthamoeba keratitis is caused by 
Acanthamoeba, the most commonly found protozoa in soil and fresh water 
(Stehr-Green et al., 1989, Schaumberg et al., 1998).  
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1.3.2 Inherited degenerations 
Corneal dystrophies include a range of rare, inherited degenerative 
conditions that are progressive and affect the cornea alone (Calhoun, 1951, 
Sacchetti et al., 2016). Corneal dystrophies were previously classified into 3 
groups according to the predominant anatomical location of the alteration at 
first occurrence of the disease: first the superficial corneal dystrophies, 
second the stromal corneal dystrophies and third the posterior corneal 
dystrophies (Franceschetti, 1954). Recently, corneal dystrophies were 
subject to a re-classification by the International Committee for Classification 
of Corneal Dystrophies (IC3D) according to clinical signs, genetic basis and 
pathological examinations of the diseased cornea. According to these 
criteria, the corneal dystrophies were categorised into 4 groups (Weiss et al., 
2008, Vincent, 2014, Weiss et al., 2015):  
 
(1) Epithelial and sub-epithelial dystrophies (e.g. Epithelial Basement 
Membrane Dystrophy (EBMD) (MIM:121820), Epithelial Recurrent 
Erosion Dystrophies (EREDs) (MIM:122400), Subepithelial Mucinous 
Corneal Dystrophy (SMCD) (MIM:612867), Meesmann Corneal 
Dystrophy (MECD) (MIM:122100), Lisch Epithelial Corneal Dystrophy 
(LECD) (MIM:300778), Gelatinous Drop-like Corneal Dystrophy 
(GDLD) (MIM:204870)). 
(2) Epithelial-stromal TGFBI dystrophies (e.g. Reis–Bücklers Corneal 
Dystrophy (CDRB) (MIM:608470), Thiel–Behnke Corneal Dystrophy 
(TBCD) (MIM:604649), Lattice Corneal Dystrophy, type 1 (Classic) 
(LCD1) (MIM:122200), Granular Corneal Dystrophy, type 1 (Classic) 
(GCD1) (MIM:121900), Granular Corneal Dystrophy, type 2 (GCD2) 
(MIM:607541)) 
(3) Stromal dystrophies (e.g. Macular Corneal Dystrophy (MCD) 
(MIM:217800), Schnyder Corneal Dystrophy (SCD) (MIM:608370), 
Congenital Stromal Corneal Dystrophy (CSCD) (MIM:610048), Fleck 
Corneal Dystrophy (FCD) (MIM:136800), Posterior Amorphous 
Corneal Dystrophy (PACD) (MIM:612868), Central Cloudy Dystrophy 
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of Franҫois (CCDF) (MIM:217600), Pre-Descemet Corneal Dystrophy 
(PDCD)) 
(4) Endothelial dystrophies (e.g. Fuchs Endothelial Corneal Dystrophy 
(FECD) (MIM:136800), Posterior Polymorphous Corneal Dystrophy 
(PPCD) (PPCD1 MIM:122000; PPCD2 MIM:609140; PPCD3 
MIM:609141), Congenital Hereditary Endothelial Dystrophy (CHED) 
(MIM:217700), X-linked Endothelial Corneal Dystrophy (XECD)). 
 
1.3.3 Ectasias 
In general, corneal ectasias are bilateral, non-inflammatory conditions 
characterized by progressive corneal steepening and thinning that causes 
visual impairment. The genetic basis or environmental trigger that causes 
these conditions is often unknown. Corneal ectasias include Keratoconus, 
Pellucid Marginal Degeneration, Keratoglobus, Postkeratorefractive ectasia 
and wound ectasia after penetrating keratoplasty-PK (Ophthalmology, 2013). 
Since keratoconus is the main focus of this thesis, the next section is 
designated to describe in details all the aspects of this ectatic disorder.  
 
1.4 Keratoconus  
1.4.1 Definition and introduction 
Keratoconus (KC) [MIM:148300] is derived from the Greek words kerato, 
which means cornea, and konos, which means cone. The condition is 
characterised by a conical-shaped protruded cornea that results from 
progressive corneal thinning. KC was originally reported by Duddell in 1736, 
whithout being called KC, in a treatise on his work in ophthalmology (Etzine, 
1954, Grzybowski and McGhee, 2013), and was first described and referred 
to as staphyloma diaphanum by Burchard Mauchart in 1748 (Nielsen et al., 
2013). It was distinguished from other corneal ectatic diseases by John 
Nottingham in 1854 (Grzybowski and McGhee, 2013). 
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KC is a non-inflammatory, generally asymmetric, progressive thinning of the 
cornea resulting in a conically shaped protrusion (Figure 1-5). The cone 
shape is a consequence of structurally weakened tissue and can result in 
irregular corneal scarring, astigmatism and myopia, eventually leading to 
loss of vision if left untreated (Rabinowitz, 1998). According to the study by 
Krachmer et al., the impaired vision is primarily due to abnormalities in light 
refraction so that the image cannot be focussed onto the retina (Krachmer et 















KC is generally detected at puberty and evolves throughout life to stabilize in 
the third and fourth decade (Rabinowitz, 1998). In its early stages, KC is not 
easy to diagnose since it is difficult to distinguish its mild or early stages from 
irregular myopic astigmatism; however, recent advances in computerized 
corneal topography have made early diagnosis easier (Maeda et al., 1994). 
The incidence of KC varies from one population to another, but several 
reports have stated that KC affects approximately one patient among 2000 
individuals in the general population (Krachmer et al., 1984, Kennedy et al., 
1986, Zadnik et al., 1996, Rabinowitz, 1998, Rabinowitz, 2003). KC is 
Cone shape in 
a KC cornea 
Dome shape in a 
normal cornea 
Figure 1-5: Photograph of a normal and KC eye in profile 
(Reused from (Lawless et al., 1989) by the permission of Copy 
Right Clearance Centre, License number: 3795370830303). 
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reported to be the principal cause of corneal transplantation in the western 
world (Zadnik et al., 1996, Legeais et al., 2001, Cassidy et al., 2013, Gomes 
et al., 2015, Parker et al., 2015, van Dijk et al., 2015). 
 
1.4.2 Epidemiology and association with other diseases 
The prevalence of KC varies from one population to another, ranging from 
0.3 per 100 000 in Russia (Gorskova and Sevost'ianov, 1998) to 3,333 per 
100 000 in Lebanon (Waked et al., 2012). This variability may be specific to 
each population since there is a four-fold increased incidence of KC in 
Asians living in the UK compared to Caucasians (Pearson et al., 2000). 
Similarly, according to Georgiou et al., this observation may have a genetic 
basis as Asians are 7.5 times more likely to develop KC than white affected 
individuals (Georgiou et al., 2004).  
 
It does not appear that KC is more prevalent in one gender than another. 
Some studies have found a greater prevalence in males (Weed and 
McGhee, 1998, Pearson et al., 2000, Owens and Gamble, 2003, Wagner et 
al., 2007), other studies have found higher incidences in females (Krachmer 
et al., 1984, Harold A. Stein, 2013), and still other studies have found no 
differences (Kennedy et al., 1986, Li et al., 2004).   
 
KC has been shown to be associated with a number of ophthalmic and 
genetic systemic conditions (Edwards et al., 2001, Sugar and Macsai, 2012). 
The types of diseases associated with KC fall into four categories. The first 
category belongs to the diseases of abnormal retinal function (e.g. Lebers 
Congenital Amaurosis (Hameed et al., 1999, Damji et al., 2001, McMahon et 
al., 2009), Retintis Pigmentosa (Bruna, 1954, Knoll, 1955), Bardet-Biedl 
syndrome (Francois et al., 1982), albinism (Rao et al., 2008) and cone 
dystrophy (Fogla and Iyer, 2002, Yeh and Smith, 2008)). The second 
category falls into the diseases associated with atopy, eczema and eye 
rubbing (e.g. Down syndrome (Koppen et al., 2010, Sabti et al., 2015), 
Turner syndrome (Macsai et al., 1997, Pinna et al., 2005), hyper-IgE 
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syndrome (Kim and Netto, 2004) and Mulvihill–Smith syndrome (Rau and 
Duncker, 1994)). The third category of diseases associated with KC belongs 
to the diseases harbouring abnormal collagen elasticity and connective 
tissue disorders (e.g. Brittle cornea syndrome (Lechner et al., 2014, 
Davidson et al., 2015), Congenital Hip Dysplasia (Nucci and Brancato, 
1991), Osteogenesis Imperfecta (Beckh et al., 1995), Marfan Syndrome 
(Dudakova and Jirsova, 2013) and Joint Hypermobility (Woodward and 
Morris, 1990). The fourth category of diseases associated to KC belong to 
the category of intellectual impairment (e.g. Crouzon syndrome (Perlman 
and Zaidman, 1994), Hyperornithinemia (Chen and Furr, 1983) and Noonan 
syndrome (Ascaso et al., 1993, Lee and Sakhalkar, 2014). 
 
KC can also be associated to other corneal dystrophies (e.g. Posterior 
Polymorphous Corneal Dystrophy (Heon et al., 2002b, Vincent et al., 
2013a), Granular dystrophy (Rho et al., 2014, Wilson et al., 2014), Fuch’s 
Endothelial Dystrophy (Salouti et al., 2010, Mazzotta et al., 2014) and Lattice 
Dystrophy (Hoang-Xuan et al., 1989), implying some common defective 
pathways and tightly linked protein networks.  
 
Interestingly, KC is also associated with diseases caused by chromosomal 
abnormalities, such as translocations and chromosomal deletions. Amongst 
these diseases are Downs and Turner Syndromes, chromosome 7;11 
translocation (Morrison et al., 2001), chromosome 22q11.2 deletion (Saffra 
and Reinherz, 2015) and the chromosome 13 ring anomaly (Heaven et al., 
2000). 
 
1.4.3 Risk factors of KC 
KC is suspected to have a multifactorial basis to disease onset, having both 
a genetic and an environmental component (Edwards et al., 2001, Sugar 
and Macsai, 2012, Patel and McGhee, 2013). In an attempt to find possible 
causative factors for KC using patients’ questionnaires, it was found that 
contact lens wear, allergy, eye rubbing, atopy and family history all 
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contributed to KC (Rabinowitz, 2003). It was suggested that the 
environmental contribution may trigger KC in genetically-susceptible 
individuals (Davidson et al., 2014). However the relative contribution of each 
of these factors remains to be established. 
 
Atopy in the form of allergy, eczema and asthma has been reported to be a 
risk factor for KC by many research groups (Crews et al., 1994, Kaya et al., 
2007, Nemet et al., 2010, Shneor et al., 2013). A negative association has 
been reported by several other groups, but the controls group were not age 
and sex matched, and atopy did not include all three sub-categories (Lowell 
and Carroll, 1970, Gasset et al., 1978, Wachtmeister et al., 1982, Bawazeer 
et al., 2000). It has long been believed that eye rubbing caused by the atopy 
itch triggers the onset of KC (Coyle, 1984). However, atopy is not the only 
provocative factor for eye rubbing in KC as KC patients with a history of eye 
rubbing present with a much higher incidence than KC patients with atopy 
(Rahi et al., 1977). 
 
Researchers over the years have associated eye rubbing with KC 
development and considered it to be a KC risk factor. Individual case reports 
(Coyle, 1984, Gritz and McDonnell, 1988, Zadnik et al., 2002, Jafri et al., 
2004, Koenig, 2008), as well as case-control studies (Bawazeer et al., 2000, 
Kim and Joo, 2008, Gordon-Shaag et al., 2013), associate habitual and 
chronic eye rubbing to the appearance and/or progression of KC. It is not the 
cause of all KC development as some KC patients develop the disease 
without any history of eye rubbing. However, eye rubbing may be a risk 
factor for genetically predisposed patients (McMonnies, 2007), since a 
number of patients develop KC after a history of eye rubbing (Kennedy et al., 
1986). 
 
Excessive exposure to UV may also be a risk factor of KC as rabbits and 
mice exposed to UV show signs of KC in their corneas (Podskochy et al., 
2000, Newkirk et al., 2007). The rabbit and mouse corneas showed 
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evidence of cell apoptosis in all layers, and additional stromal thinning and 
collagen degeneration was shown in mice. 
  
Sporadic KC is the most commonly reported form of disease, but familial 
cases have been reported with a rate ranging of 5 to 27.9% (Ihalainen, 1986, 
Kennedy et al., 1986, Rabinowitz, 2003, Weed et al., 2008, Millodot et al., 
2011, Shneor et al., 2013). Gordon-Shaag et al. recently established strong 
evidence for a genetic component in the development of KC by associating 
consanguinity and endogamy with KC (Gordon-Shaag et al., 2013). In 
addition, consanguinity and ethnic influence has been reported to be a risk 
factor for KC, where incidence of KC was much higher in first cousin than in 
second cousin married relatives, as well as a four fold increase in frequency 
Asians over Caucasians in the UK (Pearson et al., 2000). 
 
1.4.4 KC signs and symptoms - Clinical features 
The hallmark of KC diagnosis is irregular astigmatism, which can be 
detected by AS-OCT in order to detect the corneal curvature that steepens 
with the development of KC (Figure 1-6). A K-reading for corneal curvature 
in the normal cornea of between 43 and 45 D is indicative of mild KC. A 
range between 45 to 52 D is indicative of moderate KC and a K-reading 
higher than 52 D is considered to be advanced KC (Sinjab, 2012). In 
addition to conicity in advanced KC, patients exhibit varying degrees of 
blurred vision, photophobia and eye-strain that is accompanied by 
monocular diplopia (seeing a double image in one eye), multiple ghost 
images, flaring and glares around light (Lee et al., 1995). 
 
In mild KC, loss of visual acuity often manifests as an inability to reach a 6/6 
score on a snellen test. Irregular astigmatism increases with progression of 
the disease and “scissor” shadows start to appear while conducting a 
retinoscopy. Apical thinning of the apex of the cone is another characteristic 
of an early stage KC (Rabinowitz, 1998). 
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Figure 1-6: Visante OCT corneal mapping of a KC cornea. The left image 
shows the apical corneal thinning in KC cornea. The right image shows the 
central thinning detected by the pachymetry map, which reports the corneal 
thickness in multiple points of the cornea (Provided by Salina Siddiqui, Saint 
James’s University Hospital, Leeds, UK) 
 
In moderate and advanced KC, the thinning continues to progress and the 
basal layer of the epithelium presents with an accumulation of ferritin 
particles that can be seen by slit lamp examination. These particles form an 
iron, yellow-brown to olive-green coloured ring encircling the cornea, which 
is called Fleischer’s ring (Iwamoto and DeVoe, 1976, Maguire and Bourne, 
1989) (Figure 1-7, 1-8). It is localised inside and between epithelial cells as 





































Another clinical sign that is required for a KC diagnosis are the Vogt’s lines 
(Vogt’s striae) (Figure 1-9) (Krachmer et al., 1984). These fine vertical and 
Fleischer’s ring 
Figure 1-7: Fleischer’s ring in moderate KC. The arrow points to 
corneal iron deposit ring  (Photographed by Stefani Karakas, CRA, 
retrieved under a free license from Ophthalmic Atlas 
Images by EyeRounds.org, The University of Iowa) 
Figure 1-8: Perl’s stain shows intraepithelial iron deposits - Fleischer’s 
ring. The blue stain represents the iron molecules (Provided by Dr Hardeep S 
Mudhar, Consultant Ophthalmic Histopathologist, Royal Hallamshire Hospital, 
Sheffield, UK). 
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deep stromal striae are detected by slit lamp examination in the deep 
stroma, and sometimes in Descemet’s membrane, and are due to stretching 
within the deeper corneal lamellae (Von Der Heydt, 1930). Another 
characteristic sign is the visibility of corneal nerves in addition to deep 
corneal opacities. The apical thinning in the very early stages of KC can 
evolve, during later stages, into Munson’s sign which represents the bulging 
of the lower eyelid on down gaze by the protruded cornea (Figure 1-10) 
(Krachmer et al., 1984, Li et al., 2004). Rizzuti’s sign is another typical sign 
of advanced KC. It is detected in advanced stages and described as the 
penlight test for KC. Rizzuti’s sign manifests while illuminating the cornea 
from the temporal side, the beam of light sharply focuses near the nasal 
limbus (Figure 1-11) (Rizzuti, 1970). In severe cases, acute hydrops appear 
over the longer term, followed by deep stromal scarring, rupturing of the 
Descemet’s membrane and corneal oedema as a result of aqueous fluid 
passing into the stroma, leading in turn to opacification (Thota et al., 2006, 
















Figure 1-9: Vogt’s Striae in Keratoconus. The arrow points to the Vogt’s 
Striae in a KC cornea (Photographed by Toni Venckus, CRA, retrieved 
under a free license from Ophthalmic Atlas Images by EyeRounds.org, 
The University of Iowa) 

























Nasal limbus side 
Figure 1-10: Munson’s sign. The lower lid bulges forward 
on down gazing (Reused from (Krachmer et al., 1984) by 
the permission of Copy Right Clearance Centre, License 
number: 3795371398260).   
Figure 1-11: Rizzuti’s sign. The beam of light illuminating the 
cornea from the temporal side sharply focuses near the nasal 
limbus (Reused from (Krachmer et al., 1984) by the permission of 
Copy Right Clearance Centre, License number: 3795371398260).   
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1.4.5 Corneal structure and histopathological findings in KC 
corneas 
In KC, the structure of all corneal layers (the epithelium, Bowman’s layer, 
stroma, Descemet’s membrane and the endothelium) is altered (details to 
follow), preventing the cornea from executing its normal function. The 
etiology of KC is unknown so identifying, the mechanisms of corneal 
alterations in KC will enable better comprehension of the pathogenesis and 
characteristics of the disease.  
 
The main pathological features known to be hallmarks of the disease are the 
breaks in, or complete absence of, Bowman’s membrane. The breaks are 
due to fragmentation and stromal thinning (Figure 1-12) (Kenney et al., 
2000) accompanied by lower cell and innervation density (Niederer et al., 
2008).  
 
In vivo confocal microscopy (IVCM) of the non-keratinized stratified 
squamous epithelium reveals degeneration of the basal epithelial cells along 
with an approximately 25% reduction in cell density compared to control 
corneas (Niederer et al., 2008).  
 
 
Figure 1-12: Angulated breaks in Bowman’s membrane. 
Histopathological sections of KC corneas show thinning, scarring and breaks 
at the level of Bowman’s membrane (Reproduced with the permission of Dr 
Hardeep S Mudhar, Consultant Ophthalmic Histopathologist, Royal 
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Bowman’s layer shows discontinuities in the form of breaks at the early 
stages of KC. These breaks may increase in more advanced stages of 
disease and may lead to a total loss of this layer. Consistent with this loss, 
epithelial cells and stroma become directly in contact (Figure 1-13) due to 
the absence of the anchoring lamellae that extend from the epithelium into 
Bowman’s layer (Kenney et al., 2000, Morishige et al., 2007). There also 
appears to be an increased visibility of corneal nerves, consistent with nerve 
thickenings due to breaks in Bowman’s membrane (Bron, 2001, Brookes et 
al., 2003).  
 
 
Figure 1-13: Breaks in Bowman’s membrane compared to normal. 
Histological differences between intact and altered Bowman’s layer (taken 
from Global Keratoconus Foundation website). 
 
The stroma in KC corneas shows alterations in the collagen-rich lamellar 
structure, causing mechanical weakness which distorts corneal function and 
shape (Bron, 2001, Muller et al., 2001, DelMonte and Kim, 2011). These 
alterations can be considered to be the leading cause of corneal thinning 
and cone formation (Morishige et al., 2007). Furthermore, stromal thinning 
has been shown to be directly related to stromal lamellar slippage, which 
could cause biomechanical instability leading to molecular stress of the cell. 
This slippage is due to a lack of cohesion between collagen fibres and the 
non-collagenous ECM, which were reported to be broken down and 
degraded in KC (Meek et al., 2005). In addition to the decrease in number of 
collagen lamellae and the loss of arrangement of fibrils (Section 1.2.2) in the 
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anterior stroma, KC corneas demonstrate a decrease in keratocyte density 
compared to normal ones (39.2% and 27.5% decrease in anterior and 
posterior keratocyte densities respectively) (Niederer et al., 2008), consistent 
with the keratocyte apoptosis reported in KC (Kim et al., 1999, Kaldawy et 
al., 2002, Matthews et al., 2007). 
 
Descemet’s membrane, the posterior stromal non-cellular layer, is rarely 
affected in KC (Rabinowitz, 1998). However in advanced stages of disease, 
breaks in this layer can be detected (Poyales-Galan et al., 2009). 
 
The endothelium is usually not affected in KC (Rabinowitz, 1998) though in 
advanced stages of disease, lower endothelial cell density was observed 
under IVCM (Niederer et al., 2008) consistent with increased apoptosis in 
these cells (Kaldawy et al., 2002).  
 
1.4.6 Phenotypic spectrum of KC and morphology 
The introduction of computerized corneal topography and imaging (such as 
in vivo confocal microscopy) has led to the detection of minimal variations in 
corneal diseases and has permitted the detection of early and mild KC. This 
presents advantages over mainstream diagnostic methods in that such 
methods usually detect patients at more advanced stages of disease 
development. In particular, abnormalities in corneas not falling within the KC 
diagnosis range, yet which are not entirely normal, also constitute a form of 
KC referred to as “forme-fruste”. This is usually detected in unaffected 
members of families with individuals that have KC. KC corneas presenting 
as form-fruste, present at the central corneal zone an intermediate level of 
epithelial thickness between that of normal and KC corneas (Lafond et al., 
2001, Rabinowitz et al., 2014, Temstet et al., 2015). 
 
In previous years, advanced KC used to be sub-classified into three 
categories according to the morphology of the cone, these being Nipple, 
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Oval and Globus KC. All three categories were divided according to the 
shape of the cornea after KC onset. For nipple KC, the cone is near-central. 
For oval KC, the cone shape is oval and the corneal apex is usually situated 
under the corneal midline. For the Globus KC, the cone presents irregularly 
shaped and could affect over 75% of the cornea (Sinjab, 2012, Romero-
Jimenez et al., 2015).   
 
1.4.7 Possible pathways involved in KC pathogenesis 
To date, several mechanisms have been suggested to contribute to the 
onset and progression of KC, including inflammation, apoptosis of stromal 
cells, enzyme/inhibitor imbalances and oxidative damage. 
 
1.4.7.1 Inflammation in KC 
KC has always been thought to be a non-inflammatory disorder (Rahi et al., 
1977, Krachmer et al., 1984, Edwards et al., 2001). However this notion has 
been challenged recently (Lema and Duran, 2005, Lema et al., 2009, Lema 
et al., 2010, Cheung et al., 2013, Cheung et al., 2014, Galvis et al., 2015b, 
McMonnies, 2015). Indeed proteomic analysis of KC patients’ tear film 
revealed high levels of pro-inflammatory cytokines IL-4, -5, -6, and -8 
(Interleukin-4, -5, -6 and -8), TNF-α and β (Tumour Necrosis Factor-alpha 
and Beta), ICAM-1 (intercellular adhesion molecule-1), MMP-1, -3, -7, -9 and 
13 (Matrix Metalloproteinase-1, -3, -7, -9 and -13) and decreased levels of 
IL-12 and -17 (Interleukin-12 and -17) (Duran and Lema, 2003, Lema and 
Duran, 2005, Seppala et al., 2006, Lema et al., 2009, Pannebaker et al., 
2010, Jun et al., 2011, Balasubramanian et al., 2012).  
 
In addition, there is an increase of tear protein level of MMP-13, IL-6 and 
TNF-alpha in KC corneas as well as in normal eyes in response to eye 
rubbing (Balasubramanian et al., 2013), suggesting that the causal link 
between KC and eye rubbing might be directly related to the increased 
levels of these cytokines. More specifically, a wound healing ex vivo analysis 
of KC and normal corneas conducted by Cheung et al., revealed higher 
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levels of IL-1α, IGF-1 (insulin-like growth factor 1), TNF-α, and TGF-B1 
(TGFβ-1) in KC corneas compared to the normal corneas (Cheung et al., 
2013, Cheung et al., 2014).  
 
1.4.7.2 Apoptosis 
Apoptosis has been reported in kerarocytes of keratoconic corneas by 
several studies (Kim et al., 1999, Kaldawy et al., 2002, Sevost'ianov et al., 
2002, Chwa et al., 2006, Matthews et al., 2007). Wilson et al. and Helena et 
al., suggested that this pathway is triggered by mechanical injury of the 
corneal epithelium (Wilson et al., 1996b, Helena et al., 1998). As previously 
described in Section 1.4.6, KC has been associated with eye rubbing, and 
also with atopic diseases from which the corneal injury might arise, as well 
as the use of poorly fitted contact lenses (Macsai et al., 1997). Under these 
conditions it is thought that the wounded epithelial KC cells release 
cytokines TNF-α (Tumor Necrosis Factor alpha) and IL-1 (Interleukin 1) 
which induce apoptosis in the underlying stromal cellular layer (Cheung et 
al., 2013). KC corneas have indeed been shown to overexpress IL-1 
receptors, and IL-1 induces keratocytes to undergo apoptosis through the 
activation of Fas ligand (Bureau et al., 1993).  
 
Another hypothesis for a mechanistic basis for KC is the downregulation of 
TIMP-1 in the early stages of disease, which might also be a stimulus for 
keratocytes apoptosis in KC corneas (Guedez et al., 1998) since a 
progressive decrease of TIMP-1 expression during the progression of KC 
has been recorded (Cristina Kenney and Brown, 2003). Other factors that 
have been proposed as possible stimuli for keratocyte apoptosis in KC 
corneas are the imbalance between TIMP-1 and TIMP-3 levels (Matthews et 
al., 2007) and the up-regulation of Cathepsins (Chwieralski et al., 2006).  
 
1.4.7.3 Extracellular Matrix degradation and remodelling 
Two mechanisms have been shown to cause KC corneal thinning and tissue 
degradation (Section 1.4.4): lamellae slippage and ECM remodelling (Meek 
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et al., 2005, Chaerkady et al., 2013). A noticeable reduction in collagen 
lamellae has been detected in KC patients compared to controls under light 
and electron microscopy (Takahashi et al., 1990). Additionally, stromal 
degeneration and lack of epithelial integrity have been detected in KC 
corneas, along with a decrease in collagens types I, III, V and XII, lumican 
and keratocan proteins (Chaerkady et al., 2013). Given that the corneal 
stroma is composed of 75% collagen type I, with types III, IV and V 
intertwined into the lamellae (Newsome et al., 1982), and that the epithelium 
and sub-epithelial stroma are composed mainly of collagen type XII 
(Chaerkady et al., 2013, Cheung et al., 2013), loss of these proteins is 
consistent with the corneal thinning and remodelling observed. 
 
Lamellae slippage is thought to be caused by alterations in the stromal 
organization due to an increase in the interfibrillar distance. The increase in 
distance promotes excessive contact between the collagen lamellae and the 
proteoglycans, and the proteoglycans are documented as exhibiting 
abnormalities in their configuration with the progression of the disease 
(Akhtar et al., 2008). Moreover, a loss in lamellae connecting the stroma to 
Bowman’s membrane has been detected by second-harmonic imaging, 
along with a reduction and sometimes a loss in interweaving lamellae 
(Morishige et al., 2007). Anterior KC corneas express fibronectin and 
tenascin glycoproteins that are not usually found in wounded or normal 
corneas, confirming the involvement of anterior cornea in KC pathogenesis 
(Tuori et al., 1997, Filenius et al., 2003). 
 
1.4.7.4 Imbalance in proteinase activity and proteinase inhibitor level 
Increased proteinase activity and decreased proteinase inhibitor function 
have also been proposed to play a role in the pathogenesis of KC 
(Sawaguchi et al., 1989, Sawaguchi et al., 1990, Brown et al., 1993, 
Opbroek et al., 1993, Smith et al., 1995, Zhou et al., 1998, Collier, 2001). KC 
corneas present increased levels of gelatinase activity (Cristina Kenney and 
Brown, 2003), which may correlate with increased levels of lysosomal 
enzymes such as acid lipases, acid phosphatases and esterases 
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(Sawaguchi et al., 1989), increased levels of cathepsin B and G activity 
(Zhou et al., 1998), and increased activity of gelatinolytic enzymes such as 
the matrix metalloproteinases (MMPs) (Zhou et al., 1998). Among the 
MMPs, MMP-2 is suspected to be involved in KC (Smith and Easty, 2000); 
this is based on the imbalance between this enzyme and its inhibitor, TIMP-1 
(Brown et al., 2004). In addition to the reduced levels of the gelatinase 
inhibitor, TIMP-1, two other inhibitors of degradative enzymes are decreased 
in KC, α1-proteinase and α-2 macroglobulin (Whitelock et al., 1997a, 
Whitelock et al., 1997b, Zhou et al., 1998, Brown et al., 2004). This decrease 
correlates with increased levels of corresponding degradative enzymes, 
(Brown et al., 1993, Maruyama et al., 2001) favouring tissue breakdown and 
leading to stromal thinning as well as fibroblast apoptosis (Chwa et al., 2006, 
Balasubramanian et al., 2012).  
 
At the molecular level, the overexpression of cathepsin K, G and B and the 
upregulation of MMP-2 and MMP-9 could be caused by an increase in IL-1 
(Kamolmatyakul et al., 2004). In turn, cathepsins activate MMP-1, MMP-9 
and MT-MMP1 known as MMP14, which contributes to MMP-2 activation. 
An increase in MMP-2 can also be caused by low levels of TIMP-1 (at KC 
early stages) (Meijers et al., 1994). The basement membrane is then more 
prone to degradation by the stimulated MMP-1, MMP-2 and MMP-9 as well 
as by the increase in cathepsin levels (Balasubramanian et al., 2010).  
 
Another hypothesis proposed is that the ECM changes in KC corneas might 
be due to activation of the protease cascade involving the plasmin system 
and the cyclooxygenase and MMPs, by overexpression of cytokines IL-1, IL-
6, IL-8, TNF-α, TGFβ and PDGF (Platelet-Derived Growth Factor) in KC 
corneas (Cheung et al., 2013, Galvis et al., 2015a). 
 
1.4.7.5 Oxidative Stress 
Several studies have investigated the role of oxidative stress in KC corneas 
and proposed that oxidative damage plays a major role in KC pathogenesis 
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(Behndig et al., 2001; Buddi et al., 2002; Gondhowiardjo and Haeringen, 
1993; Gondhowiardjo et al., 1993; Kenney et al., 2005). KC corneas are 
deficient in antioxidant capability as well as glutathione (defence against 
chemicals and oxidative stress), leading to a deficit in processing reactive 
oxygen species (ROS). This in turn accelerates oxidative damage (Arnal et 
al., 2011, Wojcik et al., 2013b). This is known as the “Cascade Hypothesis” 
(Cristina Kenney and Brown, 2003).  
 
Consistent with this, large amounts of cytotoxic by-products were shown to 
be present in KC corneas compared to normal ones, with malondialdehyde 
(MDA) and nitrotyrosine (NT) as the primary end products emerging 
respectively from lipid peroxidation and nitric oxide pathways (Figure 1-14) 
(Buddi et al., 2002). These finding support the hypothesis that KC corneas 













Indeed, high levels of ROS, reactive nitrogen species (RNS) and cytotoxic 
aldehydes were reported in KC patients corneas, also consistent with a 
deficiency in antioxidant capacity (Buddi et al., 2002, Chwa et al., 2006, 
Arnal et al., 2011, Wojcik et al., 2013b). 
Figure 1-14: Schematic representation of oxidative stress pathways. 
eNOS is the endothelium isoform of the constitutive nitric oxide synthase 
(cNOS), and iNOS is the inducible nitric oxide synthase (taken from (Buddi 
et al., 2002). No permission needed for re-use in Doctoral dissertation). 
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Since corneas are constantly generating ROS through UV light absorption, 
they therefore possess defence mechanisms to protect them from oxidative 
stress. These mechanisms are represented by protective enzymes against 
aldehyde formation such as aldehyde dehydrogenase (ALDH3) (Kays and 
Piatigorsky, 1997), and against ROS formation such as antioxidant enzymes 
including superoxide dismutase (SOD), catalase, glutathione peroxidase and 
glutathione reductase (Figure 1-13) (Rao et al., 1987). Antioxidant enzymes 
are shown to be present in almost every layer of normal corneas (Cejkova et 
al., 2004a, Cejkova et al., 2004b). In KC corneas, the free radical 
scavengers ALDH3 and SOD are underexpressed compared to normal 
corneas (Abedinia et al., 1990, Gondhowiardjo et al., 1991, Behndig et al., 
2001). Furthermore, increased levels of catalase, an enzyme involved in 
hydrogen peroxide (H2O2) elimination, were reported in KC corneas (Kenney 
et al., 2005), suggesting therefore a defence mechanism against elevated 
quantities of H2O2 (Figure 1-15). These alterations in protective enzymes are 
consistent with the accumulation of toxic by-products such as MDA and NT 
reported in KC corneas (Buddi et al., 2002). 
 
Figure 1-15: Schematic representation of the reaction of reactive 
oxygen species with antioxidant enzymes (Reused from (Kenney et al., 
2005) by the permission of Copy Right Clearance Centre, License number: 
3780400109886). 
 
Oxidative stress in KC patients has long been thought to be restricted to the 
defective corneas (Jun et al., 2011). However, a recent study reported high 
levels of oxidative stress index in KC patients’ sera compared to controls 
(Toprak et al., 2014). 
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Additional evidence for the presence of oxidative stress in KC corneas 
comes from the finding of increased mitochondrial DNA (mtDNA) damage in 
KC corneas compared to normal ones (Atilano et al., 2005). The mtDNA 
damage also leads to increased levels of ROS production and may be 
directly correlated with tissue degeneration in corneal fibroblasts (Yakes and 
Van Houten, 1997, Chwa et al., 2006, Chwa et al., 2008). 
 
1.4.8 Treatments for KC 
1.4.8.1 Contact lenses 
The type of contact lenses used by KC patients depends on the severity of 
the disease. For KC patients with mild disease and a visual acuity of 6/12 or 
better, spectacles are an option. However, with increased irregular 
astigmatism, spectacle lenses would not suffice to correct the resultant 
astigmatism (Jhanji et al., 2011).  
 
Moderate KC patients can also achieve good visual acuity with soft lenses. 
However, patients with more severe KC wear rigid gas permeable contact 
lenses. The rigid contact lenses used have single base curve lens or multiple 
base curve lens for moderately advanced KC patients (Garcia-Lledo et al., 
2006, Rathi et al., 2013). For severe KC cases a scleral contact lens is 
required (Segal et al., 2003, Visser et al., 2007a, Visser et al., 2007b).  
 
1.4.8.2 Collagen cross-linking (CXL) 
Collagen cross-linking (CXL) is a parasurgical approach in the treatment of 
KC and is less invasive than corneal transplantation. It provides a way to 
reduce and slow the progression of KC (Wollensak et al., 2003, Cinar et al., 
2014, Li et al., 2014, Vinciguerra et al., 2014, Bonnel et al., 2015, Khan et 
al., 2015, Sedaghat et al., 2015, Seyedian et al., 2015, Sykakis et al., 2015). 
This approach involves applying topical riboflavin (vitamin B2) drops to the 
KC cornea, followed by a 30 minute UV-A (370nm) exposure. This technique 
helps to crosslink the collagen, hence stiffening the cornea and preventing 
further thinning and deforming (Jhanji et al., 2011). 
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1.4.8.3 Intracorneal ring segment (ICRS) 
Intracorneal rings do not stop the progression of KC yet they do have a role 
in stabilizing the KC ectasia (Burris et al., 1991). They are implanted in the 
corneal stroma, without invasion of the central optical zone, in order to 
modify the corneal curvature. Three models of intracorneal rings are 
available for myopia correction: the Ferrara intracorneal ring, Bisantis 
segments, and Intacs. More recently the ICRS include semicircular 
segments, intrastromal corneal ring segments and Intacs microthin 
prescription inserts (Jhanji et al., 2011). The first implantation of Intacs was 
conducted by Colin et al. in 1997 (Colin et al., 2000).  
 
1.4.8.4 Corneal Transplantation 
1.4.8.4.1 Penetrating Keratoplasty 
Penetrating keratoplasty (PKP) is mainly used for advanced cases of KC 
and has been the main treatment for KC in developed countries (Patel et al., 
2005, Ghosheh et al., 2008, Guerin et al., 2008). It consists of removing of 
all the corneal thickness and replacing it with a donor whole cornea. The 
graft survival after PKP is estimated to be 89-95% at 5-10 years (Registry, 
1993).  
 
1.4.8.4.2 Lamellar Keratoplasty 
Lamellar keratoplasty is used instead of PKP in cases where Descemet’s 
membrane is still intact and there is no hydrops or significant corneal 
scarring (Jhanji et al., 2011). The deep anterior lamellar keratosplasty 
(DALK) preserves the Descemet’s membrane and the endothelium, thus 
preventing a later transplant rejection, but removes the anterior part of the 
cornea and replaces it with a donor anterior cornea (Anwar and Teichmann, 
2002). Three types of DALK exist: air assisted lamellar keratoplasty using 
intrastromal air injection (Shimazaki et al., 2002, Noble et al., 2007), the 
DALK using Melles technique (air guided deep stromal dissection) (Melles et 
al., 1999, Melles et al., 2000) and DALK using the Anwar’s big-bubble 
technique (Foroutan and Dastjerdi, 2007, Parthasarathy et al., 2008). 
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1.4.8.4.3 Femtosecond laser-associated keratoplasty 
Femtosecond laser-associated keratoplasty (FLAK) is a femtosecond-laser 
assisted graft. The laser helps in creating a precise incision shape in the 
cornea of the KC patient undergoing the corneal transplantation thus 
matching the recipient’s corneal dimensions (Slade, 2007, Jhanji et al., 
2011).   
 
1.4.8.4.4 “Tuck in” Lamellar Keratoplasty (TILK) 
“Tuck in” Lamellar Kerastoplasty or TILK is a one-stage technique used in 
extreme corneal ectasia and pellucid marginal degeneration. A procedure in 
which peripheral intrastromal pockets are created in the host cornea, where 
the peripheral overhang of the donor cornea is tucked (Vajpayee et al., 
2002, Kaushal et al., 2008). 
 
1.4.8.4.5 TILK Microkeratome-associated Lamellar Keratoplasty 
TILK Microkeratome-associated Lamellar Kerastoplasty involves shaving off 
the surface of both donor and host KC corneas before transplantation with a 
microkeratome, to reduce the irregular interface induced by manual 
dissection (Barraquer, 1972, Haimovici and Culbertson, 1991, Springs et al., 
2002). 
 
1.4.9 Genetics of KC 
The qualification for a genetic predisposition to KC is based on reports of 
familial aggregation with prevalence of 23% approximately and increases of 
3.34% of prevalence of KC in first-degree relatives (Section 1.4.2) (Wang et 
al., 2000, Rabinowitz, 2003, Burdon and Vincent, 2013). In addition, the 
reports of bilateralism of the disorder (Bilgin et al., 2013, Rogers and 
Attenborough, 2014) strongly suggest a genetic contribution in the 
development of KC. Moreover, in twin studies, Valluri et al studied refractive 
error (RE), which is a major component for KC (astigmatism) (Section 1.4.1), 
- 31 - 
 
in a set of 20 monozygotic and 19 dizygotic twin pairs. Valluri et al. 
suggested that RE presents significant genetic basis by showing that the 
mean difference in refractive error is significantly lower (p=0.001) in 
monozygotic twins (RE=0.41) compared to dizygotic twins (RE=1.53) (Valluri 
et al., 1999). More directly, Tuft et al. investigated KC in 13 pairs of 
monozygotic twins and 5 pairs of dizygotic twins by studying the severity 
scores deduced from keratometry values. Tuft et al. showed an increased 
concordance (p=0.035) for the severity of KC in monozygotic twins (mean 
difference in severity scores = 1.4) than in dizygotic twins (mean difference 
in severity scores = 3.0), which further suggests genetics involvement in KC 
pathogenesis (Valluri et al., 1999, Tuft et al., 2012).  
 
Furthermore, central corneal thickness (CCT), which has been associated 
with KC and thought to be a KC endophenotype (Patel and McLaughlin, 
1999), has been shown by Toh et al. in a set of 256 of twin pairs, to have a 
major genetic factor with a heritability score of 0.95 (Toh et al., 2005). Thus, 
the high heritability of CCT and its association with KC provide another 
indication of the importance of genetic component contribution in KC 
development. 
 
To date, and in order to determine the genes mutated in KC, established 
techniques such as linkage analysis, genome wide association studies 
(GWAS) and candidate gene approaches based on functional evidence have 
been tried on genomic DNA from KC patients and controls deriving from 
different populations, with some successes (Burdon and Vincent, 2013, Abu-
Amero et al., 2014a). However, recent advances in next generation 
sequencing have also revealed some interesting findings.  
 
1.4.9.1 Linkage analysis studies 
In most reports, KC is transmitted as an autosomal dominant trait 
(Rabinowitz et al., 1992, Tyynismaa et al., 2002, Brancati et al., 2004, 
Burdon et al., 2008) but autosomal recessive (Wang et al., 2000, Fullerton et 
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al., 2002) and X-linked inheritance have been reported (Hammerstein, 
1971). 
 
Linkage analyses on large KC families with a dominant mode of inheritance 
or dominant with incomplete penetrance have identified several 
chromosomal loci. To date, 12 studies have mapped 17 loci in large families 
with multiple affected KC members (Table 1.1) (Wheeler et al., 2012). The 
high number of loci associated with KC suggests genetic heterogeneity in 
KC. However it should be noted that, among all the 17 loci reported and 
displayed in Table 1-1 along with their respective LOD scores, only three 
chromosomal regions, 5q21, 5q32 and 14q11, have been replicated in more 
than one study (Tang et al., 2005b, Li et al., 2006, Bisceglia et al., 2009).  
Table 1-1: Linkage analysis studies mapping KC to different 
chromosomal loci. 







(Burdon et al., 2008) 
2p24  
 
5.13 Caucasian, Arab, 
Caribbean African 
(Hutchings et al., 2005) 
2q13-q14.3 
20p13-p12.2 
- Ecuadorian (Nowak et al., 2013) 





- African-American; Asian; 
Hispanic 
(Li et al., 2006) 





- Italian (Bisceglia et al., 2009) 
9p34 4.5 African-American; Asian; 
Hispanic 
(Li et al., 2006) 
13q32 4.1 Ecuadorian (Gajecka et al., 2009) 
(Czugala et al., 2012b) 
14q24.3 3.58 British (Mixed) (Liskova et al., 2010b) 
16q22.3-q23.1 4.1 Finnish (Tyynismaa et al., 2002) 
20q12 - Tasmanian, Australian (Fullerton et al., 2002) 
 
The majority of these studies have not yet led to the identification of KC-
associated genes at the relevant loci. However, studies detailed below have 
identified some potential genes mutated in KC (miR184 and DOCK9, CAST, 
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IL1RN and SLC4A11) highlighted through linkage analysis in four large 
extended families.  
 
More recently, using a combination of linkage analysis and NGS, Hughes et 
al. identified heterozygous variants in 3 genes (miR184, IREB2, DNAJA4). 
The study was conducted on an autosomal dominant Northern Irish 
extended family with a phenotype of KC associated with anterior capsular 
cataract (Hughes et al., 2003, Hughes et al., 2011). The presence of variant 
r.57c>u in the seed region of miR184, together with a prior knowledge of the 
abundance of this particular miRNA in the cornea and lens epithelia, made it 
a good candidate for involvement in KC in this family (Hughes et al., 2011). 
The IREB2 variant was detected in the 3’UTR of the gene and DNAJA4 was 
not found to play any role in the eye, so these changes were considered 
unlikely to be causative. Furthermore, a second family presenting dominant 
congenital cataract with corneal problems, which the authors termed EDICT 
syndrome (endothelial dystrophy, iris hypoplasia, congenital cataract, and 
stromal thinning) presented the same exact mutation reported for KC (Iliff et 
al., 2012a) (Iliff et al., 2012b).  miR184 was then screened in a cohort of 780 
KC patients in order to determine whether this microRNA was involved in the 
pathogenesis of isolated KC cases. Two rare variants were found in the 
screened cohort, which led the authors to the conclusion that miR184 may 
indeed be involved in KC pathogenesis but accounts for only 0.25% of 
isolated KC cases (Lechner et al., 2013a).   
 
A variant in DOCK9 (Dedicator of Cytokinesis) was identified following 
linkage analysis in a large dominant Ecuadorian family by Gajecka et al., 
and candidate gene sequencing (Gajecka et al., 2009). The heterozygous 
variant c.2262a>c, p.Gln754His has been shown to segregate in the family 
and is absent in ethnically matched controls; however this result has not 
been replicated by other studies (Karolak et al., 2015a). This putative 
mutation was shown to cause aberrant splicing leading to exon skipping in 
one of the two DOCK9 protein isoforms (Karolak et al., 2015b). This gene is 
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expressed in both KC and normal corneas. The precise role of DOCK9 in 
normal cornea development has yet to be clarified (Czugala et al., 2012a).  
 
Li et al. screened CAST (Calpastatin, OMIM 114090) by looking at the 
candidate genes identified in a 5Mb linked region on chromosome 5q15. 
They reported a SNP (rs4434401) that was associated with both familial 
(262 cases) and sporadic (304 cases) KC in a Caucasian population (Li et 
al., 2013b).  
 
Nowak et al., identified through linkage analysis two novel loci 2q13-q14.3 
and 20p13-p12.2 (whole-genome multipoint nonparametric linkage-NPL 
score= 2.395 and 2.409 respectively) segregating in a single family (9 KC 
patients, 9 healthy family members), and screened four candidate genes 
IL1A, IL1B, IL1RN (Interleukins 1-alpha, 1 Beta and Interleukin-1 Receptor 
Antagonist Protein) and SLC4A11 in these regions (Sodium bicarbonate 
transporter-like protein 11). The screening resulted in the identification of a 
substitution in IL1RN (c.214+242C>T) and a novel deletion in SLC4A11 
(c.2558+149_2558+203del54). The IL1RN substitution was detected in nine 
KC affected family members and 3 unaffected members (P=0.004525), in 
other KC families (P=0.54) and in 10 healthy ethnically matched controls of 
22 screened controls. The SLC4A11 deletion was detected in 8 out of 9 
affected KC members (P=0.00761), in 2 healthy family members and in one 
control out of the 22 screened ethnically matched controls. Variants in IL1RN 
and SLC4A11, were observed to be significantly enriched in KC more than 
unaffected family members, suggesting a possible involvement of these two 
genes in KC pathogenesis (Nowak et al., 2013). 
 
Although a few of the loci reported by researchers were reproduced 
independently by other groups, the majority of the regions reported to be 
linked by KC in the literature were not reproduced by other researchers. That 
might be largely due to the use of conventional linkage approaches to map 
complex disease traits in small family cases numbers (Altmuller et al., 2001). 
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It might also be due to the inclusion under the KC patients’ umbrella of all 
the different subclinical forms of KC  (i.e. “forme-fruste KC”, patients with thin 
corneas with no ectasia and simple astigmatism). The likely increased 
presence of phenocopies and reduced penetrance that will result may 
complicate linkage analysis, preventing an accurate outcome (Altshuler et 
al., 2008). However, taking this data at face value, based on the evidence 
that multiple linkages have been identified, with each linkage (multiple loci in 
some cases) being assigned to a unique family, KC can be considered to be 
a genetically heterogeneous condition. 
 
1.4.9.2 Reported KC candidate genes 
Among the approaches used to understand the complex unknown aetiology 
of KC pathogenesis (Kriszt et al., 2014), researchers have screened a 
number of candidate genes selected on the basis of their known role, 
biological functions and expression patterns in corneal and disease 
pathways. The potential candidate genes in KC are ones that are associated 
with corneal dystrophies, ocular development, ECM, collagens, apoptosis, 
oxidative stress related pathways and connective tissues disorders. 
 
1.4.9.2.1 Genes reported in other corneal dystrophies and ocular 
development 
KC has been reported to be associated with other ocular dystrophies. KC 
and PPCD (posterior polymorphous corneal dystrophy) association suggests 
a potential common genetic pathway. Mendelian mutations in Visual System 
Homeobox 1 (VSX1; OMIM 605020) and Zinc Finger E-box Binding 
Homeobox 1 (ZEB1; OMIM 189909) genes have been shown to cause 
PPCD (Liskova et al., 2007b, Vincent et al., 2009, Liskova et al., 2010a, 
Vincent et al., 2013b). Since PPCD and KC are often found to occur in the 
same patients, VSX1 and ZEB1 were screened for mutations in KC patients 
(Heon et al., 2002a, Lechner et al., 2013c). Putative mutations were found to 
be associated with the KC phenotype. Several studies assessed the 
association of VSX1 variants with KC (Table 1-2) in several populations 
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(Table 1-2); however the variants found in VSX1 account for only 2-3% of 
KC cases and most of the variants identified are common polymorphisms 
(Abu-Amero et al., 2014a). The role of VSX1 variants in KC pathogenesis 
therefore requires further clarification and to date VSX1 has not been shown 
to be involved in KC pathogenesis (Aldave, 2005, Aldave et al., 2006, 
Romero-Jimenez et al., 2010, Kok et al., 2012, Karolak et al., 2015a). As for 
the ZEB1 gene, Muszynska et al. reported putative mutations in ZEB1 in 
unrelated KC European patients (Muszynska et al., 2011).  
 
Table 1-2: VSX1 variants reported in KC patients in various populations 
by different research groups. 
Gene	 Zygosity	 Mutation	 Population	 Reference	
VSX1	
	
Dominant	 R166W,	L159M,	G160D	 -	 (Heon	et	al.,	2002a)	
Dominant	 D144E,	G160D,	P247R,	L17P	 Italian	 (Bisceglia	et	al.,	2005)	
-	 None	 -	 (Aldave,	2005)	
Dominant	 None	 English	 (Liskova	et	al.,	2007a)	
-	 None	 Mixed	 (Tang	et	al.,	2008)	
Dominant	 N151S,	G160V	 Korean	 (Mok	et	al.,	2008)	
Dominant	 D144E	 Jewish	 (Eran	et	al.,	2008)	
Dominant	 Q175H	 Indian	 (Paliwal	et	al.,	2009)	
-	 p.G160D	 European	 (Dash	et	al.,	2010)	
-	 None	 Slovenian	 (Stabuc-Silih	et	al.,	2010)	
-	 None	 North	Indian	 (Tanwar	et	al.,	2010)	
Recessive	 Q175H	 Indian	 (Paliwal	et	al.,	2011)	





















-	 c.731A>G	(p.His244Arg) Australian	 (Vincent	et	al.,	2013b)	












- 37 - 
 
1.4.9.2.2 Extracellular Matrix genes 
The transforming growth factor beta induced gene (TGFBI; OMIM 190180) 
encodes an ECM protein, mutations in which are the cause of several 
corneal dystrophies. The investigation of the TGFBI gene by direct 
sequencing in KC patients revealed contradictory results in different 
populations. The most convincing data is the identification of a heterozygous 
nonsense mutation (G535X) in one patient out of 30 from a Chinese cohort 
(Guan et al., 2012). 
 
1.4.9.2.3 Collagens 
One theory of KC pathogenesis is that the alteration in collagen 
structure/function is due to a genetic factor involved in collagen modification 
in KC corneas. Thus, collagen genes have been investigated in KC patients 
without much success in identifying a variant responsible for KC 
development. COL4A3 (OMIM 120070) and COL4A4 (OMIM 120131) 
showed no pathological mutations in 104 European unrelated KC patients, 
though a significant increase in allele frequency was detected for the D326Y 
variant (p<0.0001) of COL4A3 and for M1237V (p<0.0001) and F1644F 
(p=0.002) variants in COL4A4 in KC patients (Stabuc-Silih et al., 2009). The 
same result was not confirmed by Wang et al. and Kokolakis et al., where 
they rejected the association of COL4A3 and COL4A4 with KC (Wang et al., 
2013a) (Kokolakis et al., 2014). Likewise, the role of COL4A1 (OMIM 
120130) and COL4A2 (OMIM 120090) (Karolak et al., 2011) and COL8A1 
(OMIM 120251) and COL8A2 (OMIM 120252) (Aldave et al., 2007) in KC 
has been excluded by Sanger DNA sequencing. Recently, Saravani et al., 
associated SNP rs2229813 and the GA+AA genotypes in COL4A4 as a risk 
factor for KC in the Iranian population (Saravani et al., 2015). 
 
1.4.9.2.4 Apoptosis related pathways 
As previously described, atopy is a risk factor for KC and association 
between KC and atopy has been reported to be seen in as many as 50% of 
KC cases (Droitcourt et al., 2011) (Section 1.4.5). In addition, eye rubbing 
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has been associated with KC (Section 1.4.5) and it has been shown that 
mechanical injury can induce keratocyte apoptosis in KC corneas by the IL1 
(Interleukin 1) pathway (Wilson et al., 1996a). In parallel, FLG (Filaggrin; 
OMIM 135940) mutations are thought to cause atopic dermatitis, with the 
FLG protein expressed in the corneal epithelium (Liang et al., 2015). Thus 
FLG and IL1 have been considered as KC candidate genes and investigated 
in KC patients. Additionally, Droitcourt et al. screened FLG in 89 KC patients 
and found two heterozygous loss-of-function FLG mutations (R501X and 
2282del4) (Droitcourt et al., 2011).  
 
For the IL1 genes, which lie within a 70 kb region on chromosome 2q13, 
IL1B (OMIM 147720) promoter polymorphisms rs1143627 (c.−31t>c) 
(p=0.025) and rs16944 (c.−511c>t) (p=0.022) have been reported to 
increase the risk of KC in 100 unrelated Korean patients, while the IL1A 
(OMIM 147760) intronic polymorphism c.+376c>a (rs2071376) was 
significantly different between KC patients and controls (p=0.034) (Kim et al., 
2008). The same IL1B (rs16944) polymorphism to was screened in a 121 
Turkish KC patients and 121 controls, and association between IL1B and KC 
was rejected (p=0.569) (Palamar et al., 2014). However, Mikami et al., 
studied the polymorphisms reported by Kim et al. of both IL1B and IL1A 
polymorphisms in 169 Japanese patients and 390 controls and replicated 
the association of the IL1B promoter polymorphism rs1143627 (c.−31t>c) 
(p=0.014, corrected p=0.043) (Mikami et al., 2013). Similarly, and very 
recently, the same variants in IL1B and IL1A were investigated in a 101 
unrelated Chinese Han patients and 101 controls by Wang et al., who 
established a significant association (rs1143627 (C>T p=0.017), rs16944 
(A>G p=0.002) and rs2071376 (A>C p=0.017)) between IL1 and risk of KC 
(Wang et al., 2015b). Functional analysis must be conducted in order to 
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1.4.9.2.5 Oxidative Stress genes 
In an effort to identify genes responsible for KC, Udar et al. screened the 
SOD1 (Superoxide dismutase1, OMIM 147450) gene as a candidate gene 
for KC since oxidative stress has been hypothesised to play a role in KC 
development (Kenney et al., 2000, Atilano et al., 2005, Wojcik et al., 2013b). 
SOD1 encodes the cytosolic Cu/Zn-SOD, a protein that binds copper and 
zinc ions and responsible for destroying free superoxide radicals in the body 
(You et al., 2010). As previously mentioned, KC corneas have underlying 
defects in their ability to process ROS and undergo oxidative damage that is 
translated into an increased oxidative stress (Cristina Kenney and Brown, 
2003). Udar et al. reported a 7-base deletion in intron 2 of the SOD1 gene in 
two pedigrees within which three KC patients were available for testing 
(Udar et al., 2006). However this finding was not consistent with other 
cohorts (Stabuc-Silih et al., 2010, De Bonis et al., 2011, Saee-Rad et al., 
2011, Al-Muammar et al., 2015, Moschos et al., 2015). Even if the link with 
SOD1 was proven, it would only account for 1% of KC patients.  
 
Recently, Synowiec et al. suggested the genes MUTYH (mutY DNA 
glycolase, OMIM 608456) and hOGG1 (8-oxoguanine DNA glycosylase, 
OMIM 601982) that play a role in oxidative DNA damage repair as 
candidates for involvement in KC pathogenesis. They therefore screened 
both genes in 205 Polish Subpopulation patients and 220 controls, but didn’t 
find any association (p<0.05) between the mentioned genes and KC 
pathogenesis (Synowiec et al., 2015).  
 
Wojcik et al. hypothesised that base excision repair genes (BER) may play a 
role in KC pathogenesis, since KC corneas have lost their ability to 
effectively cope with oxidative stress and BER is usually the mechanism by 
which the damage caused by oxidative stress is removed. Thus, 4 BER 
genes were checked for mutations by genotyping 5 polymorphisms in 284 
KC patients and 353 controls: g.46438521G>C in 3’ near gene NEIL1 (Nei 
endonuclease VIII-like 1, OMIM 608844), exonic c.2285T>C in PARP-1 
(poly(ADP-ribose) polymerase-1, OMIM 613867), c.–1370T>A in the 5' near 
- 40 - 
 
gene POLG (DNA polymerase γ, OMIM 174763) and exonic c.580C>T and 
c.1196A>G in XRCC1 (X-ray repair cross-complementing group 1, OMIM 
194360). This study concluded that changes in the XRCC1 and POLG 
genes may constitute a risk factor in KC since the A/A genotype of the c.–
1370T>A polymorphism of POLG and the A/G genotype and the A allele of 
the c.1196A>G polymorphism of the XRCC1 were associated with increased 
risk of KC  (Wojcik et al., 2014b). 
 
1.4.9.2.6 Other candidate genes 
Additionally, some studies looked up the regions that were previously 
reported in linkage analysis and screened the genes lying in the mapped 
region that seemed to have a particular involvement in corneal pathways. De 
Bonis et al. screened SPARC (Secreted Protein Acidic and Rich in Cysteine, 
OMIM 182120) and LOX (Lysyl Oxidase, OMIM 153455) localized on 
chromosome 5q23.2 and 5q31.3-q32, respectively, in regions that were 
previously implicated by linkage analysis in familial KC (Li et al., 2006, 
Bisceglia et al., 2009). De Bonis et al., excluded the involvement of LOX in 
KC pathogenesis but reported a novel potential deleterious heterozygous 
mutation p.M92I in SPARC in one patient out of 302 Italian KC patients 
studied and absent in 200 screened controls, suggesting a possible role for 
this gene in KC pathogenesis that needs further investigation (De Bonis et 
al., 2011). 
 
The STK24 (Serine/Threonine Kinase 24, OMIM 604984) and IPO5 
(Importin 5, OMIM 602008) genes lie in the 13q32 locus identified by 
Czugala et al. in an Ecuadorian family, IOP5 (c.2377-132A>C) 
and STK24 (c.1053+29G>C) and both have been reported in introns in 10 
KC affected patients out of 10, in 1 unaffected family member and in 1 family 
member of unknown phenotype. In addition, the IOP5 intronic change has 
been identified in 2 KC patients belonging to different KC families than the 
original one investigated and in 5 controls out of 105. The STK24 intronic 
change has been identified in 1 control out of 105  (Czugala et al., 2012b). 
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Therefore, Karolak et al. investigated the involvement of both genes but 
concluded that neither gene was mutated in KC patients from the Polish 
population (Karolak et al., 2015a). 
 
In addition, an increase in copy number variation of mitochondrial DNA 
(mtDNA), but not haplogroup, has been shown to be associated with KC 
(Hao et al., 2015b). In addition, Abu-Amero et al. sequenced the full 
mitochondrial genome in 26 Saudi patients genome and found 10 
synonymous variants in 10 different KC patients and absent in controls.  
Four changes were present in mitochondrial complex I, two variants in 
tRNALeucine2, one variant in tRNAHistidine, one variant in tRNAGlutamine, one 
variant in tRNATryptophane and one variant in tRNAAspargine (Abu-Amero et al., 
2014b). In case these results are confirmed in a large cohort and screened 
in a larger number of cohorts, they highlight a possible involvement of 
mitochondrial sequence variations in KC pathogenesis. 
 
1.4.9.3 Association studies 
Several GWASs were recently conducted, through which a number of genes 
and loci were shown to be significantly associated with KC (Burdon et al., 
2011, Bykhovskaya et al., 2012, Li et al., 2012b, Bae et al., 2013, Lu et al., 
2013, Lechner et al., 2014, Sahebjada et al., 2014). The first KC GWAS was 
conducted in 2011. By combining two genome-wide scans undertaken in 
parallel on Australian, American KC patients’ cohorts, Burdon et al. 
highlighted a SNP (rs3735520) at the HGF (Hepatocyte Growth Factor, 
OMIM 142409) locus, which was associated (P= 9.9×10−7) with KC (Burdon 
et al., 2011). The significant association (p = 8.1×10−3) of HGF (rs5745752) 
with increased risk KC was later confirmed by Sahebjada et al. in an 
Australian cohort of 157 KC patients and 673 healthy controls (Sahebjada et 
al., 2014). 
 
In 2012, Li et al. identified a SNP (rs4954218) located near RAB3GAP1 
(RAB3 GTPase activating protein subunit 1, OMIM 602536) P= 1.6 × 10−7 in 
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a study including 222 Caucasian KC patients and 3324 controls (Li et al., 
2012b). This same finding was replicated in 2013 in an Australian Caucasian 
cohort (524 KC patients and 2761 controls) and in a combined meta-analysis 
by showing a significant association of SNP rs4954218 near RAB3GAP1 
(P = 9.26 × 10−9) (Bae et al., 2013).  
 
A meta-analysis conducted in 2013 by Lu et al. combined data from multiple 
GWASs of CCT to identify 16 new CCT loci. All of the CCT loci highlighted in 
this analysis were then tested for association in 874 KC cases and 6,085 
controls. Six of the CCT associated SNPs were also significantly associated 
with KC, including: Forkhead Box O1-FOXO1 (OMIM 136533, SNP 
rs2721051), Fibronectin Type III Domain Containing 3B-FNDC3B (OMIM 
611909, SNP rs4894535), Retinoid X receptor Alpha-Collagen type V alpha 
RXRA-COL5A1 (OMIM 180245; 120215, SNP rs1536482), Multiple PDZ 
domain protein-Nuclear Factor I/B MPDZ-NFIB (OMIM 603785; 600728, 
SNP rs1324183), Collagen type V alpha 1 COL5A1 (OMIM 120215, SNP 
rs7044529) and Zinc Finger Protein 469 ZNF469 (OMIM 612078, SNP 
rs9938149) (Lu et al., 2013). The MPDZ-NF1B locus (SNP rs1324183) was 
replicated (p=0.005) in a Han Chinese cohort (210 KC patients and 191 
controls) (Hao et al., 2015a). Moreover, Lechner et al. reported in a cohort of 
significant enrichment of potentially pathogenic heterozygous alleles in 
ZNF469 associated (P = 0.00102) with KC using Sanger sequencing on 
European ethnicity patients (112 patients and 784 controls) (Lechner et al., 
2014).  
 
Furthermore, a locus on chromosome 5q has been associated with KC 
(Rabinowitz et al., 1992, Li et al., 2006) and confirmed recently 
(Bykhovskaya et al., 2012). For this locus, Bykhovskaya et al. extrapolated 
from published GWAS data in a Caucasian cohort to support their 
hypothesis that the LOX gene, encoding the protein Lysyl Oxidase, is 
involved in KC pathogenesis. They noted that LOX is located under their 
linkage peak at 5q23.2, and identified two KC associated SNPs (rs10519694 
and rs2956540) in LOX, following a combined family based and case-control 
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association study (Meta p= 4.0 × 10−5 and 4.0 × 10−7) (Bykhovskaya et al., 
2012). 
 
The previously mentioned recent GWAS studies (Burdon et al., 2011, 
Bykhovskaya et al., 2012, Li et al., 2012b, Bae et al., 2013, Li et al., 2013b, 
Lu et al., 2013, Sahebjada et al., 2014) were successful in confirming 
existing KC associated loci and highlighting a number of new genetic 
associations in candidate genes implicated in KC pathogenesis. However, 
while this approach is able to detect the influence of common alleles in the 
form of polymorphic SNPs on KC, these will generally have only modest 
effect sizes. In contrast, this approach will miss rare variants with more 
significant effect sizes. Nonetheless rare variants with major effect may 
contribute significantly to the genetics of KC, a phenomenon has been 
invoked to explain the missing heritability in a range of common multifactorial 
diseases like KC (Eichler et al., 2010, Zuk et al., 2012). 
 
1.5 Project Aim 
The aim of this project is to identify the genetic basis of KC in human 
patients. The approach used initially was to collect KC families belonging to 
highly consanguineous and endogamous populations with multiple KC 
affected members, then explore the genomic DNA of KC patients and 
controls via whole exome next generation sequencing (WES) in order to 
highlight genetic variants that might account for KC pathogenesis. The 
second aim of this project was to establish a transcriptome profile via RNA-
seq for KC and normal human corneas, in order to build the normal human 
corneal transcriptome profile and determine the extent of differential gene 
expression in KC corneas. In a third approach, WES and RNA-seq data 
were combined in samples obtained from the same patient to look for 
genetic variants that exist in genes, which are differentially expressed.  
 
 
- 44 - 
 
2 Materials and Methods 
2.1 DNA sampling in Patients 
All patients included in the study were diagnosed by an ophthalmologist 
following a topographical examination. The local Yorkshire KC patients and 
healthy controls were identified and blood or saliva sampled by Dr. Aine Rice 
and Miss Salina Siddiqui (the Eye Department, St. James’s University 
Hospital, Leeds). DNA was extracted by the Yorkshire Regional Genetics 
Service on a research basis. Blood from the Lebanese KC families (patients 
and healthy family members) and healthy controls belonging to the same 
ethnicities as the patients were sampled by qualified phlebotomists during a 
field trip to Lebanon, some of the Lebanese controls were collected in the 
UK by contacting the British Druze society and personal contacts. DNA was 
extracted at the American University of Science and Technology (AUST) 
laboratories and subsequently brought to Leeds, through a collaboration with 
Dr. Gretta Abou-Sleymane from AUST as well as Lebanese 
ophthalmologists: Dr. Naji Waked, Dr. Bassam Barakat and the late Dr. 
Ghassan Shayya. The Lebanese ethical approval to sample patients and 
extract DNA is under the governmental licence number 3087-Minister of 
Health-decree number 1/211-19/4/2005. Informed consent was obtained 
from all subjects involved in the study using a process that was approved by 
the Leeds East Research Ethics Committee (Reference number 
10/H1306/63 under the title: “Investigation of human inherited corneal 
dystrophies: genetic, tissue and transplant analyses”). The research followed 
the tenets of the Declaration of Helsinki.  
 
2.2 DNA extraction 
2.2.1 From Blood 
Blood samples for DNA extraction (2-6ml depending on age) were collected 
by venepunture from the antecubital fossa and stored in BD vacutainer® 
EDTA blood collection tubes (BD Biosciences, Oxford UK). Genomic DNA 
was extracted in Lebanon at the AUST laboratory using the phenol-
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chloroform extraction. This protocol involved adding 1000µl of Red Blood 
Cell Lysis Buffer (0.155M Ammonium Chloride, 0.01M Potassium 
Bicarbonate and 0.1mM EDTA) to every 350µl of Blood and mixing by 
inversion. The samples were incubated for 2 minutes at room temperature, 
mixed by inversion and centrifuged for 2 minutes at 12,000 rpm. The 
supernatants were discarded into disinfectant then each pellet was 
resuspended in 190µl of 0.2M of ammonium acetate and vortexed briefly. 
Next, 13µl of 10% SDS detergent and 2.5µl of proteinase K (20mg/ml H2O) 
(Sigma P-0390) was added and the mix was briefly vortexed and incubated 
for 1hour at 55ºC. Once the samples had cooled, 60µl 
phenol/chloroform/isoamyl alcohol was added then the mix was vortexed for 
30 seconds and centrifuged for 2 minutes at 12,000 rpm. The  aqueous layer 
was carefully removed to a new 1.5ml microcentrifuge tube, and 500µl of 
cold 100% ethanol was added in order to precipitate the DNA. The samples 
were then mixed, and incubated for 15 minutes at -20ºC. Subsequently, the 
samples were centrifuged for 2 minutes at 12,000 rpm in a microcentrifuge, 
and the supernatants were discarded.  The pellets were redissolved in 90 µl 
of 10:1 TE buffer, vortexed, and incubated at 55ºC for 10 minutes. 10 µl of 
protein precipitation solution (2M sodium acetate) was added and the 
samples were mixed. The DNA was precipitated by 250 µl of cold 100% 
ethanol, mixed, and centrifuged for 1 minute at 12,000 rpm. The 
supernatants were discarded and the pellets were rinsed with 500µl of 80% 
ethanol, centrifuged for 1 minute at 12,000 rpm and rewashed with 500µl of 
70% ethanol. Pellets were again centrifuged for 1 minute at 12,000 rpm in a 
microcentrifuge. The ethanol was removed and the DNA pellets were left to 
air-dry. Once dry the DNA pellets were dissolved in 100µl of 10:1 TE buffer 
and left overnight at room temperature. DNA samples were later stored at -
20˚C. 
 
For Leeds samples, DNA was extracted from peripheral blood samples by 
Yorkshire Regional Genetics, Saint James’s University Hospital using a salt 
precipitation technique. The salt precipitation technique briefly corresponds 
to extracting DNA from fresh non frozen blood samples, by aliquotting 3ml of 
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blood into polypropylene tubes and add 9ml of Red Cell Lysis solution. The 
samples were then mixed for 10 minutes at RT and then centrifuged at 3,200 
rpm for 10 minutes. The supernatant was removed. The remaining white 
cells pellet was re-suspended in 3ml of White Cell Lysis solution, and cells 
were lysed by pipetting. Add 1ml of Protein Precipitation Solution (10M 
Ammonium Acetate) to the mix in order to remove any contaminating 
proteins, and samples were vortex mixed for 20 seconds then centrifuged at 
3,200rpm for 10 minutes. The supernatant containing the DNA was 
transferred into a fresh tube and 3ml of isopropanol was added for DNA 
precipitation. The samples were then centrifuged at 3,200rpm for 10 minutes 
followed by two washes in 70% ethanol. The precipitated DNA was air dried 
and redissolved in 200µl of 1xTE buffer, incubated at 55°C for 4 hours in a 
shaking water bath to complete re-suspension then left for 1hour at RT 
before storage. 
 
2.2.2 From Saliva 
From saliva, genomic DNA was collected using Oragene kits (Oragene.ONE 
ON-500, DNA Genotek) and extracted following the manufacturer’s protocol. 
Briefly this involved transferring 750μl of saliva to a 1.5 ml tube, then adding 
30μl of PT-L2P solution supplied with the kits. The samples were incubated 
on ice for 10 minutes then centrifuged at room temperature for 10 minutes at 
3500 x g. 600μl of the supernatants were then transferred to a fresh tube, 
and the pellets were discarded. 720μl of 100% ethanol was added and the 
mix was inverted 10 times. Subsequently, the samples were incubated for 10 
minutes at room temperature then centrifuged for 10 minutes at 3500 x g. 
The supernatant was discarded and 500μl of 70% ethanol was carefully 
added to the pellet, which was then left to stand for 1 minute at room 
temperature. The ethanol was completely removed without disturbing the 
pellet and smear. Once dry, the pellet was re-dissolved in 50μl of TE. The 
samples were incubated at room temperature overnight to ensure complete 
rehydration and transferred to a 1.5mL tube. DNA samples were later stored 
at -20˚C.  
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2.3 Human corneal tissue collection and RNA extraction 
Under the same Leeds East Research Ethics Committee ethical approval 
referenced in section 1 (Reference number 10/H1306/63 ), the stroma, 
Bowman’s layer and epithelium tissues of five normal cadaveric human 
corneas were donated by five different previously healthy individuals. In 
addition, six KC corneas obtained with the consent from six different patients 
undergoing corneal transplantation at the eye department at St James's 
Hospital were obtained. The healthy donated corneas from cadavers were 
used in descemet stripping automated endothelial keratoplasty (DSEK), a 
treatment for corneal endothelial dystrophy in which the inner endothelial 
layer of the cornea is transplanted, leaving the anterior part of the cornea. 
The enucleation procedure from cadavers donor’s eye (WT corneas) takes 
place as soon as possible to a maximum of 24 hours after death. Before 
enucleation, the eye of the donor is cleaned with 3% PVPI (Povidone-Iodine) 
and 0.3% Na2S2O3 (Sodium thiosulphate) then excised and preserved in 
Minimum Essential Medium Eagle 2% FBS (Fetal Bovine Serum) at 34 
degrees for a period of time that can go no longer than 28 days. The 
keratoconus corneas were surgically removed in theatre from patients 
treated by deep anterior lamellar keratoplasty (DALK) where all corneal 
tissue is removed down to Descemet’s membrane, leaving only the healthy 
endothelial layer. Healthy and KC corneal tissue samples were therefore 
equivalent, representing the entire cornea except the endothelial cell layer. 
The enucleation of both KC and WT corneas was done following the 
“Standards for the retrieval of human ocular tissue used in transplantation, 
research and training, The Royal College of Ophthalmologists” (Figueiredo, 
2013). 
 
Blood samples were also collected from the six KC patients sampled in this 
way, from which genomic DNA samples were extracted as described above. 
Corneal tissues were preserved in RNAlater (Ambion) from which RNA was 
extracted using the Trizol reagent (Invitrogen), following the manufacturers’ 
protocols. Briefly this involved adding 1mL of TRIzol® Reagent per 50–100 
mg of tissue sample then homogenizing the sample by vortexing. The 
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homogenized samples were incubated for 5 minutes at room temperature to 
permit complete dissociation of the nucleoprotein complex and 0.2 mL of 
chloroform were added to each sample. Samples were then mixed 
vigorously by hand for 15 seconds and incubated for 2–3 minutes at room 
temperature, then centrifuged at 12,000x g for 15 minutes at 4°C. The 
aqueous phase where the RNA resides was removed from the sample by 
angling the tube at 45° and pipetting the solution out into a new tube where 
0.5 mL of 100% isopropanol was added. Samples were then incubated at 
room temperature for 10 minutes, and centrifuged at 12,000x g for 10 
minutes at 4°C. The supernatants were discarded and the pellets were 
washed with 1mL of 75% ethanol, briefly vortexed and then centrifuged at 
7500 x g for 5 minutes at 4°C. The wash was then discarded and the RNA 
pellets were left to dry for 5–10 minutes. The RNA pellets were next 
redissolved in RNase-free water by pipetting, then incubated in a water bath 
or heat block set at 55–60°C for 10–15 minutes. RNA samples were then 
stored at –70°C. 
 
2.4 PCR 
2.4.1 Standard PCR 
Oligonucleotide primers were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3/input.htm). DNA was amplified by PCR with a 
final reaction volume of 25µl using 40ng of genomic DNA, 1x PCR buffer 
(Invitrogen), 0.4mM MgCl2, 200µM each dNTPs (Invitrogen), 10picomoles of 
each primer, and 1.0 U Taq DNA polymerase (Invitrogen). PCR amplification 
initiates with a denaturation step at 95°C for 2 minutes followed by 40 cycles 
of 94°C for 30 seconds, annealing temperature for 45 seconds, 72°C for 45 
seconds and ending with a final elongation step at 72°C for 5 minutes. 
 
2.4.2 Hot-shot Master Mix 
Reactions using HotShot master mix (Clent, Lifescience) were carried out in 
a 25µl volume using manufacturer’s instructions, of the hot shot master mix 
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and primers solution using the same primer concentration as section 4.1. 
PCR amplification initiates with an initial denaturation step at 95°C for 12 
minutes followed by 40 cycles of 94°C for 30 seconds, annealing 
temperature for 30 seconds, 72°C for 45 seconds and ending with a final 
elongation step at 72°C for 5 minutes. 
 
2.5 Agarose gel electrophoresis  
PCR products were visualized under ultraviolet light following agarose gel 
electrophoresis. Molecular biology grade agarose powder (Bioline) was 
dissolved in 0.5x TBE and ethidium bromide was added to a final 
concentration of 0.5 µg/ml. Gels of 1.5% concentration were run on 100Volts 
for 40 minutes, then visualised on a Bio-Rad gel documentation system with 
an ultraviolet transilluminator and displayed using Quantity One 1-D analysis 
software (Bio-Rad, Hercules, USA). 
 
2.6 Sanger Sequencing 
PCR product clean-up was carried out using ExoSAP-IT (Affymetrix). 
Purified PCR products were then sequenced using one of the same primers 
designed for the PCR (forward or reverse), or an internal nested primer, 
using dye terminator chemistry with the BigDye terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). A final reaction volume of 10µl was 
subsequently subjected to an initial denaturation step of 96°C for 1 minute, 
followed by 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C 
for 4 minutes. After the sequencing reaction, the products were precipitated 
using 5µl of 125mM EDTA and 60µl of absolute ethanol. Sample tubes were 
centrifuged at 3000 x g for 30 min at room temperature, then spun with 70% 
ethanol at 800 x g for 15min at 4°C. After being dissolved in Hi-Di formamide 
(Applied Biosystems), the sequencing reactions were analyzed using an ABI 
PRISM 3130xl automated capillary sequencer (Applied Biosystems) and 
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checked for changes using Sequencing Analysis v.5.2 (Applied Biosystems) 
and SeqScape v.2.5 (Applied Biosystems) software. 
 
2.7 Homozygosity mapping by SNP array analysis 
500ng of genomic DNA at a concentration of 50ng/µl extracted from both 
Saliva and/or blood from affected patients was anonymously analysed on 
Affymetrix 6.0 high-density SNP microarrays by a commercial company 
(AROS Biotechnologies Ltd, Aarhus, Denmark).  The resulting SNP data 
reformatted into excel files from their original CEL files, were analysed using 
IBDfinder software (http://dna.leeds.ac.uk/ibdfinder/) (Carr et al., 2009) to 
determine the homozygous regions at a genotyping error of 1 in 100, and 
results were visualised and presented using AutoIdeogram 
(http://dna.leeds.ac.uk/AutoIdeogram/) and AgileMultiIdeogram software 
(http://dna.leeds.ac.uk/agile/AgileMultiIdeogram/).  
 
First described in 1987 by Lander and Botstein, homozygosity mapping 
aimed to seek homozygous regions in the genome of affected individuals 
from inbred consanguineous families, with the purpose of discovering 
autosomal recessive gene loci (Lander and Botstein, 1987). Called 
autozygosity mapping later on by Muller and Bishop in 1993, it comprises 
looking at runs of homozygosity in chromosomal regions thought to be 
autozygous or Identical-by-descent (IBD) (Figure 2-1), to map the location of 
disease-causing genes (Mueller and Bishop, 1993). Autozygosity mapping 
has been very successful in identifying disease causing mutations in 
autozygous segments of affected consanguineous families members, even 
in the presence of genetic heterogeneity (Moynihan et al., 1998, White et al., 
2007, Khan et al., 2011, Rehman et al., 2011, Sherva et al., 2011, Logan et 
al., 2014, El-Asrag et al., 2015). 











Figure 2-1: Schematic presentation of the concept of autozygosity 
mapping. The colour coding of haplotypes is depicted by SNPs (or genetic 
markers in general i.e. microsatellites). The common ancestral haplotype 
shown in white is harbouring the recessive mutation (red bar), which is 
transmitted as blocks to the next generations following the crossing over 
events. The consanguineous union in generation three of two individuals 
carrying heterozygous haplotypes leads to the segregation of the two copies 
of the recessive mutation present in the shared haplotype or autozygous 
segment presented as the disease interval. Taken from 
(http://autozygosity.org/about/)  
 
2.8 Whole Exome Sequencing (WES) 
For whole exome capture and next generation sequencing, 3µg of genomic 
DNA was either sent to Otogenetics Corporation (Atlanta, Georgia, United 
States), who provided an average coverage of 30X using SureSelectXT 
Human All Exon V4 reagent (Agilent), or libraries were prepared in-house. 
In-house library preparation (Figure 2-2) began with mechanically shearing 
the DNA. First 3µg of genomic DNA was dissolved in 250µl of 1X Low TE 
Buffer in a 1.5-mL LoBind tube. This was then run on a Covaris Sample 
Preparation System Covaris™ S220 for DNA shearing of a size selection of 
150-200 bp fragments. Next the samples were purified using Agencourt 
AMPure XP beads, and their quality was assessed with 2100 Bioanalyzer by 
loading 1µl of the sample on a Bioanalyzer DNA 1000 chip and visualizing 
the results on Agilent 2100 Expert Software by generating an 
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electrophoregram specific for each sample. The electropherogram should 
show a distribution of a peak size between 150 to 200 nucleotides.  In order 
to repair the ends and achieve blunt-ended fragments with 5’-
phosphorylated ends, 48µl of each sample were mixed with the following 
reagents from the SureSelect Library Prep Kit, ILM (Illumina): 32.2µl  of 
Nuclease-free water, 10µl of 10x end repair buffer, 1.6µl of dNTP mix, 1µl of 
T4 DNA polymerase, 2µl of Klenow DNA polymerase and 2.2µl of T4 
Polynucleotide Kinase. The mix was incubated in a thermal cycler for 30 
minutes at 20°C. After the incubation, the samples were purified using 
Agencourt AMPure XP beads. To 30µl of the purified samples, 11µl  of 
Nuclease-free water, 5µl  of 10x Klenow Polymerase Buffer, 1µl  of dATP 
and 3µl of Exo(-) Klenow were added in order to achieve DNA fragments 
with a 3’-dA overhang, then the mix was incubated in a thermal cycler for 30 
minutes at 37°C. Subsequently, samples were purified and indexing-specific 
paired-end adaptor were ligated by adding to 13µl of the treated DNA 
samples 15.5µl of Nucleas-free water, 10µl of 5x T4 DNA ligase buffer, 10µl 
of SureSelect Adaptor Oligo Mix and 1.5µl of T4 DNA Ligase and incubating 
for 15 minutes at 20°C in a thermal cycler. Next, samples were purified and 
the 15µl of the adaptor-ligated libraries were amplified by mixing 21µl of 
Nuclease-free water, 1.25µl of SureSelect Primer from the SureSelect 
Library Prep Kit, 1.25µl of SureSelect ILM Indexing pre capture PCR reverse 
primer from the SureSelect target Enrichment Kit ILM Indexing Hy b Module 
Box#2, 10µl of 5x Herculase II Rxn Buffer, 0.5µl of 100mM dNTP mix and 
1µl of Herculase II fusion DNA polymerase from the Herculase II Fusion 
DNA Polymerase kit (Agilent). The mix was then loaded into a thermal cycler 
for a denaturation step of 2 minutes at 98°C, amplification step of 30 
seconds at 98°C followed by 30 seconds at 65°C and 1 minute at 72°C, 
repeated for 6 times, and ending with an elongation step of 10 minutes at 
72°C. As a quality control step before incurring the cost of a run on the 
sequencer, samples were purified and assessed for quality and quantity with 
an Agilent 2100 Bioanalyzer instrument. To attain the quality required to 
proceed to sequencing, the electropherogram was required to show a single 
peak in the size range of 250 to 275 bp.  
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For hybridization, 3.4µl of 750ng of amplified DNA (221ng/µl) was mixed with 
40µl of the hybridization buffer prepared by from SureSelect Hyb buffers #1-
4, 2µl of SureSelectXT Human All Exon V4 (4Gb of targeted region) (Agilent) 
capture library mixed with 2µl of 1:3 RNase Block Dilution:water and 5.6µl of 
SureSelect Block Mix prepared by mixing SureSelect Indexing Block #1-3. 
The mix was then incubated for 5 minutes at 95°C and 65°C for 24hours in a 
thermal cycler with a heated lid of 105°C. 
 
After hybridization, hybrid capture selection was achieved by adding the 
remaining volume of approximately 25-20µl of the hybridization mixture to 
the previously prepared and washed magnetic bead solution while 
maintaining the tube at 65°C during the process. Samples of hybrid-
capture/bead solution were incubated on a Nutator mixer for 30 minutes at 
room temperature. Beads and buffer were separated by using a magnetic 
separator, where the supernatant was discarded and beads were 
resuspended in 500µl of SureSelect Wash1 Buffer and incubated for 15 
minutes a room temperature. Beads were washed for a total of 3 washes 
with 500µl of SureSelect Wash2 and recuperated by separating the solution 
from beads on a magnetic separator and dissolved in 30µl of nuclease-free 
water.While attached to the beads, captured library was amplified to add 
index tags, by adding to the 14µl of the beads solution 22.5µl of Nucleas-free 
water, 10µl of of 5x Herculase II Rxn Buffer, 0.5µl of 100mM dNTP mix and 
1µl of Herculase II fusion DNA polymerase from the Herculase II Fusion 
DNA Polymerase kit (Agilent), 1µl of SureSelect ILM Indexing post capture 
forward PCR primer from the SureSelect target Enrichment Kit ILM Indexing 
Hy b Module Box#2, and 1µl of PCR primer Index 1 through Index 16 
(depends on the number of samples) from SureSelect Library Prep Kit, ILM. 
The mix was then loaded into a thermal cycler for a denaturation step of 2 
minutes at 98°C, followed by amplification achieved by cycling through 30 
seconds at 98°C followed by a 30 seconds at 57°C and 1 minute at 72°C, 
repeated for a total of 12 times, and ending with an elongation step of 10 
minutes at 72°C. Next samples were purified and assessed for quality and 
quantity with the Agilent 2100 Bioanalyzer High Sensitivity DNA assay using 
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Bioanalyzer High Sensitivity DNA assay chip and reagent kit. The Amplified 
Capture DNA was required to show an electropherogram with a peak in the 
size range of 300-400 nucleotides before proceeding to sequencing with the 
sample. 6 samples per lane were then pooled using the following formula to 
calculate the volume needed for each sample in order to achieve a 
10nanoMolar of final concentration in a 50 µl final volume: Volume = (V(f) x 
C(f)) / (6*C(i)) where V(f) is the final desired volume of the pool, C(f) is the 
desired final concentration of the pool which is 10nanoMolar and C(i) is the 
initial concentration of each index sample. The pooled samples were then 
passed to the Leeds Sequencing Facility in order to prepare the sample for 


















Figure 2-2: NGS library preparation protocol, adopted from 
SureSelectXT Target Enrichment System for Illumina Paired-End 
Sequencing Library protocol. 
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2.9 RNA sequencing 
RNA libraries for each cornea were generated in-house by the Leeds 
Sequencing Facility using the TruSeq RNA sample preparation Kit v2 
(Illumina). The protocol of TruSeq RNA library preparation consists of nine 
major steps illustrated in figure 2-3 and briefly are: mRNA purification and 
fragmentation, First strand cDNA synthesis, Second strand cDNA synthesis, 
Repairing the ends, 3’ ends adenylation, Adapters ligation, PCR 
amplification, Library validation and Libraries normalization and pooling.  
 
The mRNA purification and fragmentation began by diluting 0.1 to 1µg of 
total RNA diluted in nuclease-free ultra pure water for a final volume of 50ul 
in a 96-well 0.3 ml PCR plate. 50ul of well vortexed RNA purification beads 
is then added to each well in order to bind the polyA RNA to the oligo-dT 
beads and mixed by pipetting up and down before sealing the plate. The 
mRNA was then denatured by incubating the plate for 5 minutes at 65°C, 
then at RT for 5min to allow binding of the mRNA to the beads before 
placing the plate ona magnetic stand at RT for 5 minutes to separate the 
beads from the solution. The supernatant was then discarded and the 
unbound mRNA removed by washing the beads by adding 200µl Bead 
Washing Buffer in each well. The samples were then mixed by pipetting. The 
plate was then placed on the magnetic stand at RT for 5minutes before 
discarding the supernatant containing ribosomal and other non-messenger 
RNA.  Add 50 µl of Elution Buffer was then added in each well and samples 
were mixed by pipetting before sealing the plate and placed on a thermal 
cycler at 80°C for 2 minutes for mRNA elution. For rebinding the mRNA to 
the beads, 50µl of the Bead Binding Buffer were added to each well and 
mixed by pipetting. The mix was then incubated at RT for 5 minutes, and 
placed on a magnetic stand at RT for 5 minutes before discarding the 
supernatant. After removing the plate from the magnetic stand, the beads 
were washed by adding 200µl of Bead Washing Buffer and mixed by 
pipetting. By replacing the plate on a magnetic stand at RT for 5 minutes and 
discarding the supernatant, all the contaminants and the residual rRNA that 
did not bind to the beads were discarded. To the beads, 19.5 µl of Elute 
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Prime, Fragment Mix that contains random hexamers for RT priming and 
serves as the first strand cDNA synthesis reaction buffer was added to the 
samples on the plate after removing it from the magnetic stand. After 
sealing, the plate was incubated at 94°C for 8 minutes then subsequently 
briefly centrifuged. 
 
The second stage consists of first incubating the plate at RT for 5minutes 
while keeping the plate on the magnetic stand while transferring 17µl of the 
supernatant from each well of the plate to the corresponding well of a new 
0.3 ml PCR plate. Then 8µl of the First Strand Master Mix and SuperScript II 
mixture were added and mixed with the samples. The plate is then sealed 
and incubated in the thermal cycler with a pre-heated lid of 100°C for 10 
minutes at b 25°C, 50 minutes at 42°C and 15 minutes at 70°C.  
 
Straight after incubation for first cDNA strand synthesis, 25µl of Second 
Strand Master Mix was added to each sample and the plate was sealed and 
incubated at 16°C for 1 hour, then the plate was left to stand. After bringing 
the plate to RT, the samples were purified using 90µl AMPure XP beads to 
each well, mixed by pipetting and incubated at RT for 15 minutes. The plate 
was then placed on a magnetic stand at RT for 5 minutes and 135µl of the 
supernatant was removed and discarded from each well of the plate. The 
beads were then washed twice with 80% ethanol while maintaining the plate 
on the magnetic stand and the beads were left to dry for 15 minutes after 
discarding all the ethanol supernatant. The beads were re-suspended in 
52.5µl of Resuspension Buffer and incubated at RT for 2 minutes. The plate 
was then place on a magnetic stand at RT for 5 minutes and 50µl of the 
supernatant containing the ds cDNA was transferred to a new 96-well 0.3 ml 
PCR plate.  
 
Stage four of the library preparation consisted of repairing the ends of the 
mRNA strands into blunt ends by adding to the 50µl of ds cDNA in each well 
10µl of Resuspension Buffer and 40µl of End Repair Mix and mixing by 
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pipetting. After the sealing, the plate was incubated at 30°C for 30 minutes. 
The same purification step described in the previous paragraph was 
repeating by adding 160µl well-mixed AMPure XP beads to each sample in 
the plate and washing twice by 80% ethanol. The beads were re-suspended 
in 17.5µl of Resuspension Buffer and incubated at RT for 2 minutes. The 
plate was then place on a magnetic stand at RT for 5 minutes and 15µl of 
the supernatant were transferred to a new 96-well 0.3 ml PCR plate. For the 
3’ends adenylation, 2.5µl of Resuspension Buffer and 12.5µl of A-Tailing Mix 
was added to each well and mixed by pipetting. After sealing, the plate was  
incubated at 37°C for 30 minutes then at 70°C for 5 minutes by choosing the 
pre-heated lid option set to 100°C. 
 
Then the process of ligating the adapters  is performed in order to prepare 
the ds cDNA, for hybridization onto a flow cell by adding 2.5µl of the 
Resuspension Buffer, 2.5µl of  Ligation Mix and 2.5µl of RNA Adapter Index 
to each well of the plate. Gently pipette  and mixing by pipetting, then the 
samples were incubated at 30°C for 10 minutes after sealing the plate. To 
inactivate the ligation, 5µl of the Stop Ligation Buffer was added. By adding 
42µl of AMPure XP beads to each well the first clean-up step previously 
described was initiated. After purification, the beads were re-suspended in 
52.5µl of Resuspension Buffer and incubated at RT for 2 minutes. The plate 
was then place on a magnetic stand at RT for 5 minutes and 50µl of the 
supernatant were transferred to a new 96-well 0.3 ml PCR plate. 
Subsequently another purification was initiated by adding 50µl of AMPure 
XP beads to each well. After purification, the beads were re-suspended in 
22.5µl of Resuspension Buffer and incubated at RT for 2 minutes. The plate 
was then place on a magnetic stand at RT for 5 minutes and 20µl of the 
supernatant were transferred to a new 96-well 0.3 ml PCR plate. For PCR 
amplification, 5µl of PCR Primer Cocktail to each well of the PCR and 25µl of 
PCR Master Mix were added to each well of the PCR plate. The PCR 
amplification step was done on the thermal cycler by incubating first the 
sealed plate at 98°C for 30 seconds and 15 cycles of 98°C for 10 seconds, 
60°C for 30 seconds and 72°C for 30 seconds, followed by 72°C for 5 
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minutes, all done with a pre-heated lid set to 100°C. By adding 50µl of 
AMPure XP beads to each well the first clean-up step previously described 
was initiated.  
 
After purification, the beads were re-suspended in 32.5µl of Resuspension 
Buffer and incubated at RT for 2 minutes. The plate was then place on a 
magnetic stand at RT for 5 minutes and 30µl of the supernatant were 
transferred to a new 96-well 0.3 ml PCR plate. For validating the libraries, 
one quality control analysis was performed, by loading 1µl of resuspended 
construct on an Agilent Technologies 2100 Bioanalyzer using an Agilent 
DNA 1000 chip. The final product should be a band at approximately 260 bp. 
Finally, the concentration of each library was normalized to 10nanoMolar by 
using Tris-HCl 10mM, pH 8.5 with 0.1% Tween 20. For pooling, 10µl of each 
normalized sample library was transferred to a new 0.3ml PCR plate to a 
total volume in each well of 10X the number of combined sample libraries 
and 20–240µl (20µl is the volume of 2 libraries and 240µl the volume of 24 
libraries). Libraries were sequenced on an Illumina HiSeq 2500 instrument. 
 
2.10 Online resources 
Oligonucleotide primers were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3/input.htm). The reference sequence for the 
genes, against which primers were designed, was downloaded from the 
Genome Browser (http://genome.ucsc.edu/). Literature searches for 
candidate genes were done using Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed). The NCBI gene database 
(http://www.ncbi.nlm.nih.gov/gene) was also used to investigate information 
about the gene, the transcript and the corresponding protein. Pubmatrix is a 
tool used to apply a pairwise comparison of specified keywords belonging to 
two different lists, in order to mine the literature in Pubmed and extract all 
the frequency of co-occurrence of both lists (Becker et al., 2003) 
(http://pubmatrix.grc.nia.nih.gov/). 




Figure 2-3: RNA seq library preparation protocol. Adopted from 
TruSeq® RNA Sample Preparation v2 Guide. 
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2.11 Quality Control of NGS data 
The raw Illumina sequencing data reads or fastq files were checked for 
quality using a java based visual interface software called FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). FastQC checks 
for quality control general criteria, most importantly it checks for quality 
scores per sequence, GC content, adapter dimer contamination and 
duplication levels. Qualimap (Garcia-Alcalde et al., 2012) was used to 
examine the sequencing alignment data in BAM format files by using the 
default settings. Qualimap (http://qualimap.bioinfo.cipf.es/) is a quality 
control application written in Java and R languages; it provides both a 
graphical user interface as well as a command line interface.  
 
2.12  Whole Exome Sequencing 
WES analysis was performed using the commands listed in Appendix 1. 
WES raw data was aligned against the human genome reference sequence 
(version hg19) using the Burrows-Wheeler Aligner (BWA) (Li and Durbin, 
2009) (http://bio-bwa.sourceforge.net/) in order to create SAM files. The 
major indexing algorithms mainly used in alignment programs are hash table 
and suffix tree. Unlike BLAST and Novalign that use the Hash table 
algorithm, SOAP2, Bowtie and BWA adopt the suffix tree or the FM-indexing 
algorithm (Yu et al., 2012). The FM-index method (Full-text index in Minute 
space), is a compressed full-text substring index based on the Burrows-
Wheeler Transform (BWT) to index the reference genome. This method 
searches for inexact matches by using a backtracking strategy (Li and 
Durbin, 2009). Furthermore, BWA generates a mapping quality score for 
each read, with higher scores corresponding to more accurate alignment, 
and indicating Phred-scaled probabilities for incorrect mapping (Yu et al., 
2012). In addition to being considered an accurate aligner for short and long 
sequencing reads,  BWA is equally regarded to be time and memory efficient 
(Li and Durbin, 2009).   
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Conversion from SAM to BAM format files as well as sorting, indexing and 
viewing were accomplished using Samtools (Li et al., 2009) 
(http://samtools.sourceforge.net/). Picard tools 
(http://broadinstitute.github.io/picard/) was used to remove duplicates.  Local 
realignment, calling variants, depth of coverage and recalibration were 
achieved using the Genome Analysis ToolKit (GATK) software package 
(McKenna et al., 2010) (https://www.broadinstitute.org/gatk/). The Integrative 
Genomics Viewer (IGV) (Robinson et al., 2011) 
(https://www.broadinstitute.org/igv/) was used as an alignment visualisation 
tool when needed.  
 
Variants were filtered out from VCF files of all the samples if they were found 
to be abundant - with a specific Minor Allele Frequency (MAF) greater than 
2% - in a set of controls of the same ethnicity as the patient. Then, the VCF 
files of patients of Pakistani and Indian origin were compared against the 
Born in Bradford (BiB) (www.borninbradford.nhs.uk/) database using an in-
house perl script developed by David Parry (University of Leeds) 
(http://sourceforge.net/projects/vcfhacks/), all the alleles with MAF > 5% in 
BiB were filtered out from these particular samples of Indian and Pakistani 
origin.  BiB is a database consisting of a collection of more than 3000 UK 
exomes to which access was granted following a collaboration on the project 
with Ian Carr (University of Leeds). On the other hand, from the WES of the 
8 Druze controls and 4 Maronites controls collected, a list for each ethnicity 
was created containing all the alleles carried by 50% of the controls of each 
set. Subsequently, all the VCF files of Lebanese Druze and Lebanese 
Maronite origin patients were compared against each corresponding list 
using a “highlight-similarities” perl script developed specifically for this study 
(Appendix 2) and all the shared alleles between the 50% alleles list and the 
patient VCF file were removed. In addition, this same perl script was used 
throughout this project to highlight shared genes/variants between excel 
lists.  
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The remaining genetic variants detected in the VCF file output of GATK were 
functionally annotated using the ANNOVAR software (Wang et al., 2010, 
Yang and Wang, 2015) (http://www.openbioinformatics.org/annovar/). 
ANNOVAR software annotates using the information of several sources 
described below in order to perform the following tasks: 
Gene-based annotation is to identify whether the SNPs or CNVs are 
functional by determining from several downloaded databases whether the 
SNP cause protein coding changes and determine which amino acids are 
affected. The databases downloaded for this analysis are the following: 
- refGene hg19 of FASTA sequences for all annotated transcripts in 
RefSeq Gene. 
- knownGene hg19 of FASTA sequences for all annotated transcripts in 
UCSC known gene 
- ensGene hg19 of FASTA sequences for all annotated transcripts in 
ENSEMBL gene 
All the three databases are used to annotate all the variants in the VCF files 
and to report the regions of occurrence of these variants whether it’s in the 
intronic, exonic or non-coding RNA regions and associating gene names to 
the appropriate regions. 
 
Filter-based annotation is to identify alleles reported previously in public 
databases with their corresponding allele frequencies (Kenna et al., 2013), 
and to calculate based on downloaded algorithms the pathogenicity and 
conservation scores of every SNP. The hg19 databases and algorithms 
downloaded for this purpose are the following: 
- Whole-exome SIFT: “Sorting tolerant from Intolerant” or SIFT 
algorithm predicts whether the amino acid substitution affects the 
protein function by looking at the important conservation  positions of 
the protein sequence (Kumar et al., 2009). SIFT scores range from 0 
to 1 with scores < 0.05 are considered damaging.  
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- Polyphen2 with HDIV and HVAR functions. Polyphen2 HVAR 
distinguishes mutations with severe effects and used for diagnostics 
of Mendelian diseases.  Polyphen2 HDIV used when evaluating rare 
alleles at loci possibly involved in complex phenotypes. The scores of 
“probably damaging” mutations range from 0.9 to 1, “possibly 
damaging” from 0.4 to 0.9 and “benign” from 0 to 0.4 (Adzhubei et al., 
2010, Adzhubei et al., 2013). 
- LRT or Likelihood Ratio Test, similar to SIFT and Polyphen, identifies 
in a protein coding sequence the deleterious mutations affecting 
highly conserved amino acids and represents three possible 
predictions: D for deleterious, N for neutral or U for unknown (Chun 
and Fay, 2009). 
- Mutation Taster similar to SIFT, Polyphen and LRT. It presents four 
different possibilities in predicting the values: A for disease causing 
automatic, D for disease causing N for neutral and P for 
polymorphism automatic (Schwarz et al., 2010). 
- MutationAssessor it classifies the variants into two groups: predicted 
functional (H for high and M for medium effects) and predicted non-
functional (L for low and N for neutral effects) (Reva et al., 2011). 
- FATHMM or Functional Analysis through Hidden Markov 
Models similar to SIFT and Polyphen. The scores generated by 
FATHMM less than -1.5 are considered as D for damaging otherwise 
the score is T for tolerated (Shihab et al., 2014). 
- Developed by Coco Dong MetaSVM and MetaLR fill out missing 
scores from all the previously mentioned annotation algorithms by 
imputing for whole-exome variants. Their scores range from 0 to 1, 
with higher scores being more deleterious 
(http://annovar.openbioinformatics.org/en/latest/user-guide/filter/#-
metasvm-annotation). 
- GERP++ predicts conservation scores for coding variants, with the 
higher scores being the most conserved sites (Davydov et al., 2010). 
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- PhyloP (Cooper et al., 2005) and SiPhy (Garber et al., 2009) similar 
to GERP++ and based on multiple alignments of 46 genomes and 29 
mammals genomes respectively. Higher scores correspond to more 
conserved.  
- SIFT, Polyphen2 HDIV, Polyphen2 HVAR, LRT, MutationTaster, 
MutationAssessor, FATHMM, MetaSVM, MetaLR, GERP++, PhyloP 
and SiPhy scores are downloaded through the non-synonymous 
single-nucleotide variants (nsSNVs) functional prediction and 
annotation dbNFSP database version 2.6 (Liu et al., 2011, Liu et al., 
2013, Liu et al., 2015a). 
- esp6500siv2 is a database from the EVS (Exome Variant Server) that 
contains exome sequencing variants from 6500 exomes for the 
NHLBI-ESP (NHLBI-Exome Sequencing Project). It includes the indel 
calls and the chrY calls and is used to identify the variants’ allele 
frequency in the VCF files (http://evs.gs.washington.edu/).  
- Exac03 or the Exome Aggregation Consortium version 0.3 contains 
exome sequencing data of 65000 exome for: AFR (African), AMR 
(Admixed American), EAS (East Asian), FIN (Finnish), NFE (Non-
finnish European), OTH (other), SAS (South Asian)) 
(http://exac.broadinstitute.org/).  
- 1000g2014oct: represents alternative allele frequency data in 1000 
Genomes for several populations: ALL, AFR (African), AMR (Admixed 
American), EAS (East Asian), EUR (European), SAS (South Asian) 
(http://www.1000genomes.org/). 
- dbSNP 138 is a database used to identify the previously reported 
variants and to report their specific rs number (Sherry et al., 2001) 
(http://www.ncbi.nlm.nih.gov/SNP/).  
- CLINVAR or Clinical Variation database represents information about 
variants clinical significance with their corresponding variant disease 
name. The variant clinical significance annotation includes: unknown, 
untested, non-pathogenic, probable-non-pathogenic, probable-
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pathogenic, pathogenic, drug-response, histocompatibility, other 
(Landrum et al., 2014) (http://www.ncbi.nlm.nih.gov/clinvar/).  
- CADD or Combined Annotation Dependent Depletion tool generates 
a score to each possible mutation in the human genome (except 
Indels and CNVs) by integrating several annotations into a Cscore 
(Kircher et al., 2014) (http://cadd.gs.washington.edu/). 
The ANNOVAR output file annotated using all these databases and 
algorithms, is a text file that is opened and modified using Microsoft excel. 
Through the sort and filter function of Microsoft excel, variants with a minor 
allele frequency (MAF) of 2% or greater in dbSNP138, were filtered out.  
 
2.13 PLINK/SEQ 
One KC aligned BAM file from each family was used in order to carry out an 
association analysis of variants present in  KC familial samples compared to 
controls, using the open source software PLINK/SEQ 
(https://atgu.mgh.harvard.edu/plinkseq/). PLINK/SEQ is an open source 
library for working with human genetic variation data, using the R interface 
for statistical computing.  Exome sequences from 24 unrelated KC cases 
were compared to 72 controls, giving a 1:3 ratio. BAM files of all the 96 files 
were pooled together using the UnifiedGenotyper and LiftOverVariants,  
functions of GATK in order to generate a combined VCF file. The VCF hacks 
package was then used to translate, annotate and filter the pooled VCF file. 
The subsequent VCF file was inputted into PLINK/SEQ using a series of 
commands (Appendix 4). Variants were analysed both pooled by gene and 
as individual rare variants.  
 
2.14 Transcriptomics 
Before alignment, adapter contamination was trimmed from RNA-seq fastq 
file reads using the python package Cutadapt 
(https://code.google.com/p/cutadapt/) (Martin, 2011). RNA-seq reads were 
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aligned to human genome version GRCh38p2 using a bowtie2-based aligner 
and splice junction mapper, TopHat2 (Kim et al., 2013) 
(http://ccb.jhu.edu/software/tophat/index.shtml). The reference GTF file used 
was the gencode GTF –release 22 (GRCH38p2) which contains the 
comprehensive gene annotation on the reference chromosomes, scaffolds, 
assembly patches and alternate loci. For novel gene/exon discovery, the 
RNA-seq Unified Mapper (RUM) (Grant et al., 2011) 
(http://cbil.upenn.edu/RUM/) was used (List of commands – Appendix 3).  
 
Differential expression analysis was conducted using the Cufflinks software 
(http://cole-trapnell-lab.github.io/cufflinks/), part of the Tuxedo set (Trapnell 
et al., 2012), and visualized using the bioinformatics tool CummeRBund 
(http://compbio.mit.edu/cummeRbund/) (List of commands – Appendix 3). 
The lists of differentially expressed genes were subjected to pathway 
analysis using the DAVID bioinformatics suite (http://david.abcc.ncifcrf.gov/) 
for functional enrichment and to discern the underlying biological processes. 
KEGG pathway analysis (Ogata et al., 1998) (http://www.genome.jp/kegg/), 
REACTOME (http://www.reactome.org/) (Joshi-Tope et al., 2003) and 
WikiPathways (http://www.wikipathways.org/index.php/WikiPathways) (Pico 
et al., 2008), were similarly used as prediction tools to assign pathways and 
functions to genes highlighted by RNA-seq analysis. 
 
For differential expression results, EdgeR - a count-based tool - was used 
for further verification. EdgeR is a freely available bioconductor software 
package that uses replicated count data to examine differential expression 
between a set of RNA-seq data 
(http://www.bioconductor.org/packages/release/bioc/html/edgeR.html) 
(Robinson et al., 2010). Jointly, Subreads package (Liao et al., 2013) 
(http://bioinf.wehi.edu.au/subread/) with its specific FeatureCounts program 
(Liao et al., 2014) was used to count the already mapped RNA-seq reads 
(http://bioinf.wehi.edu.au/featureCounts/) and create a count matrix before 
inputting it into EdgeR for differential expression analysis (List of commands 
– Appendix 3-4). Cummerbund, EdgeR and Subreads were run on R 
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platform (version R 3.1.1 GUI 1.65 Snow Leopard build) for statistical 
























- 68 - 
 
3 Screening for rare Mendelian variants of major effect in 
KC families 
3.1 Introduction 
The pathogenesis of the majority of KC is unknown but genetics is believed 
to play a significant role (Section 1.4.9). The evidence for a genetic 
component to KC comes from the increased risk of first-degree relatives and 
twin studies (Valluri et al., 1999, Tuft et al., 2012) (Wang et al., 2000, 
Rabinowitz, 2003, Burdon and Vincent, 2013) (section 1.4.9). In addition, the 
variable incidence of KC in different populations and ethnicities could also be 
a result of different genetic backgrounds (Section 1.4.2). However, the most 
striking evidence for a genetic cause of KC is the high rates of this disease 
in countries and communities that practice consanguinity or endogamy 
(Pearson et al., 2000). The incidence of KC in the general population is 50 
per 100,000 (reviewed by )(Rabinowitz, 1998) but this rises to 2340/100,000 
in Jerusalem (Millodot et al., 2011), to 2300/100,000 in India (Jonas et al., 
2009), to 830/100,000 in Shahroud-Iran (Hashemi et al., 2014) and to 
3333/100,000 in  Lebanon  (Waked et al., 2012). This data raises the 
possibility that a recessive Mendelian form of KC exists and investigating 
this hypothesis is the focus of this chapter. 
 
3.2 Results 
3.2.1 Families collection 
The centre of this study was a collection of fifteen KC families from a variety 
of ethnic backgrounds including Indian, Pakistani and Lebanese (Druze and 
Christian Maronite). The five families of Pakistani origin are all living in the 
UK (Figures 3-1 and 3-2). 










































































Figure 3-1: Pakistani family pedigrees (1). SS1F is a two generation KC family. The patients that were sampled are: V:2 or 
RP79; V:9 or YL82; V:10 or AM; V:11 or FL; V:12 or IL and V:18 or ML81. 






































































Figure 3-2: Pakistani family pedigrees (2). Pedigrees of four Pakistani families included in this study. AR1F is a two generation KC family 
and SC1, SC2 and SC3 present single KC cases originating from consanguineous marriages. The question mark in the AR1F pedigree 
represents the patients with borderline Keratoconus, i.e. they do not show KC symptoms but they harbour some corneal irregularities. 
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Family SS1F (Figure 3-1) was recruited by Dr Salina Siddiqui (The Eye 
Department, St. James’s University Hospital, Leeds). The pedigree’s 
structure shows 10 affected individuals, four of whom were born from 
consanguineous marriages (RP79, YL82, FL and IL). In addition, the the 
children of IL and FL (VI:4, VI:5 and VI:6) patients were below the age of 10 
at the time of collection and didn’t present any signs of visual impairments. 
The autosomal recessive mode of inheritance seems to best describe the 
transmission of the disease in the family.  
 
Family AR1F (Figure 3-2) was recruited by Dr Aine Rice (formerly of the Eye 
Department, St. James’s University Hospital, Leeds). This family has five 
affected members (IV-1, IV9, IV15, IV16 and V3) but only one is knowingly 
born from a consanguineous marriage (V:3) and this patient had a very 
severe case of KC and was grafted as a child. The mode of inheritance in 
this family is not clear and could be consistent with a recessive, dominant or 
even an x-linked mode of inheritance given that only males are affected and 
some of the females have forme-fruste. 
 
The three single case families (SC1, SC2 and SC3) (Figure 3-2) are all from 
different consanguineous marriages and were recruited by Dr Aine Rice 
(formerly of the Eye Department, St. James’s University Hospital, Leeds).  
 
One Indian family was included in this study, Family KF (Figure 3-3). This 
family was obtained from Professor Govindasamy Kumaramanickavel 
(Narayana Nethralaya, Bangalore, India). This family has three affected 
siblings IV:1, IV:2 and IV:3 originating from consanguineous unaffected 
parents, suggesting a recessive mode of inheritance. 
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Figure 3-3: KF family pedigree. The pedigree shows three patients in generation IV (IV-1, IV-2 and IV-3) originating from a 
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The Lebanese families were recruited by the author, in collaboration with 
Lebanese ophthalmologists, during a field trip to Lebanon (Figure 3-4). The 
Druze families were diagnosed by Dr. Bassam Barakat (Consultant 
Ophthalmologist, Mount Lebanon Hospital, Hazmieh, Lebanon) unless 
stated otherwise. Six Druze families were recruited: F2, F9, F10, F11, F12 
and F13 (Figure 3-4). The Druze families were of particular interest since the 
Druze population is famous for endogamy. This community follows social 
customs that turn it into a transnational isolate, favouring marriage from 
within the same religion, forbidding admixture with other populations and 
firmly closing the religion to new adherents (Shlush et al., 2008). In fact, the 
majority of the Druze families collected in this study were not 
consanguineous; however, most of the parents in the families (or 
grandparents) share the same surnames, indicating that they could share 
more distant ancestors in common. 
 
Family F2’s diagnosis was ascertained by Dr. Ghassan Chayya (formerly at 
Department of Ophthalmology, Al Watani Hospital, Aley, Lebanon). F2 is a 
two-generation family with four affected members and an ill-defined mode of 
transmission. The family is not known to be consanguineous but it belongs 
to an endogamous community. The parents (I:1 and I:2) are from the same 
village and share the same surname. 
 
Family F9 is a four-generation pedigree with five affected members (III:1, 
III:2, III:3, III:6, III:8) and one borderline KC case (III:7). Three of the younger 
unaffected individuals in this family (III:3, III:4, and IV:1) are below the age of 
onset for disease so they may potentially develop KC in the future. Parents 
of generation I and generation II belong to the same village. The pedigree of 
family F9 suggests an autosomal recessive mode of inheritance.  
 


































































































































































Figure 3-4: Pedigrees of Druze Lebanese KC families. Pedigrees of Lebanese Druze families F2, F9, F10, F11, F12 and F13. The light 
grey symbol in the pedigrees designates individuals with borderline KC.  
- 76 - 
 
F10 (Figure 3-4) is a four-generation pedigree, with two affected members 
(III:4 and III:5). Members III:2 and IV:1 are reported to have KC but access 
to these individuals’ medical records was not possible. All members of 
generation IV (except IV:1) were preadolescent at the time of recruitment so 
their unaffected KC status is not confirmed. The mode of inheritance is not 
well defined. 
 
The pedigree of family F11 (Figure 3-4) shows five affected individuals in 
two-generations (I:1, I:2, II:2, II:3 and II:4). Individual II:5 is a borderline KC 
case and II:6 is too young to diagnose. Parents I:1 and I:2 are distantly 
related and share one great grandparent. Thus it is possible that the mode of 
inheritance is autosomal recessive with the appearance of dominant 
inheritance. 
 
Family F12 (Figure 3-4) is a three-generation pedigree with three affected 
patients (III:2, II:2 and II:4). The mode of inheritance of family 12 is not well-
defined.  
 
Family F13’s pedigree (Figure 3-4) is a three-generation pedigree with 5 
affected members (II:2, III:4, II:6, III:9 and III:13) and two borderline KC 
cases (III:1 and III:5). This pedigree shows a dominant mode of inheritance 
with reduced penetrance but as this family belongs to an endogamous 
ethnicity a recessive mode of inheritance is also possible. 
 
Three Lebanese families of Christian Maronite origins were also collected 
(Figure 3-5). Family F6’s diagnosis was ascertained by Dr Fadi Geagea 
(Formerly at the Ophthalmology department of Saint Joseph University and 
the American University of Science and Technology). Family F6’s pedigree 
(Figure 3-5) shows four affected patients (III:2, III:3, III:7 and III:8) and the 
mode of inheritance is consistent with autosomal recessive. 
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Family F7’s diagnosis was ascertained by Dr. Naji Waked (Department of 
Ophthalmology, Saint Joseph University, and Hotel-Dieu de France Hospital, 
Beirut, Lebanon). Family F7 (Figure 3-5) has two affected patients (II:1 and 
II:3) with unaffected parents indicating an autosomal recessive mode of 
inheritance. 
 
Family F8’s diagnosis was ascertained by Dr. Naji Waked (Department of 
Ophthalmology, Saint Joseph University, and Hotel-Dieu de France Hospital, 
Beirut, Lebanon). Family F8 (F 3-5) is a four generation pedigree with three 
affected individuals (III:2, III:4 and II:6). Unfortunately, a DNA sample for II:6 
was not available. The mode of inheritance of this pedigree is consistent with 
autosomal recessive. 
 
For all the recruited Lebanese families, informed signed consent was 
obtained and blood was collected. The DNA extraction was performed by the  
author in the laboratory of Dr. Gretta Abou Sleymane (American University 
of Science and Technology, Beirut, Lebanon) (Section 2.2.1). 
 
 












































































Figure 3-5: Pedigrees of Christian Maronite Lebanese KC families. Pedigrees of the 
Christian Maronite Lebanese families F6, F7 and F8. 
F8 
Materials and Methods 
Ethnicity: Asian, Pakistani, UK residents 
Ethnicity: Lebanese, Druze 
Ethnicity: Lebanese, Christian Maronites 
 Keratoconus (KC) is a non-inflammatory, progressive thinning of the cornea resulting 
in a conically shaped protrusion. The conical distortion of the cornea results in irregular 
astigmatism and myopia leading to visual impairment requiring corneal transplantation in 
severe cases. The incidence of KC is around 1/2000. KC genetics is poorly understood. 
This project aims to identify the genetic causes of KC using a cohort of familial KC cases. 
 Our cohort consists of 6 Lebanese Druze families, 3 Lebanese Christian Maronite 
families and 6 South Asian families; all belonging to ethnic backgrounds where 
consanguinity and endogamy are common. Patients from consanguineous families were 
subjected to autozygosity mapping. At least one member of each family was analysed by 
whole exome sequencing on the Illumina Genetic Analyser.  
 We identified a large region of homozygosity shared by siblings with KC on 
chromosome 3q27-29 in one Lebanese Druze family. Our whole exome sequencing 
strategy also highlighted apparent enrichment of heterozygous variants for ZNF469 (Zinc 
Finger Protein 469) in the 12 KC patients that were analysed so far. Further 12 KC 
patients are in the process of analysis.  
 The analyses of exome sequencing at the potential new locus and elsewhere are 
ongoing. The identification of heterozygous ZNF469 variant enrichment in recessive 
families was unexpected. A fuller analysis of these findings may provide new insights into 








•  Keratoconus = Kerato (cornea) + conus (cone shaped) 
•  Incidence: 1/2000  
   (depends on the ethnicity). 
•  Bilateral, often asymetric. 
•  Non-inflammatory corneal- 
   thinning disorder. 
•  Affects patients mostly in late teens early twenties. 
•  Progresses and evolves throughout life to stabilize in the third or fourth 
decade. 
•  Characterized by progressive stromal thinning of the cornea and cone 
formation. 
•  Causes distorted vision due to increase in myopia and irregular 
astigmatism. 
•  Primary leading cause to corneal transplantation in developed countries 
•  KC’s genetics is poorly understood. 
•  No specific pathways have been shown to be directly related to KC 
pathogenesis; several mechanisms may contribute to the onset and 
progression of KC: the apoptosis of stromal cells, enzyme/inhibitor 
imbalances and oxidative damage. 
•  KC’s etiology remains unclear. 
To identify the genetic causes of KC in a cohort of familial KC cases from 
different ethnicities mostly known for high consanguinity and endogamy 
rates. 
KC is unlikely to have a classical recessive mode of transmission caused 
by autozygosity in our families cohort. 
•  Patients:  Diagnosed following topographical examination. 
•  Autozygosity mapping: Affymetrix 6.0 high-density SNP microarrays  
analysed on IBDfinder1 and AgileMultiIdeogram. 
•  High-Throughtput sequencing: Genomic DNA was captured using 
SureSelect capture Kit Agilent 4 and ran on Illumina HiSeq 2500. 
•  Bioinformatics: Reads were aligned using BWA and processed using 
GATK, Picard tools, SamTools and annotated using ANNOVAR2. 
•  PlinkSeq3: Used for association analysis on KC patients vs controls. 
1. Autozygosity Mapping 
for Family 2 revealed a 
homozygous region on 
C h r o m o s o m e 3 a t 
3q27-29. 
2. Apparent enrichment of ZNF469 was detected in the initial 12 KC NGS 
data. 
We then performed association analysis of ZNF469 using PlinkSeq on 16 
KC patients (from 15 different families) against 16 controls. The results 
failed to show significance (p=0.0588235) for an enrichment of ZNF469 
variants in our familial KC cohort. 
 
3. Autozygosity mapping of the families described here did not show any 
large regions (>1Mb) associated with Keratoconus.  





Determining the Genetic Basis of Familial Keratoconus by Autozygosity Mapping and Whole Exome Sequencing 
 




T h e W h o l e E x o m e 
Sequencing  analysis at 
ch 3q27-29 in Family 2 
members did not reveal 
any causative gene(s) 








Future directions:  
•  Increase the number of controls for a higher association significance. 
•  Transcriptome analysis and gene expression profiling on wild type 
corneas as well as on KC corneas. 
•  Perform pathway analysis. 
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3.2.2 The search for rare recessive alleles causing KC 
The families ascertained for this study were all consistent with an autosomal 
recessive mode of inheritance given their pedigree structure and/or the 
endogamous population from which they originated. These families were 
therefore used to try and identify recessive alleles responsible for KC using a 
combination of autozygosity mapping and WES (section 1.5). Autozygosity 
mapping was performed using SNP microarray genotyping and the resulting 
data was analyzed using IBDfinder, MultiIdeogram and AutoIdeogram 
(Section 2.7). WES was outsourced to Otogenetics Corporation (Atlanta, 
Georgia, United States) for a few samples but the majority of the samples 
were processed by the author and run on the Illumina HiSeq 2000/2500 
(Section 2.8). WES fastq files were checked for quality using FastQC 
software (Section 2.11). An example of the quality report is shown in figure 
3-6.  
 
Samples were deemed to have passed quality control (QC) if the mean of 
the phred scores across all bases and sequences is above 30, and all the 
samples analysed in this study were above this threshold. The fastq files for 
each sample were then aligned to the reference human genome (Section 
2.12). The aligned sequence file is called a bam file and this data was 
subjected to a further stage of QC using the qualimap application to assess 
the alignment quality of the bam file (Section 2-11). Figure 3-7 represents 
one example of a quality control report of the bam file of sample 2-3. The 
main criteria on which the quality report is based on are: the percentage of 
mapped reads, the general error rate and the mean mapping quality. There 
is no specific threshold for these criteria, instead this analysis creates a 










Figure 3-6: Example of the quality control report of the fastq file of sample 2-3. a) A box 
plot of the quality scores (Phred) obtained across the 100bp of sequence generated during the 
run. The red line shows the median and the yellow boxes the interquartile range and the 
whiskers show the range. The (y) axis represents the Phred scores. A Phred score of 30 
indicates 99.9% accuracy. b) Represents quality score distribution over all sequences. The (y) 
axis represents the number of sequence reads. 
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 Sample 2-3 
Number of reads 68,989,763 
Mapped reads  67,986,487 (98.55%) 
Unmapped reads  1,003,276 (1.45%) 
Paired reads  67,986,487 (98.55%) 
Mapped reads, only first in pair  34,052,587 (49.36%) 
Mapped reads, only second in pair  33,933,900 (49.19%) 
Mapped reads, both in pair  67,707,895 (98.14%) 
Mapped reads, singletons  278,592 (0.4%) 
Read min/max/mean length  100 / 100 / 100 
Clipped reads  736,561 / 1.07% 
Duplicated mapped reads  15,486,367 / 22.45% 
Duplication rate  20.33% 
GC Percentage 47.3% 
Mean Mapping Quality 48.2 



















Figure 3-7: Qualimap report of the quality of sample 2-3 aligned data. a) Table presenting the 
basic quality information and statistics of the aligned sample. b) Plot showing the mapping quality 
distribution across the reference. 
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A critical QC step for an aligned sample (Bam file) is the information on the 
sequencing depth of coverage. This information was acquired using GATK 
to align the sample file against the genomic regions captured during the 
preparation of the WES library (Section 2.8). Table 3-1 represents the depth 
of coverage statistics of sample 2-3 and data for other samples can be found 
in appendix 5. 
Table 3-1: Coverage statistics of sample 2-3 for WES targets generated by 
GATK. This table represents the percentage of bases targeted by the WES capture 
reagent covered in the aligned sequence of sample 2-3. 
 
Finally, the average sequencing coverage of the whole sample was 
calculated using GATK (command displayed in appendix 1.7). Table 3-2 
summarizes the average depth of coverage for all the samples sequenced  
along with the name of the sequencing facility used to generate the data and 
the sequencing platform used. 
Table 3-2: Sequencing details of all the samples included in this study. 
This table shows the sample numbers of the samples sequenced along with 
the identifier of the family they belong to, the sequencing facility responsible 




Family Sequencing facility Platform Coverage 
B1 AR1F Otogenetics Illumina 2000 33.30X 
B2 AR1F Otogenetics Illumina 2000 28.98X 
ASD433 AR1F NGS facility at UOL Illumina 2500 77.69X 
ASD434 AR1F NGS facility at UOL Illumina 2500 60.81X 
IL SSF Otogenetics Illumina 2000 40.22X 
FL SSF Otogenetics Illumina 2000 16.54X 
RP79 SSF NGS facility at UOL* Illumina 2500 65.52X 
YL82 SSF NGS facility at UOL Illumina 2500 77.08X 
ML81 SSF NGS facility at UOL Illumina 2500 60.81X 
AM SSF NGS facility at UOL Illumina 2500 77.07X 
SC1 SC1 Otogenetics Illumina 2000 80.50X 
SC2 SC2 Otogenetics Illumina 2000 72.86X 
SC3 SC3 Otogenetics Illumina 2000 58.88X 
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2-3 F2 NGS facility at UOL Illumina 2500 63.85X 
2-5 F2 NGS facility at UOL Illumina 2500 57.63X 
6-1 F6 NGS facility at UOL Illumina 2500 82.36X 
6-3 F6 NGS facility at UOL Illumina 2500 65.95X 
6-10 F6 NGS facility at UOL Illumina 2500 82.55X 
7-1 F7 NGS facility at UOL Illumina 2500 61.89X 
7-2 F7 NGS facility at UOL Illumina 2500 82.55X 
8-1 F8 NGS facility at UOL Illumina 2500 67.22X 
8-2 F8 NGS facility at UOL Illumina 2500 84.24X 
9-1 F9 NGS facility at UOL Illumina 2500 60.80X 
10-1 F10 NGS facility at UOL Illumina 2500 79.51X 
10-2 F10 NGS facility at UOL Illumina 2500 58.98X 
11-3 F11 NGS facility at UOL Illumina 2000 79.05X 
11-4 F11 NGS facility at UOL Illumina 2000 64.75X 
12-1 F12 NGS facility at UOL Illumina 2000 56.66X 
13-1 F13 Otogenetics Illumina 2000 35.27X 
13-3 F13 Otogenetics Illumina 2000 36.53X 
KF50 KF** - - 103.56X 
KF51 KF - - 83.96X 
KF52 KF - - 82.28X 
KF53 KF - - 89.49X 
KF54 KF - - 91.97X 
* NGS facility at UOL is the Next Generation facility at the University of Leeds 
** KF family data was sent by collaborators and not generated by the author.  
 
Following all these QC checks, the data from the aligned files were analysed 
by various tools to enable variant calling and recalibration (pipeline 
described in Appendix 1). This generates a VCF file for each sample, which 
was annotated using ANNOVAR software (Section 2.12). The output files of 
ANNOVAR are excel lists (termed raw lists) which underwent further filtering 
using excel to generate the final variant lists (termed the working lists) for 
each sample. First, all the intronic and intergenic variants were removed 
from the raw excel file. The resulting list was then divided in two. The first list 
included all the ncRNAs (non-coding RNAs), UTRs (Untranslated regions), 
upstream and downstream variants for future studies; the second list 
included all the exonic and splicing variants and represented the working 
excel sheet for this study. This filtering pipeline is shown in Figure 3-8. 




Two additional lists were generated to enable further filtering of the working 
variant lists. The first list, called sequencing artefacts, combined all the 
shared variants between non-KC samples sequenced alongside the KC 
samples on the same Illumina sequencing run. The second list, called the 
ethnicity specific polymorphism list, comprised all the variants shared 
between controls from the same ethnic background as the KC samples. Two 
different ethnicity specific polymorphism lists were generated for the Druze 
and Maronites Lebanese populations. A similar polymorphism list was 
generated for the Pakistani samples using data obtained from the BiB 
database (Section 2.12).  
 
Annovar output:  
Raw Excel List of all 
Variants 









Excel list of all 
non-coding 
variants 
Excel list of all Exonic 
and splicing variants 
Figure 3-8: Generation of a working excel list of variants. From the 
ANNOVAR output file at the end of WES sequencing analysis, a working excel 
list is generated by filtering out all the intergenic, intronic, ncRNAs, UTRs, 
upstream and downstream variants and leaving only the exonic and splicing 
variants. 
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All of the working excel sheets underwent a systematic filtering pipeline 
combining the autozygosity mapping data and the WES data. Although the 
original rationale for this study was to map a rare recessive homozygous 
allele, alternative models were also investigated. Figures 3-9, 3-20 and 3-21 
represent the workflows for all the different filtering strategies utilised in this 
study. 
 
Figure 3-9 describes the filtering strategy applied to the working excel sheets 
in order to screen for potential alleles with large effect sizes and a 
homozygous recessive mode of inheritance. For this model, all the variants 
with a MAF (Minor Allele Frequency) higher than 2% were filtered out, along 
with all the heterozygous variants, synonymous and non-coding variants. 
The resulting list was then compared against the list of artefacts and 
everything shared between the two lists was removed. In addition, all the 
polymorphisms identified in samples from the same ethnicity were removed. 
These polymorphisms were considered as the SNPs that appeared in more 
than 50% of the samples belonging to the same ethnicity.  
 
Although all the data presented below for each family is based on the full 
dataset, the data was not generated in one go. At the time that this study 
was initiated, WES was still quite expensive and so samples were sent in a 
sequential manner as a cost saving exercise. Similarly, SNP data was often 
generated after the WES on key individuals to try and filter variants and not 
as a locus mapping tool as is often the case for gene identification studies. 
 








Excel list of all exonic and splicing variants 
Filter out changes with MAF>= 2% on 1000g OR 
esp6500si OR exac03 
Filter out all the common polymorphisms specific to the 
ethnicity of the sample 
 
Filter out all the heterozygous variants 
Excel list of homozygous recessive functional 
variants 
Filter out all the synonymous and non-coding variants 
Filter out variants outside the regions of homozygosity  
Filter out all the artefactual variants by comparing 
against list of artefacts 
Figure 3-9: Filtering strategy for homozygous recessive hypothesis. The working 
excel file generated from ANNOVAR undergoes a series of filtering steps by removing 
any allele with a (Minor Allele Frequency) MAF>=2%, common polymorphisms specific 
to the same ethnicity, the artefactual variants, the synonymous and non-coding 
variants and all the heterozygous variants. In addition, all the variants falling outside of 
the autozygous regions were filtered out where autozygosity mapping data was 
available. 1000g is the database for the 1000 genome project, esp6500si is the 
database for the exome variant server and exac03 is the database for the exome 
aggregation consortium.  
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3.2.3 Results of the search for rare homozygous variants 
3.2.3.1 Families of South Asian origin  
3.2.3.1.1 SS1F family 
SS1F pedigree is shown in figure 3-1. Samples V:11 and V:12 (FL, IL) were 
sent to Otogenetics for WES and samples V:2, V:9, V:10 and V:18 (RP79, 
YL82, AM and ML81) were processed in Leeds. As this family had a likely 
recessive mode of inheritance, autozygosity mapping was performed on 
affected family members V:2, V:11 and V:12 (RP79, FL and IL) who are all 
joined by a clear consanguineous loop. The data was analysed using 
IBDfinder and the results are presented in Figure 3-10 using the 
MultiIdeogram software. The software was set to define regions of 














Figure 3-10: SS1F autozygosity mapping. Generated by 
AgileMultideogram software, this scheme shows in blue the homozygous 
regions of samples V:11, V:2 and V:12 (FL, RP79 and IL) respectively from 
the outside to the centre, identified from SNP genotyping data.  The only 
common autozygous region is a 1.2 Mb segment on chromosome 11 
(55093883-56295143 hg19) shared between the 3 samples, highlighted in 
red. 
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Only one 1.2Mb region of autozygosity was shared between all three 
affected individuals: chromosome 11: 55,093,883-56,295,143 hg19. SNP 
data was extracted from the raw non-filtered WES data generated for family 
members V:9, V:10 and V:18 (YL82, AM and ML81) and combined to the 
SNP mapping data using AgileMultiIdeogram 
(http://dna.leeds.ac.uk/agile/AgileMultiIdeogram/) (Section 2.7). The results 
of this combined data for all six samples is displayed in figure 3-11.  
  
 
Figure 3-11: SS1F homozygous regions of 6 samples. The 
multiIdeogram displayed in this picture does not highlight any shared 
homozygous regions between the 6 SS1F samples, it only highlights in blue 
the homozygous regions of 6 SSF samples (From outside to the centre: FL, 
RP, IL, YL82, AM, ML81). 
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Autozygosity mapping using this combined SNP and WES data for six 
affected members of SS1F did not reveal any shared homozygous regions. 
However, this way of determining the shared homozygous regions among 
the samples with WES and SNP data is not ideal as the WES data is 
enriched for SNPs in the coding region and will therefore have gaps in the 
data compared to the data generated from SNP genotyping arrays. 
Therefore, the original 1.2 Mb candidate region mapped in three individuals 
was focused upon. This region according to the UCSC genome browser is 
comprised mainly of a set of olfactory receptor genes (Table 3-3).  
Table 3-3: Gene laying in the region of chromosome 11: 55,093,883-
56,295,143 hg19. This data was obtained from the genome browser UCSC 
(https://genome.ucsc.edu/).  
Gene	name	 Strand	 Start	 End	 Exon	Count	
OR4A16 +	 55110676	 55111663	 1	
OR4A15 +	 55135359	 55136394	 1	
OR4C15 +	 55321782	 55322895	 1	
OR4C16 +	 55339603	 55340536	 1	
OR4C11 -	 55370829	 55371874	 1	
OR4P4 +	 55405833	 55406772	 1	
OR4S2 +	 55418379	 55419315	 1	
OR4C6 +	 55432642	 55433572	 1	
OR5D13 +	 55540913	 55541858	 1	
OR5D14 +	 55563031	 55563976	 1	
OR5L1 +	 55578942	 55579878	 1	
OR5D18 +	 55587105	 55588047	 1	
OR5L2 +	 55594694	 55595630	 1	
OR5D16 +	 55606227	 55607214	 1	
TRIM51 +	 55650772	 55659284	 7	
TRIM51 +	 55653455	 55659284	 5	
OR5W2 -	 55681125	 55682058	 1	
OR5I1 -	 55702931	 55703876	 1	
OR10AG1 -	 55735033	 55735939	 1	
OR7E5P  -	 55746178	 55753881	 4	
OR5F1 -	 55761156	 55762101	 1	
OR5AS1 +	 55797894	 55798869	 1	
OR8I2  +	 55860783	 55861716	 1	
OR8H2  +	 55872518	 55873457	 1	
OR8H3 +	 55889848	 55890787	 1	
OR8J3 -	 55904246	 55905194	 1	
OR8K5 -	 55926869	 55927793	 1	
OR5J2 +	 55944093	 55945032	 1	
OR5T2 -	 55999581	 56000661	 1	
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OR5T3 +	 56019675	 56020698	 1	
OR5T1 +	 56043114	 56044095	 1	
OR8H1 -	 56057602	 56058538	 1	
OR8K3 +	 56085782	 56086721	 1	
OR8K1 +	 56113514	 56114474	 1	
OR8J1 +	 56127690	 56128764	 1	
OR8U8 +	 56143099	 56508560	 2	
OR5R1 -	 56184733	 56185708	 1	
OR5M9 -	 56229944	 56230877	 1	
OR5M3 -	 56236963	 56238014	 1	
OR5M8 -	 56257910	 56258846	 1	
 
The 1.2Mb region was closely examined in the unfiltered raw WES data of 
the SSF family samples. No homozygous variants in this region segregated 
in all the samples of the SSF family. However, all the patients were manually 
looked at. Variants in this region were only detected in the three samples 
where the 1.2 Mb region was highlighted (RP79, FL and IL). However none 
of the variants in the same gene segregated in the family patients, indicating 
that there is no single recessive homozygous allele which is the primary 
cause of KC in this family. 
 
3.2.3.1.2 AR1F family 
AR1F family’s pedigree is displayed in figure 3-2. Patient V:3 was sent 
to Otogenetics for WES and samples IV:9, IV:15 and IV:16 were sequenced 
in Leeds. The mode of inheritance in this pedigree is not well-defined as 
previously described in Section 3.2.1. SNP microarray genotyping data for 
patient V:3 was analysed using IBDfinder and the results are presented in 
table 3-4. Combining The WES data with the SNP data of V:3 patient reveals 
a long list of variants. 
Table 3-4: Autozygosity mapping results of sample AR1F V:3. Physical 
autozygosity mapping regions with the corresponding coordinates (hg19) for 
sample V:3 family AR1F. 





















































































































































To test the hypothesis that all affected members of this family have 
recessive homozygous mutations in the same gene, the SNP data from 
sample V:3 and raw non-filtered WES data from samples IV:9, IV:15 and 
IV:16 were combined using the multiIdeogram software in order to check for 
shared homozygous regions. The result of this combination is shown in 
figure 3-12, which does not reveal any shared homozygous region between 
the samples. In order to confirm this result, the raw WES data of all the four 
samples V:3, IV:9, IV:15 and IV:16 were checked for shared homozygous 
variants that were subsequently combined with the SNP data. A list of 
variants was highlighted (Table 3-5). This list of homozygous variants shown 
to be shared between all the affected members of AR1F and falling into the 
autozygous regions in sample V:3 can be excluded from harbouring any 
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variant that can be potentially responsible for KC pathogenesis, since all of 
these variants have MAF > 2%. 
 
Figure 3-12: Homozygous regions in the four tested samples from the 
AR1F family. The multiIdeogram displayed in this picture does not highlight 
any shared homozygous regions between the 4 AR1F samples, it only 
highlights in blue the homozygous regions of the 4 AR1F samples (From 
outside to the centre: V:3, V:9, V:15 and V:16). 
 
Table 3-5: Homozygous variants in the AR1F family. This table shows 
the homozygous variants shared between all the affected members of the 
AR1F family found in the autozygous regions observed in sample V:3. The 
MAF of all the variants presented in this table is > 2%. 
Gene		 Function	 AA	Change	 esp6500si	 1000g	 exac03	 snp138	










0.081034	 0.0585064	 0.054	 rs12075997	
TUBA4B	 ncRNA_exonic	 .	 .	 0.502396	 .	 rs10166888	
LOC100507291	 ncRNA_exonic	 .	 .	 0.25	 .	 rs11706576	
PDGFRL	 Splicing	 .	 .	 0.767372	 .	 rs2705051	
KRT19P2	 ncRNA_exonic	 .	 .	 0.951877	 .	 rs2289029	
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In order to confirm the exclusion of any homozygous autosomal variants 
from the potential involvement in KC pathogenesis in this family, the WES 
analysis was explored differently by applying the filtering strategy shown in 
Figure 3-9 to all the sequenced affected AR1F members. The filtered lists of 
samples V:3; IV:9; IV:15 and IV:16 were compared using an in house 
comparison perl script (Section 2.12) and checked for homozygous shared 
variants. The list of shared variants was then filtered according to the filtering 
strategy shown in Figure 3-9. The results are displayed in table 3-6, and 
show only one change on chromosome X, TENM1: exon29 c.A6554T 
p.H2185L, that is shared between all the AR1F affected members. This 
result is consistent with the pedigree structure and raises the suggestion of 
an X-linked variant underlying KC. 
 
TENM1 encodes a protein of a heparin binding function and involved in the 
immune response, negative regulation of cell proliferation and nervous 
system development processes (Brandau et al., 1999, Minet et al., 1999). In 
the AR1F family (Table 3-6), this gene harbours a change in exon 29 of the 
NM_014253 transcript and presents a high conservation score of 669 
according to the phastConsElements46way annotation and a MAF < 2% on 
esp6500 (0.007), 1000g (0.003) and ExAc03 (0.005).  
 
Table 3-6: Homozygous variant shared between the AR1F affected members.  
Details of the variant on chromosome X shared between AR1F affected members 
Gene	 Chr	 Function	 AA	Change	 SNP	 CADD	
Phred	
TENM1	 Xq25	 Nonsynonymous		 exon29:c.A6554T:p.H2185L	 rs144335593	 17.35	
3.2.3.1.3 Single cases (SCs) 
DNA samples of patients SC1, SC2 and SC3 were analysed by SNP 
microarray genotyping by AROS Biotec (Section 2.7) and WES by 
Otogenetics (Section 2.8). The genotyping results are presented in figures 3-
13, 3-14 and 3-15 and summarized in tables 3-7, 3-9 and 3-11. All three 
samples were filtered on the basis of harbouring a homozygous recessive 
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mutation (Figure 3-9) in order to generate lists of homozygous variants. 
None of the parents were available for sequencing or microarray genotyping, 
so the lists were not compared to any other family members for filtering 
purposes. The list of homozygous variants resulting from the combination of 
the two methods of microarray genotyping and WES were prioritized on 
CADD Phred scores and Tables 3-8, 3-10 and 3-12 show the variants with 
scores > 10.  
For Sample SC1: 
 
Figure 3-13: Autozygosity results for sample SC1. The autozygous regions 
found in sample SC1 are highlighted in red. The numbers listed down the left hand 
side correspond to the numbers of the Chromosomes and the (x) axis gives the 
genomic location in Mb. 
 
Table 3-7: Autozygosity mapping results of sample SC1. Physical autozygosity 
mapping regions in patient SC1 with the corresponding coordinates. 




















































































































Table 3-8: Homozygous variants in sample SC1.  Homozygous variants in the 
autozygous regions observed in sample SC1 and having CADD Phred scores > 10. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
CUEDC1	 Nonsynonymous	 17q22	 exon2:c.G110C:p.R37P	 .	 34	
ADAMTS5	 Nonsynonymous	 21q21.3	 exon5:c.G1729A:p.G577S	 rs146717299	 34	
COL28A1	 Nonsynonymous	 7p21.3	 exon19:c.C1544T:p.P515L	 rs79817423	 32	
NWD1	 Nonsynonymous	 19p13.11	 exon5:c.G433A:p.A145T	 .	 26.3	
EPHX3	 Nonsynonymous	 19p13.12	 exon1:c.C191T:p.P64L	 .	 24.2	
CYP4F2	 Nonsynonymous	 19p13.12	 exon9:c.C1021G:p.L341V	 rs145174239	 24	
ARHGEF10	 Nonsynonymous	 8p23.3	 exon27:c.G3256C:p.V1086L	 .	 23.9	
ACE	 Nonsynonymous	 17q23.3	 exon12:c.T1811C:p.L604P	 rs140941300	 23.7	
CYP4F11	 Nonsynonymous	 19p13.12	 exon5:c.C538T:p.R180C	 rs148197835	 21.6	
INTS2	 Nonsynonymous	 17q23.2	 exon25:c.G3605T:p.S1202I	 .	 20.4	
C16orf62	 Nonsynonymous	 16p12.3	 exon27:c.G2635A:p.A879T	 rs34342607	 19.79	
TLN2	 Nonsynonymous	 15q22.2	 exon15:c.G1838C:p.R613T	 rs115132378	 18.89	
KRTAP26-1	 Nonsynonymous	 21q22.11	 exon1:c.C562A:p.P188T	 rs12483584	 15.91	
KRTAP27-1	 Nonsynonymous	 21q22.11	 exon1:c.G284A:p.C95Y	 rs117534873	 15.36	
IFNA17	 Frameshift	
Insertion	
9p21.3	 exon1:c.170dupA:p.H57fs	 rs200400518	 15.36	
NIT1	 Nonsynonymous	 1q23.3	 exon1:c.A4G:p.T2A	 rs138523655	 14.46	
PTPRB	 Nonsynonymous	 12q15	 exon14:c.G3281A:p.R1094Q	 .	 14.46	
PDILT	 Nonsynonymous	 16p12.3	 exon3:c.A319G:p.K107E	 rs139688634	 13.5	
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For sample SC2: 
 
Figure 3-14: Autozygosity results for sample SC2. The autozygous regions of 
sample SC2 are highlighted in red. The numbers listed to the left hand side 
correspond to the numbers of the Chromosomes and the (x) axis gives the genomic 
location in Mb. 
 
 
Table 3-9: Autozygosity mapping results of sample SC2. Physical autozygosity 
mapping regions with the corresponding coordinates for sample SC2. 


















































































Table 3-10: Homozygous variant of sample SC2.  Details of homozygous 
variants falling in the autozygous regions observed in sample SC2 and having 
CADD phred scores > 10. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
IP6K1	 Nonsynonymous		 3p21.31	 exon4:c.G484T:p.V162F	 rs199967442	 33	
ABHD14B	 Nonsynonymous		 3p21.2	 exon3:c.G424A:p.V142M	 .	 32	
TRAPPC6B	 Nonsynonymous		 14q21.1	 exon4:c.C317G:p.S106C	 .	 28.5	
ABHD10	 Nonsynonymous		 3q13.2	 exon5:c.G737C:p.G246A	 .	 27	
MYH7	 Nonsynonymous		 14q11.2	 exon27:c.G3667C:p.E1223Q	 .	 24.5	
PLEKHH1	 Nonsynonymous		 14q24.1	 exon7:c.C938T:p.P313L	 rs200665235	 24.3	
DPF3	 Nonsynonymous		 14q24.2	 exon9:c.G1190A:p.R397H	 .	 23.5	
LRRC16B	 Nonsynonymous		 14q11.2	 exon33:c.C3385T:p.R1129C	 rs116307579	 23.4	
NGB	 Nonsynonymous		 14q24.3	 exon3:c.G292C:p.A98P	 .	 23.2	
PELI2	 Nonsynonymous		 14q22.3	 exon2:c.A97G:p.N33D	 .	 22.5	
KRT5	 Nonsynonymous		 12q13.13	 exon1:c.G110A:p.R37Q	 rs61747181	 21.6	
PARP3	 Nonsynonymous		 3p21.2	 exon7:c.G943C:p.V315L	 .	 18.41	











DDHD1	 Nonsynonymous		 14q22.1	 exon1:c.G181C:p.G61R	 .	 15.03	
KRT6C	 Nonsynonymous		 12q13.13	 exon1:c.T2C:p.M1T	 rs199806927	 14.78	
KDELC2	 Nonsynonymous		 11q22.3	 exon1:c.C28A:p.L10M	 .	 14.7	
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For sample SC3: 
 
Figure 3-15: Autozygosity results for sample SC3. The autozygous regions 
observed in sample SC3 are highlighted in red. The numbers listed on the left hand 
side are the numbers of the Chromosomes and the (x) axis gives the genomic 
location in Mb. 
 
Table 3-11: Autozygosity mapping results for sample SC3. Physical 
autozygosity mapping regions with the corresponding coordinates observed in 
sample SC3. 
























































































































Table 3-12: Homozygous variants observed in sample SC3.  Details of 
homozygous variants falling in the autozygous regions observed in sample 
SC3 and having CADD phred scores > 10. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
TAS1R1	 Nonsynonymous	 1p36.31	 exon5:c.1284_1285del:p.F428fs	 .	 35	
ESPN	 Nonsynonymous	 12q12	 exon8:c.C1894T:p.R632C	 .	 34	
PDZRN4	 Nonsynonymous	 12q13.12	 exon1:c.G511A:p.E171K	 rs151202383	 32	
TROAP	 Frameshift	
Deletion	
1p36.31	 exon13:c.C2036T:p.P679L	 .	 27	
DBX2	 Nonsynonymous	 12q12	 exon2:c.C469T:p.R157W	 rs138216785	 26.1	
NRAP	 Splicing(+2)	 10q25.3	 exon17:c.1635+2T&gt;C,	 .	 25	
P2RX7	 Nonsynonymous	 12q24.31	 exon8:c.G827A:p.R276H	 rs7958316	 24.2	
ACACB	 Nonsynonymous	 12q24.11	 exon36:c.C5057G:p.P1686R	 rs61739667	 24.1	
PLG	 Nonsynonymous	 6q26	 exon11:c.G1335T:p.R445S	 rs371661937	 23.9	
ST6GAL2	 Nonsynonymous	 2q12.2	 exon2:c.T89A:p.F30Y	 rs62155507	 23.8	
PTPRQ	 Nonsynonymous	 12q21.31	 exon6:c.C769G:p.Q257E	 rs61729287	 23.6	
LRP1B	 Nonsynonymous	 2q22.1	 exon41:c.G6436T:p.V2146F	 rs145744070	 23.1	
KLHL17	 Nonsynonymous	 1p36.33	 exon12:c.G1819A:p.A607T	 .	 22.9	
POU3F3	 Nonsynonymous	 2q12.1	 exon1:c.C875A:p.P292Q	 .	 22.8	
PHLPP1	 Nonsynonymous	 18q21.33	 exon1:c.G1066A:p.A356T	 rs12957017	 22.4	
CBX8	 Nonsynonymous	 17q25.3	 exon5:c.G1077C:p.E359D	 .	 21	
KCNH3	 Nonsynonymous	 12q13.12	 exon12:c.C2219T:p.T740M	 .	 18.07	
CCDC177	 Nonsynonymous	 14q24.1	 exon2:c.T1952C:p.L651P	 .	 17.2	
DACH1	 Nonsynonymous	 13q21.33	 exon1:c.G244A:p.G82S	 rs202136379	 11.44	
 
 
3.2.3.2 Family KF  
Family KF’s pedigree (Figure 3-3) is consistent with autosomal recessive 
inheritance with affected individuals having consanguineous parents, so 
autozgosity mapping was performed. Affected siblings IV:1 and IV:2 were 
genotyped by SNP microarray and all three affected siblings (IV:1, IV:2 and 
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IV:3) along with their parents (II:3 and III:4) underwent WES analysis. The 















Figure 3-16: Autozygosity mapping in family KF. Visualisation of 
autozygous regions observed in patients IV:1 and IV:2 respectively, from the 
outside to the centre. The shared autozygous regions are highlighted in red. 
The homozygous regions observed in individual samples are shown in blue. 
 
Table 3-13: Autozygosity mapping results in patients IV:1 and IV:2 of 
family KF. Regions highlighted by autozygosity mapping in patients IV:1 and 
IV:2 from the family KF with the corresponding coordinates for shared 
regions. 
Chromosome	 Start	 End		 Length	(Mb)	
9	 24026560	 33046299	 9.01	
17	 69210898	 74785180	 5.57	
19	 58998630	 63786938	 4.78	
1	 221701053	 223938150	 2.23	
12	 12925252	 15159222	 2.23	
14	 20027606	 21921082	 1.89	
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Since the WES data from the third sibling IV:3 is available, these regions 
were checked for homozygosity in the raw unfiltered WES data of sample 
IV:3. Table 3-14 shows the autozygous regions shared between the three 
affected siblings of family KF. 
Table 3-14: Autozygosity mapping results from analysis of all three 
affected members of family KF. Regions highlighted by autozygosity 
mapping in samples IV:1 and IV:2 of KF family, with the corresponding 
coordinates for shared regions. 
Chromosome	 Start	 End		 Length	(Mb)	
9	 25678887	 30408448	 4.72	
12	 13370236	 15066849	 1.69	
17	 72542827	 73062038	 0.51	
17	 74498068	 74709434	 0.21	
 
In addition, the WES data from the parents exist for this family. A closer look 
at the data from the unaffected parents (II:2 and III:4) highlighted a 
homozygous segment of 1.5Mb on Chromosome 9: 25,779,193-27,330,031 
in sample II:2 and a homozygous segment of 1.6Mb on Chromosome 9: 
25,679,024-27,330,031, which can be excluded from the autozygous regions 
highlighted in Table 3-14 in the affected siblings as potential regions 
harbouring potential homozygous pathogenic variants. The final regions of 
autozygosity > 1Mb highlighted in the affected members of family KF is 
presented in Table 3-15.  
Table 3-15: Autozygosity mapping results observed in analysis of all 
affected members of family KF and excluded from the unaffected 
parents. Physical autozygosity mapping regions with the corresponding 
coordinates, for regions shared in samples IV:1 and IV:2 of KF family, in 
addition to sample IV:3. 
Chromosome	 Start	 End		 Length	(Mb)	
9	 27330031	 30408448	 3.07	
12	 13370236	 15066849	 1.69	
 
In order to detect the homozygous variants falling in these regions of 
homozygosity, shared between the affected siblings of KF and excluded 
from the homozygous variants list of the unaffected parents, the filtering 
strategy shown in Figure 3-8 was applied to all the sequenced affected 
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siblings (IV:1, IV:2 and IV:3) and unaffected parents (II:3 and III:4) of KF 
family to generate working excel lists. Subsequently, two major lists were 
generated: the first list includes all the shared homozygous variants between 
all the affected siblings (IV:1, IV:2 and IV:3) and the second list represents 
all the shared homozygous variants between the unaffected parents (II:3 and 
III:4). Then the two filtered lists were compared using an in house 
comparison perl script (Section 2.12). The resulting list excluded all the 
homozygous variants shared between the parents and the siblings and was 
then filtered according to the filtering strategy shown in Figure 3-9. This 
strategy did not highlight any homozygous variant shared between the KF 
affected siblings and absent in the parents in the homozygous form. Thus no 
potentially pathogenic homozygous alleles of major effect predisposing the 
KC were observed in the autozygous regions in the KF family. 
 
3.2.3.3 Families of Lebanese origin and Druze ethnicity 
3.2.3.3.1 Family F2 
Family F2 (Figure 3-4) is not known to be consanguineous but belongs to an 
endogamous community, where the parents are from the same village and 
carry the same surname, which means they could possibly share the same 
great-grandparents. Consequently, autozygosity mapping was performed by 
SNP genotyping all the affected family members (I:3, II:1, II:2 and II:3) 
(Figure 3-17). The results show that the affected members of F2 do not 
share any autozygous regions. In parallel, WES analysis was performed in 
Leeds for individuals I:3, II:1 and II:2 (2/5, 2/1 and 2/3).  














Figure 3-17: Autozygosity mapping in family F2. Visualisation of 
autozygous regions observed in patients II:1, II:2, I:3 and II:3 respectively, 
from the outside to the centre.  Autozygous regions in individual samples are 
highlighted in blue. 
 
Although autozygosity mapping failed to highlight a shared autozygous 
region shared between the affected patients of family F2, homozygous 
variants were still screened for in the WES data available from affected 
members of family F2. Since the SNPs in the autozygosity mapping are 
filtered on locus size (1Mb), double checking the WES data is essential to 
ensure that mutation(s) in small regions of autozygosity are not missed.  
 
The filtering strategy shown in Figure 3-9 was applied to the working excel 
lists of the sequenced affected members of F2 (I:3, II:1 and II:2). Next, the 
filtered lists were compared using an in house comparison perl script 
(Section 2.12) to check for shared homozygous variants. However, this 
strategy failed to highlight any homozygous variants shared between the 
affected F2 members. 
 
- 105 - 
 
3.2.3.3.2 Family F9 
Only one patient DNA was available for family F9 (Figure 3-4), this being 
individual III:8 (9/1). WES analysis was performed and the filtering strategy 
for homozygous recessive mutations, shown in Figure 3-9, was applied. The 
resulting list was prioritized based on CADD Phred scores and table 3-16 
shows only the homozygous variants having scores > 10.  
Table 3-16: Homozygous variants observed in patient III:7 of family F9.  
Details of homozygous variants identified in family F9 having CADD phred 
scores > 10. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
LMOD3	 Nonsynonymous	 3p14.1	 exon1:c.G248A:p.R83H	 rs35740823	 26.9	
GTF2IRD2	 Nonsynonymous	 7q11.23	 exon16:c.A2105C:p.Y702S	 .	 24.4	
MYO18B	 Nonsynonymous	 22q12.1	 exon43:c.C6901T:p.L2301F	 rs182723137	 24.4	
APPL1	 Nonsynonymous	 3p14.3	 exon20:c.G1888C:p.E630Q	 rs142229340	 24.3	
GPATCH4	 Nonsynonymous	 1q23.1	 exon8:c.G500A:p.R167H	 rs199804048	 23.7	
GALNT12	 Nonsynonymous	 9q22.33	 exon1:c.G179A:p.R60Q	 .	 20.2	
UHRF1	 Nonsynonymous	 19p13.3	 exon4:c.G757C:p.D253H	 rs17886098	 17.24	
POTEF	 Nonsynonymous	 2q21.1	 exon17:c.C2661A:p.D887E	 rs201255735	 17.16	





















PGBD5	 Nonsynonymous	 1q42.13	 exon1:c.G286T:p.A96S	 rs113202442	 11.99	
SCAF1	 Nonsynonymous	 19q13.33	 exon7:c.G1742C:p.R581P	 .	 11.71	
LRP5	 Nonsynonymous	 11q13.2	 exon1:c.G4A:p.E2K	 .	 10.39	
3.2.3.3.3 Family F10 
For family F10 (Figure 3-4) WES analysis was undertaken on patients III:4 
and III:5 (10/1 and 10/2). The data was filtered as described in figure 3-9 
then analysed on the hypothesis of a homozygous recessive mutation being 
shared by both individuals (Figure 3-9). The resulting list was prioritized on 
CADD Phred scores and table 3-17 shows only the homozygous variants 
having scores > 10.  
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Table 3-17: Homozygous variants shared by the sequenced affected 
members of F10.  Details of homozygous variants shared by III:4 and III:5, 
KC patients from family F10, and having CADD phred scores > 10. 







ASB18	 Nonsynomymous	 2q37.2	 exon4:c.G722T:p.R241L	 rs56247246	 11.2	
 
3.2.3.3.4 Family F11 
In Family F11 (Figure 3-4), WES analysis and SNP genotyping was 
performed on samples from patients II:2 and II:3 (11/3 and 11/4). Due to the 
pedigree structure and the endogamous nature of the community from which 
the family derived, the data was analysed under a homozygous recessive 
mutation model. The autozygosity mapping data shows that these patients 
have no shared autozygous regions (Figure 3-18). Due to the resolution 
limits of the autozygosity mapping software, the WES data was still analysed 
under the same shared recessive homozygous allele model but without 
filtering based on mapping data (Figure 3-9). The resulting list was prioritized 
on the basis of CADD Phred scores and table 3-18 shows only the 










Figure 3-18: Autozygosity mapping in family F11. Visualisation of 
autozygous regions observed in patients II:2 and II:3 respectively, from the 
outside to the centre. The shared homozygous regions in each individual are 
highlighted in blue. 
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Table 3-18: Homozygous variants shared in common by the sequenced 
affected members of F11.  Variants that are homozygous in both 
sequenced affected members of family F11 and which have CADD phred 
scores > 10. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	






FLG2	 Nonsynomymous	 1q21.3	 exon3:c.G2167A:p.E723K	 rs16842865	 17.82	
AGAP3	 Frameshift	
Insertion	











DMKN	 Nonsynomymous	 19q13.12	 exon5:c.G839A:p.G280D	 rs148799704	 14.43	
AGAP3	 Frameshift	
Insertion	
7q36.1	 exon1:c.92_93insG:p.V31fs	 .	 13.32	






3.2.3.3.5 Family F12 
For family F12 (Figure 3-4), DNA samples were only available for patients 
II:2 and III:2. WES analysis was undertaken on patient II:2 (12/1) and filtered 
using a homozygous recessive model (Figure 3-9). The resulting list was 
prioritized on CADD Phred scores and table 3-19 shows only the 
homozygous variants having scores > 10. 
Table 3-19: Homozygous variant of sample II:2 member of F12.  Details 
of F12 homozygous variants having CADD phred scores > 10. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
GDPD3	 Nonsynonymous	 16p11.2	 exon10:c.G844A:p.E282K	 rs148974984	 33	
CDH7	 Nonsynonymous	 18q22.1	 exon3:c.G505A:p.G169R,	 .	 28.9	
LAMA5	 Nonsynonymous	 20q13.33	 exon32:c.G4037A:p.C1346Y	 rs371144423	 28.9	
PABPC1	 Nonsynonymous	 8q22.3	 exon13:c.A1816G:p.K606E	 .	 28.1	
ZNF366	 Splicing	 5q13.2	 .	 .	 26.2	
PCDHA12	 Nonsynonymous	 5q31.3	 exon1:c.G1528A:p.V510M	 rs191376557	 26.1	
RALGAPA1	 Nonsynonymous	 14q13.2	 exon9:c.T877C:p.C293R	 .	 25.9	
IFT88	 Splicing		 13q12.11	 .	 .	 24.4	
ZNF366	 Splicing		 5q13.2	 .	 .	 24.3	
CFAP46	 Nonsynonymous	 10q26.3	 exon41:c.T5767C:p.W1923R	 rs151247898	 24.3	
- 108 - 
 
PRKRIR	 Nonsynonymous	 11q13.5	 exon5:c.T506A:p.L169Q	 .	 23.8	
USP35	 Nonsynonymous	 11q14.1	 exon6:c.C1088T:p.S363L	 rs147270370	 23.7	
PABPC1	 Splicing	(+2)	 8q22.3	 exon14:c.1818+2T&amp;gt;A	 .	 23.6	
RBBP4	 Nonsynonymous	 1p35.1	 exon8:c.C941T:p.S314L	 .	 23.4	
ABI3BP	 Splicing	(-2)	 3q12.2	 exon14:c.1160-2A&amp;gt;T	 .	 23.4	
HLTF	 Nonsynonymous	 3q24	 exon8:c.A932G:p.N311S	 rs2305868	 23.2	






INF2	 Nonsynonymous	 14q32.33	 exon8:c.C1280T:p.P427L	 .	 20.2	






ST13	 Nonsynonymous	 22q13.2	 exon1:c.C85A:p.R29S	 .	 19.32	
CHEK2	 Nonsynonymous	 22q12.1	 exon7:c.G799T:p.A267S	 .	 17.81	
TPK1	 Nonsynonymous	 7q35	 exon2:c.C28T:p.P10S	 .	 17.64	











OBFC1	 Nonsynonymous	 10q24.33	 exon6:c.A572T:p.E191V	 .	 15.2	
THPO	 Stopgain	 3q27.1	 exon2:c.G229T:p.E77X	 .	 15.16	
RFX2	 Nonsynonymous	 19p13.3	 exon5:c.G476T:p.S159I	 .	 14.84	
NPAS3	 Nonsynonymous	 14q13.1	 exon11:c.G2246T:p.S749I	 .	 14.78	
CCT8L2	 Nonsynonymous	 22q11.1	 exon1:c.C1030A:p.P344T	 rs41277596	 13.62	
LAMA5	 Nonsynonymous	 20q13.33	 exon80:c.G10995A:p.M3665I	 .	 13.41	
NFKBIZ	 Splicing	(+2)	 3q12.3	 exon11:c.1635+2-&amp;gt	 .	 10.79	
C3AR1	 Nonsynonymous	 12p13.31	 exon2:c.T998C:p.L333P	 rs56136109	 10.53	
 
3.2.3.3.6 Family F13 
For family F13 (Figure 3-4), DNA samples were only available from patients 
II:2, II:6 and III:13 (13/2, 13/3 and 13/1 respectively). WES analysis was 
performed on patients II:6 and III:13 (13/3 and 13/1) by Otogenetics, the 
data was analysed using a shared homozygous recessive mutation model 
(Figure 3-9) and the resulting list prioritized by CADD Phred scores are 
shown in table 3-20. 
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Table 3-20: Homozygous variant shared by sequenced affected 
members of F13.  Details of homozygous variant observed in all members 
of family F13 and having a CADD phred score > 10. 







3.2.3.4 Families of Lebanese origin and Christian Maronite 
ethnicity 
3.2.3.4.1 Family F6 
For family F6 (Figure 3-5), the family was analysed using a recessive 
homozygous mutation model due to the endogamous nature of the 
population from which the family originates. Samples from affected members 
III:2, III:7 and III:8 were SNP genotyped and autozygosity mapping was 












Figure 3-19: F6 autozygosity mapping. Visualisation of autozygous 
regions shared by genomic DNA from samples from patients III:2, III:7 and 
III:8 respectively, from the outside to the centre. The homozygous regions 
are highlighted in blue. 
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In parallel, WES analysis was performed on III:2, III:7 and III:8 (6/10, 6/1 and 
6/3). When this data was analysed with the same homozygous recessive 
mutation model, two homozygous variants were highlighted (Table 3-21). 
Table 3-21: Homozygous variants shared by the sequenced members 
of F6.  Details of homozygous variants shared by both sequenced affected 
members of family F6 and having CADD Phred scores > 10. 












3.2.3.4.2 Family F7 
For family F7 (Figure 3-5) WES analysis was performed on samples from 
patients II:1 and II:3 (7/2 and 7/1) and a filtering strategy for a recessive 
homozygous mutation was undertaken as detailed in Figure 3-9. This 
highlighted only two shared homozygous variants (Table 3-22). 
Table 3-22: Homozygous variants shared by the sequenced members 
of F7.  Details of homozygous variants shared by both sequenced affected 
patients in family F7 and which have CADD Phred scores > 10. 













3.2.3.4.3 Family F8 
For family F8 (Figure 3-5), to check for the presence of a shared recessive 
homozygous mutation causing the KC phenotype, autozgosity mapping was 
performed by SNP genotyping samples from patients III:2 and III:4 (8/1 and 
8/2). The data shows that these patients do not share any autozygous 
regions. WES analysis of the same patients using the same model and 
filtering as described in figure 3-9 highlighted four shared homozygous 
variants with a CADD Phred scores >10 (Table 3-23). 
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Table 3-23: List of homozygous recessive variants shared by the 
affected members of family F8. Details of homozygous variants shared by 
affected members of family F8 having CADD Phred scores > 10 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	











CFHR1	 Stoploss	 1q31.3	 exon6:c.A992G:p.X331W	 rs145057542	 11.82	
 
 
3.2.3.5 Combining the homozygous recessive mutation model 
data for all families 
For all the homozygous variants identified in section 3.2.3, a shared list was 
generated for the genes implicated in at least two families (Table 3-24). All 
the shared genes were checked for their association in the literature with 
terms related to KC using Pubmatrix analysis (Section 2.10) in which all the 
genes were checked against a list of 10 words associated with KC: 
Keratoconus, Cornea, Oxidative Stress, Collagen, Eye, Inflammation, 
Proteinase, Apoptosis, Epithelial cells and Keratocytes. 
Table 3-24: List of all genes harbouring homozygous mutations in 
affected members of at least two KC families. List of genes sharing 
homozygous variants between the affected family members of KC families 
and their association in the literature with terms related to KC. 











LOC400863	 21q22.11	 F10,	F12	 8.965	 -	
RNF19B	 1p35.1	 F9,	F10	 6.34	 Apoptosis		
ZFPM1	 16q24.2	 F11,	F12	 23	 Epithelial	Cells,	Inflammation,	
Apoptosis,	Proteinase	and	Eye	
NOP9	 14q12	 F9,	F13	 0.61-0.46	 -	
AGAP3	 7q36.1	 F11,	F12	 16.76-0.002	 -	
MUC3A	 7q22.1	 F11,	F12,	F13	 6.38-2.21	 Epithelial	Cells,	Eye,	Apoptosis	
and	Inflammation	
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Out of the 8 genes represented in table 3-24, only 5 genes have been shown 
by Pubmatrix to be associated to terms related to KC. These genes are the 
following: Cholinergic Receptor Nicotinic Alpha 3 (CHRNA3), Farnesyl-
Diphosphate Farnesyltransferase 1 (FDFT1), Ring Finger Protein 19B 
(RNF19B), Zinc Finger Protein FOG Family Member 1 (ZFPM1) and Mucin 
3A Cell Surface Associated (MUC3A).  
 
 
3.2.4 Recessive inheritance: screening for compound 
heterozygous mutations  
In order to investigate a recessive mode of inheritance caused by two 
different deleterious heterozygous variants in the same gene, the filtering 
strategy explained in figure 3-20 was applied to the WES data generated for 
each family. This strategy consisted of filtering out all the variants with a 
MAF>=2% on 1000g, esp6500si and exac03 databases and removing all the 
synonymous, non-coding and homozygous variants. From this list, only 
genes which contained at least two heterozygous variants were highlighted. 
In addition, similar to the strategy previously used (section 3.2.3), artefacts 


































3.2.4.1 Families of South Asian origin  
3.2.4.1.1 SS1F family 
To search for compound heterozygous mutations in family SS1F (Figure 3-
1), the WES generated for individuals V:11 (FL), V:12 (IL), V:2 (RP79), V:9 
(YL79), V:10 (AM) and V:18 (ML81) was analysed using this inheritance 
model (Figure 3-20) and variants prioritized according to their predicted 
Excel list of compound heterozygous recessive 
functional variants 
Filter out all the variants in genes presenting only 
one change in the list  
Excel list of all exonic and splicing variants 
 
Filter out changes with maf>= 2% on 1000g OR 
esp6500si OR exac03 
Filter out all the homozygous variants 
Filter out all the synonymous and non-coding 
variants 
Filter out all the artefactual variants by comparing 
against list of artefacts  
 
Filter out all the common polymorphisms specific of 
same ethnicity 
Figure 3-20: Filtering strategy for compound heterozygous recessive 
hypothesis. The working excel file generated from ANNOVAR undergoes a 
series of filtering steps by removing any allele with MAF>=2%, common 
polymorphisms specific to the same ethnicity, the artefactual variants, the 
synonymous and non-coding variants and all the homozygous variants. 
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pathogenicity using CADD Phred scores. The data for each individual was 
compared to look for shared variants present in all the affected family 
members using the perl script described in Section 2.12. 
 
This analysis highlighted only one gene on chromosome 12, GSG1 (Germ 
Cell Associated 1) (Table 3-25). The first variant is a known SNP (c.C619T, 
p.R207C, rs376340949) and has a CADD Phred score of 15.19. It is 
relatively rare, with a frequency of 0.00139776 on the 1000g database and 
0.0007578 on ExAc database. The second variant is also a known SNP 
(c.C514T, p.P172S, rs369468787) but this has a very low CADD Phred 
score of 6.267 and is present in the databases with a frequency of 
0.00419329 on the 1000g database and 0.002125 on ExAc database.  
Table 3-25: Compound heterozygous variants shared by the sequenced 
SS1F KC affected members. Details of the only SS1F compound 
heterozygous variant pair observed, which was found in GSG1 gene. 




Nonsynonymous	 12p13.1	 exon4:c.C619T:p.R207C	 rs376340949	 15.19	
Nonsynonymous	 12p13.1	 exon4:c.C514T:p.P172S	 rs369468787	 6.267	
 
3.2.4.1.2 AR1F family 
To search for compound heterozygous mutations involved in KC in family 
AR1F (Figure 3-2), the WES data generated for individuals IV9, IV15, IV16 
and V3 was filtered using this inheritance model (Figure 3-20) and variants 
identified were prioritized according to their predicted pathogenicity using 
CADD Phred scores. The data for each individual was compared to look for 
shared variants and/or genes present in all the affected family members 
using the perl script described in Section 2.12. Table 3-26 shows all the 
compound heterozygous variants that segregated with KC in family AR1F. 
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Table 3-26: Compound heterozygous variants shared between AR1F 
affected members. Details of compound heterozygous variants 
cosegregating with KC in family AR1F with both variants having at least 
CADD Phred scores ≥ 10. 




Nonsynonymous	 exon24:c.C3862T:p.R1288C	 rs374546648	 24.6	
Nonsynonymous	 exon18:c.C2870T:p.S957L	 rs141074403	 14.44	
KLLN	
(10q23.31)	
Nonsynonymous	 exon1:c.C382G:p.R128G	 rs201652303	 23.6	
Nonsynonymous	 exon1:c.A392G:p.N131S	 rs144811392	 10.41	
3.2.4.1.3 Single cases 
To search for compound heterozygous mutations in the single cases, the WES 
data generated for each was filtereded for genes with two pathogenic variants. 
Tables 3,27 3-28 and 3-29 display the results of the highlighted genes 
respectively for SC1, SC2 and SC3 but only for genes where both variants had a 
CADD Phred score ≥ 20 to reduce the size of the lists. Full lists can be found in 
Appendix 6. 
Table 3-27: Compound heterozygous variants in sample SC1. Details of 
compound heterozygous variants found in patient SC1 for which both variants 
have CADD Phred scores ≥ 20. 




Nonsynonymous exon2:c.G167A:p.R56H	 rs199998539	 34	
Nonsynonymous exon27:c.G2305C:p.V769L	 rs141302553	 23.1	
AGAP1	
(2q37.2)	
Nonsynonymous exon12:c.G1390C:p.D464H	 .	 25.4	
Nonsynonymous exon12:c.T1402C:p.S468P	 .	 24.2	
C2CD5	
(12p12.1)	
Nonsynonymous exon8:c.G982T:p.G328W	 rs142327845	 29.1	
Nonsynonymous exon8:c.G983T:p.G328V	 rs147669786	 22.7	
CXCR1	
(2q35)	
Nonsynonymous exon2:c.C1003T:p.R335C	 rs16858808	 25.4	













Nonsynonymous exon10:c.G1469A:p.R490H	 .	 26.2	
Nonsynonymous exon8:c.G1141A:p.V381I	 rs145769654	 21.8	
FAM186B	
(12q13.12)	
Nonsynonymous exon2:c.G321C:p.W107C	 rs141974060	 31	
Nonsynonymous exon7:c.G2556C:p.E852D	 rs144854212	 24.8	
FES	
(15q26.1)	
Nonsynonymous exon14:c.A1778G:p.E593G	 .	 29.7	
Nonsynonymous exon2:c.G263A:p.R88Q	 .	 28.1	
HCLS1	 Nonsynonymous exon11:c.T1021C:p.Y341H	 .	 23.5	
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(3q13.33)	 Nonsynonymous exon11:c.A1015C:p.N339H	 .	 23.3	
MRGPRD	
(11q13.3)	
Nonsynonymous exon1:c.C616T:p.R206W	 rs146025023	 24.8	
Nonsynonymous exon1:c.G641A:p.R214Q	 .	 23.2	
OBSL1	
(2q35)	
Nonsynonymous exon5:c.G1850A:p.R617H	 rs369705959	 25.2	
Nonsynonymous exon11:c.A3730C:p.T1244P	 .	 21.6	
OPLAH	
(8q24.3)	
Nonsynonymous exon13:c.G1750T:p.G584C	 rs10107332	 27	
Nonsynonymous exon10:c.C1331T:p.P444L	 .	 21.2	
OR52N1	
(11p15.4)	
Nonsynonymous exon1:c.G769C:p.A257P	 .	 26.6	
Nonsynonymous exon1:c.C767A:p.P256Q	 rs201810252	 26.3	
RECQL4	
(8q24.3)	
Nonsynonymous exon9:c.C1561T:p.R521W	 .	 25.6	
Nonsynonymous exon10:c.C1625T:p.S542F	 rs369852601	 24.4	
SLC5A4	
(22q12.3)	
Nonsynonymous exon9:c.G1007A:p.R336H	 rs62239049	 35	
Stopgain	 exon5:c.G415T:p.E139X	 rs62239058	 31	
SPATA20	
(17q21.33)	
Nonsynonymous exon11:c.C1487A:p.P496H	 .	 33	
Nonsynonymous exon11:c.C1486A:p.P496T	 .	 29.7	
TIAM2	
(6q25.3)	
Stopgain	 exon13:c.T1343A:p.L448X	 rs116268446	 40	
Nonsynonymous exon13:c.G1340C:p.S447T	 rs114239511	 24.1	
TMTC2	
(12q21.31)	
Nonsynonymous exon2:c.C415G:p.R139G	 rs200268500	 26.8	
Nonsynonymous exon6:c.C1730T:p.T577M	 rs117020331	 21.7	
VWA8	
(13q14.11)	
Nonsynonymous exon43:c.A5351C:p.Q1784P	 rs200850191	 28.9	
Nonsynonymous exon43:c.C5350A:p.Q1784K	 rs201654359	 23	
HDGFRP2	
(19p13.3)	
Nonsynonymous exon15:c.G1744C:p.G582R	 .	 25.8	
Nonsynonymous exon15:c.G1750A:p.E584K	 .	 24.7	
Nonsynonymous exon15:c.G1745A:p.G582E	 .	 23.8	
Nonsynonymous exon15:c.T1739C:p.L580P	 .	 22	
Nonsynonymous exon15:c.G1741C:p.A581P	 .	 20.2	
SDK1	
(7p22.2)	
Nonsynonymous exon16:c.T2324C:p.I775T	 rs374147324	 25.6	
Nonsynonymous exon45:c.C6563A:p.T2188K	 rs117504728	 24.7	
Nonsynonymous exon21:c.C3080T:p.T1027M	 rs61735696	 23.4	
TTN	
(2q31.2)	
Nonsynonymous exon177:c.G70223A:p.R23408H	 .	 26.5	
Nonsynonymous exon154:c.G49727A:p.R16576H	 rs369707906	 23.8	
Nonsynonymous exon154:c.C47839T:p.R15947W	 rs368914555	 21	
 
Table 3-28: Compound heterozygous variants in sample SC2. Details of 
compound heterozygous variants found in patient SC2 for which both variants 
have CADD Phred scores ≥ 20. 




Nonsynonymous exon12:c.G1390C:p.D464H	 .	 25.4	
Nonsynonymous exon12:c.T1402C:p.S468P	 .	 24.2	
C17orf96	
(17q12)	
Nonsynonymous exon1:c.A326T:p.D109V	 .	 24.4	
Nonsynonymous exon1:c.G318T:p.E106D	 .	 20.2	
CAPN5	
(11q13.5)	
Nonsynonymous exon2:c.T95C:p.F32S	 rs201256547	 25.2	
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Table 3-29: Compound heterozygous variants in sample SC3. Details of 
compound heterozygous variants in patient SC3 for which both variants have 
CADD Phred scores ≥ 20. 




Nonsynonymous exon1:c.G58C:p.A20P	 rs142719529	 28.6	
Nonsynonymous exon2:c.G547C:p.A183P	 rs201454609	 25.5	
FANCM	
(14q21.2)	
Nonsynonymous exon10:c.G1706A:p.R569H	 .	 34	








Nonsynonymous exon15:c.G1469T:p.C490F	 rs199856746	 24.4	
KCNE1L	
(Xq23)	
Nonsynonymous exon1:c.G88T:p.G30C	 .	 24.2	
Nonsynonymous exon1:c.G87T:p.L29F	 rs200894798	 22.9	
P2RY4	
(Xq13.1)	
Nonsynonymous exon11:c.1635+2-&gt;TTAATAACC	 rs202027224	 25	
Nonsynonymous exon11:c.1635+1G&gt;C	 .	 23.5	
SCNN1A	
(12p13.31)	
Nonsynonymous exon10:c.C1931G:p.A644G	 rs5742912	 29.1	
Nonsynonymous exon1:c.G674C:p.R225P	 rs201553658	 26.9	
TMTC2	 Nonsynonymous exon1:c.G677C:p.R226P	 rs200268500	 26.8	
Nonsynonymous	 exon1:c.C65T:p.T22M	 .	 20.3	
DENND2A	
(7q34)	
Nonsynonymous exon1:c.C890G:p.P297R	 rs374255633	 24.1	
Nonsynonymous exon1:c.C54G:p.S18R	 rs200642129	 20.8	
GPR124	
(8p11.23)	
Nonsynonymous exon9:c.C1204T:p.R402W	 rs200841231	 32	
Nonsynonymous exon12:c.C1648T:p.P550S	 rs200624144	 24.5	
KIAA0226	
(3q29)	
Nonsynonymous exon13:c.G1954T:p.V652F	 rs80094312	 28	
Nonsynonymous exon20:c.C2828G:p.A943G	 .	 24.8	
SORBS1	
(10q24.1)	
Nonsynonymous exon28:c.G3292T:p.G1098W	 rs372968425	 26.9	
Nonsynonymous exon28:c.C3095G:p.S1032C	 .	 24.4	
L3MBTL2	
(22q13.2)	
Nonsynonymous exon6:c.G697C:p.A233P	 .	 32	
Nonsynonymous exon8:c.T905G:p.V302G	 rs200870155	 23.9	
MYO1E	
(15q22.2)	
Nonsynonymous exon27:c.C3146A:p.P1049H	 rs147579391	 31	
Nonsynonymous exon7:c.A554G:p.D185G	 rs141565214	 25	
NEB	
(2q23.3)	
Nonsynonymous exon89:c.G13328T:p.S4443I	 .	 32	
Nonsynonymous exon47:c.G6025C:p.D2009H	 rs370790324	 29.5	






Splicing	(+1)	 exon11:c.1635+1G&gt;C	 .	 24.9	
Nonsynonymous exon10:c.C1931G:p.A644G	 .	 23.5	
P2RY4	
(Xq13.1)	
Nonsynonymous exon1:c.G674C:p.R225P	 rs202027224	 25	
Nonsynonymous exon1:c.G677C:p.R226P	 .	 23.5	
RNF213	
(17q25.3)	
Nonsynonymous exon29:c.G7583A:p.R2528Q	 rs202143169	 27.8	
Nonsynonymous exon57:c.C13913T:p.T4638I	 rs141301945	 24.6	
UNC13D	
(17q25.1)	
Nonsynonymous exon13:c.G1076T:p.R359L	 .	 25.2	
Nonsynonymous exon3:c.G175A:p.A59T	 rs9904366	 21.6	
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(12q21.31)	 Nonsynonymous exon9:c.T1654C:p.W552R	 .	 26.4	
UTP23	
(8q24.11)	
Nonsynonymous exon3:c.G1018C:p.A340P	 .	 24.5	
Nonsynonymous exon2:c.C415G:p.R139G	 .	 23.9	
NFKBIZ	
(3q12.3)	
Splicing	(+1)	 exon2:c.T410G:p.V137G	 .	 24.9	
Splicing	(+2)	 exon1:c.T65G:p.V22G	 .	 24.9	
Nonsynonymous exon1:c.C67G:p.R23G	 .	 23.5	
 
3.2.4.2 Family KF of Indian origin  
To search for compound heterozygous mutations in family KF (Figure 3-3), the 
WES data generated for affected siblings (IV:1, IV:2 and IV:3) were filtered using 
this inheritance model (Figure 3-20) and the variants prioritized according to their 
predicted pathogenicity using CADD Phred scores. The data for the affected 
individuals was then compared to look for compound heterozygous variants 
carried by all affected members using the perl script described in Section 2.12. 
The resulting list was compared against the heterozygous variants list of the 
mother (III:4) and the heterozygous variants list of the father (II:3), and the alleles 
that were both inherited from one parent (ie in the same phase) were excluded. 
The final list of compound heterozygous variants shared between the siblings is 
given in Table 3-30. 
Table 3-30: Compound heterozygous variants shared by the affected 
siblings of KF family. Details of compound heterozygous variants found in all 
three affected members of family KF for which both variants have at least CADD 
Phred scores ≥ 10. 




Nonsynonymous exon13:c.C1841T:p.P614L	 .	 28.8	
Nonsynonymous exon31:c.G6782C:p.G2261A	 rs201990436	 19.28	
ATRN	
(20p13)	
Nonsynonymous exon7:c.C802T:p.R268C	 rs147164307	 24.5	
Splicing	(-2)	 exon16:c.2197-2A&amp;gt;C	 rs200054755	 24.1	
CAND2	
(3p25.2)	
Nonsynonymous exon8:c.C1489T:p.R497W	 .	 33	
Nonsynonymous exon8:c.C2231T:p.T744M	 rs370800520	 22.5	
DNAH11	
(7p15.3)	
Nonsynonymous exon76:c.A12442G:p.I4148V	 .	 28.3	
Nonsynonymous exon66:c.C10768G:p.P3590A	 .	 19.99	
IGFN1	
(1q32.1)	
Nonsynonymous exon14:c.C8981A:p.T2994N	 .	 25.4	
Nonsynonymous exon20:c.C10265G:p.T3422R	 rs369378003	 23.2	
SHROOM3	
(4q21.1)	
Nonsynonymous exon5:c.C2659T:p.R887C	 .	 34	
Nonsynonymous exon4:c.G520A:p.D174N	 rs192760386	 23.2	
TTN	
(2q31.2)	
Nonsynonymous exon24:c.G4184C:p.R1395P	 rs72647876	 23.9	
Nonsynonymous exon3:c.G178T:p.D60Y	 rs35683768	 23.4	
Nonsynonymous exon83:c.A21148G:p.R7050G	 rs72648982	 13.38	
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3.2.4.3 Families of Lebanese origin and Druze ethnicity 
3.2.4.3.1 Family F2 
To search for compound heterozygous mutations in family F2 (Figure 3-4), the 
WES data generated for affected members (II:1, II:2, I:3) were analysed using 
this inheritance model (Figure 3-20) and the variants prioritized according to their 
predicted pathogenicity using CADD Phred scores. The data for the affected 
individuals was compared to look for shared compound heterozygous variants 
using the perl script described in Section 2.12. The final list of compound 
heterozygous variants shared by the affected patients is given in Table 3-31 
Table 3-31: Compound heterozygous variants shared by the affected 
siblings of F2 family. Details of compound heterozygous variants found in 
affected members of family F2 for which both variants have at least CADD Phred 
scores ≥10. 





Nonsynonymous		 exon12:c.G5152A:p.E1718K	 rs76484008	 19.42	 I:3	
Nonsynonymous	 exon12:c.G5179A:p.G1727S	 rs76698423	 22.7	 II:1,	II:2,	I:3	
Frameshift	
Insertion	
exon12:c.G5179A:p.G1727S	 .	 24.1	 II:1,	II:2	
FAM193A	
(4p16.3)	
Nonsynonymous	 exon11:c.C1271A:p.P424Q	 rs34435530	 23.5	 II:1,	II:2,	I:3 
Nonsynonymous	 exon6:c.C452A:p.T151N	 rs145745319	 23.3	 II:1,	II:2,	I:3 
SEMA6A	
(5q23.1)	
Nonsynonymous	 exon2:c.C14G:p.A5G	 rs114860630	 18.08	 II:1,	II:2,	I:3 
Nonsynonymous	 exon19:c.G2383A:p.G795S	 rs374035190	 22.6	 II:1,	II:2,	I:3 
 
3.2.4.3.2 Family F9 
To search for compound heterozygous mutations in sample (III:8) of family F9 
(Figure 3-4), the WES data generated for sample (III:8) was analysed using this 
inheritance model (Figure 3-20) and checked for genes with two pathogenic 
variants.  The variants were prioritized according to their predicted pathogenicity 
using CADD Phred scores. The final list of compound heterozygous variants  is 
given in Table 3-32. 
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Table 3-32: Compound Heterozygous variants in sample III:8 from family 
F9. Details of compound heterozygous variants found in individual III:8 from 
family F9 for which both variants have at least CADD Phred scores ≥ 20. 




Nonsynonymous exon12:c.C2882T:p.A961V	 rs149800737	 24.6	
Nonsynonymous exon12:c.G2881T:p.A961S	 .	 23.9	
DYNC2H1	
(11q22.3)	
Stopgain	 exon26:c.C4018T:p.Q1340X	 .	 40	
Nonsynonymous exon89:c.G12865C:p.G4289R	 rs144717489	 22.7	
HEXDC	
(17q25.3)	
Nonsynonymous exon12:c.G1454A:p.C485Y	 rs140743740	 24.6	
Nonsynonymous exon12:c.C1526A:p.A509E	 rs150076334	 22.7	
LTBP1	
(2p22.3)	
Nonsynonymous exon20:c.T2692A:p.S898T	 .	 25.9	
Nonsynonymous exon21:c.G2885A:p.R962Q	 rs141080282	 24.2	
NEB	
(2q23.3)	
Nonsynonymous exon104:c.T15023C:p.L5008P	 rs111517514	 28.3	
Nonsynonymous exon71:c.G10383C:p.M3461I	 rs149025191	 20.3	
NOD2	
(16q12.1)	
Nonsynonymous exon3:c.C1540T:p.R514W	 .	 24.9	
Nonsynonymous exon3:c.C1969T:p.R657W	 rs5743276	 23.2	
PCNT	
(21q22.3)	
Nonsynonymous exon39:c.T8924C:p.L2975P	 rs35881595	 26.1	
Nonsynonymous exon31:c.C6986G:p.P2329R	 rs35848602	 23.3	
POLR3B	
(12q23.3)	
Nonsynonymous exon13:c.C940T:p.L314F	 .	 28.4	
Nonsynonymous exon13:c.A933T:p.L311F	 .	 25.1	
TAS2R31	
(12p13.2)	
Nonsynonymous exon1:c.G843T:p.W281C	 rs139069360	 24	
Nonsynonymous exon1:c.A711T:p.L237F	 rs116926686	 21	
TTN	
(2q31.2)	
Nonsynonymous exon154:c.G55303A:p.E18435K	 rs375422359	 22.9	
Nonsynonymous exon184:c.G72901A:p.V24301I	 rs55675869	 22.2	
IGSF10	
(3q25.1)	
Stopgain	 exon4:c.G4804T:p.E1602X	 rs79363433	 36	
Stopgain	 exon2:c.G220T:p.E74X	 .	 35	
Nonsynonymous exon2:c.A1507T:p.R503W	 rs3732775	 25	
 
3.2.4.3.3 Family F10 
To search for compound heterozygous mutations in family F10 (Figure 3-4), the 
WES data generated for affected members (III:4 and III:5) were analysed using 
this inheritance model (Figure 3-20) and the variants prioritized according to their 
predicted pathogenicity using CADD Phred scores. The data for the affected 
individuals was compared to look for compound heterozygous variants carried by 
all affected family members using the perl script described in Section 2.12. The 
final list of compound heterozygous variants shared between the affected 
patients is given in Table 3-33. 
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Table 3-33: Compound heterozygous variants shared by the affected 
siblings in F10 family. Details of compound heterozygous variants 
cosegregating with KC in affected members of family F10 for which both variants 
have at least CADD Phred scores ≥ 10. 





Nonsynonymous exon16:c.C4583G:p.T1528R	 rs192957612	 24.4	 III:4,	III:5	
Nonsynonymous exon16:c.C6559G:p.L2187V	 .	 21.1	 III:4,	III:5	
KLHL8	
(4q22.1)	
Nonsynonymous exon8:c.G1028A:p.R343Q	 rs144074504	 29.1	 III:4,	III:5	
Nonsynonymous exon7:c.G982A:p.V328I	 .	 34	 III:4,	III:5	
HK3	
(5q35.2)	
Nonsynonymous exon13:c.G1800C:p.Q600H	 rs61749650	 16.27	 III:4,	III:5	






Nonsynonymous exon1:c.G250A:p.A84T	 rs150210620	 25.4	 III:5	
Nonsynonymous exon5:c.C1208G:p.T403R	 rs141489829	 23	 III:4,	III:5	
Nonsynonymous exon4:c.G320A:p.R107H	 rs200868536	 23.8	 III:4,	III:5	
TNS3	
(7p12.3)	
Nonsynonymous exon20:c.G2648A:p.R883H	 rs200980382	 12.19	 III:4,	III:5	
Nonsynonymous exon17:c.C1363T:p.R455C	 rs148721285	 26.4	 III:4,	III:5	
ROBO3	
(11q24.2)	
Nonsynonymous exon5:c.G850A:p.D284N	 rs142090631	 29.1	 III:4,	III:5	
Nonsynonymous exon21:c.C3150A:p.Y1050X	 .	 35	 III:4,	III:5	
ABCC4	
(13q32.1)	
Nonsynonymous exon26:c.C3284T:p.T1095M	 rs11568644	 26.6	 III:4,	III:5	
Nonsynonymous exon1:c.C52A:p.L18I	 rs11568681	 12.46	 III:4,	III:5	
ADAMTS18	
(16q23.1)	
Nonsynonymous exon20:c.C3157T:p.R1053W	 rs148703569	 28.1	 III:4,	III:5	
Nonsynonymous exon18:c.A2752G:p.K918E	 rs138435590	 24.4	 III:4,	III:5	
SSC5D	
(19q13.42)	
Nonsynonymous exon6:c.C615A:p.H205Q	 .	 15.42	 III:4,	III:5	
Nonsynonymous exon6:c.G851A:p.R284Q	 .	 25.8	 III:4,	III:5	
 
3.2.4.3.4 Family F11 
To search for compound heterozygous mutations in family F11 (Figure 3-4), the 
WES data generated for affected members (II:2 and II:3) were analysed using 
this inheritance model (Figure 3-20) and the variants prioritized according to their 
predicted pathogenicity using CADD Phred scores. The data for the affected 
individuals was compared to look for shared compound heterozygous variants 
using the perl script described in Section 2.12. The final list of compound 
heterozygous variants shared by the affected patients is given in Table 3-34. 
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Table 3-34: Compound heterozygous variants shared by the affected 
siblings of F11 family. Details of compound heterozygous variants carried by 
both affected members of family F11 for which both variants have at least CADD 
Phred scores ≥  20. 




Nonsynonymous exon3:c.C5671T:p.R1891W	 rs36006086	 24.2	
Nonsynonymous exon3:c.C4309T:p.R1437C	 rs12750571	 22.3	
XIRP2	
(2q24.3)	
Nonsynonymous exon7:c.T748C:p.S250P	 rs143400009	 27.3	
Nonsynonymous exon7:c.G9464A:p.G3155E	 rs16853333	 23.2	
NFKBIZ		
(3q12.3)	
Nonsynonymous exon3:c.T857C:p.I286T	 .	 23.5	
Splicing	(+1)	 exon2:c.C712T:p.P238S	 .	 24.9	
OR8D4	
(11q24.1)	








Nonsynonymous exon1:c.G716A:p.S239N	 rs4987133	 26.2	
Nonsynonymous exon1:c.304dupT:p.L101fs	 rs61747605	 26.2	
USH2A	
(1q41)	
Nonsynonymous exon35:c.A6713C:p.E2238A	 rs41277212	 27.1	
Nonsynonymous exon13:c.G2384A:p.C795Y	 .	 26.5	
Nonsynonymous exon8:c.G1434C:p.E478D	 rs35730265	 23.8	
3.2.4.3.5 Family F12 
To search for compound heterozygous mutations in sample (II:2) of family F12 
(Figure 3-4), the WES data generated for sample (II:2) was analysed using this 
inheritance model (Figure 3-20) and checked for genes with two pathogenic 
variants. The variants were prioritized according to their predicted pathogenicity 
using CADD Phred scores. The final list of compound heterozygous variants is 
given in Table 3-35. 
 
Table 3-35: Compound Heterozygous variants in sample II:2 of family F12. 
Details of compound heterozygous variants found in patient II:2 of family F12 for 
which both variants have at least CADD phred scores ≥ 20. 




Nonsynonymous exon1:c.T1226C:p.F409S	 .	 27.4	
Nonsynonymous exon1:c.C475T:p.R159C	 .	 23.5	
AHNAK	
(11q12.3)	
Nonsynonymous exon5:c.C16168A:p.P5390T	 rs77640901	 23.2	
Nonsynonymous exon5:c.G3292T:p.V1098F	 rs79639272	 22.9	
ANO2	
(12p13.31)	
Nonsynonymous exon22:c.C2371T:p.R791W	 .	 26.5	
Nonsynonymous exon19:c.A1973C:p.Y658S	 .	 26.2	
ATP4A	 Nonsynonymous exon21:c.G3077T:p.G1026V	 .	 33	
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(19q13.12)	 Nonsynonymous exon21:c.G3076A:p.G1026R	 .	 28.3	
CEP192	
(18p11.21)	
Nonsynonymous exon20:c.C4180T:p.L1394F	 rs61740922	 27.7	
Nonsynonymous exon10:c.G1375A:p.E459K	 rs116020861	 21.8	
GPRC5C	
(17q25.1)	
Nonsynonymous exon1:c.C40T:p.R14W	 .	 23.5	
Nonsynonymous exon4:c.G1333A:p.V445I	 rs139362972	 23.4	
LRP1B	
(2q22.1)	
Nonsynonymous exon89:c.C13438T:p.P4480S	 rs75758215	 25.1	
Nonsynonymous exon70:c.G10844C:p.G3615A	 rs76554185	 24.2	
MPHOSPH10	
(2p13.3)	
Nonsynonymous exon10:c.G1784A:p.R595Q	 rs115361918	 33	
Nonsynonymous exon3:c.G826T:p.D276Y	 .	 29.9	
NFKBIZ	
(3q12.3)	
Splicing	(+1)	 exon11:c.1635+1G&amp;gt;C	 .	 24.9	
Nonsynonymous	 exon10:c.C1931G:p.A644G	 .	 23.5	
PGPEP1	
(19p13.11)	
Stopgain	 exon2:c.C85T:p.Q29X	 .	 37	
Nonsynonymous exon2:c.A56G:p.H19R	 .	 23.6	
PLEKHG2	
(19q13.2)	
Nonsynonymous exon18:c.G2308A:p.A770T	 rs111487768	 33	
Nonsynonymous exon13:c.C1358G:p.P453R	 rs34975345	 26.4	
SYNE1	
(6q25.2)	
Nonsynonymous exon123:c.A22303G:p.S7435G	 rs35763277	 27.9	
Nonsynonymous exon66:c.G10619A:p.R3540H	 rs145911138	 23.6	
 
3.2.4.3.6 Family 13 
To search for compound heterozygous mutations in family F11 (Figure 3-4), the 
WES data generated for affected members (II:6 and III:13) were analysed using 
this inheritance model (Figure 3-20) and the variants prioritized according to their 
predicted pathogenicity using CADD Phred scores. The data for the affected 
individuals was compared to look for shared compound heterozygous variants 
using the perl script described in Section 2.12. The final list of compound 
heterozygous variants shared by the affected patients is given in Table 3-36. 
 
Table 3-36: Compound Heterozygous variants shared by the affected 
siblings of F13 family. Details of compound heterozygous variants affected 
individuals II:6 and III:13 for which both variants have at least CADD phred 
scores ≥  10. 





Nonsynonymous exon20:c.C4180T:p.L1394F	 rs61740922	 27.7	 III:13,	II:6	
Nonsynonymous exon10:c.G1375A:p.E459K	 rs116020861	 21.8	 III:13,	II:6	
DNAH14	
(1q42.12)	
Nonsynonymous exon55:c.C8410T:p.R2804C	 rs140066130	 34	 III:13,	II:6	
Nonsynonymous exon46:c.G7022A:p.G2341E	 rs41303311	 28.2	 III:13,	II:6	
Nonsynonymous exon68:c.A10597G:p.M3533V	 rs74147200	 19.74	 III:13,	II:6	
OBSCN	 Nonsynonymous exon94:c.G20746A:p.E6916K	 rs200269110	 24.5	 III:13	
Nonsynonymous exon34:c.T9185G:p.V3062G	 rs202022683	 23.4	 III:13	
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(1q42.13)	 Nonsynonymous exon94:c.C21488T:p.P7163L	 rs72762066	 22	 II:6	
Nonsynonymous exon22:c.G6373T:p.A2125S	 rs75280352	 14.82	 III:13,	II:6	
TTN	
(2q31.2)	
Nonsynonymous exon87:c.C22204T:p.R7402C	 rs72648987	 23.1	 III:13,	II:6	
Nonsynonymous exon102:c.A26080T:p.T8694S	 rs72650006	 19	 III:13,	II:6	
3.2.4.4 Families of Lebanese origin and Christian Maronite ethnicity 
3.2.4.4.1 Family F6 
To search for compound heterozygous mutations in family F6 (Figure 3-5), the 
WES data generated for affected members (III:2, III:7 and III:8) were analysed 
using this inheritance model (Figure 3-20) and the variants prioritized according 
to their predicted pathogenicity using CADD Phred scores. The data for the 
affected individuals was compared to look for shared compound heterozygous 
variants/genes using the perl script described in Section 2.12. The final list of 
compound heterozygous variants shared between the affected patients are 
described in Table 3-37. 
Table 3-37: Compound heterozygous variants shared by the affected 
siblings of F6 family. Details of compound heterozygous variants found in all 
affected members of family F6 for which both variants have at least CADD Phred 
scores ≥ 10. 





Nonsynonymous exon1:c.C47T:p.P16L	 rs146450609	 17.72	 III:7,	III:8,	III:2	
Nonsynonymous exon11:c.T982C:p.F328L	 rs41273175	 22.1	 III:7,	III:8,	III:2	
MUC4	
(3q29)	
Nonsynonymous exon2:c.C9358T:p.P3120S	 rs77902873	 11.66	 III:2	
Nonsynonymous exon2:c.C4625T:p.P1542L	 rs202029925	 13.77	 III:7	
Nonsynonymous exon2:c.G12184A:p.A4062T	 rs370995233	 14.23	 III:7,	III:8,	III:2	
Nonsynonymous exon2:c.C5038T:p.P1680S	 rs7374593	 10.15	 III:8	
 
3.2.4.4.2 Family F7 
To search for compound heterozygous mutations in family F7 (Figure 3-5), the 
WES data generated for affected members (II:1 and II:3) were analysed using 
this inheritance model (Figure 3-20) and the variants prioritized according to their 
predicted pathogenicity using CADD Phred scores. The data for the affected 
individuals was compared to look for shared compound heterozygous variants 
using the perl script described in Section 2.12. The final list of compound 
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heterozygous variants shared between the affected patients are described in 
Table 3-38. 
Table 3-38: Compound Heterozygous variants shared by the affected 
siblings of F7 family. Details of compound heterozygous variants found in both 
affected members of family F7 for which both variants having at least CADD 
Phred scores ≥  10. 




Nonsynonymous exon2:c.G9415C:p.V3139L	 rs114676657	 22.9	
Nonsynonymous exon2:c.G12616A:p.A4206T	 rs139868374	 23.4	
MUC4	
(3q29)	
Nonsynonymous exon36:c.G38821A:p.E12941K	 .	 10.62	
Nonsynonymous exon12:c.G36581A:p.R12194Q	 rs58500707	 10.9	
 
3.2.4.4.3 Family F8 
To search for compound heterozygous mutations in family F7 (Figure 3-5), the 
WES data generated for affected members (III:2 and III:4) were analysed using 
this inheritance model (Figure 3-20) and the variants prioritized according to their 
predicted pathogenicity using CADD Phred scores. The data for the affected 
individuals was compared to look for shared compound heterozygous variants 
using the perl script described in Section 2.12. The final list of compound 
heterozygous variants shared by the affected patients is given in Table 3-39. 
Table 3-39: Compound Heterozygous variants shared between the affected 
siblings of F8 family. Details of compound heterozygous variants found in both 
affected members of family F8 for which both variants have at least CADD Phred 
scores ≥ 10. 




Nonsynonymous	 exon11:c.G962C:p.R321P	 rs149593163	 23.4	
Nonsynonymous	 exon4:c.G244A:p.A82T	 rs112366230	 27.5	
SHROOM3	
(4q21.1)	
Nonsynonymous	 exon5:c.A1691C:p.E564A	 rs76656494	 17.44	
Nonsynonymous	 exon5:c.C3035A:p.T1012N	 rs147732653	 13.36	
PCDHGB1	
(5q31.3)	
Nonsynonymous	 exon1:c.G557T:p.S186I	 rs62378414	 10.98	
Nonsynonymous	 exon1:c.A1195G:p.K399E	 rs77250251	 18.12	
ANKK1	
(11q23.2)	
Nonsynonymous	 exon2:c.G365A:p.R122H	 rs35877321	 11.25	
Nonsynonymous	 exon5:c.G766A:p.E256K	 .	 23	
DNAH17	
(17q25.3)	
Nonsynonymous	 exon2:c.G12073A:p.A4025T	 rs146968926	 11.85	
Nonsynonymous	 exon2:c.C7727G:p.P2576R	 rs61736352	 22.8	
LAMA5	
(20q13.33)	
Nonsynonymous	 exon76:c.G12335A:p.R4112Q	 rs147290767	 23.8	
Nonsynonymous	 exon26:c.G3880A:p.E1294K	 rs143551466	 25.4	
TTN	 Nonsynonymous	 exon53:c.G7052A:p.R2351Q	 rs66961115	 20.8	
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(2q31.2)	 Nonsynonymous	 exon28:c.G3467A:p.R1156Q	 rs67254537	 18	
Nonsynonymous	 exon186:c.C78593T:p.A26198V	 rs56324595	 23.6	
Nonsynonymous	 exon186:c.G78592T:p.A26198S	 rs199506676	 22.3	
Nonsynonymous	 exon186:c.G78574A:p.E26192K	 .	 15.3	
Nonsynonymous	 exon151:c.G41629A:p.E13877K	 rs72955213	 18.73	
Nonsynonymous	 exon150:c.C31066A:p.R10356S	 rs33917087	 21.9	
 
 
3.2.5 Dominant inheritance: heterozygous mutations  
Although the majority of the families collected for this study had a pedigree 
structure consistent with recessive inheritance, they are also consistent with 
autosomal dominant Mendelian inheritance with reduced penetrance. Indeed, in 
a few families a vertical inheritance is seen with an affected parent having an 
affected child (for example families F12, F13 and AR1F).  In order to investigate 
a possible dominant mode of inheritance, the filtering strategy explained in figure 
3-21 was applied to the WES data generated from each family. As in the 
previous models (section 3.2.3), all the variants with a MAF≥2% on 1000g, 
esp6500si and exac03 databases were removed, all the synonymous, non-
coding and homozygous variants were filtered and the ethnically matched 
variants polymorphisms and artefacts were removed. Where data was available 
for multiple affected family members, variants lists were compared and those not 
shared by all affected family members were removed. The data from unaffected 































Figure 3-21: Filtering strategy for heterozygous dominant hypothesis 
 
 
3.2.5.1 Families of South Asian origin  
3.2.5.1.1 SS1F family 
The results of the shared heterozygous variants present in all six sequenced 
members of SS1F are listed in Table 3-40. Three genes are highlighted: MUC3A 
(Mucin 3A, Cell Surface Associated), OR9G9 (Olfactory Receptor, Family 9, 
Subfamily G, Member 9) and MAP2K3 (Mitogen-Activated Protein Kinase Kinase 
Excel list of heterozygous functional variants 
Filter out all the artefactual variants by comparing 
against list of artefacts 
 
Filter out all the synonymous and non-coding 
variants 
Filter out all the homozygous variants 
Excel list of all exonic and splicing variants 
 
Filter out changes with maf>= 2% on 1000g OR 
esp6500si OR exac03 
Filter out all the common polymorphisms specific of 
same ethnicity 
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3). Analysis of the highlighted genes in the ExAc databases shows that null 
alleles in MUC3A are very common in the heterozygous state. The CADD phred 
scores cut off varied from one family to the other in this section, only to keep the 
size of the lists displayed in this chapter concise. The choice of the cut off was 
made in order to keep the minimal number of entries in the tables using the 
lowest CADD phred score cut-off. 
Table 3-40: Heterozygous variants shared between the affected siblings of 
family SS1F. This table details the heterozygous variants found in all affected 
members of family SSF1 which have CADD Phred scores ≥ 10. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
MUC3A	 Stopgain	 7q22.1	 exon2:c.C3319T:p.Q1107X	 rs79874934	 28	
MUC3A	 Splicing	(+1)	 7q22.1	 exon7:c.3934+1A&amp;gt;C	 rs73714276	 20.6	
OR9G9	 Nonsynonymous 11q12.1	 exon1:c.C505T:p.R169C	 rs11228733	 22.9	
MAP2K3	 Nonsynonymous 17p11.2	 exon12:c.G928A:p.V310M	 rs2363198	 26.1	
 
3.2.5.1.2 AR1F family 
The shared heterozygous variants found in all five sequenced affected members 
of family AR1F and which have a CADD Phred score ≥ 25 are listed in Table 3-
41.  
Table 3-41: Heterozygous variants shared between the affected members of 
family AR1F. This table details the list of heterozygous variants found in all 
affected members of family AR1F which have CADD Phred scores ≥  25. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
CLYBL	 Stopgain	 13q32.3	 exon6:c.C775T:p.R259X	 rs41281112	 35	
DOCK5	 Nonsynonymous	 8p21.2	 exon30:c.G3056A:p.R1019H	 rs148483229	 34	
FERMT3	 Nonsynonymous		 11q13.1	 exon12:c.G1393A:p.E465K	 rs373999037	 30	
SLC9A9	 Nonsynonymous	 3q24	 exon1:c.T65A:p.V22E	 .	 28.7	
ITGB6	 Nonsynonymous		 2q24.2	 exon8:c.G1027A:p.V343M	 rs61737764	
	
28.2	
ULK4	 Nonsynonymous		 3p22.1	 exon33:c.C3379T:p.R1127W	 .	 27.9	
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3.2.5.1.3 Single Cases 
Tables 3-42, 3-43 and 3-44 show the heterozygous variants found in patients 
SC1, SC2 and SC3 which have CADD scores ≥ 35.  
Table 3-42: Heterozygous variants in sample SC1. This table lists 
heterozygous variants found in patient SC1 and having CADD Phred scores ≥  
35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
LOR	 Stopgain	 1q21.3	 exon2:c.G592T:p.G198X	 .	 40	
TIAM2	 Stopgain	 6q25.3	 exon13:c.T1343A:p.L448X	 rs116268446	 40	
C15orf65	 Stopgain	 15q21.3	 exon2:c.C263A:p.S88X	 rs201241267	 39	
CHIT1	 Stopgain	 1q32.1	 exon9:c.G1016A:p.W339X	 rs201320385	 37	











TMEM222	 Nonsynonymous 1p36.11	 exon6:c.C622T:p.R208W	 rs150461998	 35	
SCN10A	 Nonsynonymous 3p22.2	 exon24:c.G4085A:p.R1362Q	 rs369399424	 35	
C3orf67	 Nonsynonymous 3p14.2	 exon16:c.G1609A:p.E537K	 rs139831294	 35	
CSRP3	 Nonsynonymous 11p15.1	 exon7:c.G538T:p.G180C	 .	 35	
ITGB7	 Nonsynonymous 12q13.13	 exon15:c.C2263T:p.R755C	 .	 35	
PLEKHH1	 Nonsynonymous 14q24.1	 exon13:c.C1852T:p.R618W	 .	 35	
ZNF544	 Stopgain	 19q13.43	 exon7:c.C1843T:p.R615X	 rs79258645	 35	
TGM2	 Stopgain	 20q11.23	 exon9:c.G1303T:p.E435X	 .	 35	
PLA2G3	 Stopgain	 22q12.2	 exon1:c.C436T:p.R146X	 rs201767666	 35	
SLC5A4	 Nonsynonymous	 22q12.3	 exon9:c.G1007A:p.R336H	 rs62239049	 35	
 
Table 3-43: Heterozygous variants in sample SC2. This table details the 
heterozygous variants found in patient SC2 which have CADD Phred scores ≥ 
35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
C15orf65	 Stopgain	 15q21.3	 exon2:c.C263A:p.S88X	 rs201241267	 39	
MAP3K10	 Stopgain		 19q13.2	 exon4:c.G1072T:p.E358X	 .	 39	
TRIM45	 Frameshift	
Deletion	






CLCN6	 Nonsynonymous	 1p36.22	 exon13:c.G1337A:p.R446Q	 rs368875103	 35	
BBS7	 Nonsynonymous	 4q27	 exon15:c.1468_1469insTTT
TTTT:p.C490fs	
rs372685495	 35	
RNF10	 Nonsynonymous	 12q24.31	 exon5:c.C646T:p.R216C	 .	 35	
LAMA1	 Nonsynonymous	 18p11.31	 exon50:c.C7141T:p.R2381C	 rs142063208	 35	
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KIAA1683	 Stopgain	 19p13.11	 exon3:c.C3004T:p.Q1002X	 rs200745939	 35	
 
Table 3-44: Heterozygous variants in sample SC3. This table details 
heterozygous variants found in patient SC3 and having CADD Phred scores ≥ 
35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
GCLC	 Stopgain 6p12.1	 exon10:c.C1139A:p.S380X	 .	 44	
GABRP	 Stopgain 5q35.1	 exon10:c.C1186T:p.R396X	 .	 41	
C15orf65	 Stopgain 15q21.3	 exon2:c.C263A:p.S88X	 rs201241267	 39	
DCDC2C	 Stopgain 2p25.3	 exon5:c.C581G:p.S194X	 rs199703744	 37	
TMEM175	 Stopgain 4p16.3	 exon6:c.C271T:p.Q91X	 .	 35	
BAIAP2L2	 Nonsynonymous 22q13.1	 exon12:c.C1273T:p.R425W	 rs371417992	 35	
MRPS18A	 Nonsynonymous 6p21.1	 exon3:c.G221A:p.R74H	 rs377393438	 35	
COBL	 Nonsynonymous 7p12.1	 exon2:c.G59C:p.R20P	 rs200229807	 35	






DDX31	 Nonsynonymous 9q34.13	 exon7:c.C904T:p.R302C	 rs374539267	 35	
MPP4	 Nonsynonymous 2q33.1	 exon19:c.G1421A:p.R474H	 rs190854787	 35	
 
 
3.2.5.2 Family KF of Indian origin  
The shared heterozygous variants with CADD Phred scores ≥ 35 present in all 
three sequenced affected siblings of family KF are listed in Table 3-45.  
Table 3-45: Heterozygous variants shared by the affected siblings of family 
KF. This table details heterozygous variants found in all three affected individuals 
from family KF and having CADD Phred scores ≥ 35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
WDR90	 Stopgain 16p13.3	 exon35:c.G4385A:p.W1462X	 .	 43	
EPYC	 Stopgain 12q21.33	 exon5:c.C562T:p.R188X	 rs143768297	 37	
RTN4	 Nonsynonymous 2p16.1	 exon7:c.G587A:p.R196H	 rs202245854	 35	
MAGI1	 Nonsynonymous 3p14.1	 exon22:c.C3592T:p.R1198C	 rs201117026	 35	
FGFBP2	 Stopgain	 4p15.32	 exon1:c.C664T:p.R222X	 .	 35	
KDM7A	 Nonsynonymous 7q34	 exon3:c.C379T:p.R127C	 .	 35	
LCTL	 Nonsynonymous 15q22.31	 exon6:c.G227A:p.R76H	 .	 35	
HOXB9	 Nonsynonymous 17q21.32	 exon2:c.G548A:p.R183H	 rs201792149	 35	
FBXO17	 Nonsynonymous 19q13.2	 exon6:c.C730T:p.R244C	 rs140379005	 35	
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3.2.5.3 Families of Lebanese origin and Druze ethnicity 
3.2.5.3.1 Family F2 
The shared heterozygous variants with CADD Phred scores ≥ 35 present in all 
sequenced affected siblings of family F2 are listed in Table 3-46.  
Table 3-46: Heterozygous variants shared between the affected siblings of 
F2 family. This table details heterozygous variants shared by all affected 
individuals in family F2 and having CADD Phred scores ≥ 35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 CADD	
Phred	
ANKEF1	 Stopgain		 20p12.2	 exon9:c.C2045A:p.S682X	 rs375202162	 36	
BCAT1	 Nonsynonymous	 12p12.1	 exon4:c.G341A:p.R114Q	 .	 35	
C14orf105	 Stopgain	 14q22.3	 exon5:c.C544T:p.Q182X	 rs34960436	 35	
 
3.2.3.3.2 Family F9 
The heterozygous variants with CADD Phred scores ≥ 35 present in III:8 from 
family F9 are listed in Table 3-47.  
Table 3-47: Heterozygous variants in Family F9. This table details 
heterozygous variants with CADD Phred scores ≥ 35 found in individual III:8 from 
family F9. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
HINT3	 Stopgain 6q22.32	 exon2:c.A289T:p.R97X	 rs201833844	 40	
DYNC2H1	 Stopgain 11q22.3	 exon26:c.C4018T:p.Q1340X	 .	 40	
SMAD9	 Stopgain 13q13.3	 exon4:c.T693A:p.Y231X	 .	 38	
KBTBD13	 Stopgain 15q22.31	 exon1:c.C1309T:p.Q437X	 .	 38	
FAM71A	 Stopgain 1q32.3	 exon1:c.A1663T:p.K555X	 rs143861665	 36	
GCKR	 Stopgain 2p23.3	 exon9:c.C679T:p.R227X	 rs149847328	 36	
IGSF10	 Stopgain 3q25.1	 exon4:c.G4804T:p.E1602X	 rs79363433	 36	
PCDHGA10	 Stopgain 5q31.3	 exon1:c.C2188T:p.Q730X	 rs62378454	 36	
OR8K3	 Stopgain 11q12.1	 exon1:c.C778T:p.Q260X	 rs117366703	 36	






NFASC	 Nonsynonymous 1q32.1	 exon11:c.C1378T:p.R460W	 rs184631101	 35	
CDK18	 Nonsynonymous 1q32.1	 exon3:c.G260A:p.R87H	 rs368734289	 35	
IGSF10	 Stopgain 3q25.1	 exon2:c.G220T:p.E74X	 .	 35	
ROPN1L	 Stopgain 5p15.2	 exon2:c.T135A:p.Y45X	 rs41280363	 35	
OR1J4	 Stopgain 9q33.2	 exon1:c.C221G:p.S74X	 .	 35	
POLL	 Nonsynonymous	 10q24.32	 exon7:c.G1126A:p.G376S	 rs200623399	 35	
CCDC67	 Stopgain 11q21	 exon5:c.C364T:p.R122X	 .	 35	
SERPINA10	 Stopgain 14q32.13	 exon2:c.C262T:p.R88X	 rs2232698	 35	
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TRAP1	 Nonsynonymous	 16p13.3	 exon3:c.G224A:p.R75H	 rs61758086	 35	
3.2.3.3.3 Family F10 
The heterozygous variants with CADD Phred scores ≥ 35 shared between III:4 
and III:5 from family F10 (10/1 and 10/2) are listed in Table 3-48.  
Table 3-48: Heterozygous variants shared between the affected siblings of 
family F10. This table details heterozygous variants found in both affected 
members of family F10 and having CADD Phred scores ≥ 35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
AIM1	 Stopgain		 6q21	 exon2:c.C2812T:p.R938X	 rs372779090	 37	
LAMC3	 Frameshift	
Deletion	
9q34.12	 exon3:c.695delC:p.T232fs	 .	 35	
ROBO3	 Stopgain	 11q24.2	 exon21:c.C3150A:p.Y1050X	 .	 35	
 
3.2.3.3.4 Family 11 
The heterozygous variants with CADD Phred scores ≥ 35 shared between II:2 
and II:3 from family F11 are listed in Table 3-49.  
Table 3-49: Heterozygous variants shared by affected siblings of family 
F11. This table details heterozygous variants found in both affected members of 
family F11 and having Cadd phred scores ≥ 35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
IRAK3	 Stopgain 12q14.3	 exon7:c.C616T:p.R206X	 rs367600113	 39	
NT5C3B	 Stopgain 17q21.2	 exon7:c.C505T:p.Q169X	 .	 39	






TAAR2	 Stopgain	 6q23.2	 exon1:c.C604T:p.R202X	 rs147900465	 36	
ARHGEF10L	 Nonsynonymous 1p36.13	 exon27:c.C3577T:p.R1193C	 .	 35	
MGAT4D	 Nonsynonymous 4q31.1	 exon10:c.C1024T:p.R342X	 rs62346874	 35	
DKK1	 Nonsynonymous 10q21.1	 exon2:c.G359T:p.R120L	 rs149268042	 35	
RASSF8	 Nonsynonymous 12p12.1	 exon5:c.C1183T:p.R395W	 rs370277680	 35	
SDCBP2	 Nonsynonymous 20p13	 exon3:c.G317A:p.R106Q	 rs35367003	 35	
 
3.2.3.3.5 Family F12 
The heterozygous variants with CADD Phred scores ≥ 35 present in III:2 from 
family F12 are listed in Table 3-50.  
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Table 3-50: Heterozygous variants in Family F12. This table details 
heterozygous variants in individual III:2 from family F12 with Cadd phred scores 
≥ 35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
EML6	 Stopgain 2p16.1	 exon5:c.G531A:p.W177X	 .	 39	
ARL6IP4	 Stopgain 12q24.31	 exon1:c.G472T:p.E158X	 .	 37	






AFF1	 Stopgain	 4q21.3	 exon3:c.C1031G:p.S344X	 .	 36	
PCK2	 Frameshift	
Insertion	
14q11.2	 exon10:c.1468dupA:p.P489fs	 .	 35	
ANGEL1	 Frameshift	
Deletion	
14q24.3	 exon5:c.1091delT:p.V364fs	 .	 35	
NFASC	 Nonsynonymous	 1q32.1	 exon11:c.C1378T:p.R460W	 rs184631101	 35	
ZNF445	 Stopgain	 3p21.31	 exon3:c.C58T:p.R20X	 .	 35	
MAP3K5	 Nonsynonymous 6q23.3	 exon17:c.G2300A:p.R767H	 rs114243010	 35	
LRGUK	 Nonsynonymous 7q33	 exon10:c.C1196T:p.P399L	 rs61749957	 35	
NYNRIN	 Stopgain	 14q12	 exon4:c.C1810T:p.Q604X	 .	 35	
PYGL	 Nonsynonymous 14q22.1	 exon5:c.C625T:p.R209C	 .	 35	
DNAH17	 Nonsynonymous 17q25.3	 exon66:c.G10675A:p.E3559K	 .	 35	
GCAT	 Nonsynonymous 22q13.1	 exon9:c.C1237T:p.R413W	 rs17856459	 35	
 
3.2.3.3.6 Family F13 
The heterozygous variants with CADD Phred scores ≥ 35 shared between II:6 
and III:13 from family F13 are listed in Table 3-51.  
Table 3-51: Heterozygous variants shared between the affected siblings of 
family F13. This table details heterozygous variants in both affected members of 
family F13 having CADD Phred scores ≥ 35. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
BRCA2	 Stopgain	 13q13.1	 exon27:c.A9976T:p.K3326X	 rs11571833	 38	
OTOR	 Frameshift	
Insertion	
20p12.1	 exon3:c.300dupC:p.F100fs	 .	 35	
FLNB	 Nonsynonymous 3p14.3	 exon14:c.C2095T:p.R699W	 rs200554477	 35	
ARID1B	 Nonsynonymous 6q25.3	 exon7:c.C2405T:p.S802L	 rs150140314	 35	
P2RX5	 Nonsynonymous 17p13.2	 exon8:c.C856T:p.R286C	 rs146166049	 35	
STARD6	 Stopgain	 18q21.2	 exon1:c.C55T:p.R19X	 rs17292725	 35	
CC2D1A	 Nonsynonymous	 19p13.12	 exon4:c.C314T:p.A105V	 rs192358667	 35	
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3.2.5.4 Families of Lebanese origin and Christian Maronite ethnicity 
3.2.5.4.1 Family F6 
The heterozygous variants with CADD Phred scores ≥ 30 shared between III:2, 
III:7 and III:8 affected members from family F6 are listed in Table 3-52.  
 
Table 3-52: Heterozygous variants shared between the affected siblings of 
family F6. This table details heterozygous variants carried by all three affected 
members of family F6 having CADD Phred scores ≥ 30. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
BMP8B	 Nonsynonymous	 1p34.2	 exon7:c.G1166A:p.R389H	 rs41267039	 35	
PKD2L1	 Nonsynonymous	 10q24.31	 exon8:c.C1273T:p.R425C	 rs147426900	 33	
 
3.2.5.4.2 Family F7 
The heterozygous variants with CADD Phred scores ≥ 30 shared between II:1 
and II:3 affected members from family F7 are listed in Table 3-53.  
Table 3-53: Heterozygous variants shared between the affected siblings of 
F7 family. This table details heterozygous variants carried by both affected 
members of family F7 having CADD Phred scores ≥ 30. 
Gene	 Function	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
LRP4	 Nonsynonymous 11p11.2	 exon10:c.C1117T:p.R373W	 rs118009068	 33	
N4BP3	 Nonsynonymous 5q35.3	 exon4:c.G950A:p.R317H	 rs115186199	 32	
PPID	 Nonsynonymous 4q32.1	 exon2:c.C145T:p.R49C	 rs2070631	 31	
 
3.2.5.4.3 Family F8 
The heterozygous variants with CADD Phred scores ≥ 35 shared between III:2 
and III:4 affected members from family F8 are listed in Table 3-54.  
Table 3-54: Heterozygous variants shared between the affected siblings of 
family F8. This table details heterozygous variants carried by both affected 
members of family F8 having CADD Phred scores ≥ 35. 
Gene	 Chr	 Chr	 AA	Change	 SNP	 Cadd	
Phred	
TRAF3IP3	 Stopgain 1q32.2	 exon16:c.C1525T:p.R509X	 .	 47	
FILIP1L	 Stopgain 3q12.1	 exon2:c.C2542T:p.Q848X	 rs202015243	 39	
BCLAF1	 Stopgain 6q23.3	 exon5:c.G1201T:p.E401X	 rs61731960	 39	
KRTAP2-4	 Stopgain 17q21.2	 exon1:c.G282A:p.W94X	 rs200049107	 38	
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GSG1	 Stopgain 12p13.1	 exon4:c.C409T:p.Q137	 rs141509089	 37	





















KIAA1614	 Nonsynonymous 1q25.3	 exon2:c.C901T:p.R301C	 rs79485039	 35	
PYGM	 Nonsynonymous 11q13.1	 exon18:c.G2183A:p.R728H	 rs139230055	 35	
 
 
3.2.5.5 Combining the potential compound heterozygous and 
dominant mutations data for all families 
A large number of genes were highlighted in this study with compound 
heterozygous variants (section 3.2.4) and dominant mutations (section 3.2.5) in 
each family. Clearly this data set is too big to take forward, so to prioritise 
candidates, the lists were analysed to look for genes highlighted in more than 
one family. A shorter version of this list is shown in Table 3-55. This shortened 
table only shows the genes that were highlighted in two or more families 
belonging to the different ethnicities studied in this project (South Asian, 
Lebanese Druze and Lebanese Maronites). In addition, the genes were 
prioritised by checking for associations in the literature with terms related to KC 
using pubmatrix: Keratoconus, Cornea, Oxidative Stress, Collagen, Eye, 
Inflammation, Proteinase, Apoptosis, Epithelial cells and Keratocytes. Finally, the 
highlighted genes listed in table 3-55 contained variants with CADD Phred 
scores ≥ 10 and presenting at least 1 hit of association with terms related to KC 
in the literature. The full list is shown in appendix 8. 
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Table 3-55: List of genes containing heterozygous variants in multiple KC 
families. This table presents a list of genes in which heterozygous variants were 
observed in at least two families out of 15 belonging to at least two different 














































































































































SHROOM3	 KF,	F8,	F9,	F12	 Epithelial	Cells,	Eye,	Collagen	and	Inflammation	 19	



























UBXN11	 SC1,	SC2,	F8,	F9,	 Epithelial	Cells	and	Proteinase	 2	












IGFN1	 SC3,	KF,	F2,	F9	 Inflammation	 1	








This analysis highlighted nine (p.E679K, p.D1458E, p.Q1623R, p.P2477L, 
p.P2781L, p.V2803I, p.R3414S, p.R3426Q, p.Q3858H) rare functional ZNF469 
variants (MAF < 2%) which were detected in 5 families AR1F, F2, F6, F11 and 
F12. Mutations in ZNF469 have been reported to contribute to the pathogenesis 
of KC (Section 1.4.9.3) (Rohrbach et al., 2013, Sahebjada et al., 2013, De Baere, 
2014, Lechner et al., 2014, Vincent et al., 2014, Davidson et al., 2015). Thus 
PCR primers were designed (Appendix 9), and all identified variants , presented 
in Table 3-56, were Sanger sequenced in the available family members to check 
that they segregated with the phenotype in each family. However, none of these 
families segregated the ZNF469 mutations in a perfect manner. 
Table 3-56: ZNF469 segregation results. This table shows the variants 
revealed in ZNF469 after Sanger sequencing and the families in which they were 
found.  
Mutation	 M1	 M2	 M3	 M4	 M5	 M6	 M7	 M8	 M9	
AR1F	 E679K	 V2803I	 -	 -	 -	 -	 -	 -	 -	
F2	 -	 -	 -	 -	 -	 -	 R3414S	 Q1623R	 P2477L	
F6	 -	 -	 -	 D1458E	 Q3858H	 -	 -	 -	 -	
F11	 -	 -	 -	 -	 -	 R3426Q	 -	 -	 -	
F12	 -	 -	 P2781L	 -	 -	 -	 -	 -	 -	
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3.2.6 Enrichment of potentially pathogenic alleles analysis 
The families analysed in this study are from communities with a strong tradition 
of consanguinity and endogamy. While this led to the original hypothesis that 
homozygous recessive alleles were responsible for the KC phenotype in the 
pedigrees, it is possible that the consanguineous and endogamous practices in 
these communities have led to the enrichment of multiple pathogenic alleles. 
Thus, instead of a single Mendelian allele causing the KC in these families, 
oligogenic inheritance may be responsible. In this part of the study, the WES 
data generated was analysed to look for enrichment of multiple pathogenic 
alleles in this cohort.  
 
For this analysis, the WES data from one affected member of each KC family 
from this study (Indian, Pakistani, Druze, Maronite) (Section 3.2.2), together with 
WES data from nine unrelated KC families belonging to the Institute of 
Ophthalmology/University College London (IoO/UCL) KC cohort were used 
(Middle Eastern, Caucasians, Asians and Iranians) through collaboration with 
Professor Alison Hardcastle (IoO/UCL). To undertake the analysis of all these 
large datasets, the PLINK/SEQ programme was used (section 2.13). Ethnically 
matched control data was added to the dataset in the ratio of 1:3. The controls 
used were derived from other genetics projects on-going in the Leeds laboratory, 
or were specifically sampled and sequenced for this study. While they were 
selected as individuals not known to have any eye defect, they were not 
specifically examined to exclude KC. The controls collected were sex matched, 
and aged above 25 years old to make sure that they had passed the age when 
they are most prone to develop KC. In total, WES from 72 ethnically and 
ancestry matched controls were added (Table 3-57). Unfortunately, there was a 
shortage of Middle Eastern, Druze and Maronite Lebanese controls so additional 
Caucasian controls downloaded from the 1000 genome project were added for 
the Lebanese ethnicities and Pakistani controls were added to the Middle 
Eastern ethnicity group in order to achieve the 1:3 ratio. 
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Table 3-57: PLINK/SEQ analysis samples. List of KC patients and controls 
used in the PLINK/SEQ analysis and their ethnicities 
Cohort Patients Ethnicity  Number of controls 
Leeds 5 Pakistani 15 
6 Druze, Lebanese 8 Druze + 10 Caucasians 
3 Maronites, Lebanese 4 Maronites + 5 Caucasians 
1 Indian 3 
London 2 Caucasian  6 
4 Middle Eastern 9 Middle Eastern + 3 Pakistanis 
1 Iranian 3 
1 Pakistani 3  





















   
 
 
Figure 3-22: PLINK/SEQ results generation. The pipeline described in this 
figure represents step by step the stages of generating the PLINK/SEQ 
results, starting from sample collection and WES, to combining the results, 
annotating the variants and running PLINK/SEQ software. 
Exomes of 24 
patients from 24 
different families 
 







Combine 96 aligned exomes 
Generate one VCF file for all 
the 96 individuals 
Annotate VCF file and filter 
out non-functional variants  
 
Filter out all the variants with 
maf >2% on dbSNP 138 and 
the Exome Variant Server  
Run on PLINK/SEQ 
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The strategy used for PLINK/SEQ analysis is described in Figure 3-22. Briefly, 
the raw sequence data (the fastq files) of the controls and IoO/UCL cases were 
subjected to the NGS workflow described in Section 3.2.2 previously used to 
analyse the Leeds cohort. Once aligned to hg19, all of the 96 aligned sequence 
(all cases and controls) files were combined together and called for variants 
using GATK (section 2.12). The resulting VCF files were processed using 
annotateSnps.pl and FilterOnEvsMaf.pl developed by Dr. David Parry (University 
of Leeds) (https://github.com/gantzgraf/vcfhacks) to remove all the variants with 
MAF above 2% in dbSNP138 and Exome Variant Server respectively. 
Subsequently, the filtered VCF files were translated using the perl script 
translateVCF.pl (developed by Dr. David Parry) and all the synonymous, non-
coding, intronic and intergenic variants were filtered out using filter_by_anno.pl 
developed by Dr. James Poulter (University of Leeds). Finally, these filtered VCF 
files were used as the input files for PLINK/SEQ (section 2.13). Potential 
enrichments were examined at two levels using PLINK/SEQ: enrichment of 
variants in a given coding sequence of a gene, and enrichment of single variants. 
 
3.2.6.1 Enrichment of variants in a particular gene 
Gene enrichment analysis of gene-based rare-variants (MAF <2%) were 
identified by running PLINK/SEQ using the combined VCF files. This analysis 
compared the burden of non-reference genotypes (the variations compared to 
the reference genome) in cases to controls within a gene. The results of this 
gene enrichment analysis, where variants in reported genes appeared enriched 
in cases while no variations were detected in controls (DESC n/0) where DESC 
is number of case/control minor alleles, are shown in Table 3-58. The full list of 
enrichments can be found in appendix 10. 
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Table 3-58: Gene enrichment results. This table represents the genes that 
have been detected by PLINK/SEQ to carry variants (NVAR) that are totally 
absent in controls compared to KC samples. This test has been conducted using 
the Burden statistical test (Lee et al., 2014) and generating respective p-values 
(p < 0.05).   






















2	 0.00507063	 0.0112319	 3/0	
		chr7:6438337-6438337	 		RAC1	 1	 0.006941	 0.0143849	 3/0	
		chr9:36651842-36651842	 		MELK	 1	 0.00619469	 0.0146082	 3/0	
1The number of variants in the corresponding gene. 
2The empirical significance, based on permutations. 
3The measure of the discreteness of the empirical distribution of the test statistic  
4The number of case/control minor alleles.  
 
 
3.2.6.2 Single site enrichment - Specific allele enrichment. 
Single variant enrichment in cases compared to controls was also investigated 
using PLINK/SEQ. This analysis generated a list of specific variants with their 
respective values, most importantly p-values and Odds ratios. This list was 
sorted according to p-values and only variants with p-values less than 0.05 were 
retained. This data was not corrected for multiple testing since this analysis has 
been used to check for enrichment only but not for association analysis. These 
constituted 1233 variants summarised in table 3-59. 
 
Since this list of variants is un-annotated with respect to pathogenic prediction 
status in the PLINK/SEQ output, the variants were annotated using the variant-
effect-predictor.pl perl script following the command line described in Appendix 
4.3. This programme determines the SIFT and Polyphen predictions (section 
2.12), in addition to determining the MAF of known variants by using the 1000 
genome project data. The list of variants enriched in KC cases with a p-value < 
0.05 are listed in table 3-60. The full list can be found in appendix 10. 
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Table 3-59: General PLINK/SEQ statistics after annotation of the variants. 
This table represents how many variants were taken through to PLINK/SEQ 
(Input reads), how many variants were processed for annotation (Variants 
processed) and the percentage of the novel variants and the existing variants 
among the overall variants. 
Line of input reads 1233 
Variants processed 1227 
Novel Variants 460 (37.5%) 
Existing variants 767 (62.5%) 
 
Table 3-60: List of enriched variants in KC. This list represents the variants 
enriched in KC patients compared to controls. 




























































































































































































chr7:100807151	 G	 C	 		VGF	 Nonsynonymous	 		0.00869543	 		9.09091	
1Odds Ratio 
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3.2.6.3 Pathway analysis of PLINK/SEQ data 
The two levels of potential enrichment (gene and single variant) examined by 
PLINK/SEQ generated a list of genes for which variants have been found to be 
enriched in cases compared to controls along with a list of variants that show 
enrichment with KC in the cohort of familial cases studied. Table 3-61 displays 
the association of the genes mentioned in both lists (Table 3-58 and 3-60) with 
terms that are related to KC (Keratoconus, Cornea, Oxidative Stress, Collagen, 
Eye, Inflammation, Proteinase, Apoptosis, Epithelial cells and Keratocytes) 
generated using Pubmatrix (Section 2.10), and thus highlights some genes that 
might be functionally significant in KC pathogenesis.  
Table 3-61: Pubmatrix results. This table presents the association of the genes 
































































According to Pubmatrix results table 3-61, the genes that are showing high 
association with KC terms in the literature are: Ras-related C3 botulinum toxin 
substrate 1- (RAC1), Mucin 4- (MUC4), Toll-like receptor 6- (TLR6), Endoplasmic 
reticulum to nucleus signalling 2- (ERN2), Melanoma cell adhesion molecule- 
(MCAM), Nebulin- (NEB) and Titin-(TTN). 
 
Pathway analysis (Table 3-62) was undertaken using DAVID (Section 2.14) on 
the proteins encoded by the list of 7 genes presented in the previous paragraph 
(RAC1, MUC4, TLR6, ERN2, NEB, MCAM, TTN). This revealed the involvement 
of RAC1, TTN and TLR6 in the pathways of regulation of kinase and transferase 
activities, regulation of phosphate and phosphorus metabolic processes and in 
the phosphorylation pathway. In addition, MCAM, MUC4 and RAC1 have been 
shown to be involved in the cell adhesion pathway as well as plasma membrane 
with the additional involvement of TLR6 in the latter.  
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Table 3-62: Pathway analysis of six genes (RAC1, MUC4, TLR6, ERN2, 
MCAM, TTN) highlighted as showing high association with KC terms in the 
literature. Table showing the functional annotation clustering of all the possible 
pathways/processes in which the 6 highlighted genes are involved. The column 


































The existence of rare Mendelian forms of complex disease is well established 
with classic examples including Alzheimer’s disease, diabetes and autoimmune 
disease (Peltonen et al., 2006). While these familial cases only account for a 
small proportion of the patient population, they allowed gene identification 
studies to be performed which highlighted disease pathways important in their 
aetiology. To identify the genetic components underlying the majority of complex 
disease cases, genome wide association studies have been performed to identify 
the “common disease-common variants” traditionally believed to underlie 
complex disease (Risch and Merikangas, 1996). However, with the realisation 
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that these common risks variants fail to account for the majority of the heritability 
observed in the majority of complex diseases (Manolio et al., 2009), recently 
there has been switch to the idea that rare variants with a large risk may underlie 
a significant proportion of complex disease (Cirulli and Goldstein, 2010, 
MacArthur et al., 2014). Indeed, for some disorders historically regarded as 
complex, such as schizophrenia and autism, it has been reported that these 
actually represent a heterogeneous collection of rare monogenic disorders 
(McClellan and King, 2010). It was with this background of knowledge that this 
study set out to identify Mendelian alleles causing KC. 
 
The basis of this study was a collection of KC families which were collected on a 
field trip to Lebanon, through clinical colleagues at St James’s Hospital or 
through collaboration. The pedigree structure of the KC families, or the 
endogamous nature of the community they originated from, suggested that an 
autosomal recessive homozygous mutation was responsible for the KC 
phenotype. The “endogamous families” were all Lebanese and although these 
families did show a pedigree structure indicative of recessive inheritance of KC 
or consanguinity, the choice of studying KC in these families was due to the high 
levels of consanguinity and endogamy in the Lebanese population. The 
consanguinity rate in Lebanon is 35.5% (Barbour and Salameh, 2009) and 88% 
of marriages occur within the same religious communities (Klat and Khudr, 
1986). There are high levels of endogamy in the different religious and ethnic 
groups forming the Lebanese population as there are 17 officially recognized 
religious communities in Lebanon, despite the country only having a population 
of 4.5 million (Nakouzi et al., 2015). In particular, the Druze community, which is 
the religion of many of the endogamous families in this study, follows social 
customs that turns it into transnational isolates, by favouring marriage from within 
the same religion and forbidding admixture with other populations by firmly 
closing the religion to new adherents (Shlush et al., 2008). 
 
The hypothesis of an autosomal recessive form of KC is also backed up by the 
published literature. The majority of KC cases are sporadic (Patel and McGhee, 
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2013) (which can be indicative of recessive inheritance in small outbred 
communities) but familial KC is prominent with a rate ranging from 5 to 27.9% 
(Wang et al., 2000). The increased prevalence of KC in populations with high 
levels of consanguineous marriage also suggests the existence of recessive 
alleles (Jonas et al., 2009, Millodot et al., 2011, Waked et al., 2012, Shneor et 
al., 2013, Hashemi et al., 2014). 
 
The strategy used to investigate the presence of recessive alleles underlying KC 
was a combination of autozygosity mapping and WES. Traditional gene 
identification studies start with a whole genome linkage search to identify a locus, 
followed by candidate gene screening. However, with the advent of high 
throughput sequencing technologies, it is now possible to circumvent these steps 
and identify a candidate gene by WES alone. Miller syndrome was the first 
example of a Mendelian disorder identified by WES (Ng et al., 2010). Similar to 
this study, the inheritance pattern for this disorder was unconfirmed at the time of 
the experiment due to the majority of cases being sporadic with only a few sib 
pairs reported. However, the combination of analysing WES data from the 
affected individuals of multiple families under both recessive and dominant 
models led to the successful identification of recessive mutations in DHODH 
(Dihydroorotate Dehydrogenase) (Ng et al., 2010). Since this first example, many 
disease genes have been identified using WES for both Mendelian disorders and 
complex diseases.  
 
In this study, the first experiment focused on sequencing the exome of a single 
key individual in each family with the hope that convincing homozygous 
pathogenic mutations in a common gene(s) would be identified. Unfortunately 
this was not the case so further family members were sequentially sent for WES 
analysis to try and narrow the number of possible mutations. When this failed to 
highlight a clear candidate gene, SNP genotyping was undertaken to try and 
narrow down the list of possible variants further. The data presented in this thesis 
shows the final dataset by combining all of this data. 
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Autozygosity mapping was undertaken using a combination of SNP microarray 
genotyping data and with SNPs derived from the WES data. For many families a 
clear locus could not be identified. Based on the manual inspection of the 
autozygosity data, SSF and KF families presented autozygous regions. Family 
SSF presented a 1.2Mb on chromosome 11, 11q11. Family KF presented two 
autozygous regions on 9p21.1 and 12p13.1 of 3.07Mb and 1.69Mb respectively. 
The lack of a shared region of homozygosity in affected family members would 
indicate that there is no single recessive gene mutated in the family but there are 
limitations with the methodology used which prevent this conclusion being fully 
accurate. One important limitation is the rule-based nature of autozygosity 
mapping. Unlike traditional genetic mapping approaches (Lod scores), for 
autozygosity mapping it is not possible to factor in variables such as 
phenocopies and non-penetrance. The non-penetrance cases were avoided by 
only including affected family members in the mapping analysis, but there was no 
way to avoid phenocopies and given the frequency of KC this could be a 
significant risk. 
 
Another reason for the failure to map a locus could be the resolution of the 
mapping software. The default setting of 1Mb was used in this study, but given 
that some of the families were endogamous the IBD (Identity By Descent) region 
in these cases may be small and may be below this resolution limit. However, for 
the families with a visible consanguineous loop this is unlikely to be problem as it 
has been shown that the disease associated region of homozygosity in these 
situations tend to be large (5-70 cM for offspring from first cousin marriages) 
(Woods et al., 2006). 
 
The SNP data derived from WES was used for autozygosity mapping in 2 
families (SSF, AR1F). This data is not as good as the data derived from SNP 
microarrays. The SNPs on microarrays are chosen for their high levels of 
heterozygosity and for their even distribution throughout the genome. The SNPs 
derived from WES data have much lower levels of heterozygosity, for example, 
one study has shown that ~95% of 0.53 million known polymorphic positions 
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identified by the 1000 Genomes Project are homozygous by state for the 
reference allele in six unrelated WES datasets (Carr et al., 2013). Similarly, they 
only span the targeted exons which are unevenly distributed across the genome 
so there are significant gaps in the genotyping coverage. This means that 
smaller regions of autozygosity may be missed in gene poor regions. However, 
given that the majority of mutations effect the coding portion of a gene (Stenson 
et al., 2009), this shouldn’t be a significant limitation. For all of these reasons, the 
WES data was still analysed independently of autozygosity mapping data if no 
autozygous regions were identified. 
 
Despite highlighting autozygous regions in 2 large families (KF and SSF), 1.2Mb 
on 11q11 of family SSF and 3.07Mb and 1.69Mb on 9p21.1 and 12p13.1 
respectively of family KF, no predicted pathogenic mutation was observed in this 
locus state that this could be due to the limitations of using WES as discussed 
below.  
 
The majority of the analysis in this study was performed using WES, so the 
quality of this data was key to the success of this experiment. All the data used in 
this study was vigorously checked before starting the downstream analysis. This 
quality control comprises, most importantly, the quality scores across all bases 
(Example Figure 3-6a). This analysis showed a very good quality scores across 
the bases across all the samples included in this study with a mean quality score 
ranging from 28 to 32. Adding to the quality reports, and after NGS analysis the 
coverage statistics (Example Figure 3-7), which represents the percentage of 
bases covered above a certain value (n) (n= 5, 10, 15 and 20) was reported for 
every sample (Appendix 5) and the coverage across the sequenced exome is 
reported for all the samples in table 3-2. The WES performed in Leeds gave 
much better coverage than sequencing performed at Otogenetics with a mean 
average of coverage of 44.78 (±21.27) for Leeds compared to 69.59 (±9.55) for 
Otogenetics. This is why the method of WES switched mid way through the 
project. 
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The results for the homozygous autosomal recessive inheritance model didn’t 
provide a clear causative gene but candidates were identified for most of the 
families. The list of candidates was too large to take forward so the whole data 
set was analysed to look for genes identified in multiple families which 
highlighted eight genes; CHRNA3, FDFT1, RNF19B, ZFPM1, MUC3A, NOP9, 
AGAP3 and LOC400863. The first five of these have been associated in the 
literature with terms relating to KC. 
 
The mutations in MUC3A (F11, F12 and F13) and RNF19B (F9 and F10) 
(MUC3A: exon2:c.C3319T:p.Q1107X and exon7:c.3934+1A&amp;gt;C and 
RNF19B: RNF19B:  exon1:c.A185C:p.Q62P) have CADD Phred scores < 6, 
which suggests that they are unlikely to be pathogenic. ZFPM1 represents an 
interesting candidate for KC since it is involved in the down regulation of IL-4 
(Interleukine 4) (Kitamura et al., 2011) and the expression of IL-4 is reported to 
be altered in KC tear samples. Jun et al. reported IL-4 expression to be 
decreased in KC tear samples (Jun et al., 2011), whereas Balasubramanian et 
al. showed an increase in IL-4 expression in KC tear samples (Balasubramanian 
et al., 2012). The ZFPM1 variant shared between the affected members of F12 
and F11 is a 4bp frameshift deletion (exon10:c.1335_1338del:p.P445fs) that is 
part of a 6bp inframe (exon10:c.1334_1339del:p.445_447del) deletion 
polymorphisms occurring in more than 50% of the 8 Druze controls sequenced in 
this study. The change detected in Druze controls is already a known SNP 
(rs149145771), of 0.951118 MAF on esp 6500si and of 0.001418 on ExAc03.	
ZFPM1 or zinc finger protein FOG family member 1, is involved in RNA 
polymerase II transcription factor binding (Mehaffey et al., 2001, Rodriguez et al., 
2005). It is involved in the negative regulation of IL-4 biosynthesis, negative 
regulation of transcription from RNA polymerase II promoter and positive 
regulation in the interferon-gamma biosynthetic process (Rodriguez et al., 2005, 
Kitamura et al., 2011). 	
 
For CHRNA3, the same 3bp in-frame deletion (exon1:c.67_69del:p.23_23del) 
was identified in families F6, F7, F8, F9, F11 and F12 families. Transcriptome 
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profiling has identified CHRNA3 as one of the retinal pigment epithelium (Logan 
et al.) key genes (Strunnikova et al., 2010) and in directional migration of corneal 
epithelial cells (Chernyavsky et al., 2014). Similarly, the same 6bp in frame 
deletion (exon1:c.193_198del:p.65_66del) in FDFT1 has been identified in 
families F6, F7, F8, F9, F11, F12 and F13 families. FDFT1 or farnesyl-
diphosphate farnesyltransferase 1, is involved in the farnesyl-diphosphate 
farnesyltransferase activity as well as the oxidoreduxtase activity (Robinson et 
al., 1993). 
 
Given the lack of a clear pathogenic homozygous recessive gene mutated in the 
families, alternative modes of inheritance were investigated including compound 
heterozygous recessive and dominant inheritance. Reduced penetrance and 
variable expression of autosomal dominant keratoconus has been reported in 
several pedigrees (Rabinowitz et al., 1992, Fullerton et al., 2002, Tyynismaa et 
al., 2002, Brancati et al., 2004, Tang et al., 2005a, Burdon et al., 2008, Udar et 
al., 2009, Saee-Rad et al., 2011) and some of the families in this study were 
consistent with dominant inheritance. As expected, large lists of variants were 
obtained from this analysis so again, the families were compared to look for 
commonality in the potentially mutated genes but no clear candidates were 
identified. 
 
The only genes in Table 3-52 that are associated to KC are: Dystonin (DST), 
FIlaggrin (FLG) and Zinc Finger Protein 469 (ZNF469). Starting by DST, 
detected in SC3, KF, F10 and F12 families. It has been shown to be a 
component of the human and KC corneal basement membrane (Millin et al., 
1986, Cheng et al., 2001). It is involved in integrin binding, microtubule plus-end 
binding and  protein C-terminus binding (Favre et al., 2001, Camargo et al., 
2007, Honnappa et al., 2009, Steiner-Champliaud et al., 2010, Kapur et al., 
2012, Blandin et al., 2013, Hein et al., 2015). It is equally involved in the cell 
motility and cytoskeleton organization processes, hemidesmosome assembly, 
integrin mediated signalling pathway, maintenance of cell polarity and response 
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to wounding (Favre et al., 2001, Okumura et al., 2002, Koster et al., 2003, Hamill 
et al., 2009). 
 
As for FLG, detected in families SC1, SC2, F10 and F11, null mutations in this 
gene has been reported in KC patients with and without Atopic Dermatitis and/or 
Ichtiyosis Vulgaris (Droitcourt et al., 2011). It is involved in the protein binding 
and structural molecule activity (McKinley-Grant et al., 1989, Sakabe et al., 
2013). It is equally involved in the process of keratinocyte differentiation (Zigrino 
et al., 2007). 
 
Finally, mutations in ZNF469 have been thought to contribute to the 
pathogenesis of KC (Rohrbach et al., 2013, Sahebjada et al., 2013, De Baere, 
2014, Lechner et al., 2014, Vincent et al., 2014, Davidson et al., 2015). Thus 
ZNF469 was sequenced and checked for segregation in the 5 families where 
these changes occurred. However, none of these families segregated the 
ZNF469 mutations in a perfect manner (Table 3-52). It is thought to be a 
transcription factor involved in the synthesis of collagen fibres in the cornea and 
regulating the expression of certain extracellular matrix components (Rohrbach 
et al., 2013). Mutations in this gene are thought to cause Brittle Cornea 
Syndrome (Khan et al., 2010). 
 
The original aim of finding a clear major Mendelian gene mutated in the KC 
families was not achieved. This finding is consistent with other studies (De Bonis 
et al., 2011, Nowak and Gajecka, 2011, Nielsen et al., 2013, Nowak and 
Gajecka, 2015), and most importantly the study by Kriszt et al. which suggests 
that KC results from non-Mendelian alleles of major effect and is a complex 
disease (Kriszt et al., 2014). Indeed, complexity can be one explanation why the 
family studies described in this thesis were not able to identify one Mendelian 
recessive or dominant allele responsible for KC in the large consanguineous 
families. 
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The complexity of the disease may lie in polygenic inheritance, indeed digenic 
inheritance of KC has been suggested in several studies (Bisceglia et al., 2005, 
Burdon et al., 2008, Steele et al., 2008). Polygenic or oligogenic inheritance is 
consistent with the findings in this study, since multiple genes were highlighted in 
the families. Alternatively, the complexity of KC aetiology may reside in the 
intertwining of multiple genetics and environmental factors making it a 
heterogeneous, multifactorial disease. KC may therefore be due to the presence 
of predisposing alleles triggered by environmental factors (Davidson et al., 2014), 
such as eye rubbing, atopy and ultra violet exposure (Gordon-Shaag et al., 
2015).  
 
Clinical heterogeneity in KC may have been another complication preventing the 
detection of pathogenic alleles. The clinical observation of KC varies between 
complex pattern of inheritance, inherited (dominant and recessive) and sporadic 
forms, environmental causes, unilateral and bilateral presentation, different cone 
shapes, different degrees of severities in different stages of the disease and 
different speed of development. Consequently, some patients included in the 
same study might have different phenotypes classified under different clinical 
subtypes. This might be overcome by the unification and standardization of KC 
diagnosis, by differentiating all the clinical subtypes under the utilisation of the 
appropriate diagnostic guidelines and methods. 
 
The methodology used to detect the pathogenic variants may have contributed to 
the reason why a clear Mendelian gene was not identified. The WES technique 
used to highlight variants only detects mutations in the coding part of the genome 
(and non-coding RNAs) including the splice sites and dismisses the majority of 
non-coding regions. Pathogenic alleles residing in the promoter or UTRs (or even 
intronic) regions might have been missed. Large deletions or duplications and 
rearrangements will also have been missed. In addition, all the non-pathogenic 
variants (synonymous) were filtered out from the final variants lists, which might 
have missed some variants that could give rise to cryptic splice site events and 
so might contribute to the genetic predisposition of KC. 
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Copy number variations (CNV) will also not have been detected using WES. 
CNVs have been shown to play an important role in many ocular diseases 
(Chanda et al., 2008, Liu and Allingham, 2011, Liu et al., 2012, Xu et al., 2015) 
and two studies have investigated CNVs in KC (Abu-Amero et al., 2011a, 
Rosenfeld et al., 2011). Deletions of locus 5q31.1-q35.3 is associated with 
abnormal corneal phenotypes abnormalities showing duplications and deletions 
has been shown identified in an autosomal dominant KC family, however this 
result was not replicated by any other study (Rosenfeld et al., 2011). New 
software programmes and computational tools have been developed which allow 
the analysis of CNV in WES and these can be used to interrogate the data 
generated in the future (Shi and Majewski, 2013, Zhao et al., 2013, Wang et al., 
2014). 
 
Imprinted alleles (Reik et al., 2001) and trinucleotide repeat expansions also 
weren’t investigated in this study. Since KC is a progressive disorder and 
susceptible to environmental factors, imprinted genes should be investigated 
since these genes are likely epigenetic targets for environmental interactions with 
the genome (Waterland, 2006). Similarly, trinucleotide repeat expansions are a 
possible cause of disease as has recently been shown for Fuchs’ endothelial 
corneal dystrophy (Mootha et al., 2015). This disease mechanism is especially 
interesting in families where the severity of KC increases through subsequent 
generations e.g. family AR1F (Marquis Gacy et al., 1995, Mitas, 1997). 
 
Mitochondrial defects were not investigated in this project, as mitochondrial 
inheritance is not consistent with the pedigree structure (except possibly family 
KF and F11). However, mitochondrial mutations have been linked to KC 
pathogenesis (Pathak et al., 2011, Abu-Amero et al., 2014b) as have 
mitochondrial copy number variation (Abu-Amero et al., 2014b, Hao et al., 
2015b) and the accumulation of mitochondrial DNA damage (Atilano et al., 
2005). 
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Gender related differences are not well understood in KC, however the 
differences in sex hormones in men and women have been suggested to be a 
possible cause of KC pathogenesis (Bilgihan et al., 2011). However, some 
studies have found a greater differences in females (Krachmer et al., 1984, Fink 
et al., 2005) others have found a greater difference in males (Owens and 
Gamble, 2003, Wagner et al., 2007); while others have not found any evidence 
of gender bias in KC (Levy et al., 2004, Ertan and Muftuoglu, 2008). This 
ambiguity could be explained by an X-inactivation mosaicism or lyonisation since 
it has been already revealed in a mouse model of human filamin A diseased 
corneas (Douvaras et al., 2012). 
 
As mentioned earlier, KC could be a di-genic, polygenic or a complex disorder. 
Although this study was not designed to find such genetic variants, it is possible 
that the high frequency of KC cases in the consanguineous or endogamous 
families studies in this project may be due to the enrichment of multiple 
pathogenic alleles in the families. As such, the PLINK/SEQ tool was used in this 
study to try and tease out multiple variants that didn’t segregate in a Mendelian 
fashion in the families but were enriched in this cohort, as the large datasets 
were too large to manually do this. Enrichment analysis of rare variants through 
association studies is very challenging and much larger sample sizes than that 
used in this study are required (Lee et al., 2014). Therefore, this PLINK/SEQ 
study is severely underpowered.  
 
Another limitation of this study is using ancestral control data instead of ethnically 
matched controls. This is suboptimal but is an acceptable alternative since up 
until recently the Lebanese population had been considered as Caucasian (Baz 
et al., 2001, Zalloua et al., 2008). However, the major problem in the Lebanese 
population is the population stratification, which causes false positive results in 
enrichment and association analysis studies caused by systemic differences 
between ancestry in the subpopulation rather than an actual alleles association 
(Jiang et al., 2013). Similarly the lack of Middle Eastern controls was 
compensated for by use of Pakistani controls due to geographical and population 
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similarities. However, the future of this project involves being part of a large scale 
association studies with other research teams and collaborators, where the data 
generated throughout this project will be included (Section 5.2.3).  
 
Despite the limitations, this PLINK/SEQ study has several advantages. Firstly, it 
is based on patients selected from multiplex KC families and no sporadic cases 
are included. This strategy increases the chances of finding genetic variants, 
since familial KC patients are more likely to have the condition as a result of 
genetic factors for KC pathogenesis, while sporadic patients might potentially 
have been subject to other factors (e.g environmental) which may have played a 
role in their condition.  
 
In spite of these listed PLINK/SEQ advantages, the very small sample size 
means that this study is underpowered, and findings should therefore be 
regarded as tentative. Nevertheless this study forms a complementary analysis 
to be considered alongside the family and transcriptional analyses also 
conducted throughout this project, that can shed the light on possible genes/rare 
alleles involved in the genetics of familial KC. 
 
Although KC is not a common disease, filtering variants with MAF <2% may have 
risked the elimination of some common variants contributing to KC pathogenesis 
as well.  
 
In conclusion, in this study attempts were made to identify a Mendelian allele in a 
cohort of KC families. Disappointingly the results are inconclusive. There was no 
clear stand out candidate mutant genes but long lists of potential candidates. 
These were too numerous to take forward without further evidence implicating 
them in the pathogenesis of KC. In the next chapter additional strategies were 
used to gather more evidence to help highlight candidates for future studies.  
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4 Transcriptome analysis of keratoconic and healthy human 
corneas 
4.1 Introduction 
The aim of this study was to perform transcriptome analysis of normal human 
cornea and KC corneas using RNAseq to help prioritise candidate genes 
involved in the pathogenesis of KC. At the time this experiment was initiated 
there was no corneal RNA-seq data published or in databases, however, a 
recent report has documented the RNA-seq profile of normal human corneal 
endothelial tissue (Frausto et al., 2014), as well as the transcriptome of the 
mouse cornea (Pronin et al., 2014). However, to date, the healthy human 
anterior corneal transcriptome as well as the KC corneal transcriptome, have not 
been explored by RNA-seq, though microarray data are available in the literature 
(Ha et al., 2004, Mace et al., 2011, Ghosh et al., 2013). In this project, RNA-seq 
was used to study the WT anterior corneal profile along with the differential gene 
expression profile between KC and wild-type corneas. Thus, this study is the first 
to use RNA-seq to evaluate differential gene expression between KC and healthy 
corneas.   
 
The corneas used in this project originated from two different groups: patients 
and controls (Section 2.3). The KC corneas (n=6) were surgically removed in 
theatre from patients undergoing a deep anterior lamellar keratoplasty (DALK) 
where all of the anterior corneal tissue was removed but the endothelial healthy 
part was left in place. The stroma, Bowman’s layer and epithelial tissues were 
then preserved in RNAlater (Ambion) for a later RNA extraction. Healthy (WT) 
corneas (n=5) were cadaveric in origin, donated by five different previously 
healthy individuals, and were used prior to donation in descemet stripping 
automated endothelial keratoplasty (DSEK), where the inner endothelial layer of 
the cornea was transplanted, leaving its anterior part. As with KC corneas, the 
stroma, Bowman’s layer and epithelium tissues of the WT corneas were then 
preserved for a later RNA extraction. Therefore, samples from both groups of 
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corneas (KC and WT) were anatomically comparable, and consisted of only the 
anterior corneal part most commonly affected in KC disease.  
 
After collection, the RNA was extracted according to the protocol described in 
Section 2.3, and RNA libraries for each cornea were generated in-house using 
the TruSeq RNA sample preparation Kit v2 (Illumina) according to protocol 
described in Section 2.9 and then sequenced on an Illumina HiSeq 2500 
instrument. The RNA-seq paired-end reads generated were then used to study 
the transcriptomic profiles of KC and WT corneas. 
 
The transcriptomic study carried out in this chapter was divided into three main 
sections: WT anterior corneal RNA-seq expression gene profiling; Differential 
expression (DE) analysis between pooled KC and pooled WT corneas; and the 
combined analysis of WES variations detected in the corresponding genomic 
DNA of each individual KC cornea, along with its list of RNA-seq differentially 
expressed (DE) genes by comparison to WT.  
 
The purpose of investigating the DE between pooled KC and pooled WT corneas 
was to highlight genes and pathways altered in KC diseased corneas compared 
to healthy-WT corneas. While this approach may potentially also detect primary 
genetic causes, it is better able to gain insight into the secondary disease 
processes underway in a KC cornea. Conversely, the purpose of running DE of 
every KC cornea without its biological replicates was to establish an individual 
DE profile specific for each KC cornea. By comparing this to the WES variants 
detected in this particular KC cornea, it was hoped that this might allow 
correlation between genetic variations and differences in the level of expression 
of the corresponding genes, potentially highlighting primary causative variants or 
changes that increase susceptibility to KC.  
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4.2 Results 
4.2.1 Study design and RNA-seq data analysis 
The overall pipelines applied in this chapter were developed by the author at the 
start of the transcriptomic study, by partially adapting available software 
(Example Figure 4-2). The first steps of RNA-seq analysis processing were the 
same for the three different analyses conducted in this chapter (Figures 4-1 and 
4-2). RNA-seq reads were first checked for quality by running the raw fastq files 
on the fastQC software (Section 2.11), then they were processed using CutAdapt 
to trim the ends contaminated by the Illumina adapter sequence 
(GATCGGAAGAGCG) as well as the bases with low quality scores (<20 phred 
score) (Section 2.14). The RNA-seq read alignment, the transcriptome assembly, 
anterior WT cornea profile and DC between the two conditions (KC, WT) were all 
adapted from the Tuxedo set pipeline (Figure 4-2) (Trapnell et al., 2012). The list 
of commands used to run all the software is given in appendix 3.  
 
In the analysis workflow, RNA-seq reads of all the samples incorporated in this 
study were aligned to the reference genome Gencode GRCh38p2 
(http://www.gencodegenes.org/releases/20.html) using the Tophat2 function 
(Section 2.14) of the Tophat software (Kim et al., 2013), which is a gap aligner 
based around Bowtie2 which allows the alignment of reads around indels with 
high accuracy. Afterwards, the aligned bam files were assembled and quantified 
for expression via Cufflinks software using a guided reference transcriptome 
GRCh38p2, with the purpose of producing a GTF file of annotated transcripts for 
































RNA-Seq reads for WT and KC corneas 
FastQC: Quality control 
CutAdapt: Trimming the ends 
Trimmed RNA-Seq reads 
Aligned bam files 
Tophat: Align to the 
reference genome  
Assembled reads (GTF files generation) 
Cufflinks: Reads assembly, guided 
by a reference transcriptome 
Merge 5WT GTF 
files  
 





GTF files  
WT corneal profile Global DE of  
KC/WT    
    




Figure 4-1: Tuxedo suite analysis pipeline. Flowchart describing the analysis 
pipeline workflow of the three topics described in this chapter, using the Tuxedo 
suite tool. In addition, it represents the first steps of quality control using the 
FastQC online software as well as trimming the ends using cutadapt software. 

























Keratoconus WT corneas 
Figure 4-2: Tuxedo suite RNA-seq analysis pipeline. The analysis in 
this study is based on this flowchart that is the original RNA-seq analysis 
workflow presented by Trapnell et al. (Trapnell et al., 2012) http://cole-
trapnell-lab.github.io/cufflinks/manual/  
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Depending on the downstream analysis and the end results (Figure 4-1), the 
GTF file assemblies produced by Cufflinks were merged together using 
Cuffmerge into a master transcriptome suitable for downstream software analysis 
with Cuffnorm and Cuffdiff, described further below in Sections 4.2.1.1 and 
4.2.1.2. While merging the assemblies and assisted by a supplied genomic DNA 
reference file (GRCh38p2) supplied from the Gencode website 
(http://www.gencodegenes.org/releases/22.html), Cuffmerge filtered probable 
artifacts (e.g. repeats) by automatically running Cuffcompare. In addition, 
Cuffmerge was supplied by a reference GTF file (GRCh38p2) for the purpose of 
maximizing the overall assembly quality by merging known and novel isoforms.  
 
4.2.1.1 WT corneal gene expression profiling and novel gene/exon 
discovery. 
The RNA-seq data of the WT corneas were processed in order to generate a 
healthy corneal gene expression profile. Thus, Cuffnorm was used only on the 
merged transcripts of WT corneas and tables of normalized FPKM (Fragments 
Per Kilobase Of Exon Per Million Fragments Mapped) values of expressed 
genes and isoforms were consequently generated. The annotation of the results 
generated by Cuffnorm was assisted by the GRCh38p2 reference transcriptome, 
by running the command presented in Appendix 3. 
 
For the characterization of novel genes and exons, an additional experiment was 
conducted by following the protocol described by Farkas et al. (Farkas et al., 
2013), which required the use of a new alignment algorithm, the RNA-Seq 
Unified Mapper (RUM) (Section 2.14). The RNA-seq reads checked for quality on 
FastQC, were then realigned to human genome version hg19 throughout RUM 
(Section 2.14). RUM generates separate output files containing information on 
junctions (details presented in Section 4.2.2.2) from which novel junctions 
delimiting novel exons and/or genes were extracted and further validated by 
computational means (Section 4.2.2.2).  
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4.2.1.2 Differential expression with Cuffdiff 
What followed the WT anterior corneal transcriptome generation, was the 
comparison of the pooled WT and pooled KC anterior corneal gene profiles in 
order to check for significantly differentially expressed genes. As previously 
described in figure 4-1, in parallel to Cuffnorm and once all the samples’ relevant 
transcripts GTF files were merged, the software Cuffdiff was executed in order to 
compare the expression levels of genes in both conditions’ RNA-seq data. The 
analysis, visualization and manipulation of the differentially expressed data 
generated by Cuffdiff were accomplished by CummeRbund (Trapnell et al., 
2012). CummeRbund (Section 2.14) is a plotting tool that provides rapid analysis 
and visualization of Cufflinks analysed high-throughput sequencing RNA-seq 
data. It is an R package that parses and outputs Cufflinks files and connects 
them to the R statistical computing environment 
(http://compbio.mit.edu/cummeRbund/). 
 
4.2.1.3 Differential expression with EdgeR 
In order to compare the list of differentially expressed genes following 
Cufflinks/Cuffdiff analysis, a second analysis approach was adopted (Section 
2.14). It is mainly based on using the bioconductor package EdgeR (Robinson et 
al., 2010) accompanied by Subreads for creating a counts matrix (Liao et al., 
2013). 
 
Accordingly, RNA-seq data was run on a different pipeline using different 
software for quantification, read counting and differential expression analysis 
(see Figure 4-3). The subread package (Section 2.14) with the featureCounts 
program was used to assign paired end fragments to genomic features after 
being aligned using the Tophat software, as well as counting the RNA-seq reads. 
After counting the reads and creating a matrix of the read counts for each sample 
replicate, the matrix was then processed through edgeR, which is an R language 
based software package. The data was processed, analysed and visualised by 
edgeR on the R platform (Section 2.14). 

















4.2.1.4 Pathway analysis 
The information gathered in sections 4.2.2 and 4.2.3 (DE and gene expression 
profile of normal corneas), was uploaded online to DAVID (The Database for 
Annotation Visualization and Integrated Discovery) pathway analysis 
(https://david.ncifcrf.gov/) software in order to generate significantly enriched 
gene clusters, providing information on the pathways up- or down-regulated in 
normal vs KC corneas (Section 2.14).  
 
 
RNA-Seq reads for WT and KC corneas 
Aligned bam files 
Tophat: Align to the 
reference genome  
Read count matrix 
Subreads: Assigning mapped reads to 
genomic features and creating a 
count matrix 
Differential analysis by 
EdgeR 
Global DE of  
KC/WT    
DE of 1KC/5WT    
Figure 4-3: Differential expression analysis pipeline carried out using the 
bioconductor package EdgeR. It represents the alignment by Tophat in the first 
steps and then the read counts and DE by subreads and edgeR respectively. 
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4.2.2 The normal anterior corneal gene expression profile 
4.2.2.1 Analysis of gene expression using Cufflinks/Cuffnorm 
The WT cornea RNA-seq data were run on the Cufflinks’ program Cuffnorm, in 
order to generate normalized expression values for each gene, transcript, TSS 
(transcript’s inferred start site) group and CDS (coding sequence) group, 
expressed in disease-free corneas. The pipeline of this experiment is illustrated 
in Figure 4-1. Data from all the 5 WT corneas were inputted into Cuffnorm using 
the command stated in appendix 3.3.  
 
The output from Cuffnorm consisted of tab delimited text files of normalized 
FPKM values using the default settings of classic-FPKM, which implies that the 
library size factor is adjusted to 1, meaning that no scaling is applied to the 
FPKM values or the fragment counts.  
 
The tab delimited file for FPKM-tracking of genes, which displays the summed 
FPKM values of transcripts sharing the same gene ID, was opened and analysed 
using Microsoft excel. The normalized FPKM values for genes expressed in 
individual WT corneas are averaged for the summed values in the 5 WT corneas, 
resulting in one global FPKM value for each gene.  
 
Table 4-1 displays the first 30 genes with the highest averaged FPKM values 
expressed in WT corneas. In addition, the first 2500 protein coding genes with 
the highest FPKM values were exported to DAVID pathway analysis, and the 
results of the most significantly enriched pathways are listed in Table 4-2. 
Table 4-1: The genes expressed in WT corneas. This table represents only the 
















































Table 4-2: The most significantly enriched pathways in WT corneas. Table 
showing the first 7 mostly enriched clusters of pathway analysis of WT corneas, 
along with each pathway’s p-value, Benjamini corrections and number of genes 









Ribonucleoprotein	 3.6E-64	 1.2E-61	 139	
Translational	elongation	 5.7E-53	 2.1E-49	 79	
Ribosome	 7.9E-53	 1.8E-50	 64	
Protein	biosynthesis	 1.7E-51	 2.8E-49	 102	
Ribonucleoprotein	complex	 2.2	E-51	 7.0E-49	 192	
Translation	 3.0E-45	 5.4E-42	 139	
Cytosolic	part	 2.5E-39	 3.2E-37	 86	
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Structural	molecule	activity	 6.9E-31	 4.2E-28	 174	
2		
(ES:	16.54)	
Respiratory	chain		 7.0E-28	 5.9E-26	 46	
Oxidative	phosphorylation	 6.1E-26	 5.7E-24	 72	
Mitochondrial	membrane	 1.2E-25	 1.1E-23	 125	
Organelle	inner	membrane	 2.8E-25	 2.3E-23	 111	




Mitochondrion	 8.2E-24	 6.2E-22	 227	
Electron	transport	 6.5E-18	 3.6E-16	 44	
Transit	peptide	 3.5E-13	 1.6E-11	 101	












Cytoskeleton	 9.3E-5	 1.1E-3	 211	
4		
(ES:	12.43)	
Ubl	conjugation	 4.1E-13	 1.7E-11	 117	
Isopeptide	bond	 1.1E-12	 4.2E-11	 76	
5		
(ES:	11.75)	
Melanosome	 9.4E-24	 3.7E-22	 51	
Vesicle	 1.1E-7	 1.9E-6	 127	
Membrane-bounded	vesicle	 9.6E-7	 1.6E-5	 108	
Cytoplasmic	vesicle	 1.7E-6	 2.6E-5	 118	
Cytoplasmic	membrane-bounded	vesicle	 2.1E-6	 3.0E-5	 104	
6		
(ES:	10.89)	
RNA	processing	 1.4E-14	 3.3E-12	 127	
RNA	splicing	 5.0E-14	 9.6E-12	 80	
RNA	splicing	via	spliceosome	 5.8E-14	 1.1E-11	 54	
Spliceosome	 3.3E-9	 7.0E-8	 40	
7	
(ES:	9.31)	
Membrane	enclosed	lumen	 1.6E-14	 4.0E-13	 327	
Nuclear	lumen	 7.6E-8	 1.3E-6	 239	
Nucleolus		 8.5E-6	 1.2E-4	 123	
Nucleoplasm	 1.7E-4	 1.9E-3	 142	
 
The results represented in Table 4-2, show the combined expression of miRNA 
genes, ribonucloprotein genes, protein coding genes and pseudogenes. The 20 
most highly expressed protein coding genes are represented in Table 4-3. 
Table 4-3: Most highly expressed protein coding mRNAs. This table presents 































4.2.2.2 Identification of previously un-annotated coding exons and 
genes in the normal cornea 
For novel gene and exon discovery in the WT corneas, the RNA-seq reads were 
realigned to human genome version hg19 using the RNA-seq Unified Mapper 
(RUM) (Section 2.14). In addition to RUM being an aligner implemented in Perl, it 
is also capable of junction calling and feature quantification, which makes it able 
to accurately identify novel splice variants, including splicing events and novel 
junctions with low read depth (Grant et al., 2011). Combining information on 
novel junctions with the genome browser UCSC facilitated the locating of new 
junctions, which could potentially highlight a new exon or gene.  
 
The alignment pipeline of RUM maps reads in three phases. First, it uses Bowtie, 
based on the Burrows–Wheeler algorithm, to map the reads against the hg19 
version of the genome. In the second step it maps the reads against the 
transcriptome database. Finally, in the third step it maps against the genome 
using BLAT. Afterwards, Bowtie and BLAT alignments are merged after 
processing the aligned reads for RUM. This takes advantage of both algorithms 
by combining the speed of Bowtie with the sensitivity of BLAT (Grant et al., 
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2011). Table 4-4 shows statistics on the mapping data generated by RUM in 
each WT cornea.  
Table 4-4: RUM mapping statistics for every individual WT cornea. This 
table shows the statistics from RUM mapping. It represents the mapping 
percentage of bases covered in the exomes of the WT corneas across the whole 
genome. The percentages shown in column number two indicate the number of 
bases covered in the whole genome by reads that map uniquely to one genomic 
location. Column number three represents the number of bases covered in the 
whole genome by reads that map to multiple locations. The consistency between 
forward and reverse mapping is reported in terms of percentage and displayed in 
the last column. 
Sample No. bases covered 
by unique reads 






MA28	 139,146,189	(4.48%)	 20.726,871	(0.66%)	 27,935,376	(85.3%)	
MA35	 113,146,533	(3.64%)	 17,463,784	(0.56%)	 35,807,738	(87.7%)	
MA51	 111,306,258	(3.58%)	 15,411,901	(0.49%)	 6,405,133	(85%)	
MA67	 63,168,897	(2.03%)	 10,911,345	(0.35%)	 26,386,559	(86.1%)	
MA82	 67,280,262	(2.16%)	 11,218,305	(0.36%)	 19,039,207	(80.3%)	
 
RUM generated basic alignment information for each paired end read in 2 files, 
the first being a file of unique alignments which mapped to only one genomic 
location and the second a file of non-unique alignments mapping to multiple 
genomic locations. The SAM file with all the alignments of unique and non-
unique mapped reads is also an output of RUM, along with a Depth-of-coverage 
file which gives the number of reads mapping to each genome location. 
Quantified values of genes, exons, introns and junctions are generated and 
written in a feature quantification file. In addition, three output files are generated 
containing information on junctions that span gaps of 15 bases or more, which 
are determined by the default settings of RUM to be introns. The first file is a tab 
delimited spread sheet file containing expanded information on each junction. 
The second file is a bed file containing all the junctions, within which the colour 
blue is assigned to all the high quality junctions and all the other junctions are 
coloured red. The high quality junctions are listed separately in a third bed file, 
reporting all of the junctions that have the known splice signals and are uniquely 
mapping reads with at least eight bases on each side of the junction. In this file 
the junctions that are not known are shown in green, while the colour blue is 
assigned to the known junctions (http://cbil.upenn.edu/RUM/). 
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In this section of the results, only the high quality junctions bed file was of 
interest. The high quality bed files of all the 5WT corneas were uploaded 
individually into genome browser through the “mydata, custom track” function. 
The file was then exported to “Table Browser” under the “Tools” function. In order 
to only pick up novel genes/exons, the option that allows the online tool to extract 
the entries in the uploaded file that have no overlap with UCSC genes was 
selected under the intersection tab. Otherwise all the other setting were kept to 
default. This allowed the filtering out of all the junctions that overlapped with 
known genes in the UCSC records, leaving only the novel ones. 
 
The bed files of all the 5 WT corneas were then checked for shared junctions 
among all the 5 corneas assigned with a green colour in the bed file (RGB code 
0,255,127), using the perl script described in Section 2.12. 
 
The result is a list of potentially novel junctions harbouring novel exons and/or 
genes (Table 4-5) appearing in the RNA-seq data for all 5WT corneas. The 
annotation of these junctions was carried out by inputting their coordinates to the 
UCSC browser and checking where these coordinates fall in the genome. 
Results are shown in the description column in Table 4-5.  
Table 4-5: Table presenting the coordinates and description of potentially 
novel exons and genes shared between all 5 WT corneas. The chromosome 
and position represent the location of the new gene/exon on the genome, the 
average reads represent the average of the read coverage in all the 5 corneas 
and the description gives the gene within which this feature lies where known. 
Chr	 Position	(hg19)	 Average	reads	 Description	
4	 22728688…22728804	 28.2	 GBA3	gene	
11	 16996210…16996433	 26.6	 PLEKHA7	gene	
X	 100110437…100110693	 18.8	 NOX1	
2	 171608929…171609086	 12.6	 AK023515	
19	 45952452…45954783	 11.2	 ERCC1	
3	 169200949…169201452	 6.6	 MECOM	
1	 12053433…12053848	 6.0	 MFN2	
2	 27939549…27939763	 5.2	 -	
9	 94767588…94768059	 5.2	 -	
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8	 56963001…56963225	 5.0	 -	
2	 127314138…127314258	 4.8	 -	
3	 169200948…169201452	 3.6	 MECOM	
10	 98510015…98510163	 3.2	 -	
15	 41849322…41849490	 2.8	 -	
11	 3991910…3992032	 2.2	 STIM1	
3	 169200951…169201452	 2.0	 MECOM	
1	 12053433…12053849	 1.6	 MFN2	
6	 166999922…167000071	 1.4	 RPS6KA2	
 
 
4.2.3 Differential expression (DE) 
4.2.3.1 Global statistics and quality control of processed RNA-reads 
prior to DE 
This section describes the quality control and global analysis of cufflinks results 
after running the pipeline on data from all the 6 KC corneas pooled together and 
compared with the 5 pooled WT corneas. The results of Cuffdiff analysis 
following the Cufflinks pipeline (Figure 4-1 and 4-2) were reported in a set of tab-
delimited text files for 4 classes: genes, isoforms, coding sequence (cds) and 
primary transcript (tss). The gene classes were explored by CummeRbund using 
the R commands described in appendix 3.4. Through CummeRbund, 
dendrograms, box plots and density plots were generated, which aimed to 
assess the variability for the class “genes” between replicates for each condition 
(WT and KC) and identify outliers in order to exclude them in the downstream 
analysis. The outliers are presented in the dendrogram shown in figure 4-4.a. 
The dendrogram provided insight into the relationships between conditions for 
the gene classes and revealed that sample KC_3, WT_3 and WT_4 were outliers 
compared to all the other replicates included in this study. Therefore, the analysis 
was repeated after removing these outliers from the study, in order to 
homogenise the statistical distribution in each set of conditions. The results of the 
new analyses that included 5 KC corneal replicates and 3 WT corneal replicates 
are presented in figures 4-5.b. 












In addition, the same conclusion on outliers can be drawn from the density plots 
and box plots displayed in figure 4-5. The density plot was generated in order to 
assess the distributions of FPKM scores across WT and KC corneas (figure 4-
5.a) as well as across each and every individual replicate (figure 4-5.b). Figure 4-
5.c and figure 4-5.d show the box plots of the FPKM distributions for KC and WT 
conditions together with individual replicates. The box plot of figure 4-5.d in 
particular shows that the statistical distribution of the FPKM of the class “genes” 
is different between the sample replicate KC_3 and all the other KC replicates 
(KC_0, KC_1, KC_2, KC_4 and KC_5). The same is true for the replicates WT_3 
and WT_4, for which the statistical distribution of the FPKM values does not 
constitute a box plot homogenous and similar to the box plot of the other WT 
replicates (WT_3, WT_4 and WT_5). In addition to finding replicate outliers, the 
WT and KC sets showed differences in terms of the FPKM distribution and that 
might be due to a number of factors discussed in Section 4.3. 
Figure 3-1: Dendrogram identifying the outlier replicates for both 
conditions a) shows all the condition replicates b) after removing the 
outliers in each condition, KC_3 for Keratoconus condition and WT_3 and 
WT_4 for Wild-type Corneas condition. 
 
a) b) 
Figure 4-4: Dendrograms identifying the outlier replicates for each condition (KC or 
WT). a) Shows all the condition replicates, while b) shows results after removing the outliers 
in each condition, namely KC_3 for Keratoconus and WT_3 and WT_4 for Wild-type 
Corneas. The (y) axis represents the Height. 






























Figure 4-5: CummeRbund analysis exploration of 6 KC corneas compared to 5 
WT corneas. a) Density plot shows the FPKM distribution for KC and WT conditions. 
b) Density plot exposes each individual replicate’s FPKM distributions for all the 
samples included in the study and belonging to both conditions. c) Box plot of FPKM 
distributions for individual conditions (KC and WT). d) Box plot showing individual 
replicate’s FPKM distributions for all the samples included in the study and belonging 
to both conditions. 
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Figure 4-6 displays the same statistics and plots shown in figure 4-5 after 
elimination of the replicate outliers. This resulted in a more homogenous FPKM 
distribution within the different condition sets (Figure 4-6.a and figure 4-6.b). In 
addition, the box plots of the replicates belonging to the same condition have a 




















Figure 4-6: CummeRbund analysis of RNA-seq data from 5 KC corneas compared to 3 
WT corneas after removing the outliers. a) Density plot shows the FPKM distribution for 
pooled KC and WT RNAseq data. b) Density plot of each individual WT vs KC RNA-seq 
profile exposes the individual replicate FPKM distributions for each sample included in the 
study. c) Box plot of FPKM distributions for individual conditions (5KC and 3WT). d) Box plot 
showing FPKM distributions for each individual WT and KC replicate included in the study. 
The black line in the box plots shows the median and the boxes the interquartile range and 
the whiskers show the range and the dots show the outliers. 
- 176 - 
 
After removing the two WT and one KC replicate outliers, the estimated 
dispersion for each sample was calculated by CummeRbund and visualised as a 
quality control measure by using the Cuffdiff replicate-dispersion method default 
settings. The dispersion modelling by Cuffdiff used pooled data within each 
condition to build a model, then provided a single global model for both 
conditions by averaging all the models. The plot in figure 4-7 shows some 
overdispersion in the data. However this does not illustrate poor data, since 
Cuffdiff takes into account the overdispersion while analysing differential 

















Figure 4-7: Count vs Dispersion plot by conditions (KC and WT 
corneas) for all the genes. The graphs of dispersion of KC (left) and WT 
(right) are skewed to the left which represents an overdispersion in the 
data. 
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4.2.3.2 Differential gene expression analysis of KC and WT corneas 
using the Cufflinks/Cuffdiff pipeline 
Changes in expression at the level of transcripts, primary transcripts and genes 
are produced by Cuffdiff in a number of tab-delimited output files. Cuffdiff 
additionally features changes in splicing by tracking changes in the relative 
abundance of transcripts sharing a common transcription start site using a tss_ID 
(the ID of the transcript’s inferred start site). It provides as well a list of changes 
in relative promoter use within a gene by tracing changes in the relative 
abundances of the primary transcripts of each gene by giving a p_ID for the 
coding sequence. 
 
For each of the four classes (genes, isoforms, coding sequence-cds and primary 
transcript-tss), Cuffdiff outputs one of the following files per class: 
- FPKM tracking file, which constitutes the FPKM calculation of each transcript, 
primary transcript, and gene in each sample.  
- Count-tracking file, which constitutes the estimation of the number of fragments 
that originated from each transcript, primary transcript, and gene in each sample.  
- Read Group tracking file, which comprises the expression calculations and 
fragment count for each transcript, primary transcript, and gene in each replicate.  
- Differential expression test tab-delimited file, which lists the differential 
expression testing between samples for spliced transcripts, primary transcripts, 
genes, and coding sequences.  
 
In addition, Cuffdiff calculates the differential splicing between isoforms 
processed from a single primary transcript, differential CDS and differential 
promoter use between samples, and outputs this data into tab-delimited files. 
 
Table 4-6 represents the number of significantly and non-significantly 
differentially expressed genes, isoforms, coding sequence and primary 
transcripts, as well as the number of upregulated and dowregulated genes, 
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isoforms, cds and tss in pooled 5 KC corneas compared to 3 WT corneas. 
However, in this project, only the differential gene expression files were studied. 
 
CummeRbund allowed visualization of the Cuffdiff results of the differential gene 
expression data. Figure 4-8 displays the volcano plot matrix for both KC and WT 
conditions.  
 
Table 4-6: Cufflinks/Cuffdiff statistics. Table representing the numbers of 
Cufflinks/Cuffdiff significantly and non-significantly differentially expressed genes, 
isoforms, cds and tss along with their status of up or down regulation in 5 pooled 




In this section, the top 10 mostly significant hits of upregulated and 
downregulated genes from the Cufflinks results are shown in Table 4-7. In 
addition, the top genes that are totally absent in the KC corneas compared to 
















Genes	 52005	 28815	 23346	 5472	
Isoforms	 289592	 21409	 18381	 3030	
Cds	 81744	 5841	 3502	 2341	
Tss	 137146	 32675	 24217	 8460	





























Table 4-7: Differentially expressed genes generated by Cufflinks. The 10 
most differentially expressed genes downregulated in the data of pooled KC 
corneas, and the 10 most upreglated genes, as generated by Cufflinks and 
sorted by their corresponding FDR values. The positive log2FC values 
correspond to the downregulated genes in pooled KC compared to WT, while the 
negative log2FC values correspond to the upregulated genes in pooled KC 
corneas compared to WT. The q-values are the corrected p-values calculated by 
Cufflinks using the Benjamini-Hochberg method. 
Status	 Symbol	 Feature	 Log2FC	 q-value	
Downregulated	in	
KC	compared	to	WT	
B2M	 protein_coding	 11.2169	 8.89E-05	
ALDOA	 protein_coding	 10.7145	 8.89E-05	
RPLP1	 Pseudogene	 10.5149	 8.89E-05	
FTH1	 protein_coding	 10.4474	 8.89E-05	




KRT14	 protein_coding	 9.96943	 8.89E-05	






Figure 4-8: Volcano plot matrix of DE between KC and WT. Volcano 
plot matrix of genes that are differentially expressed between normal and 
keratoconic corneas. The red dots correspond to the significant hits, the 
black dots correspond to non significant differentially expressed genes. 
The x axis corresponds to the log2(Fold change) and the y axis 
corresponds to the –log10(p value). 






CST3	 protein_coding	 9.51004	 8.89E-05	
Upregulated	in	KC	
compared	to	WT	
LEF1-AS1	 processed_transcript	 -21.0433	 8.89E-05	
NRXN1	 protein_coding	 -13.5154	 8.89E-05	
CA1	 protein_coding	 -12.9627	 8.89E-05	
ADORA3	 protein_coding	 -12.6881	 8.89E-05	
SLC14A1	 protein_coding	 -12.4454	 8.89E-05	
CCDC38	 protein_coding	 -12.2557	 8.89E-05	
ITK	 protein_coding	 -12.2356	 8.89E-05	
IL5RA	 protein_coding	 -12.1758	 8.89E-05	
TTC6	 protein_coding	 -11.8669	 8.89E-05	
MYOCD	 protein_coding	 -11.8069	 8.89E-05	
 
 
Table 4-8: List of genes present in KC and absent in WT corneas or vice 
versa. The 10 most highly expressed genes that are present in WT corneas and 
totally absent in KC cornea, followed by the 10 genes most highly expressed in 
KC corneas that are totally absent in WT corneas. The q-values are the 












HLA-C	 protein_coding	 0	 255.713	 8.89E-05	
RP3-340B19.2	 pseudogene	 0	 108.34	 8.89E-05	
RPS18	 protein_coding	 0	 88.5531	 8.89E-05	
SEPT2P1	 pseudogene	 0	 53.507	 8.89E-05	
RP11-367G18.2	 pseudogene	 0	 20.2826	 8.89E-05	
CIDEB	 protein_coding	 0	 18.6623	 8.89E-05	
DEFB4A	 protein_coding	 0	 16.0385	 8.89E-05	
APOBEC3A	 protein_coding	 0	 14.7865	 8.89E-05	
DDR1	 protein_coding	 0	 13.0465	 8.89E-05	




WI2-2373I1.1	 pseudogene	 251.369	 0	 8.89E-05	
AC003101.1,	MIR365B	 lincRNA,	miRNA	 217.97	 0	 8.89E-05	
MIR299,	MIR411	 miRNA	 194.478	 0	 8.89E-05	
OR4M1	 protein_coding	 126.335	 0	 8.89E-05	
OR4K5	 protein_coding	 110.402	 0	 8.89E-05	
OR4F15,	OR4F6	 protein_coding	 109.251	 0	 8.89E-05	
OR14A2,	OR6F1	 protein_coding	 101.487	 0	 8.89E-05	
AC006539.6	 pseudogene	 99.6426	 0	 8.89E-05	
OR4K2	 protein_coding	 98.2316	 0	 8.89E-05	
OR4K1	 protein_coding	 8.89E-05	 0	 8.89E-05	
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4.2.3.3 Differential gene expression analysis of pooled KC and WT 
corneas using the edgeR pipeline 
In parallel to Cufflinks, the same RNA-seq data was run on a different pipeline 
using different software for quantification and counting of the reads, and for DE 
analysis. The subread package (Section 2.14) with the featureCounts program 
was used in order to assign paired end fragments to genomic features, as well as 
counting the RNA-seq reads. After counting the reads and creating a matrix of 
the read counts for each sample replicate, the matrix is then processed through 
edgeR, an R language based software package (Section 2.14).  
 
EdgeR is specifically designed to detect the relative changes in expression levels 
between two conditions i.e pairwise comparison, using empirical Bayes 
estimation and exact tests based on a negative binomial model, but is not 
concerned with quantification of expression levels (Robinson et al., 2010). In 
other words, EdgeR does not estimate the absolute expression levels of a certain 
transcript, it rather looks at the relative changes in expression of this particular 
transcript between the two conditions in question (Chen et al., 2008, revised 
2015). The result of edgeR is an excel list of differentially expressed genes with 
their specific log fold change (log FC), the log count per million (logCPM) which 
can be converted to RPKM (Read Per Kilobase per Million mapped reads) for 
single end RNA-seq data or FPKM values for paired-end data, along with their 
corresponding p-values and FDR (False Discovery Rate) values (Li et al., 
2012a). The differentially expressed gene list is filtered for significant genes 
(FDR > 0.05) and a minimum fold change of 2 (-1 < logFC < +1 filtered out). 
 
Table 4-9 represents the number figures of significantly and non-significantly 
differentially expressed genes along with the upregulated and downregulated 
genes. 
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Table 4-9: EdgeR statistics. Table detailing the numbers of significantly 
differentially expressed genes detected by EdgeR analysis, grouped according to 
whether they are up or down regulation. 
 
In addition to the list of differentially expressed genes, visualization of data can 
be performed using R, by plotting a smear graph to show the distribution of 
differentially expressed genes by counts per million. Figure 4-9 shows the smear 
graph of differentially expressed genes between the 5 KC corneas and 3 WT 
















Genes	 30028	 35220	 26309	 8911	




Figure 4-9: EdgeR DE plot. A smear graph showing the distribution of the 
differentially expressed genes detected in RNA-seq data analysed by edgeR, 
displayed by plotting the average logCPM (log2 counts per million) for each gene 
against its logFC (log2 Fold change). The blue lines delimit the threshold of a 2 
fold-change (logFC range= -1, +1). All the genes falling in the area delimited 
between the blue lines have a 0-2 range of fold change, and are excluded from 
the final analysis. The genes falling outside the blue line range are considered for 
further analysis. 
 
From the edgeR results, the 10 most significant upregulated and 10 most 
significant downregulated genes in KC corneas compared to WT are presented 
in Table 4-10.  
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Table 4-10: Differentially expressed genes between pooled WT and pooled 
KC corneas detected in RNAseq data by edgeR. The 10 most significantly 
upregulated and 10 most significantly downregulated genes in KC vs WT 
corneas, generated by edgeR and sorted by their corresponding FDR values. 
The negative logFC values correspond to the downregulated genes in KC 
compared to WT, and in contrast the positive logFC values correspond to the 
upregulated genes in KC corneas compared to WT. The FDR (false discovery 
rate) values are the corrected p-values calculated by edgeR using the Benjamini-
Hochberg method. 




	EEF1A1P5	 processed_pseudogene	 -12.22586709	 1.4867E-277	
MT-CO2	 protein_coding	 -11.36332101	 5.9962E-269	
MT-CO3	 protein_coding	 -11.242322	 1.4741E-265	
MT-ATP6	 protein_coding	 -11.14214094	 2.147E-259	
RP11-234A1.1	 processed_pseudogene	 -11.99410887	 6.2517E-254	
RPL13AP5	 processed_pseudogene	 -11.24404978	 2.5852E-251	
KRT5	 protein_coding	 -10.43234188	 8.4098E-247	
MT-ND4	 protein_coding	 -10.50619684	 5.7367E-246	
MT-RNR2	 protein_coding	 -10.39711274	 3.6219E-242	




TTN	 protein_coding	 14.80004336	 7.3408E-172	
MUC17	 protein_coding	 15.59338905	 4.6454E-142	
MUC19	 processed_transcript	 13.62085338	 1.2085E-139	
DNAH8	 protein_coding	 15.08070662	 8.1949E-133	
XIRP2	 protein_coding	 15.05058135	 2.8313E-132	
PKHD1L1	 protein_coding	 14.5968029	 3.938E-124	
RYR3	 protein_coding	 10.26310516	 7.354E-124	
RYR2	 protein_coding	 10.37602748	 8.6621E-124	
CCDC168	 protein_coding	 12.11510674	 1.5279E-123	
LRP2	 protein_coding	 14.48650695	 3.6734E-122	
 
4.2.3.4 Differential gene expression analysis of KC and WT corneas 
using the Cufflinks/Cuffdiff pipeline 
In order to minimize the error and get confirmation from two different software 
packages on the results presented in this chapter, only the genes deemed to be 
differentially expressed in both Cufflinks/Cuffdiff and edgeR analyses were taken 
forward for Pathway analysis. Table 4-11 shows the number of genes that are 
classed as having DE by both edgeR and Cufflinks/Cuffdiff analyses. The 
difference between the outcomes of both analyses is explained in Section 4.3.3. 
Table 4-12 shows the 10 most significantly upregulated and 10 most significantly 
downregulated genes that appeared to overlap between the two previously 
mentioned software packages. The significance was reported equally by both 
software results (q-values by Cufflinks/Cuffdiff and FDR values by edgeR). In 
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addition, the overlapped results, in particular results of Table 4-12, were reported 
uniformly by both software to go in the same direction of upregulation or 
downregulation. 
Table 4-11: EdgeR and Cufflinks/Cuffdiff overlap. Table representing the 
edgeR numbers of genes that are significantly differentially expressed genes 
overlapping between edgeR and Cufflinks/Cuffdiff results along with their status 
of up or down regulation. 
 
 
Table 4-12: Genes analysed by RNAseq and found to be differentially 
expressed between pooled KC and pooled WT corneas by both the 
Cufflinks/Cuffdiff and edgeR programmes. The edgeR results of the 10 most 
significantly upregulated and 10 most significantly downregulated genes between 
pooled KC and WT corneas, detected in RNAseq data by both Cufflinks/Cuffdiff 
and edgeR analyses, and sorted by their corresponding FDR values. The 
negative logFC values correspond to the downregulated genes in KC compared 
to WT, and in contrast the positive logFC values correspond to the upregulated 
genes in KC corneas compared to WT. The FDR (false discovery rate) values 
are the corrected p-values calculated by edgeR using the Benjamini-Hochberg 
method. 




	EEF1A1P5	 processed_pseudogene	 -12.22586709	 1.4867E-277	
RP11-234A1.1	 processed_pseudogene	 -11.99410887	 6.2517E-254	
RPL13AP5	 processed_pseudogene	 -11.24404978	 2.5852E-251	
KRT14	 protein_coding	 -10.21555574	 1.3102E-236	




FTH1	 protein_coding	 -10.03571653	 2.682E-231	
RPL3P4	 processed_pseudogene	 -10.69199626	 7.0413E-228	
MTATP6P1	 unprocessed_pseudogene	 -10.38725886	 1.6355E-228	




TTN	 protein_coding	 14.80004336	 7.3408E-172	
MUC17	 protein_coding	 15.59338905	 4.6454E-142	
MUC19	 processed_transcript	 13.62085338	 1.2085E-139	
DNAH8	 protein_coding	 15.08070662	 8.1949E-133	
XIRP2	 protein_coding	 15.05058135	 2.8313E-132	
RYR3	 protein_coding	 10.26310516	 7.354E-124	
RYR2	 protein_coding	 10.37602748	 8.6621E-124	
LRP2	 protein_coding	 14.48650695	 3.6734E-122	
COL6A5	 protein_coding	 14.36963531	 4.5616E-120	
PTPRQ	 protein_coding	 14.21170612	 3.1612E-117	
FAT3	 protein_coding	 9.920727171	 5.0790E-117	
EdgeR	result	 Significant	Difference	 Upregulated	KC/WT	 Downregulated	KC/WT	
Genes	 18006	 12846	 5160	
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4.2.3.5 Pathway analysis  
4.2.3.5.1 Pathway analysis of DE genes detected by both Cufflinks/Cuffdiff 
and edgeR 
The top 3000 protein coding genes, appearing on edgeR FDR values -regardless 
of their status of up or downregulation- to be the most significantly differentially 
expressed genes and detected as such by the results of Cufflinks/Cuffdiff 
program, were uploaded online for DAVID (The Database for Annotation 
Visualization and Integrated Discovery) pathway analysis (Section 2.14). Only 
the genes that were shown to be significantly differentially expressed in the same 
manner (up-regulated in both analyses and down-regulated in both analyses) 
were considered in this analysis. The functional annotation clustering tool was 
used in order to determine computationally the major biological functions 
specifically enriched in the differentially expressed gene list.  
 
The results of DAVID functional clustering of the top 3000 most significantly 
differentially expressed  genes  detected in Cufflinks/Cuffdiff and edgeR analysis, 
are summarized in Table 4-13. In addition, Tables 4-14 and 4-15 show 
respectively the pathways that are enriched in the upregulated and 
downregulated genes. 
Table 4-13: Pathways enriched in the DE expressed genes in pooled KC 
compared to WT corneas. Table showing the functional annotation clustering of 
the top 3000 significantly differentially expressed genes reported by FDR values 
of edgeR and detected by both Cufflinks/Cuffdiff and edgeR analyses. Only the 
clustering pathways with significant corrected p-values (Benjamini value < 0.05) 









Glycoprotein	 8.70E-72	 6.90E-69	 1000	
Glycosylation	site:	N-linked	(GlcNAc...)	 2.60E-69	 1.70E-65	 964	
Topological	domain:	Extracellular	 3.50E-59	 1.10E-55	 686	
Topological	domain:	Cytoplasmic	 1.30E-57	 2.90E-54	 799	
Membrane	 5.30E-48	 2.10E-45	 1232	
2	
(ES:	32.24)	
Disulfide	bond	 1.70E-32	 2.70E-30	 636	
Signal	 1.10E-21	 7.50E-20	 645	
Secreted	 6.20E-04	 7.30E-03	 289	
Extracellular	region	 2.10E-01	 6.40E-01	 352	




Plasma	membrane	part	 4.00E-30	 1.30E-27	 561	
Intrinsic	to	plasma	membrane	 2.40E-27	 5.30E-25	 348	
Integral	to	plasma	membrane	 1.30E-26	 2.10E-24	 340	
4	
(ES:	16.38)	
cell	adhesion	 2.60E-22	 2.10E-20	 139	
biological	adhesion	 1.20E-17	 9.90E-15	 200	
cell-cell	adhesion	 9.70E-11	 3.10E-08	 88	
5	
(ES:	12.18)	
Ribosome	 5.90E-27	 5.90E-25	 52	
translational	elongation	 4.60E-24	 2.00E-20	 62	
protein	biosynthesis	 7.20E-11	 2.10E-09	 63	
Translation	 2.50E-05	 4.00E-03	 83	
ribonucleoprotein	complex	 1.90E-03	 1.80E-02	 113	
6	
(ES:	11.37)	
synaptic	transmission	 1.80E-14	 1.30E-11	 102	
transmission	of	nerve	impulse	 3.90E-13	 2.00E-10	 111	
cell-cell	signaling	 9.90E-10	 2.30E-07	 154	
7	
(ES:	10.79)	
cell	junction	 8.30E-16	 3.60E-14	 120	
Synapse	 4.90E-11	 2.10E-09	 110	
postsynaptic	cell	membrane	 2.50E-08	 5.90E-07	 40	
8	
(ES:	10.65)	
Receptor	 3.00E-26	 2.60E-24	 378	
neurological	system	process	 8.90E-24	 1.90E-20	 325	
Transducer	 2.00E-19	 1.20E-17	 224	
Cognition	 2.80E-14	 1.70E-11	 233	
GPCR,	rhodopsin-like	superfamily	 8.80E-11	 7.40E-08	 177	
Olfaction	 1.80E-10	 5.00E-09	 108	
Olfactory	receptor	 6.00E-07	 1.70E-04	 105	
9	
(ES:	10.03)	
insoluble	fraction	 1.60E-12	 1.00E-10	 220	
membrane	fraction	 1.50E-11	 7.70E-10	 210	
cell	fraction	 3.30E-08	 1.10E-06	 250	
10	
(ES:	9.76)	
Sodium	transport	 1.00E-12	 4.30E-11	 49	
metal	ion	transport	 3.20E-11	 1.20E-08	 131	
monovalent	inorganic	cation	transport	 1.50E-10	 4.60E-08	 97	
Receptor	 3.00E-26	 2.60E-24	 378	
15	
(ES:	5.09)	
Na+	channel	 3.90E-07	 1.20E-04	 10	
Sodium	ion	transport-associated	 3.90E-07	 1.20E-04	 10	
voltage-gated	sodium	channel	complex	 1.50E-05	 2.90E-04	 10	
16	
(ES:	4.55)	
Dynein	 2.90E-07	 6.30E-06	 18	
Axoneme	 1.70E-04	 2.20E-03	 18	
microtubule-based	movement	 3.10E-04	 2.60E-02	 34	
Cilium	 2.20E-03	 1.90E-02	 36	
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Table 4-14: Pathways enriched among genes upregulated in pooled KC 
corneas compared to WT. Table showing the functional annotation clustering of 
the top 3000 significantly differentially expressed genes reported by FDR values 
of edgeR and detected by both Cufflinks/Cuffdiff and edgeR analyses. Only the 
clustering pathways with significant corrected p values (Benjamini value < 0.05) 









glycosylation	site:	N-linked	(GlcNAc)		 3.10E-153	 1.90E-149	 1147	
disulfide	bond		 4.30E-97	 1.60E-94	 807	
membrane		 3.20E-64	 2.60E-62	 1278	
signal	peptide		 8.50E-43	 7.50E-40	 723	
Secreted		 3.80E-14	 1.30E-12	 348	
extracellular	region		 2.90E-09	 1.30E-07	 407	
2		
(ES:	59.14)	
receptor		 7.70E-81	 1.90E-78	 507	
cell	membrane		 2.90E-80	 5.20E-78	 630	
neurological	system	process		 4.20E-71	 1.70E-67	 416	




cognition		 1.80E-53	 2.30E-50	 315	
sensory	perception		 7.00E-53	 6.90E-50	 291	
Olfactory	receptor		 2.50E-48	 1.80E-45	 188	
3		
(ES:	32.37)	
integral	to	plasma	membrane		 6.70E-35	 8.90E-33	 346	
intrinsic	to	plasma	membrane		 1.20E-34	 1.30E-32	 351	
plasma	membrane	part		 9.50E-30	 8.50E-28	 530	
4	
(ES:	18.03)	
synaptic	transmission		 6.10E-21	 2.70E-18	 110	
transmission	of	nerve	impulse		 9.20E-20	 3.60E-17	 120	
cell-cell	signaling		 1.50E-15	 4.10E-13	 164	
5	
(ES:	14.92)	
ion	transport		 5.30E-37	 3.00E-35	 202	
substrate	specific	channel	activity		 4.70E-28	 2.00E-25	 150	
ion	channel	activity		 4.80E-28	 1.60E-25	 147	
channel	activity		 2.80E-27	 7.30E-25	 152	
voltage-gated	channel	activity		 3.40E-12	 3.00E-10	 70	
potassium	ion	transport		 4.30E-08	 6.50E-06	 52	
transport		 7.80E-08	 1.60E-06	 312	
6	
(ES:	12.1)	
metal	ion	transport		 1.50E-18	 5.30E-16	 143	
Sodium	transport		 1.40E-13	 4.50E-12	 50	
7		
(ES:	11.56)	
cell	adhesion		 1.40E-15	 4.40E-13	 184	
biological	adhesion		 1.70E-15	 4.40E-13	 184	
Cadherin		 2.70E-12	 9.40E-10	 47	
8		
(ES:	9.25)	
synapse		 1.80E-15	 1.10E-13	 116	
neurotransmitter	binding		 1.10E-14	 1.10E-12	 50	
postsynaptic	cell	membrane		 5.70E-14	 1.90E-12	 49	
neurotransmitter	receptor	activity		 8.10E-13	 7.60E-11	 45	
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postsynaptic	membrane		 7.80E-12	 4.20E-10	 55	
cell	junction		 4.60E-10	 2.30E-08	 136	
chloride	channel		 7.50E-07	 1.30E-05	 24	
anion	binding		 7.50E-05	 2.20E-03	 30	
9		
(ES:	7.28)	
peptide	receptor	activity		 9.10E-11	 6.60E-09	 47	
neuropeptide	receptor	activity		 1.60E-06	 7.90E-05	 20	
10		
(ES:	6.6)	
extracellular	matrix		 1.20E-07	 2.40E-06	 66	
proteinaceous	extracellular	matrix		 3.40E-07	 1.10E-05	 86	
extracellular	matrix		 3.70E-07	 1.10E-05	 91	
 
Table 4-15: Pathways enriched in genes downregulated in pooled KC 
corneas compared to WT. Table showing the functional annotation clustering of 
the top 3000 significantly differentially expressed genes reported by FDR values 
of edgeR and detected by both Cufflinks/Cuffdiff and edgeR analyses. Only the 
clustering pathways with corrected p values (Benjamini value < 0.05) are 









ribonucleoprotein	complex		 9.70E-49	 3.40E-46	 222	
translation		 1.30E-40	 5.40E-37	 157	
translational	elongation		 1.40E-39	 2.90E-36	 77	
protein	biosynthesis		 5.90E-39	 6.10E-37	 104	
2		
(ES:	12.53)	
pigment	granule		 3.40E-23	 3.40E-21	 57	
melanosome		 3.40E-23	 3.40E-21	 57	
vesicle		 1.40E-08	 2.90E-07	 165	
cytoplasmic	vesicle		 1.60E-07	 2.80E-06	 155	
3		
(ES:	12.31)	
ubl	conjugation		 4.80E-16	 2.30E-14	 159	
isopeptide	bond		 1.20E-14	 5.30E-13	 100	
4		
(ES:	12.3)	
Apoptosis		 9.30E-14	 3.70E-12	 111	
programmed	cell	death		 1.80E-13	 3.20E-11	 170	
5		
(ES:	12.03)	
membrane-enclosed	lumen		 6.60E-18	 3.10E-16	 433	
organelle	lumen		 2.10E-16	 8.20E-15	 421	
nuclear	lumen		 9.60E-12	 2.40E-10	 330	
nucleoplasm		 8.00E-08	 1.40E-06	 203	
6		
(ES:	11.91)	
RNA	splicing		 6.60E-17	 9.30E-14	 104	
mRNA	metabolic	process		 7.80E-14	 1.60E-11	 118	
RNA	processing		 5.00E-13	 7.30E-11	 155	
spliceosome		 4.90E-10	 1.10E-08	 52	
7		
(ES:	11.11)	
organelle	membrane		 1.60E-22	 1.40E-20	 300	
mitochondrion		 1.30E-20	 1.20E-18	 219	
organelle	envelope		 4.20E-19	 2.40E-17	 188	
respiratory	chain		 1.80E-17	 1.30E-15	 42	
Oxidative	phosphorylation		 6.60E-15	 4.10E-13	 66	
electron	transport	chain		 4.10E-11	 4.60E-09	 49	
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transit	peptide		 4.60E-07	 7.80E-06	 109	
NADH	dehydrogenase	activity		 8.70E-06	 5.30E-04	 20	
8		
(ES:	10.87)	
non-membrane-bounded	organelle		 3.40E-16	 1.10E-14	 564	
cytoskeleton		 2.10E-02	 1.20E-01	 253	
9		
(ES:	10.06)	
protein	localization		 4.80E-16	 2.10E-13	 235	
protein	transport		 3.60E-14	 1.00E-11	 204	
transport		 2.10E-08	 4.40E-07	 318	
intracellular	protein	transport		 2.90E-08	 1.90E-06	 103	
protein	targeting		 4.20E-07	 2.40E-05	 65	
10		
(ES:	10.05)	
protein	catabolic	process		 2.10E-10	 1.90E-08	 162	
macromolecule	catabolic	process		 2.30E-10	 2.00E-08	 194	
proteolysis		 4.00E-04	 1.30E-02	 212	
 
4.2.3.5.2 Pathway analysis of genes detected as differentially expressed by 
Cufflinks/Cuffdiff  and totally absent in either pooled KC or 
pooled WT corneas 
In this sub-section, genes found to be differentially expressed in analyses with 
Cufflinks/Cuffdiff and totally absent in KC corneas compared to WT corneas are 
subjected to DAVID functional clustering, the results of which are displayed in 
Table 4-16. DAVID analyses of genes found to be differentially expressed with 
Cufflinks/Cuffdiff and totally absent in WT corneas compared to KC corneas are 
presented in Table 4-17.  
Table 4-16: Pathways enriched in the genes expressed in pooled KC and 
absent in pooled WT corneas. Table showing the functional annotation 
clustering of the 800 genes of significant q-values that appear on 
Cufflinks/Cuffdiff to be totally absent in WT corneas compared to KC. Only the 
clustering pathways with significant corrected p values (Benjamini value < 0.05) 









Olfactory	receptor	 2.2E-259	 27.4E-257	 241	
G-protein	coupled	receptor	 6.9E-236	 1.2E-233	 287	
GPCR	Rhodopsin-like	superfamily	 4.4E-235	 1.2E-232	 280	
Transducer	 2.9E-227	 2.6E-225	 288	
Sensory	transduction	 2.9E-217	 4.2E-215	 245	
Olfactory	transduction	 1.6E-202	 1.4E-200	 224	
Sensory	perception	 6.4E-180	 2.3E-177	 254	
Cognition	 1.3E-169	 3.7E-167	 257	
Receptor	 7.0E-160	 4.8E-158	 299	
Neurological	system	process	 3.4E-148	 8.1E-146	 268	
Cell	surface	receptor	linked	signal	 5.9E-138	 1.2E-135	 308	
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transduction	
Cell	membrane	 3.7E-127	 2.1E-125	 308	
Disulfite	bond	 8.5E-125	 4.1E-123	 347	
Glycoprotein	 1.9E-104	 8.1E-103	 389	
Plasma	membrane	 5.6E-63	 1.3E-60	 343	
Integral	to	membrane	 1.4E-46	 1.6E-44	 384	
Intrinsic	to	membrane	 1.8E-44	 1.3E-42	 388	
2		
(ES:	2.8)	
Four	helical	cytokine,	core		 3.5E-6	 3.9E-4	 11	
Sematotropin	hormone	 8.0E-4	 4.8E-2	 4	
4	
(ES:	1.97)	
IFabd	 6.8E-7	 8.0E-5	 7	
Interferon	alpha/beta/delta	 1.7E-5	 1.5E-3	 7	
Interferon	alpha	 5.4E-5	 4.3E-3	 6	
Leucocyte	 8.1E-5	 2.1E-3	 6	
Antiviral	 8.5E-4	 1.9E-2	 5	
5	
(ES:	1.65)	
Keratin	 4.4E-6	 1.3E-4	 18	
Intermediate	filament	cytoskeleton	 7.0E-4	 3.9E-2	 19	
10	(ES:	1.35)	 Secreted	 9.1E-4	 1.8E-2	 79	
11	(ES:	1.09)	 LRRNT	 9.0E-4	 5.2E-2	 9	
 
Table 4-17: Pathways enriched in the genes expressed in pooled WT and 
absent in pooled KC corneas. Table showing the functional annotation 
clustering of the 26 genes of significant q-values that appear on Cufflinks/Cuffdiff 
analysis to be totally absent in KC corneas compared to WT. Only the clustering 
pathways with significant corrected p value (Benjamini value < 0.05) are 









MHC	class	I	protein	complex	 5.1E-5	 4.4E-3	 3	
Antigen	processing	and	presentation	 2.5E-3	 3.8E-2	 3	
4.2.4 Differential expression profile for each cornea and its WES 
4.2.4.1 WES and RNA-Seq combination for each individual KC  
The RNA-seq data for each of the 6 KC corneas were checked individually for 
differential expression, by running the edgeR protocol (Section 2.14) and the 
Cufflinks/Cuffdiff protocol (Section 2.14) on each individual cornea and compared 
with the pooled 3 WT corneal replicates. Using the pipeline described in Figure 
4-10, the differential gene expression profiles generated by both software 
packages were checked for significant changes (Cufflinks/Cuffdiff q-values and 
edgeR FDR values < 0.05), then a common list of genes between both files was 
generated. In parallel, WES libraries were prepared from the DNA extracted from 
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blood of the KC cornea donors according to the protocol described in Section 
2.9. The WES reads were checked for quality, aligned, processed using GATK 
and annotated by ANNOVAR following the pipeline described in appendix 1.6. 
The result is a raw, non-filtered, annotated list of changes specific to every 
individual who donated their KC corneas.  
 
Next, the list of significant differentially expressed genes identified in analyses by 
both software packages was compared against the list of changes from WES, in 
order to check for genomic mutations in these particular differentially expressed 
genes. The results displayed in Tables 4-18 to 4-23 show, patient by patient, the 
exonic and splicing variants detected in WES in genes that have been shown to 
be differentially expressed in the cornea of that KC patient compared to WT, and 
having the highest CADD scores (≥ 30) along with MAF<2%.  
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For each KC patient:  
List of significantly differentially 
expressed genes detected by 
both software analyses 
List of exonic and splicing 
variants with MAF<2% 
For each KC patient:  
List of variants in genes that are significantly DE 
in analyses with both software packages  
WES List of variants in genes shared in all the 6 
KC corneas and being significantly differentially 
expressed in both software analyses 
Figure 4-10: Combining RNA-seq and WES data. The pipeline presented in this 
chart combines the analysis of DE in KC vs WT corneal RNA-seq data with WES data 
of from the patients from whom the KC corneas were taken, to produce a list of genes 
differentially expressed and containing potentially biologically significant genetic 
variants 
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Table 4-18: MA18-KC (KC-0) WES and DE results combined. Genes with coding variants detected in WES of MA18-KC (KC-0) 
cornea, with CADD Phred score > 30, differentially expressed (FDR < 0.05) by comparison with WT in analyses with both edgeR 
and Cufflinks, and listed in descending order of CADD score. logFC and FDR values outputted by edgeR are also given. The 
negative logFC values correspond to the downregulated genes in KC compared to WT. The positive logFC values correspond to 
the upregulated genes in KC corneas compared to WT. The FDR (false discovery rate) values are the significant corrected p-values 
calculated by edgeR using the Benjamini-Hochberg method.  
Gene	 Location	 	Cadd	
Phred	
AA	Change	 Function	 esp6500	 1000g	 exac03	
	
snp138	 Status	 logFC	 FDR	
GJD3	 17q21.2	 36	 exon1:c.C237A:p.L79L	 synonymous	 0.0148	 0.0058	 0.0120	 rs141158879	 het	 4.6270	 8.607E-07	




.	 0.0012	 0.0040	 .	 het	 -3.7916	 7.750E-09	
ERCC6	 10q11.23	 35	 exon9:c.1918dupT:p.W640fs	 frameshift	
insertion	
0.0001	 .	 .	 .	 het	 1.8119	 5.714E-04	
KIAA1919	 6q21	 35	 exon4:c.T545A:p.L182X	 stopgain	 .	 0.0070	 0.0180	 rs117505745	 het	 2.9732	 2.303E-08	
CDC6	 17q21.2	 34	 exon6:c.G883A:p.D295N	 nonsynonymous	 0.0156	 0.0056	 0.0130	 rs4135012	 het	 3.6574	 1.122E-06	
GLP1R	 6p21.2	 34	 exon13:c.C1261T:p.R421W	 nonsynonymous	 0.0007	 .	 0.0004	 rs146868158	 het	 11.5732	 7.380E-24	
ITGA7	 12q13.2	 34	 exon15:c.C2191T:p.R731W	 nonsynonymous	 .	 .	 0.0000	 .	 het	 5.4918	 3.726E-19	
LCA5	 6q14.1	 34	 exon5:c.G902A:p.R301H	 nonsynonymous	 0.0004	 0.0006	 0.0005	 rs139142572	 het	 2.9487	 1.959E-07	
MINK1	 17p13.2	 34	 exon24:c.C2830T:p.R944W	 nonsynonymous	 .	 .	 .	 .	 het	 -3.5925	 5.617E-10	
RYR3	 15q14	 34	 exon50:c.C7613T:p.T2538M	 nonsynonymous	 .	 .	 0.0001	 .	 het	 10.2694	 9.010E-51	
KRT76	 12q13.13	 33	 exon6:c.C1234T:p.R412W	 nonsynonymous	 0.0028	 0.0004	 0.0018	 rs147080851	 het	 4.5511	 2.354E-04	
MUC6	 11p15.5	 33	 exon31:c.C5760A:p.Y1920X	 stopgain	 .	 .	 0.0002	 rs75482640	 het	 10.9099	 6.703E-18	
NEB	 2q23.3	 33	 exon118:c.G16546C:p.D5516H	 nonsynonymous	 0.0020	 0.0002	 0.0019	 rs201979610	 het	 7.7729	 1.472E-47	
SLC14A2	 18q12.3	 33	 exon20:c.G2687A:p.R896H	 nonsynonymous	 0.0115	 0.0052	 0.0082	 rs41301139	 het	 8.6663	 2.573E-29	
CLEC18B	 16q23.1	 32	 exon12:c.G1288A:p.D430N	 nonsynonymous	 .	 .	 0.0001	 rs616457	 het	 3.8842	 1.363E-05	
IQGAP2	 5q13.3	 32	 exon11:c.C1169T:p.T390I	 nonsynonymous	 0.0153	 0.0054	 0.0170	 rs34950321	 het	 8.3978	 2.174E-39	
PCDHA3	 5q31.3	 31	 exon1:c.525_528del:p.T175fs	 frameshift	
deletion	
0.0084	 0.0052	 0.0095	 rs141677026	 het	 9.1078	 3.641E-24	
CLIC5	 6p21.1	 31	 exon3:c.C770A:p.P257H	 nonsynonymous	 0.0198	 0.0080	 0.0160	 rs35822882	 het	 3.8150	 2.159E-04	
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CYP4F12	 19p13.12	 31	 exon7:c.C820T:p.R274W	 nonsynonymous	 0.0008	 0.0032	 0.0038	 rs140750774	 het	 1.9135	 7.211E-03	
SGK2	 20q13.12	 30	 exon11:c.C1045T:p.H349Y	 nonsynonymous	 0.0012	 0.0002	 0.0015	 rs35793869	 het	 2.6070	 4.301E-04	
 
 
Table 4-19: MA26-KC (KC-1) WES and RNA results combination. Genes with coding variants detected in WES of MA26-KC 
(KC-1) cornea, with CADD Phred score > 30, differentially expressed (FDR < 0.05) by comparison with WT in analyses with both 
edgeR and Cufflinks, and listed in descending order of CADD score. logFC and FDR values outputted by edgeR are also given. 
The negative logFC values correspond to the downregulated genes in KC compared to WT. The positive logFC values correspond 
to the upregulated genes in KC corneas compared to WT. The FDR (false discovery rate) values are the significant corrected p-
values calculated by edgeR using the Benjamini-Hochberg method. 
Gene	 Location	 	Cadd	
Phred	
AA	change	 Function	 esp6500	 1000g	 exac03	
	
snp138	 Status	 logFC	 FDR	
EXOC3L1	 16q22.1	 40	 exon9:c.C1405T:p.R469X	 Stopgain	 0.002	 0.005	 0.003	 rs141772271	 het	 1.3891	 3.741E-02	
ARF3	 12q13.12	 37	 exon4:c.C295T:p.R99X	 Stopgain	 .	 .	 .	 .	 het	 1.8946	 1.907E-04	
CLTCL1	 22q11.21	 36	 exon15:c.C2409G:p.Y803X	 Stopgain	 .	 0.0001	 0.00007	 .	 het	 11.5639	 6.262E-24	
ADAMTS14	 10q22.1	 35	 exon6:c.C988T:p.R330C	 nonsynonymous	 0.002	 0.002	 0.003	 rs41307534	 het	 5.5164	 7.262E-19	
CHRNA1	 2q31.1	 35	 exon6:c.G686A:p.R229H	 nonsynonymous	 .	 .	 0.000008	 .	 hom	 1.7616	 7.652E-04	
DNAH10	 12q24.31	 35	 exon71:c.C12227T:p.P4076L	 nonsynonymous	 .	 .	 0.00001	 .	 het	 6.6654	 8.088E-25	
EPHA2	 1p36.13	 35	 exon15:c.G2627A:p.R876H	 nonsynonymous	 0.01	 0.007	 0.01	 rs35903225	 het	 -6.3393	 2.231E-21	
HOXB9	 17q21.32	 35	 exon2:c.G548A:p.R183H	 nonsynonymous	 .	 0.01	 0.005	 rs201792149	 het	 11.2620	 5.211E-21	
ITGB5	 3q21.2	 35	 exon14:c.G2290A:p.A764T	 nonsynonymous	 .	 .	 0.00001	 .	 het	 2.7821	 7.123E-05	







.	 .	 .	 .	 het	 14.982	 2.676E-65	
CELA1	 12q13.13	 34	 exon2:c.G53A:p.R18H	 nonsynonymous	 0.006	 0.0027	 0.003	 rs74336876	 het	 10.2626	 1.060E-13	
ENO3	 17p13.2	 34	 exon9:c.G1079A:p.R360H	 nonsynonymous	 .	 0.001	 0.001	 .	 het	 10.7091	 1.543E-16	
FAT4	 4q28.1	 34	 exon9:c.C7466T:p.A2489V	 nonsynonymous	 .	 0.002	 0.001	 .	 het	 11.3575	 7.591E-22	
FGF6	 12p13.32	 34	 exon3:c.G563A:p.R188Q	 nonsynonymous	 0.002	 0.0003	 0.002	 rs71583765	 het	 3.2039	 8.573E-07	
MYOF	 10q23.33	 34	 exon24:c.G2483T:p.G828V	 nonsynonymous	 .	 .	 .	 .	 het	 -2.5609	 1.929E-05	
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PLEKHG5	 1p36.31	 34	 exon20:c.G2458A:p.G820S	 nonsynonymous	 .	 0.001	 0.001	 rs202191898	 het	 10.6194	 7.579E-16	
SEMA5B	 3q21.1	 34	 exon8:c.G761A:p.R254H	 nonsynonymous	 0.0003	 0.0003	 0.0002	 rs184302192	 het	 -3.0496	 2.429E-02	
SULT6B1	 2p22.2	 34	 exon6:c.G662T:p.R221L	 nonsynonymous	 0.01	 0.01	 0.005	 rs11569761	 hom	 2.1783	 8.268E-03	
SVOPL	 7q34	 34	 exon5:c.G224A:p.R75Q	 nonsynonymous	 0.001	 0.002	 0.001	 rs144481050	 het	 -4.1790	 5.034E-12	
TUFM	 16p11.2	 34	 exon8:c.G1001A:p.R334Q	 nonsynonymous	 .	 .	 0.00001	 .	 het	 9.2492	 2.816E-38	
ABCA4	 1p22.1	 33	 exon42:c.G5882A:p.G1961E	 nonsynonymous	 0.003	 0.003	 0.005	 rs1800553	 het	 9.2492	 2.816E-38	
HPS5	 11p15.1	 33	 exon6:c.C452T:p.S151L	 nonsynonymous	 .	 .	 0.000008	 .	 het	 7.8064	 6.103E-32	
LYST	 1q42.3	 33	 exon23:c.G6524T:p.C2175F	 nonsynonymous	 .	 .	 0.000008	 .	 het	 5.4436	 2.223E-19	
MUC6	 11p15.5	 33	 exon31:c.C5760A:p.Y1920X	 stopgain	 .	 .	 0.0001	 rs75482640	 het	 -3.7400	 6.860E-06	
SIM1	 6q16.3	 33	 exon10:c.G1427T:p.R476M	 nonsynonymous	 .	 .	 0.000008	 .	 het	 5.0471	 1.011E-14	
FAAH	 1p33	 32	 exon8:c.C1067T:p.A356V	 nonsynonymous	 0.0009	 0.008	 0.003	 rs77101686	 het	 1.5615	 1.431E-02	
GRIK5	 19q13.2	 32	 exon8:c.A935T:p.H312L	 nonsynonymous	 .	 .	 .	 .	 het	 2.9500	 3.285E-06	
MAP2	 2q34	 32	 exon4:c.G163A:p.E55K	 nonsynonymous	 0.009	 0.004	 0.009	 rs139310749	 het	 4.7500	 8.979E-12	
QRICH2	 17q25.1	 32	 exon15:c.C4618T:p.R1540W	 nonsynonymous	 0.001	 0.0009	 0.001	 rs143270448	 het	 6.9976	 5.273E-35	
LIPH	 3q27.2	 31	 exon4:c.C539G:p.A180G	 nonsynonymous	 0.00007	 .	 0.0002	 rs138900382	 het	 2.2893	 1.253E-05	
NRG3	 10q23.1	 31	 exon9:c.G1951A:p.E651K	 nonsynonymous	 0.002	 0.002	 0.004	 rs138878772	 het	 10.3015	 7.012E-14	
BEST3	 12q15	 30	 exon2:c.G34A:p.D12N	 nonsynonymous	 0.00007	 .	 0.0003	 rs143236582	 het	 11.9206	 8.038E-28	
CORO2A	 9q22.33	 30	 exon7:c.G862A:p.V288M	 nonsynonymous	 .	 0.0003	 0.00009	 .	 het	 5.2176	 8.361E-09	
 
Table 4-20: MA46-KC (KC-2) WES and RNA results combination. Genes with coding variants detected in WES of MA46-KC 
(KC-2) cornea, with CADD Phred score > 30, differentially expressed (FDR < 0.05) by comparison with WT in analyses with both 
edgeR and Cufflinks, and listed in descending order of CADD score. logFC and FDR values outputted by edgeR are also given. 
The negative logFC values correspond to the downregulated genes in KC compared to WT. The positive logFC values correspond 
to the upregulated genes in KC corneas compared to WT. The FDR (false discovery rate) values are the significant corrected p-
values calculated by edgeR using the Benjamini-Hochberg method. 
Gene	 Location	 	Cadd	
Phred	
AA	change	 Function	 esp6500	 1000g	 exac03	
	
snp138	 Status	 logFC	 FDR	
EXOC3L1	 16q22.1	 40	 exon9:c.C1405T:p.R469X	 stopgain	 0.002	 0.005	 0.003	 rs141772271	 het	 4.5691	 3.308E-11	
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ARF3	 12q13.12	 37	 exon4:c.C295T:p.R99X	 stopgain	 .	 .	 .	 .	 het	 -7.5381	 1.084E-23	
CLTCL1	 22q11.21	 36	 exon15:c.C2409G:p.Y803X	 stopgain	 .	 0.0001	 0.00007	 .	 het	 2.6967	 6.811E-05	
ADAMTS14	 10q22.1	 35	 exon6:c.C988T:p.R330C	 nonsynonymous	 0.002	 0.002	 0.003	 rs41307534	 het	 2.1090	 8.203E-04	
CHRNA1	 2q31.1	 35	 exon6:c.G686A:p.R229H	 nonsynonymous	 .	 .	 0.000008	 .	 hom	 10.4161	 6.120E-15	
DNAH10	 12q24.31	 35	 exon71:c.C12227T:p.P4076L	 nonsynonymous	 .	 .	 0.00001	 .	 het	 9.4395	 9.365E-40	
EPHA2	 1p36.13	 35	 exon15:c.G2627A:p.R876H	 nonsynonymous	 0.01	 0.007	 0.01	 rs35903225	 het	 -4.1715	 9.710E-07	
HOXB9	 17q21.32	 35	 exon2:c.G548A:p.R183H	 nonsynonymous	 .	 0.01	 0.005	 rs201792149	 het	 9.5784	 1.717E-10	
ITGB5	 3q21.2	 35	 exon14:c.G2290A:p.A764T	 nonsynonymous	 .	 .	 0.00001	 .	 het	 -3.0929	 2.665E-07	




.	 .	 .	 .	 het	 14.982	 2.676E-65 
QARS	 3p21.31	 35	 exon21:c.G2036A:p.R679H	 nonsynonymous	 .	 0.0001	 0.0001	 rs201781920	 het	 -3.8537	 2.098E-10	
RFX3	 9p24.2	 35	 exon2:c.C107G:p.S36X	 Stopgain	 .	 .	 .	 .	 hom	 4.3896	 1.625E-14	
CELA1	 12q13.13	 34	 exon2:c.G53A:p.R18H	 nonsynonymous	 0.006	 0.002	 0.003	 rs74336876	 het	 9.9630	 2.421E-12	
ENO3	 17p13.2	 34	 exon9:c.G1079A:p.R360H	 nonsynonymous	 .	 0.001	 0.001	 .	 het	 5.5094	 5.202E-20	
FAT4	 4q28.1	 34	 exon9:c.C7466T:p.A2489V	 nonsynonymous	 .	 0.002	 0.001	 .	 het	 7.1999	 3.523E-37	
FGF6	 12p13.32	 34	 exon3:c.G563A:p.R188Q	 nonsynonymous	 0.002	 0.0003	 0.002	 rs71583765	 het	 9.8691	 6.936E-12	
MYOF	 10q23.33	 34	 exon24:c.G2483T:p.G828V	 nonsynonymous	 .	 .	 .	 .	 het	 -1.7159	 1.805E-03	
PLEKHG5	 1p36.31	 34	 exon20:c.G2458A:p.G820S		 nonsynonymous	 .	 0.001	 0.001	 rs202191898	 het	 -3.1372	 1.471E-06	
SEMA5B	 3q21.1	 34	 exon8:c.G761A:p.R254H	 nonsynonymous	 0.0003	 0.0003	 0.0002	 rs184302192	 het	 4.0324	 2.880E-05	
SULT6B1	 2p22.2	 34	 exon6:c.G662T:p.R221L	 nonsynonymous	 0.01	 0.01	 0.005	 rs11569761	 hom	 10.0014	 1.590E-12	
SVOPL	 7q34	 34	 exon5:c.G224A:p.R75Q	 nonsynonymous	 0.001	 0.002	 0.001	 rs144481050	 het	 5.8807	 8.508E-11	
TUFM	 16p11.2	 34	 exon8:c.G1001A:p.R334Q	 nonsynonymous	 .	 .	 0.00001	 .	 het	 -3.8814	 1.576E-09	
VPS13D	 1p36.22	 34	 exon18:c.C2225T:p.T742M	 nonsynonymous	 0.00007	 0.0001	 0.00009	 rs370784596	 het	 0.9944	 4.361E-02	
ABCA4	 1p22.1	 33	 exon42:c.G5882A:p.G1961E	 nonsynonymous	 0.003	 0.003	 0.005	 rs1800553	 het	 7.3277	 6.235E-31	
HPS5	 11p15.1	 33	 exon6:c.C452T:p.S151L	 nonsynonymous	 .	 .	 0.000008	 .	 het	 1.9566	 4.309E-04	
LYST	 1q42.3	 33	 exon23:c.G6524T:p.C2175F	 nonsynonymous	 .	 .	 0.000008	 .	 het	 2.8186	 9.247E-08	
MUC6	 11p15.5	 33	 exon31:c.C5760A:p.Y1920X	 stopgain	 .	 .	 0.0001	 rs75482640	 het	 10.6192	 3.118E-16	
PLEKHG2	 19q13.2	 33	 exon18:c.G2308A:p.A770T	 nonsynonymous	 0	 0.004	 0.006	 rs111487768	 het	 1.2152	 2.979E-02	
SIM1	 6q16.3	 33	 exon10:c.G1427T:p.R476M	 nonsynonymous	 .	 .	 0.000008	 .	 het	 11.2230	 5.050E-21	
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FAAH	 1p33	 32	 exon8:c.C1067T:p.A356V	 nonsynonymous	 0.0009	 0.008	 0.003	 rs77101686	 het	 1.6595	 8.508E-03	
GRIK5	 19q13.2	 32	 exon8:c.A935T:p.H312L	 nonsynonymous	 .	 .	 .	 .	 het	 5.1611	 5.996E-11	
MAP2	 2q34	 32	 exon4:c.G163A:p.E55K	 nonsynonymous	 0.009	 0.004	 0.009	 rs139310749	 het	 4.0142	 1.450E-17	
QRICH2	 17q25.1	 32	 exon15:c.C4618T:p.R1540W	 nonsynonymous	 0.001	 0.0009	 0.001	 rs143270448	 het	 4.7309	 6.931E-16	
LIPH	 3q27.2	 31	 exon4:c.C539G:p.A180G	 nonsynonymous	 0.00007	 .	 0.0002	 rs138900382	 het	 -2.0507	 1.185E-03	
NRG3	 10q23.1	 31	 exon9:c.G1951A:p.E651K	 nonsynonymous	 0.002	 0.002	 0.004	 rs138878772	 het	 12.5978	 9.644E-36	
BEST3	 12q15	 30	 exon2:c.G34A:p.D12N	 nonsynonymous	 0.00007	 .	 0.0003	 rs143236582	 het	 11.3476	 3.287E-22	
CORO2A	 9q22.33	 30	 exon7:c.G862A:p.V288M	 nonsynonymous	 .	 0.0003	 0.00009	 .	 het	 -2.7944	 4.694E-06	
 
Table 4-21: MA47-KC (KC-3) WES and RNA results combination. Genes with coding variants detected in WES of MA47-KC 
(KC-3) cornea, with CADD Phred score > 30, differentially expressed (FDR < 0.05) by comparison with WT in analyses with both 
edgeR and Cufflinks, and listed in descending order of CADD score. logFC and FDR values outputted by edgeR are also given. 
The negative logFC values correspond to the downregulated genes in KC compared to WT. The positive logFC values correspond 
to the upregulated genes in KC corneas compared to WT. The FDR (false discovery rate) values are the significant corrected p-
values calculated by edgeR using the Benjamini-Hochberg method. 
Gene	 Chr	 Cadd	
Phred	
AA	change	 Function	 esp6500	 1000g	 exac03	
	
snp138	 Status	 logFC	 FDR	
MELK	 9p13.2	 37	 exon15:c.T1389A:p.Y463X		 Stopgain	 .	 .	 .	 .	 het	 3.0609	 1.135E-06	
DNAH14	 1q42.12	 35	 exon21:c.3392delA:p.E1131fs	 frameshift	
deletion	
0.00316	 0.003	 0.00540	 .	 het	 6.9016	 4.035E-38	
MYOF	 10q23.33	 35	 exon43:c.4915delC:p.H1639fs	 frameshift	
deletion	
.	 .	 .	 .	 het	 -1.3893	 1.252E-02	
RAPGEFL1	 17q21.1	 35	 exon15:c.C1297T:p.R433C	 Nonsynonymous	 .	 .	 0.00001	 .	 het	 -2.4690	 4.338E-04	
ABCC8	 11p15.1	 34	 exon32:c.G3938A:p.R1313H	 Nonsynonymous	 0.00008	 .	 0.00002	 rs372153432	 het	 12.8512	 6.087E-39	
CBLC	 19q13.32	 34	 exon5:c.C790T:p.R264W	 Nonsynonymous	 .	 .	 .	 .	 het	 -2.0362	 2.011E-03	
DIXDC1	 11q23.1	 34	 exon7:c.G644T:p.R215L	 Nonsynonymous	 .	 0.0014	 0.00069	 .	 het	 1.2164	 3.380E-02	
FAT4	 4q28.1	 34	 exon9:c.C7466T:p.A2489V	 Nonsynonymous	 .	 0.0022	 0.00178	 .	 het	 6.9778	 2.017E-34	
OBSCN	 1q42.13	 34	 exon52:c.G13765A:p.G4589R	 Nonsynonymous	 .	 0.0002	 0.00016	 .	 het	 2.4176	 1.923E-07	
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PRB2	 12p13.2	 34	 exon3:c.C511T:p.R171X	 Stopgain	 0.00008	 .	 0.00036	 rs201606820	 het	 6.0079	 2.441E-02	
LAMB1	 7q31.1	 33	 exon32:c.G4940A:p.R1647H	 Nonsynonymous	 .	 0.0006	 0.00015	 .	 het	 -1.3644	 2.971E-02	
MUC6	 11p15.5	 33	 exon31:c.C5760A:p.Y1920X	 Stopgain	 .	 .	 0.00018	 rs75482640	 het	 10.6229	 9.366E-16	
ZNF407	 18q22.3	 33	 exon8:c.G5702A:p.R1901Q	 Nonsynonymous	 0.00008	 0.0004	 0.00018	 rs201662777	 het	 2.9746	 1.021E-08	
EXOC3L1	 16q22.1	 32	 exon5:c.C640T:p.R214W	 Nonsynonymous	 .	 .	 0.00007	 .	 het	 4.9289	 1.092E-13	
MAP7D1	 1p34.3	 32	 exon2:c.C310T:p.R104W	 Nonsynonymous	 0.00046	 0.0144	 0.00629	 rs2296266	 het	 -3.3991	 9.654E-08	
TJP1	 15q13.1	 32	 exon5:c.G353T:p.R118L	 Nonsynonymous	 0.00017	 0.0008	 0.00055	 rs148793257	 het	 -2.4484	 4.939E-02	




0.00637	 0.004	 0.00645	 rs201624048	 het	 7.6983	 1.135E-17	
ABCA12	 2q35	 31	 exon8:c.C1013T:p.P338L	 Nonsynonymous	 0.00008	 0.0004	 0.00024	 rs374169066	 het	 2.0576	 2.614E-05	
ATP12A	 13q12.12	 31	 exon17:c.C2373A:p.D791E	 Nonsynonymous	 .	 0.0010	 0.00044	 rs369210106	 het	 9.7798	 1.695E-30	
MRPL57	 13q12.11	 31	 exon2:c.C109T:p.R37C	 Nonsynonymous	 0.00823	 0.0040	 0.00822	 rs117575190	 het	 -3.3080	 1.449E-06	
SH3BP1	 22q13.1	 31	 exon14:c.G1243A:p.V415M	 Nonsynonymous	 .	 .	 0.00002	 .	 het	 -2.6176	 1.612E-05	
PREPL	 2p21	 30	 exon13:c.T1967C:p.F656S	 Nonsynonymous	 .	 .	 .	 .	 het	 1.7669	 1.773E-03	
 
Table 4-22: MA52-KC (KC-4) WES and RNA results combination. Genes with coding variants detected in WES of MA52-KC 
(KC-4) cornea, with CADD Phred score > 30, differentially expressed (FDR < 0.05) by comparison with WT in analyses with both 
edgeR and Cufflinks, and listed in descending order of CADD score. logFC and FDR values outputted by edgeR are also given. 
The negative logFC values correspond to the downregulated genes in KC compared to WT. The positive logFC values correspond 
to the upregulated genes in KC corneas compared to WT. The FDR (false discovery rate) values are the significant corrected p-
values calculated by edgeR using the Benjamini-Hochberg method. 
Gene	 Location	 	Cadd	
Phred	
AA	change	 Function	 esp6500	 1000g	 exac03	
	
snp138	 Status	 logFC	 FDR	
MAP3K15	 Xp22.12	 40	 exon24:c.C3364T:p.R1122X	 Stopgain	 0.001	 .	 0.001	 rs140104197	 het	 10.505	 2.416E-31	
ADAP2	 17q11.2	 37	 exon6:c.C606A:p.Y202X	 Stopgain	 .	 .	 .	 .	 het	 3.1543	 2.513E-08	
TMEM184A	 7p22.3	 36	 exon2:c.C166T:p.R56X	 Stopgain	 .	 .	 0.000	 .	 het	 -4.206	 6.460E-12	




.	 .	 .	 .	 het	 8.2956	 5.038E-20	
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.	 .	 .	 .	 het	 13.699	 4.673E-47	
LCNL1	 9q34.3	 35	 exon3:c.C217T:p.R73X	 Stopgain	 0.002	 0.0004	 0.001	 rs201231448	 het	 4.7379	 4.028E-07	
NINL	 20p11.21	 35	 exon6:c.A562T:p.K188X	 Stopgain	 .	 .	 .	 .	 het	 2.6532	 4.719E-05	
ZNF341	 20q11.22	 35	 exon14:c.C1810T:p.R604C	 nonsynonymous	 .	 0.0002	 0.000	 .	 het	 2.5897	 1.731E-06	
PCSK6	 15q26.3	 34	 exon11:c.G1381A:p.D461N	 nonsynonymous	 0.0002	 .	 0.000	 rs369879412	 het	 1.7383	 2.874E-03	
PDE6A	 5q32	 34	 exon5:c.C878T:p.P293L	 nonsynonymous	 0.0036	 0.0018	 0.003	 rs114973968	 het	 2.9627	 4.899E-08	
PGA5	 11q12.2	 34	 exon9:c.G1066T:p.E356X	 Stopgain	 .	 .	 .	 .	 hom	 9.6352	 1.892E-10	
XDH	 2p23.1	 34	 exon35:c.C3886T:p.R1296W	 nonsynonymous	 0.0131	 0.0068	 0.014	 rs45564939	 het	 -3.209	 2.097E-08	
CSRNP3	 2q24.3	 33	 exon4:c.C671T:p.T224M	 nonsynonymous	 0.0001	 .	 0.000	 rs371859963	 het	 5.7549	 2.549E-11	
FLNB	 3p14.3	 33	 exon35:c.G6001A:p.V2001M	 nonsynonymous	 .	 .	 .	 .	 het	 -1.558	 6.565E-03	
KIF20A	 5q31.2	 33	 exon19:c.C2516T:p.P839L	 nonsynonymous	 0.0113	 0.0054	 0.011	 rs3172747	 het	 5.4441	 5.522E-18	
MUC6	 11p15.5	 33	 exon31:c.C5760A:p.Y1920X	 Stopgain	 .	 .	 0.000	 rs75482640	 het	 10.850	 1.823E-17	
ABCG4	 11q23.3	 32	 exon11:c.G1184A:p.R395Q	 nonsynonymous	 0.0002	 .	 0.000	 rs149710791	 het	 5.8140	 2.679E-21	
ANKRD45	 1q25.1	 32	 exon5:c.G634A:p.E212K	 nonsynonymous	 0.0048	 0.0016	 0.003	 rs34387166	 het	 5.0854	 1.890E-11	
LAMC3	 9q34.12	 32	 exon19:c.C3371T:p.S1124F	 nonsynonymous	 0.0095	 0.0032	 0.007	 rs113259170	 het	 7.4532	 4.396E-29	
NOL6	 9p13.3	 32	 exon6:c.C787T:p.R263C	 nonsynonymous	 0.0002	 .	 0.000	 rs116746143	 het	 -1.749	 4.317E-03	
PRSS12	 4q26	 32	 exon8:c.G1583A:p.G528E	 nonsynonymous	 .	 .	 .	 .	 het	 3.5565	 4.068E-09	
SH3BP2	 4p16.3	 32	 exon11:c.C1429T:p.R477W	 nonsynonymous	 0.0032	 0.0042	 0.005	 rs148761331	 het	 -3.779	 3.431E-10	
RTN4RL1	 17p13.3	 31	 exon2:c.G439A:p.G147S	 nonsynonymous	 0.0111	 0.0048	 0.008	 rs181444163	 het	 4.1425	 2.787E-06	
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Table 4-23: MA58-KC (KC-5) WES and RNA results combination. Genes with coding variants detected in WES of MA58-KC 
(KC-5) cornea, with CADD Phred score > 30, differentially expressed (FDR < 0.05) by comparison with WT in analyses with both 
edgeR and Cufflinks, and listed in descending order of CADD score. logFC and FDR values outputted by edgeR are also given. 
The negative logFC values correspond to the downregulated genes in KC compared to WT. The positive logFC values correspond 
to the upregulated genes in KC corneas compared to WT. The FDR (false discovery rate) values are the significant corrected p-
values calculated by edgeR using the Benjamini-Hochberg method. 
Gene	 Location	 	Cadd	
Phred	
AA	change	 Function	 esp6500	 1000g	 exac03	 snp138	 Status	 logFC	 FDR	
SERPINA12	 14q32.13	 40	 exon12:c.C1027T:p.R343C	 Stopgain	 0.0055	 0.0016	 0.00526	 rs61757459	 het	 11.0433	 1.105E-18	
STAP2	 19p13.3	 38	 exon4:c.1566delG:p.E522fs	 Stopgain	 0.0082	 0.0040	 0.00988	 rs79657645	 het	 -2.8014	 3.394E-06	
NAA38	 17p13.1	 37	 exon12:c.C1984T:p.R662C	 Stopgain	 0.0095	 0.0040	 0.00895	 rs144163075	 het	 -1.8149	 5.299E-03	
OR52L1	 11p15.4	 36	 exon5:c.G674A:p.R225H	 Stopgain	 0.0003	 0.0026	 0.00499	 rs186343423	 het	 9.9348	 7.873E-12	
ITGB3	 17q21.32	 35	 exon3:c.C220T:p.R74W	 Nonsynonymous	 .	 0.0002	 0.00001	 rs151219882	 het	 6.4788	 1.627E-05	
LAMA1	 18p11.31	 35	 exon31:c.C5760A:p.Y1920X	 Nonsynonymous	 0.0072	 0.0022	 0.00642	 rs140718292	 het	 5.9761	 1.032E-16	
MTHFSD	 16q24.1	 35	 exon1:c.G168A:p.W56X	 Nonsynonymous	 .	 0.0002	 0.00002	 rs36053000	 het	 1.5067	 1.611E-02	
SLX4IP	 20p12.2	 35	 exon1:c.819delG:p.L273fs	 Nonsynonymous	 0.0003	 0.0056	 0.00327	 rs78689061	 het	 2.6782	 3.555E-04	
SYT6	 1p13.2	 35	 exon1:c.G890A:p.W297X	 Nonsynonymous	 .	 .	 0.00001	 .	 het	 11.5635	 2.029E-23	
TTI2	 8p12	 35	 exon12:c.G1891A:p.V631M	 Nonsynonymous	 0.0038	 0.0016	 0.00308	 rs138108276	 het	 1.5734	 9.210E-03	
ARGFX	 3q13.33	 34	 exon3:c.C631T:p.R211X	 Stopgain	 .	 .	 .	 .	 het	 10.5894	 1.620E-15	
ARMC9	 2q37.1	 34	 exon5:c.C289T:p.R97C	 Nonsynonymous	 .	 .	 0.00001	 .	 het	 4.5931	 1.433E-13	
ADAM19	 5q33.3	 33	 exon6:c.C507G:p.Y169X	 Nonsynonymous	 0.0003	 0.0004	 0.00027	 rs146453088	 het	 3.8431	 1.051E-10	
MUC6	 11p15.5	 33	 exon5:c.G974A:p.R325Q	 Stopgain	 .	 .	 0.00018	 rs75482640	 het	 11.3245	 3.328E-21	
TFR2	 7q22.1	 33	 exon15:c.G1742A:p.R581H	 Nonsynonymous	 0.0201	 0.0082	 0.01900	 rs41295942	 het	 4.0148	 1.280E-12	
ANGPTL6	 19p13.2	 32	 exon4:c.C1063T:p.R355C	 Nonsynonymous	 .	 0.0038	 0.00132	 .	 het	 6.4644	 1.923E-08	
UGGT2	 13q32.1	 32	 exon33:c.A3802T:p.N1268Y	 Nonsynonymous	 0.0229	 0.0082	 0.01900	 rs45473699	 het	 1.2701	 3.601E-02	
PLA2R1	 2q24.2	 31	 exon2:c.33_34del:p.V11fs	 Nonsynonymous	 0.0010	 0.0008	 0.00054	 rs146287694	 het	 1.4065	 1.317E-02	
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4.2.4.2 Significant DE genes harbouring changes in all 6 individual 
KC corneas 
In addition to checking for variants in genes that are significantly differentially 
expressed in each individual KC cornea, the lists of variants in DE genes for 
all 6 KC corneas were compared to look for shared DE genes containing 
variants in the WES data profiles generated from blood DNA of all KC 




Table 4-24: Genes containing variants in the WES all of the 6 KC corneas 
and being significantly differentially expressed. This table shows the 
genes, which were significantly differentially expressed between KC and WT 
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4.3 Discussion 
Over the years, human genetic research has enabled the significant 
advancement of the understanding of many molecular aspects underlying 
human inherited disorders. However, most of the human genetic disease 
studies, and in particular, the studies investigating complex diseases i.e. 
GWAS variants do not generally provide relevant clues to the contribution of 
the associated genetic variations or the functional impact of the DNA variation 
to disease onset. In addition finding the causative variations for these complex 
diseases is not an easy task in the first place (Costa et al., 2013, Pouladi et 
al., 2015). Thus, global gene expression-transcriptomics studies were 
adopted as a powerful tool for providing functional insights into the secondary 
disease process of many inherited diseases, as well as investigating the 
primary pathogenesis of complex and common genetic conditions (Morley et 
al., 2004, Twine et al., 2011). 
 
Transciptome studies have progressed from hybridization methods including 
microarrays, to tag methods (Horan, 2009, Wang et al., 2009). However, 
RNA-seq presents many advantages over other methods (reviewed by (Wang 
et al., 2009, Garber et al., 2011)), consequently in the recent years, RNA-Seq 
has become the method of choice for transcriptomic studies. Moreover, RNA-
seq gives researchers the opportunity to characterize the sequences and 
quantify all the RNAs present in a sample as well as the discovery of new 
transcripts and splicing events (Nagalakshmi et al., 2008, Wang et al., 2009, 
Trapnell et al., 2012, Finotello and Di Camillo, 2015).  
 
In this study, RNA was extracted from the anterior section (Epithelium, 
Bowman’s Layer, and Stroma) of 5 WT and 6 KC corneas, and the 
transcriptome data for each cornea was generated. Using the RNA-seq data 
generated, three main areas of study were explored: 1- the RNA profile of 
healthy human corneas; 2- the differential expression between the RNA 
profile of KC vs. WT corneas; and 3- the individual RNA profile of each KC 
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cornea, considered in combination with the WES data of the same KC cornea 
investigated.  
 
For all the mentioned strategies, RNA-seq paired-end reads were mapped 
using the Tophat software (Kim et al., 2013) and aligned to a reference 
genome (Gencode GRCh38p2), but not a reference transcriptome, allowing 
the discovery of novel transcripts; however the reference transcriptome 
(GRCh38p2) was used as an annotation guide. Tophat was the aligner of 
choice in this study since one of the advantages it offers over other available 
software packages is the gap-alignment function, which allows the alignment 
of reads containing indels (Kim et al., 2013). In addition, Tophat is a spliced-
read mapper, which, after mapping the reads to the genome, performs the 
analyses of the mapping results, in order to build all possible exon-exon 
junctions for splice junction identification (Trapnell et al., 2012). 
 
4.3.1 The RNA profile of healthy human corneas.  
As previously described in Figure 4-1, the RNA-seq data of the WT corneas 
was generated in order to observe a healthy anterior corneal gene expression 
profile. Thus, Cuffnorm was used only on the merged transcripts of WT 
corneas, in order to normalize the expression levels among all the replicates 
by applying an additional step of normalization for library size. Cuffnorm 
reports FPKM and normalized estimates of the number of fragments for each 
class (genes, TSS group, transcript and CDS group) which basically accounts 
for differences in library size (Trapnell et al., 2012). In this Cuffnorm analysis, 
the library size factor used was 1 by applying the default cufflinks settings, 
which suggest multiplying the gene read counts for each sample by 1 and 
multiplying it by the mean read counts of the same gene across all samples 
(Aleksic et al., 2014). FPKM and library size present challenges and introduce 
some biases to the data (Zheng et al., 2011, Aleksic et al., 2014). FPKM can 
be biased in reporting expression values for genes expressed at low levels 
and presenting small transcripts (Dillies et al., 2013). This is because small 
transcripts can present low read counts but when accounting for length biases 
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the library normalized value would be multiplied by the exon length of each 
transcript, leading to an overrepresentation of the actual biological 
significance of the expression (Aleksic et al., 2014). The library size 
normalization may be a source of bias only in case of the presence of large 
differences in a particular set of mRNAs between samples.(Robinson and 
Oshlack, 2010).  
 
4.3.1.1 The RNA profile results 
After running Cuffnorm, the tab-delimited “gene.fpkm_tracking” was the file of 
interest for this study which represented the normalised FPKM of transcripts 
sharing the same gene-id. The averaged FPKM values were sorted according 
to expression levels from high to low and mitochondrial genes (mt-genes) 
were removed from the final list. The exclusion of the mt-genes risks missing 
biologically important observations, since their expression might be prominent 
in corneal tissues and removing these genes from the expression data might 
be introducing bias. However their high FPKM values do not necessarily 
correlate with their high expression. Indeed, it is not really clear whether their 
high FPKM values are due to the biological overexpression of these particular 
genes in corneal tissues or to the overrepresentation of mitochondrial DNA in 
the cells. This will be overcome in the future work of this project, by running 
RNA-seq analysis on several other different tissues than cornea and 
comparing mitochondrial gene expression levels in different tissues. 
	
The pathways and functional structures that are most enriched in normal 
human corneas, as presented in Table 4-2, are ribonucleoproteins, 
translational elongation, protein biosynthesis, oxidative phosphorylation, 
mitochondrial structure/function, the cytoskeleton, mRNA processing and 
RNA splicing.  
 
There are several considerations to take into account while interpreting this 
data. First, the pathway analysis can be biased due to the fact that only the 
first 3000 protein coding genes can be uploaded to DAVID, risking the 
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omission/overrepresentation/misrepresentation of crucial pathways involved in 
human corneal function or structure. Second, none of these data have been 
confirmed in the lab by RT-PCR, and that specific point is one of the future 
directions of this project (Section 5.2.3). Third and most importantly, the 
corneal profiles from these donors might not be totally representative of the in-
vivo corneal mRNA profile. The enucleation procedure from the donor’s eye 
takes place as soon as possible to a maximum of 24 hours after death, so the 
time between enucleation and preservation may vary quite significantly 
between samples and may extend to a full 24 hours. In addition, after 
enucleation, the tissue from the donor is preserved in an EAGLES 2% FBS 
medium (Section 2.3) at 34 degrees a period of time that can go no longer 
than 28 days. Then in the theatre, while performing DSEK (Section 2.3) the 
tissue remains in open air for at least 20 minutes before disposing it into 
RNAlater (Section 2.3). While undergoing all of this procedure, the mRNA is 
prone to degradation. However this degradation is expected to be minimal, 
since this same procedure is followed for the tissues that are extracted for 
transplantation. Thus, the difference in the RNA profiles of KC and WT 
corneas in Figures 4-4 and 4-5 might be due to a combination of difference in 
freshness in both tissues as well as the manifestation of the disease.  
 
4.3.1.2 Discovery of potential novel genes/exons 
Note that replication and confirmation of these results in the lab by RT-PCR 
was not carried out before writing this thesis, but is an essential next step in 
the future direction of this project. 
 
In addition to annotating transcripts expressed in the normal cornea, these 
data facilitated a search for potential novel cornea-specific isoforms of existing 
genes or novel genes. Following the protocol described by Farkas et al. 
(Farkas et al., 2013), a new alignment algorithm, the RNA-Seq Unified 
Mapper (RUM), was used for novel gene and exon discovery. 
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In order to pursue that goal, the RNA-seq data was aligned on RUM, which is 
a different aligner to Tophat (Section 4.2.2.2). In addition to RUM being an 
aligner implemented in Perl, it is a junction calling and feature quantification 
software which makes it able to accurately identify novel splice variants, 
including splicing events and novel junctions with low read depth (Grant et al., 
2011). Combining information on novel junctions with the genome browser 
UCSC, leads to the identification of the location of the new junctions, which 
sometimes consists in the identification of a new exon or a new gene. The 
alignment pipeline of RUM consists of mapping reads in three phases. First, it 
uses Bowtie -based on the Burrows–Wheeler algorithm- to map the reads 
against the hg19 version of the genome, then in the second step it maps the 
reads against the transcriptome database and finally in the third step the non-
mapped reads by Bowtie are mapped against the hg19 version of the genome 
by BLAT. Afterwards, the results from the three mappings are merged 
together. Thus, the RUM alignment approach improves the quality of mapping 
by combining the speed of Bowtie with the sensitivity of BLAT.  
 
The list of the novel findings in genes or exons represented in Table 4-4 
represents the canonical novel junctions (GT-AG splice site pairs).  The novel 
junctions mapping within existing genes can be divided into four clusters: 3 
novel junctions genes (MECOM), 2 novel junctions genes (MFN2), 1 novel 
junction genes (GBA3, PLEKA7, NOX1, AK023515, ERCC1, SITM1 and 
RPS6KA2) and novel junctions in specified regions of the genome that don’t 
fall into known genes regions (6 novel junctions). In the known genes, these 
novel junctions might be indicative of novel exons. However, the novel 
junctions that fall in un-annotated regions of the genome might be indicative of 
novel genes. According to the Table 4-4 results, the novel genes might be 
composed of two exons only (1 junction), unless there are other non-
canonical junctions (GC-AG splice site) contributing to the splice sites of other 
exons composing the genes. Further analyses are in progress in order to 
answer for the speculations postulated in this section and section 4.2.2.2.  
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The results of Table 4-4 need to be verified in the lab by RT-PCR and looked 
at in different tissues in order to confirm the existence of these features and to 
determine whether these are novel findings unique to the cornea only or 
whether similar findings occur in different tissues. 
 
4.3.2 Sample assessment and differential expression analysis 
DE analyses were first conducted by running the Cufflinks package (4.2.3.2) 
on all the 6 KC and 5 WT corneas, and visualized using the plotting tool, part 
of the Tuxedo suite pipeline CummeRbund (Trapnell et al., 2012). The initial 
visualization of the data (Figures 4-4, 4-5) served as an evaluation of the 
quality of the RNA-seq data of the samples used, both WT and KC, and as a 
quality control step which revealed a heterogeneous distribution of FPKM 
values among samples: samples KC_3 for the Keratoconus condition and 
WT_3 and WT_4 of the wild-type corneas condition were tagged as outliers in 
the biological replicates of each condition.  
 
Since this is a new project and working out how to deal better with data of 
different quality status is still an on-going task, it has been (perhaps naively) 
decided to remove the samples that were revealed to be outliers and did not 
uniformly conform with the profiles of the other samples. It is known with RNA-
seq data that the more replicates used, the better the outcome of the data is. 
However, a conservative approach was taken in this respect while conducting 
this project. 2 samples have been removed from the WT samples (WT_3 and 
WT_4) to drop the number of samples from 5 to 3 which is still acceptable in 
terms of number of biological replicates, and one KC sample (KC_3) has been 
removed as well to drop the number of samples from 6 to 5. 
 
Another subject that catches the attention while doing the quality control 
assessment is the differences in the profiles between the KC and WT 
corneas. The RNA seq data profiles emerging from the two different 
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conditions, KC and WT, are very different even though they derive from the 
same type of tissue (anterior cornea).  
 
The differences might be due to: (1) the method of handling the tissues during 
collection. For KC corneas, the tissues were surgically removed in theatre and 
directly preserved in RNA later Ambion solution. As for the WT corneas, the 
tissues were extracted as soon as possible but up to no longer than 24 hours 
after death. Hence, the low and larger range of FPKM values (presented in a 
wider base in Figure 4-5 a,c) in the RNA profile of WT corneas might be due 
to the degradation of RNA caused by the delay in the tissue extraction of the 
WT corneas. However, this degradation is thought to be minimal since this 
same procedure of extraction of WT tissues is used to extract tissues for 
research as well as for transplantation (Figueiredo, 2013). Thus the WT 
tissues for donation, extracted through the same protocol, are still biologically 
viable. (2) The difference in tissue organisation between KC and WT caused 
by the disease progression. It is well known that KC corneas show keratocyte 
apoptosis and major changes in the structure of the cornea (Described in 
details in Section 1.4.5). Thus, these changes might be produced by the 
actual differences in molecules composition between KC and WT corneas, 
which are basically reflected by the changes in mRNA levels presented in 
Section 4.2.3.2.  
 
All things considered, these changes in profiles between KC and WT corneas, 
are most likely due to the a mixture of both factors: slight RNA degradation 
due to the handling of the corneal tissues in addition, it is due to the actual 
differences between both KC and WT tissues caused by the development of 
the disease.  
 
4.3.3 Differential expression analyses 
Since there is no clear consensus about the best pipeline or method for DE 
yet (Seyednasrollah et al., 2015), two methods have been used in this project 
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for DE: these are the Cuffdiff2 part of the Cufflinks package (Trapnell et al., 
2013) and the bioconductor package edgeR (Robinson et al., 2010) preceded 
by Subreads (Liao et al., 2013) for creating a counts matrix.  
 
The previously mentioned software, Cufflinks/Cuffdiff on one side and 
Subreads/edgeR on the other side, present differences in the processing of 
the RNA mapped reads at many levels: read counts, normalization and 
differential expression analysis.  
 
In general, the most widely adopted approach for calculating read counts is 
summing up the total number of reads overlapping the exons of a gene 
(Finotello and Di Camillo, 2015). For Cufflinks, counting the fragments or 
paired end reads is modelled in order to account for the abundance of 
different splicing isoforms of a gene (Trapnell et al., 2010). The RNA counts 
are normalized for library size as well as gene length bias by using the FPKM 
(Fragments Per Kilobase of exon per Million Fragments mapped) method. 
According to Mortazavi et al., FPKM values are computed by “dividing the 
number of fragments aligned to gene exons by the total number of mapped 
reads and by the sum of exonic bases” (Mortazavi et al., 2008) it also 
estimates fragment abundances in relation to the estimated number of 
fragments (Trapnell et al., 2010). 
 
As for the edgeR approach, the counting of the reads was done by the 
command FeatureCount of the Rsubread package (Liao et al., 2013) where 
only the fragments that have both ends mapped were considered for counting.  
The read counts are then normalised by edgeR using the TMM (Trimmed 
Mean of M-values) normalization method, which takes into account the high 
count genes in terms of sample-specific effect, a bias induced by the 
sequencing depth of a sample, and accounts for library composition 
differences (i.e. sequencing depth) between samples (Robinson and Oshlack, 
2010). It has been shown to remove up to 30% of the genes of extreme M-
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values i.e. fold-change between samples to correct for library size differences 
(Robinson et al., 2010).  
 
As for differential expression analysis, both tools use a negative binominal 
parametric model for their ability to capture technical and biological variation 
(Robles et al., 2012, Seyednasrollah et al., 2015). Cuffdiff by default uses a 
beta negative binomial model for fragment counts in order to control for 
variability and read mapping ambiguity and minimise the count data 
overdispersion (Trapnell et al., 2012). As for edgeR, the negative binominal 
model is again used in the gene-wise dispersion estimates shrinking towards 
a “trend” estimated value across genes instead of a single value in order to 
minimise data overdispersion (Robinson et al., 2010). The negative binominal 
based methods have been shown to present higher performance in dealing 
with differential expression than other tools (i.e. Poisson-based models) 
(Zhang et al., Di et al., 2011, Kvam et al., 2012, Zhang et al., 2014).  
 
The previously presented technical differences between the two software 
packages can be interpreted by the ability of Cufflinks to identify the 
abundance of different transcripts within a sample and the difference in 
transcript expression, in addition to identifying novel transcripts through 
assembly. In addition, it provides information on differentially spliced genes or 
genes undergoing other types of isoform-level regulations (Trapnell et al., 
2012). As for edgeR, it is interpreted by the ability to identify if the observed 
differences in total expression of known transcripts between the two 
conditions (KC and WT corneas) can be attributed significantly to the 
experimental condition alone and not due to the biological variability 
(Robinson et al., 2010). This method represents an advantage over the other 
method of differential expression analysis, since it simplifies the technical 
influences that need to be taken into account during the analysis course (e.g. 
the length bias) (Robinson et al., 2010). 
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After briefly overviewing the differences between edgeR and Cuffdiff it is not 
surprising to observe differences in the DE results outputted by the two 
software packages. However since no particular RNA seq method can be 
optimal under all circumstances (Seyednasrollah et al., 2015), and knowing 
the advantages and disadvantages of both methods used in this project 
(Cuffdiff and edgeR), it was decided to only take into consideration the genes 
that appeared to be differentially expressed in both analyses. In parallel, the 
Cuffdiff method was used to detect genes that were totally absent in KC 
corneas compared to WT and vice versa, and later on in the future of the 
project it can be used for the detection of novel isoforms and splicing events. 
 
4.3.4 Differential expression results 
It is important to note that the transcriptomics project discussed in this chapter 
remains an on-going project and the results presented are preliminary and 
need more exploration and further validation. 
 
The main focus in this section was to study the genes that were highly 
significantly downregulated in pooled KC corneas (Table 4-12) as well as the 
pathway analysis of the downregulated genes and the overall differentially 
expressed genes in pooled KC corneas. EdgeR was able to pick up 
mitochondrial genes that Cufflinks wasn’t able to detect (Tables 4-10 and 4-
25) (MT-CO2, MT-CO3, MT-ATP6, MT-ND4, MT-RNR2). The downregulation 
of mt-genes may be read in two ways.  
 
Firstly it is plausible that mitochondria may be involved in KC pathogenesis. 
The downregulation of mt-genes in KC corneas might be due to mtDNA 
mutations, which have previously been reported in KC corneas (Abu-Amero et 
al., 2014b, Hao et al., 2015b) and might be the result of mitochondrial 
dysfunction (Chwa et al., 2008). Both mtDNA damage – which has been 
shown to be increased in KC (Atilano et al., 2005) - and mt-dysfunction in KC 
corneas (Chwa et al., 2008, Ishii et al., 2013) might be related to the elevation 
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of oxidative stress in KC corneas (Chwa et al., 2006, Arnal et al., 2011, Wojcik 
et al., 2013a, Wojcik et al., 2013b, Karamichos et al., 2014, Toprak et al., 
2014, Goncu et al., 2015). In fact, the downregulation of MT-RNR2 detected 
by edgeR in this study (Tables 4-10 and 4-25), if confirmed by RT-PCR, would 
be a confirmation of the elevation of oxidative stress in KC corneas, since it 
has been reported by Crawford and co-workers that the downregulation of 
16S rRNA (product of MT-RNR2) is specific to mitochondria in response to 
stress and is a protection mechanism of cells against oxidative stress 
(Crawford et al., 1997).  
 
An alternative explanation for the apparent downregulation of mt-genes in KC 
corneas is that it might be due to the decreased number of mitochondria in KC 
corneas compared to WT, which may in turn be the result of the decreased 
number of cells present in the tissue due to keratocyte apoptosis in KC (Kim 
et al., 1999, Kaldawy et al., 2002, Matthews et al., 2007, Synowiec et al., 
2014).  
 
However, either phenomenon, if proven, could be accounted for by elevation 
of oxidative stress, causing mitochondrial DNA damage and the apoptosis of 
KC fibroblasts (Section 1.4.7.2) (Chwa et al., 2006). 
 
Table 4-25: Mitochondrial genes found in edgeR analysis of RNAseq 
data to be differentially expressed between pooled KC and pooled WT 
corneas. 
Symbol	 Feature	 logFC	 FDR	
MT-CO2	 protein_coding	 -11.36332101	 5.9962E-269	
MT-CO3	 protein_coding	 -11.242322	 1.4741E-265	
MT-ATP6	 protein_coding	 -11.14214094	 2.147E-259	
MT-ND4	 protein_coding	 -10.50619685	 5.7367E-246	
MT-RNR2	 Mt_rRNA	 -10.39711274	 3.6219E-242	
MT-CO1	 protein_coding	 -10.17871168	 1.3102E-236	
MT-ND1	 protein_coding	 -10.14822195	 3.0305E-234	
MT-ND2	 protein_coding	 -10.13405602	 1.0652E-232	
MT-ND4L	 protein_coding	 -10.42501571	 2.2202E-229	
MT-ATP8	 protein_coding	 -10.64143114	 1.0031E-227	
MT-CYB	 protein_coding	 -9.569938616	 4.0729E-218	
MT-RNR1	 Mt_rRNA	 -9.371262465	 3.8672E-210	









DAVID pathway analysis of genes found in both Cufflinks/Cuffdiff and EdgeR 
analyses to be dowregulated in pooled KC corneas highlighted several 
pathways (Table 4-15). The main pathways/structures/functional groups 
reported computationally by DAVID, to which the encoded proteins belong are 
ribonucleoproteins, protein biosynthesis, translational elongation, 
mitochondrial structure/function, the respiratory chain, oxidative 
phosphorylation, apoptosis, membrane-bounded vesicle trafficking, protein 
ubiquitination and the proteasome, regulation of ligase activity, RNA splicing 
and the spliceosome, protein folding, GTPase activity and response to 
oxidative stress.  
 
The genes that were taken further for pathway analysis were those which 
appeared to be significantly differentially expressed in both DE analyses. The 
global DE analysis between healthy and disease corneas revealed the 
enrichment of several pathways (Table 4-13); among these pathways the 
glycosylation, glycoprotein and membrane components were the most 
enriched, followed mainly by proteins related to the extracellular domain, the 
intrinsic and integral to plasma membrane, the neurological system process 
and most particularly sensory perception, cell adhesion and signalling, 
translational elongation, cytosolic ribosomes, protein synthesis, ion transport, 
neurotransmitter receptor activity, cilium and many more pathways. These 
pathways have shown significant enrichment in the differentially expressed 
genes between pooled KC and pooled WT corneas, suggesting that these 
pathways may be the downstream secondary changes in KC corneas 
compared to WT and the end result of pathways to be altered in KC 
pathogenesis. 
 
MT-ND3	 protein_coding	 -9.482230403	 1.097E-203	
MT-ND5	 protein_coding	 -8.742280986	 2.5622E-196	
MT-TT	 Mt_tRNA	 -6.488225382	 2.57429E-85	
MT-TL1	 Mt_tRNA	 -6.129903761	 9.8316E-66	
MT-ND6	 protein_coding	 -4.077143136	 5.9182E-57	
MT-TV	 Mt_tRNA	 -4.41231946	 2.17498E-32	
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In addition, the subset of genes that were found to be totally absent in pooled 
KC corneas compared to WT, and vice versa, were checked for enriched 
pathways (Table 4-16 and 4-17). Surprisingly, the genes that were shown to 
be totally absent in WT corneas compared to KC belong to the olfactory 
pathway which was enriched in KC corneas compared to other pathways, 
along with the G-protein coupled receptor, sensory transduction, disulfide 
bond, cell membrane and glycoprotein functional groups. The olfactory 
signalling genes have previously been reported to be expressed in the eye by 
Pronin et al., who suggested that they may play a role in sensing chemicals in 
the ocular environment (Pronin et al., 2014). However, the reason behind the 
upregulation or the activation of the genes involved in ocular signalling ought 
to be further studied in details in KC corneas. 
 
As for the genes that are absent in KC corneas compared to WT, these 
clustered in only two significant pathways, the MHC class I protein complex 
and the antigen processing and presentation grouping. These pathways need 
to be closely looked at and further investigated.  
 
4.3.5 Differential expression profile for each cornea and its WES 
Table 4-24 shows 13 genes shown to harbour high CADD Phred score 
variants in the WES data generated from blood DNA of 6 KC patients who 
donated their KC corneas. Among these genes, 5 have no known function: 2 
long intergenic non-coding RNA (LINC00910 and LINC00955), 2 
pseudogenes (ANKRD36BP2 and GXYLT1P3) and 1 antisense gene 
(MCM3AP-AS1). The functions and pathways which belong to the rest of the 
genes are mainly: Calcium ion binding (HRNR and FAT4), protein and DNA 
binding (MUC2, ZNF738, HNRNPL and FAT4), extracellular matrix structural 
constituent (MUC6), cell-cell adhesion pathway (FAT4), mRNA splicing 
process (HNRNPL), Ubiquitin-protein tranferase activity (ZNF738) and 
oxidoreductase activity (FDFT1). 
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Along with harbouring potential pathogenic variants, these genes were picked 
according to the criteria of being significantly differentially expressed in these 
particular individual KC corneas. Therefore, since these variants appear 
equally in WES data from all 6 individuals who donated KC corneas, they 
might be or artefacts and data noise or variants in genes that present some 
susceptibility to KC development. Thus, further validation of the reported 
variants is crucial in order to make the differentiation between the two 
hypotheses.  
 
4.3.6 DE of KC genes in the literature and comparison with data 
obtained in this project 
So far, KC transcriptomics studies were mainly limited to microarrays (Bochert 
et al., 2002, Bochert et al., 2003, Ha et al., 2003, Nielsen et al., 2003, Mootha 
et al., 2009, Sutton et al., 2010, Mace et al., 2011, Ghosh et al., 2013, 
Lackner et al., 2014). These studies have highlighted a number of molecules 
that have been reported by several groups to be significantly differentially 
expressed in KC corneal epithelium. 
 
Lysyl Oxidase (LOX) mRNA has been reported by Nielsen et al. to be 
downregulated in KC corneal epithelium (Nielsen et al., 2003). Indeed, a 
correlation has been found between the downregulation of LOX mRNA levels 
(Nielsen et al., 2003, Shetty et al., 2015c) and the downregulation of LOX 
enzymes and activity in KC corneal tissues (Dudakova et al., 2012, Dudakova 
et al., 2015a, Shetty et al., 2015b). By immunohistochemistry Dudakova et al. 
found that the LOX enzyme distribution in KC corneas is decreased about 
63% and LOX activity is reduced by 38% in KC corneas compared to control 
tissue (Dudakova et al., 2012, Dudakova and Jirsova, 2013). In addition to 
LOX, Dudakova et al. investigated the presence and activity of lysyl oxidase-
like enzymes in KC corneas (LOXL1-4) by IHC and found LOXL2, 3 and 4 
enzymes are present at decreased levels in KC corneas compared to normal 
corneas (Dudakova et al., 2015b).  
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Tissue inhibitor of metalloproteinase 1 and 3 (TIMP1 and TIMP3) mRNA 
levels were shown to be downregulated in cultured keratoconic corneal 
stromal fibroblasts (Lee et al., 2009) and the alterations in expression of these 
two transcripts have been shown to have an effect on keratocyte apoptosis in 
Keratoconus (Matthews et al., 2007). However, TIMP3 mRNA has been 
shown to be upregulated in KC corneal epithelium (Nielsen et al., 2003) but 
Kenny et al. also reported a TIMP1 mRNA downregulation in KC corneas 
(Kenney et al., 2005). 
 
The Wnt/beta-catenin signalling pathway has been shown to be involved in 
KC pathogenesis by Katoh et al. who found the angiopoietin isoform 
(ANGPTL7) mRNA to be upregulated in KC corneas (Katoh and Katoh, 2006). 
In addition to ANGPTL7, the mRNA for another protein belonging to the Wnt 
signalling pathway, Secreted Frizzled-related protein 1 (SFRP1), has been 
shown to be significantly upregulated in KC corneal epitheliums compared to 
controls (Sutton et al., 2010). This correlated with an upregulation of SFRP1 
protein levels in keratoconic tear samples (You et al., 2013a) and SFRP1 
expression in KC corneas detected by immunostaining (Iqbal et al., 2013, You 
et al., 2013b). Furthermore, Iqbal et al. established a link between the 
expression of SFRP1 and microtubule-associated protein light chain 3 
(MAPLC3), and showed correlation of expressivity between the two molecules 
in KC epithelium (Iqbal et al., 2013). 
 
In addition, inflammatory molecules and abnormal levels of inflammatory 
enzymes have been shown to be present in subjects with KC (Lema and 
Duran, 2005, Lema et al., 2009, Lema et al., 2010, Balasubramanian et al., 
2012, Balasubramanian et al., 2013, Sorkhabi et al., 2015, Wisse et al., 2015) 
and several research groups have suggested that KC may be an inflammatory 
disorder (Galvis et al., 2015a, Galvis et al., 2015b, McMonnies, 2015, 
Sorkhabi et al., 2015, Wisse et al., 2015). 
 
- 218 - 
 
Tears of KC patients showed increased protein levels for Interleukin 4, 5, 6 
and 8 (IL-4, -5, -6 and -8), Tumor necrosis factor alpha and beta (TNF-α and -
β) and matrix metalloproteinases 1, 3, 7, 9 and 13 (MMP-1, -3, -7, -9 and -13) 
(Lema and Duran, 2005, Lema et al., 2009, Lema et al., 2010, 
Balasubramanian et al., 2012, Balasubramanian et al., 2013). Indeed, Shetty 
et al. demonstrated increased MMP9 transcript levels in KC corneal 
epithelium (Shetty et al., 2015b). Membrane-Type-1 Matrix Metalloproteinase 
(MT1-MMP also known as MMP14) and MMP1 proteins have been shown to 
be present at elevated levels in KC corneas compared to healthy corneas 
(Collier et al., 2000). Along with MMP1, Seppälä et al. showed elevated 
protein levels of extracellular matrix metalloproteinase inducer (EMMPRIN-
also known as BASIGIN or BSG) in KC corneas compared to controls 
(Seppala et al., 2006). In a recent study, Sorkhabi et al. by applying ELISA 
(enzyme-linked immune-adsorbent assay) reported the elevation levels of IL6, 
IL-1b and interferon gamma (IFN-γ) in the tear film of patients with KC 
compared to controls and reduced levels of the anti-inflammatory molecule IL-
10 (Sorkhabi et al., 2015). 
 
- 219 - 
 
Table 4-26ː The expression status in the transcriptomic study of this project of molecules reported to be up- or down-
regulated in KC in the literature, either as transcripts or proteins. The negative fold change (logFC) values in the edgeR 
results represent the genes downregulated in KC compared to WT and the positive logFC values represent the upregulated genes. 
The opposite is displayed by Cufflinks/Cuffdiff results, where negative values indicate upregulated genes and positive values 
indicate downregulated genes in KC compared to WT. The EdgeR false discovery rate (FDR) and Cufflinks q-value are measures 
of significance for these findings. 
Molecule	 In	the	literature	 Location	 In	this	project’s	data	
EdgeR	 Cufflinks/Cuffdiff	





Downregulated	 Epithelium	 -2.078918	 2.162E-18	 1.34894	 0.000088	
Downregulated	 Epithelium,	keratocytes	and	ECM	 1.599106	 2.930E-09	 -2.5646	 0.000088	
Downregulated	 Corneal	Stromal	ECM,	keratocytes	 4.211806	 1.793E-40	 -3.55227	 0.000175	
Downregulated	 Cornea	 5.079647	 9.267E-48	 -5.90001	 0.000088	
TIMP1	 Downregulated		 Cultured	stromal	fibroblasts	 -3.678936	 1.295E-51	 2.91972	 0.000088	
TIMP3	 Downregulated	 Cultured	stromal	fibroblasts	 -1.307778	 3.673E-06	 4.60986	 0.000088	
Upregulated	 Epithelium	
ANGPTL7	 Upregulated	 Cornea	 -1.438655	 4.138E-09	 0.572331	 Not	significant	















Upregulated	 Tear	film	 3.430826	 1.060E-25	 -4.88189	 0.000088	
Upregulated/Downregulated	 Tear	 10.38126	 5.261E-52	 Absent	in	WT	 0.000088	
Upregulated	 Tear	 8.199380	 9.506E-47	 -9.22236	 0.007634	
Upregulated	 Tear	and	tear	film	 4.255837	 2.641E-33	 -4.99882	 0.031938	







Upregulated	 Tear	 -	 -	 -	 -	
Downregulated	 Tear	film	 9.507738	 4.852E-39	 Absent	in	WT	 0.000088	
Downregulated	 Tear	 -	 -	 -	 -	
Downregulated	 Tear	 3.937115	 1.307E-27	 -5.63766	 0.00026	
Downregulated	 Tear	 -	 -	 -	 -	
TNF-α	(TNF)	
TNF-β	(LTA)	
Upregulated/Downregulated	 Tear	 0	 Not	significant	 0	 Not	significant	






Upregulated	 Tear	and	epithelium	 -3.751623	 1.072E-53	 4.38037	 0.000088	
Upregulated	 Tear	 -4.151740	 9.757E-64	 3.57976	 0.000088	
Upregulated	 Tear	 3.151356	 2.723E-25	 -4.99721	 0.000088	
Upregulated	 Tear	and	epithelium	 -0.630913	 0.014244	 0.989254	 0.018816	
Upregulated	 Tear	 8.780041	 1.938E-65	 -8.19363	 Not	significant	
MT1-MMP	(MMP14)	 Upregulated	 Epithelium,	stroma	 -3.662756	 1.071E-51	 2.91814	 0.000088	
IFNG	 Upregulated/Downregulated	 Tear	film	 9.831951	 1.001E-43	 Absent	in	WT	 0.000088	
EMMPRIN	(BSG)	 Upregulated	 Epithelium	 -4.486983	 1.186E-72	 3.86172	 0.000088	
CCL5	 Downregulated	 Tear	 0	 Not	significant	 0	 Not	significant	
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Indeed, Jun et al. reported an increase in IL6 in the tear samples of KC 
patients (Jun et al., 2011). However, contrary to what was reported by other 
studies (Lema and Duran, 2005, Lema et al., 2009, Balasubramanian et al., 
2012, Sorkhabi et al., 2015), Jun et al. reported a decrease in TNF-α, IFN-γ 
and IL4 along with a decrease in IL12, IL13, IL17 and chemokine C-C motif 
ligand 5 (CCL5) protein levels (Jun et al., 2011). 
 
As displayed in Table 4-26, the concordance between the published 
transcripts and proteins expression results in KC corneal tissues and tear 
samples, and the transcriptomic results of this project was not met. What is 
worth mentioning however is the concordance between the edgeR and the 
Cufflinks/Cuffdiff results (Table 4-26). All the molecules that were shown to 
be upregulated by edgeR (positive values) were shown similarly to be 
upregulated by Cufflinks/Cuffdiff (negative values), and likewise for 
downregulated genes. The consistency between both software packages is 
reassuring and suggests reproducibility.  
 
The upregulation of SFRP1, INFG, IL1B, IL4, IL5 and IL6 proteins in the 
tears of KC patients, as reported the literature (Lema and Duran, 2005, 
Lema et al., 2009, Lema et al., 2010, Balasubramanian et al., 2012, 
Balasubramanian et al., 2013, Sorkhabi et al., 2015, Wisse et al., 2015), was 
reproduced at the mRNA level in this study in the anterior cornea (Epithelium 
and stroma). However, in contrast to what was previously reported in the 
literature, Jun et al. reported the downregulation of INFG and IL4 by tears of 
KC patients (Jun et al., 2011). This is refuted in the anterior corneal tissues 
of KC patients belonging to this study, data from which confirm the prevalent 
view that these molecules are upregulated in KC. 
 
IL10 and IL13 showed upregulation in this study, contrary to what was 
reported in tear film by Sorkhabi et al. and Jun et al. (Jun et al., 2011, 
Sorkhabi et al., 2015). IL8 mRNA, also reported to be upregulated, was 
entirely absent in this transcriptomics data. As for IL12 and IL17, Table 4-3 
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shows all the different levels of expression of the Interleukins belonging to 
the family of both molecules. The data shown in Table 4-27, in contrast to 
that reported in the literature, shows an overall overexpression of IL12 and 
IL17 molecules in KC corneas compared to WT ones, with IL17A, IL17B, 
IL17C, IL17F and IL17REL totally absent in WT corneas compared to KC 
corneas. 
Table 4-27: IL12 and IL17 mRNA expression in KC vs WT corneas. This 
table presents the relative mRNA expression levels in KC vs WT corneas of 
the different molecules of the IL12 and IL17 gene families in this study data, 
generated by edgeR and Cufflinks/Cuffdiff software. The negative values in 
the edgeR results represent the downregulated genes in KC compared to 
WT and the positive values represent the upregulated genes. The opposite 
is displayed by Cufflinks/Cuffdiff results, where negative values indicate 
upregulated genes in KC compared to WT and positive values indicate 
downregulated genes in KC compared to WT. The grey highlighted rows 
indicate the non-significant expression at least in one software out of two of 
the respective genes under the gene name. 
	
 
Gene name EdgeR Cufflinks/Cuffdiff 
LogFC FDR Log2(FC) q-value 
IL12A 7.337325317 2.22472E-61 -8.28369 0.00017521 
IL12A-AS1 7.364415973 4.37403E-15 Absent in WT 1 
IL12B 8.167424774 1.11908E-44 -9.11893 0.00741423 
IL12RB1 6.995871078 3.13826E-63 -6.41503 8.89E-05 
IL12RB2 3.622758594 3.86764E-25 -4.74611 8.89E-05 
IL17A 10.02478206 1.39228E-46 Absent in WT 8.89E-05 
IL17B 10.07562421 2.44396E-47 Absent in WT 8.89E-05 
IL17C 9.13894429 4.38385E-34 Absent in WT 8.89E-05 
IL17D 2.789039895 1.56606E-15 4.11254 0.00949148 
IL17F 8.973326452 6.98790E-32 Absent in WT 8.89E-05 
IL17RA -0.765742346 0.002171404 -0.447973 0.165678 
IL17RB 5.522428596 6.43264E-54 -4.23767 0.0052161 
IL17RC -1.168080397 1.32906E-06 -0.214326 0.324508 
IL17RD 3.053661123 9.33650E-26 -4.44741 8.89E-05 
IL17RE 0.673512442 0.013778942 -1.71264 8.89E-05 
IL17REL 10.21871012 1.64510E-49 Absent in WT 8.89E-05 
- 223 - 
 
The notion of concordance in expressivity between SFRP1 and LC3 proteins 
(represented here by MAP1LC3A and MAP1LC3B) that was proposed by 
Iqbal et al. was not supported by this study at the mRNA level. SFRP1 
transcript was shown to have low expression in KC corneas compared to 
WT. However, although the LC3 proteins, MAP1LC3A and MAP1LC3B, 
were not concordant with this expression pattern, they both showed high 
expression in KC corneas compared to WT, with MAP1LC3B showing higher 
expression then MAP1LC3A (Iqbal et al., 2013). 
 
The downregulation of LOX in the epithelium and TIMP1, TIMP3 transcripts 
in the cultured stromal fibroblasts reported in the literature by Lee et al. 
(Kenney et al., 2005, Lee et al., 2009) was replicated in this study; however 
the reported upregulation of TIMP3 in the epithelium (Nielsen et al., 2003) 
and the downregulation of the LOX-like molecules (LOXL2, LOXL3 and 
LOXL4) (Dudakova et al., 2015b) is not supported by the data presented 
here; all the LOXL mRNA levels have been shown to be upregulated by both 
analysis pipelines in this study.   
 
The upregulation of matrix metalloproteinases -1, -3, -9 and -14 (MMP1, 
MMP3, MMP9 and MT1-MMP or MMP14) proteins in the literature (Collier et 
al., 2000, Mackiewicz et al., 2006, Rohini et al., 2007, Predovic et al., 2008, 
Honda et al., 2010, Balasubramanian et al., 2012, Ortak et al., 2012) was 
not replicated by this study at the mRNA level. MMP1, MMP3 and MMP14 
mRNAs showed an obvious downregulation (logFC(MMP1)=-3.75 by edgeR 
and 4.38 by Cufflinks/Cuffdiff; logFC(MMP3)=-4.15 by edgeR and 3.57 by 
Cufflinks/Cuffdiff; logFC(MMP14)=-4.48 by edgeR and 3.86 by 
Cufflinks/Cuffdiff) and MMP9 showed a slight downregulation with a logFC of 
-0.63 by edgeR and 0.9 by Cufflinks/Cuffdiff. On the other hand, the 
upregulation of proteins MMP7 and MMP13 reported in the literature (Lema 
and Duran, 2005, Lema et al., 2009, Lema et al., 2010, Balasubramanian et 
al., 2012, Balasubramanian et al., 2013) was replicated at the mRNA level in 
this study. The upregulation of MMP7 mRNA was reproduced by both 
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software pipelines, but upregulation of MMP13 mRNA was only significant 
as detected using the EdgeR software. 
 
ANGPTL7 and EMMPRIN (BSG) mRNAs were shown to be downregulated 
in this study, contrary to what was reported in the literature for ANGPTL7 
mRNA and EMMPRIN protein in KC corneas (Katoh and Katoh, 2006, 
Seppala et al., 2006). The EMMPRIN (BSG) downregulation was 
reproduced in both software pipelines, but ANGPTL7 downregulation was 
not significant as detected by Cufflinks/Cuffdiff.  
The tumor necrosis factor alpha and beta (TNF and LTA) and CCL5 were 
not shown to be expressed at all in this study in KC or WT samples; however 
Table 4-28 displays the expression of all the molecules belonging to the TNF 
superfamily.  
Table 4-28: Tumor Necrosis Superfamily (TNFSF) molecule relative 
expression in KC and WT corneas. This Table presents the relative mRNA 
expression levels of the different molecules of the TNF superfamily in the 
RNAseq data obtained in this study, generated by edgeR and 
Cufflinks/Cuffdiff software. The negative values in the edgeR results 
represent the downregulated genes in KC compared to WT and the positive 
values represent the upregulated genes. The opposite is displayed by 
Cufflinks/Cuffdiff results, where negative values indicate upregulated genes 
and positive values indicate downregulated genes in KC compared to WT. 
The grey highlighted rows indicate the non-significant expression of the 
respective genes under the gene name.	
Gene	name	 EdgeR	 Cufflinks/Cuffdiff	
LogFC	 FDR	 Log2(FC)	 q-value	
TNFSF1	(LTA)	 2.650751436	 0.041229871	 Absent	in	KC	 1	
TNFSF2	(TNF)	 0	 1	 0	 1	
TNFSF3	(LTB)	 0	 1	 0	 1	
TNFSF4	 4.992927245	 2.18387E-31	 -7.53996	 0.000756584	
TNFSF5	(CD40LG)	 8.887583083	 7.95553E-56	 -9.2253	 0.257105	
TNFSF6	(FASLG)	 8.649235383	 4.58784E-52	 -10.8772	 0.254251	
TNFSF7	(CD70)	 7.583993723	 2.89235E-46	 -6.56671	 0.117423	
TNFSF8	 10.44992465	 4.62908E-53	 -10.2661	 0.269479	
TNFSF9	 -0.609435043	 0.023303107	 0.142394	 0.477428	
TNFSF10	 -3.894716008	 5.09477E-56	 2.55883	 0.000088859	
- 225 - 
 
TNFSF11	 11.23240834	 1.2093E-65	 Absent	in	WT	 0.000088859	
TNFSF12	 -0.073982827	 1	 -5.94882	 0.125906	
TNFSF13	 -3.105703745	 7.14221E-32	 -3.96242	 0.0336818	
TNFSF13B	(TNFSF20)	 3.185847597	 2.37689E-24	 -5.0593	 0.000088859	
TNFSF14	 4.353447709	 1.08589E-32	 -7.72964	 0.0504677	
TNFSF15	 1.133696812	 6.80362E-05	 -3.59291	 0.000088859	
TNFSF18	 6.516246397	 3.66526E-31	 -8.46529	 0.200658	
EDA	 0.643243885	 0.022177547	 -2.3049	 0.00306173	
TFAIP1	 -3.463682655	 3.03821E-46	 0.997899	 0.0122231	
TNFAIP2	 -3.595703891	 6.12697E-50	 2.69266	 8.89E-05	
TNFAIP3	 -0.786289	 0.001617244	 -1.51856	 8.89E-05	
TNFAIP6	 2.613333204	 5.74200E-20	 -3.10054	 8.89E-05	
TNFAIP8	 -0.469464215	 0.085289828	 -1.4191	 8.89E-05	
TNFAIP8L1	 0.617835524	 0.057100961	 -2.06762	 0.0305103	
TNFAIP8L2	 9.606790967	 1.78336E-40	 -	 -	
TNFAIP8L3	 -0.138344396	 0.811626743	 -1.75773	 8.89E-05	
 
The reason of the obvious discordance in the majority of cases between the 
literature and the data generated in this project might be largely due to the 
differences in tissues where these molecules were investigated. Most of the 
literature investigated the differential expression in tears or in the general 
cornea and not in anterior corneas. In addition, the differences in methods 
(microarray, RT-PCR, western blots, immunohistochemistry and RNA-seq) 
might present a major difference between studies especially if different 
protocols were adopted between studies.  
 
In addition, the data presented in the literature and not replicated by other 
researchers is rather preliminary and requires more validation through 
replication. The data reported in this project were computationally replicated 
by two different software packages suggesting a certain level of reliability. 
However, reproducibility by RT-PCR and immunohistochemistry of the same 
results is crucial in order to validate these findings.  
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4.3.7 Limitations of this study 
In addition to the major limitations of RNA-seq method (Discussed in details 
in Section 5.1.2.2), one of the limitations of this study lies in the experimental 
design at the level of pooling the samples in the Illumina sequencing 
machine, thus creating an undesirable batch effect (Auer and Doerge, 2010, 
Leek et al., 2010). The batch effect trap in this study consisted of pooling the 
KC corneas together on one lane of the Illumina machine on one run, and 
then pooling WT corneas on a different run on a different day. This 
potentially created differences between conditions that are purely related to 
technical management rather than to biological variables. This specific 
technical behaviour risked the validity of the biological conclusions (Baggerly 
et al., 2004, Akey et al., 2007) from this study however the valid surrogate 
variable analysis (sva) statistical analysis (Leek, 2014) can help undo the 
batch effect. This limitation will be overcome in the future of this study by 
repeating in one run and at low coverage all the samples included in this 
study and eliminate all the variations that were due mainly to the batch 
effect. The effect of this issue on the results of this project is not yet known 
however only replication of the results reported is going to define how 
accurate the findings are.  
 
A second limitation lies in sampling routes for KC corneas and WT corneas, 
as the donation process was different. In the case of WT corneas, after 
removal from a deceased donor (as soon as possible and no longer than 24 
hours after death) the tissue has gone into a process of incubation at 34 
degrees for an unknown time, which could potentially have been up to but 
not exceeded 28 days. In contrast the cornea from a KC patient has been 
obtained fresh from theatre, from a living donor and with no incubation or 
long preservation in anything but RNAlater. This accounts for the technical 
difference that might slightly affect the profiles of KC and WT corneas. 
However, this should not present a major difference since the WT corneas 
follow a protocol in order to be suitable for transplantation, thus they are 
biologically viable. 
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In addition to the limitations, 3 main points are worth bearing in mind while 
interpreting the results and discussing the analysis: first point is that the RNA 
extracted from the corneas originates from different cell types (epithelial, 
stromal keratocytes and other cells) which implies that the RNA extracted is 
not cell specific but rather tissue specific. This presents a limitation when it 
comes to KC since in one condition (KC per say) one type of cells (epithelial) 
will be overrepresented due to the apoptosis of the other type of cells 
(keratocytes) (Section 1.4.5), which will lead theoretically to an 
overrepresentation of markers that are cell specific instead of molecules that 
are disease specific. This only affects the results of the pooled KC corneas 
against WT, since it looks for secondary effects highlighting the pathways of 
the end effects. Looking at individual KC corneas’ RNA-seq profiles 
combined with the WES data of the same individual corneas might highlight 
the primary cause and overcome this issue. 
 
Second, KC is a progressive disease and the stage of getting the KC 
corneas from patients is a stage where the disease has reached a severe 
end-point that requires corneal transplantation, the RNA-seq data generated 
from these KC corneas are not displaying the changes that occur at the 
beginning of the KC disease process, they are rather secondary effects. This 
data is therefore more representative of the transcriptomic profile of the end 
point in the disease development. However, this point was overcome by 
looking at the profiles of individual corneas. 
 
Third, the reduction of the number of replicates in the DE analysis from 6 KC 
corneas to 5 KC corneas and the WT from 5 WT corneas to 3 WT corneas 
because of the odd profiles that they have shown on cummeRbund (Figure 
4-5 and 4-6). However, using 3 replicates per condition is still biologically 
valid. New corneas will be recruited to continue the work on this project, 
which will improve the quality of the results by enhancing reproducibility. 
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Since this is an ongoing project and the time to generate this set of data and 
present it was limited, the investigation was limited to one class of output 
files generated by Cufflinks software. In the future work of this project, all the 
other output files will be studied in order to pull out all the new isoforms 
specific to corneas and in particular KC corneas. Additionally, miRNAs and 
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5 General Summary and Concluding Remarks 
5.1 General Summary 
KC presents with a variable prevalence across populations and ethnicities 
(Section 1.4.5) ranging from 0.3 to 3,333 per 100,000 (Gorskova and 
Sevost'ianov, 1998, Waked et al., 2012). Indeed, KC is the most common 
corneal ectasia. It appears around puberty and progresses until it is 
stabilised by the fourth decade of life. KC is thought to be a multifactorial 
disease with both genetic and environmental contributions (Gordon-Shaag et 
al., 2015), making the discovery of the mechanisms underlying the disease a 
challenging task. Despite efforts over the years to determine the aetiology of 
keratoconus, the underlying pathology remains poorly understood. 
 
5.1.1 Candidate gene study replication 
Candidate gene studies, linkage analysis and association studies have been 
the main approaches used to date in an attempt to identify genetic variants 
contributing to susceptibility to KC (Section 1.4.9). Findings from these 
studies have identified a number of genes (Appendix 11) potentially involved 
in KC pathogenesis, described in Section 1.4.9. To determine whether 
variants in these genes might be involved in causing KC in the cohort 
described in this study, coding variants and splice sites in these genes were 
identified and are listed below. Only changes that segregated in the 
sequenced patients of the families are reported  in Table 5-1. 
Table 5-1: Variants in known KC candidate genes found in the Leeds 
families. Genetic variants found in the KC patients deriving from families in 
the Leeds cohort, in genes previously reported to be involved with KC 
development in the literature.  
Genes	 Family	 Amino	Acid	Change	 snp138	 CADD	
Phred	
COL4A1	(13q34)	 F11	 exon45:c.G3997A:p.D1333N	 rs141395813	 28.4	
F8	 exon32:c.C2624G:p.P875R	 rs201964644	 15.08	
COL4A3	(2q36.3)	 SC2	 exon49:c.A4484G:p.Q1495R	 rs77964815	 13.09	
COL8A2	(1p34.3)	 F11	 exon4:c.G1504A:p.G502S	 rs142307403	 18.89	
FLG	(1q21.3)	 F11	 exon3:c.C5671T:p.R1891W	 rs36006086	 24.2	
F10	 exon3:c.G3095C:p.R1032T	 .	 22.6	
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	 F11	 exon3:c.C4309T:p.R1437C	 rs12750571	 22.3	
F11,	SC1	 exon3:c.C9808T:p.R3270C	 rs35621145	 17.89	
SC2	 exon3:c.G5332T:p.A1778S	 .	 15.1	
F11	 exon3:c.C4568T:p.T1523I	 rs12750081	 12.76	
F11,	SC1	 exon3:c.C6045A:p.D2015E	 rs71626704	 12.11	
SC2	 exon3:c.G3896A:p.R1299Q	 rs150251062	 12.02	
KF	 exon3:c.G5212A:p.G1738R	 rs376237195	 9.808	
SC1	 exon3:c.C7618T:p.R2540W	 .	 8.219	
FOXO1	(13q14.11)	 F10	 exon1:c.C251T:p.P84L	 .	 7.596	
HGF	(7q21.11)	 KF	 exon16:c.G1765A:p.V589I	 .	 8.201	
MPDZ	(9p23)	 F8	 exon22:c.C3203A:p.A1068D	 .	 32	
F9	 exon14:c.C1739G:p.S580C	 rs149265684	 28.7	
NEIL1	(15q24.2)	 SC1	 exon2:c.C404G:p.A135G	 rs184655220	 23	
PARP1	(1q42.12)	 F12	 exon6:c.G727A:p.D243N	 rs200470832	 23	
SC3	 exon7:c.G943A:p.V315I	 .	 11.61	
RAB3GAP1	(2q21.3)	 SC1	 exon22:c.G2540A:p.R847Q	 .	 23	
RXRA	(9q34.2)	 F10	 exon2:c.G10A:p.V4I	 rs137938878	 17.48	
XRCC1	(19q13.31)	 F9	 exon16:c.A1727C:p.N576T	 rs2307177	 24.1	
SC2	 exon14:c.A1526C:p.E509A	 .	 23.1	
ZNF469	(16q24.2)	 F11	 exon2:c.G10277A:p.R3426Q	 rs75288466	 23.7	




F9	 exon1:c.A3062C:p.E1021A	 .	 12.24	
F12,	F9	 exon2:c.C8342T:p.P2781L	 .	 9.066	
 
The changes presented in Table 5-1 are exonic/splice site non-synonymous 
variants with CADD Phred scores > 7, a MAF of < 2% in the 1000 genome 
database, the exome server database (esp6500si) and Exac (Exac03) and 
were excluded from controls of the same ethnicities They have all been 
shown to segregate in the affected patients of the corresponding family. The 
full list of all the variants (including variants having lower CADD Phred 
scores) in the genes associated with KC in the literature in the Leeds cohort 
KC families is displayed in Appendix 11. Of the 43 genes reported in the 
literature to be potentially involved in KC pathogenesis (Genes listed in 
Appendix 11 and described in details in Section 1.4.9) (Wilson et al., 1996a, 
Heon et al., 2002a, Aldave, 2005, Aldave et al., 2006, Udar et al., 2006, 
Aldave et al., 2007, Kim et al., 2008, Stabuc-Silih et al., 2009, Liskova et al., 
2010a, Romero-Jimenez et al., 2010, Burdon et al., 2011, De Bonis et al., 
2011, Karolak et al., 2011, Muszynska et al., 2011, Bykhovskaya et al., 
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2012, Czugala et al., 2012b, Guan et al., 2012, Kok et al., 2012, Li et al., 
2012a, Lu et al., 2013, Mikami et al., 2013, Wang et al., 2013a, Kokolakis et 
al., 2014, Lechner et al., 2014, Sahebjada et al., 2014, Wojcik et al., 2014a, 
Hao et al., 2015a, Karolak et al., 2015a, Saravani et al., 2015, Synowiec et 
al., 2015, Wang et al., 2015a), 13 have single base pair (bp) substitutions in 
the coding region leading to missense variants (Table 5-1) and one of these 
also has a nonsense variant, a nonframeshift 15bp deletion in ZNF469 
(Table 5-1).  
 
The variants in the genes COL4A1, COL8A2, FLG, MPDZ, NEIL1, PARP1, 
RAB3GAP1, RXRA, XRCC1, ZNF469 are more highly ranked by CADD 
Phred scores, having scores of > 15. These relatively high pathogenicity 
scores in rare variants segregating with KC in families, together with the fact 
that these genes have already been implicated in KC pathogenesis in 
previous studies, suggest that these variants have the potential to contribute 
to KC pathogenesis in the corresponding families. However, a number of 
further tests need to be carried out to determine whether this is indeed the 
case.  
 
Firstly, these variants have not yet been checked for segregation in all of the 
unaffected members of the families. Testing the segregation of these 
variants in the complete families may help to confirm or refute their 
contribution to KC development. Secondly, while the changes appearing in 
Table 5-1 and Appendix 11 were all excluded from ethnically matched 
controls (BiB database, Lebanese Druze and Lebanese Maronites), the 
numbers for Lebanese Druze and Maronites were low and more controls 
need to be tested. Thirdly, more common variants, both functional and 
synonymous or non-coding, detected in these genes, should ideally be 
further investigated in KC patients in the future work of this project. This is 
because the involvement of these genes in KC might be the result of 
variants laying in important functional elements belonging to the non-coding 
regions of the genes (Lomelin et al., 2010). Such a detailed examination of 
all changes will not be possible for whole exomes or genomes as the 
- 232 - 
 
number of variants would be too great to analyse, but specific genes 
implicated by multiple lines of evidence could be examined in this way. 
 
Indeed, looking only at the frequency of specific variants in KC cases and 
controls may lead to bias because by definition rare variants have been 
selected and these are less likely to be found in controls than common 
variants. Ideally the entire genes should be screened for all variants in well 
phenotyped “KC-free” individuals, in order to determine the range of variants 
found, or “mutational load” in these genes in healthy individuals. Therefore, 
looking at the mutational load of the 13 genes reported in Table 5-1 in the 
KC cases and ethnically matched controls is a crucial analysis to follow up 
on this study. 
 
Furthermore, specific genes and variants for which there is already strong 
evidence of involvement in KC from multiple different lines of evidence 
should also be looked at in sporadic KC cohorts, in order to establish a clear 
association with KC in the general population and not only in families. To 
achieve this on a larger scale, a multiplex assay which involves screening all 
the coding and non-coding regions of the corresponding genes as well as 
the promoter, upstream and downstream regions should be considered in 
order to make sure that all these parts of the genes are covered in the 
screened patients.  
 
Interestingly, several families segregated variants in more than one of the 
genes listed in Table 5-1. For example, members of family F11 carried 
variants in four different candidate genes (COL4A1, COLA8A2, FLG, 
ZNF469). It is possible that all of these variants contribute to KC 
pathogenesis, which, if proven, would confirm the high level of genetic 
complexity for KC that has been postulated by many groups working on the 
condition. 
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In spite of the weaknesses described above and the incomplete nature of 
this study, the fact that 10 genes (COL4A1, COL8A2, FLG, MPDZ, NEIL1, 
PARP1, RAB3GAP1, RXRA, XRCC1, ZNF469) previously reported to carry 
variants contributing to KC also have potentially pathogenic changes in this 
KC cohort suggests that these variants are strong candidates for 
involvement in KC pathogenesis in the families investigated by the author. 
The remaining 30 genes were not replicated in this study. However this 
conclusion is based on the assumption that rare alleles of major effect are 
the main contributors to KC pathogenesis. Common variants with small 
effect might also contribute to the disease, and genes harbouring such 
changes will have been missed.  
 
5.1.2 WES and RNA-seq combined analysis in this study  
5.1.2.1 WES in families 
Linkage analysis reported by researchers studying large KC families 
identified potential candidate genes for KC (Fullerton et al., 2002, Brancati et 
al., 2004, Hutchings et al., 2005, Tang et al., 2005b, Li et al., 2006, Burdon 
et al., 2008, Bisceglia et al., 2009, Czugala et al., 2012b). However, these 
studies only detected rare variants which were rarely reproduced by other 
researchers. Similarly, with genome-wide association analysis in large KC 
cohorts (Burdon et al., 2011, Li et al., 2012b, Lu et al., 2013), common 
variants have been found to be associated, and some have been replicated 
in multiple studies, suggesting a potential involvement in KC pathogenesis 
(Section 1.4.9.3) (Bae et al., 2013, Lechner et al., 2014, Sahebjada et al., 
2014, Hao et al., 2015a). However, missing heritability is still a major 
problem in KC. Thus in this study, several approaches have been followed in 
order to implicate key genes via multiple lines of evidence. Familial KC 
patients’ coding regions have been sequenced by WES (Chapter 3), and in 
addition, the transcriptome of WT corneas and differentially expressed 
profiles of KC corneas have been characterised (Chapter 4).  
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5.1.2.1.1 Advantages of the approach used 
GWAS addresses common variants of modest effect, testing the common 
disease common variant hypothesis. However, this current study tests the 
alternative hypothesis of common disease caused by rare variants, by 
looking for rare alleles of major effect causing a significant portion of KC in 
patients. Thus, the family based WES, where at least two KC patients from 
each family were subject to WES, has been a method of choice in this study 
to determine the genetic basis of KC for several reasons. First, it is a global 
approach which allows the screening of coding regions of all genes in KC 
patients (and controls/unaffected familial members). It is of course also 
possible that non-coding variants lying outside the coding regions screened 
by WES might be contributing to the disease pathogenesis and several 
examples in the literature confirm this statement (Cui et al., 2010, Herdewyn 
et al., 2012, Roessler et al., 2012, Cavalieri et al., 2013, Makrythanasis and 
Antonarakis, 2013, van de Ven et al., 2013, Liu et al., 2015b). However, the 
exome represents an enriched subset of the genome where protein-altering 
variants are more likely to have functional consequences (MacArthur et al., 
2014).  
 
Second, WES is a valid approach for novel gene discoveries, as distinct 
from the candidate gene approach which aims to discover novel variants and 
thus replicate previous studies rather than identifying novel KC implicated 
genes. Thus it is a hypothesis independent approach with the potential to 
identify new pathways and mechanisms in corneal development and 
maintenance. Similarly, it has an advantage over the GWAS studies since it 
looks for rare variants with major effect instead of common variants with 
minimal effects, meaning that it can be applied to a relatively small cohort of 
families with the possibility of success. In order to achieve significance in 
GWAS studies, a large number of cases (WES or SNP data) should be 
incorporated in the study design, making it very costly.  
 
Third, WES is a tool to search for rare variants laying in the coding region. 
The idea of rare variants involved in causing common genetically complex 
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diseases is still somewhat controversial. However several examples in the 
literature support the occurrence of rare variants in complex traits and the 
contribution of these variants to complex disease aetiology (Schork et al., 
2009, Helbig et al., 2013, Lettre, 2014, Moutsianas et al., 2015). Indeed, 
Hirschsprung disease (Alves et al., 2013) and age-related macular 
degeneration (AMD) (van de Ven et al., 2013) represent model for the 
involvement of common and rare variants in disease pathogenesis.  
 
The results of performing WES on KC patients in this study have proved 
inconclusive so far, but analysis is as yet incomplete. The starting 
hypothesis of this study was that one or a few recessive KC alleles would be 
enriched in endogamous consanguineous populations and would thus be 
easier to detect. 15 families belonging to such populations were therefore 
sampled. Families were tested by both WES and autozygosity mapping. 
However, unfortunately the 15 families incorporated in this study did not 
present any prominent shared autozygous regions to focus on, and no single 
gene proved to be commonly mutated in KC families. The results obtained 
so far therefore suggest that, if recessive alleles of large effect exist, they 
are rare and can occur in multiple different genes, there is no common 
recessive locus or loci shared between the families of this study, and the 
condition seems more genetically complex than anticipated. 
 
5.1.2.1.2 Limitations of the approach used 
Following the approach described in the previous paragraph was justifiable 
at the start of this project, since there was less evidence for genetic 
complexity in KC and it remained possible that relatively common alleles of 
major effect underlay a proportion of KC cases. Further evidence of the 
complexity of KC emerged during the course of this project, while data from 
families was being generated (reported by (Kriszt et al., 2014) and reviewed 
by (Jeyabalan et al., 2013, Abu-Amero et al., 2014a, Davidson et al., 2014, 
McMonnies, 2014)), which corroborated the main conclusion of family 
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studies, namely that no single recessive allele or mutations in a single gene 
accounted for a large number of cases/families.  
 
In addition, some technical and analytical limitations to WES should be taken 
into consideration when interpreting the WES data. The technical limitations 
derive from the fact that some genes or part of genes, do not fall into the 
WES targeted region, or there is insufficient coverage of certain regions 
where possibly the causative gene/variants reside. Additionally, mismapped 
reads and/or alignment errors, may lead to false calling of a certain variant 
that could be mistaken for a real one. Indeed, in some occurrences, a variant 
could be truly covered but not accurately called. Moreover, genetic 
heterogeneity may create an analytical bias in case discontinuous filtering 
strategies are adopted (Wang et al., 2013b, Tetreault et al., 2015). Indeed, 
the use of stringent filtering strategies could lead to exclusion of variants 
important in the disease aetiology. These technical and analytical limitations 
can be overcome for false-positive variants, by the verification of supposedly 
causative variants by directed sequencing (i.e. Sanger sequencing), as well 
as checking in case-control cohorts. However, the false-negative variants 
are the most problematic, since they are usually missed from the final 
shortlist of variants.  
 
The strategy followed in this study was to combine the data from WES with 
the differential expression data of KC corneas against WT corneas in order 
to shortlist the WES variants according to the expression study. A recent 
study focusing only on WES case studies in order to detect rare variants 
implicated in complex diseases used a similar approach (Wu et al., 2015). 
The study design proposed by Wu et al. closely resembled the study design 
developed in this project, endorsing the work done in this project. It 
comprised calling variants from WES data of complex disease cases then 
filtering according to allele frequency first then according to functionality and 
disease phenotype spectrum, leading to a gene prioritization process. 
Following up comes the combination of the information from WES with 
information from other data (i.e. mRNA data, somatic DNA variations data, 
- 237 - 
 
epigenetics data, open source available databases) then confirming the 
variants and gene involvement through targeted deep sequencing.  
 
5.1.2.2 RNA-seq in KC and WT corneas 
The RNA-seq analyses presented in this study are preliminary results, with 
further analysis still ongoing. There were three aims behind conducting this 
analysis; firstly to characterise the normal anterior corneal RNA profile; 
secondly to characterise the transcriptome during the keratoconus disease 
process, and finally, by combining with WES data, to look for potential 
primary causative variants.  
 
Variants that could constitute the primary cause of, or major contributors to 
the susceptibility for, KC were screened for by first extracting the RNA 
differential gene expression profiles of each individual KC cornea against the 
pooled WT RNA-seq data. The genes highlighted as having significantly 
differential gene expression profiles in RNA were then checked for 
deleterious variants in the WES data of the corresponding individual KC 
cornea. The rationale behind this approach was to look for variants that 
might be directly responsible for the changes in the RNA differential 
expression profiles, in genes expressed in the anterior cornea, at the level of 
each individual cornea. Knowing that the causative variants KC might vary 
between different individuals, this method aimed to identify potential KC 
associated variants unique to each one of the six individual KC corneas 
analysed. In addition it was hoped that combined analysis of the genes 
implicated from each cornea could potentially detection of common 
pathways involved in the development of KC. 
  
The secondary consequences of KC were looked for by comparing the RNA-
seq data from the pooled KC corneas against the RNA-seq data from the 
pooled WT corneas. This analysis aimed to highlight transcripts that are 
differentially expressed in all KC corneas and might therefore be 
components of pathways that are altered during the KC disease process.  
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Both approaches are equally important in the study of KC, since the 
aetiology of KC has remained a mystery until now, and much of the current 
understanding of the development of KC pathology is speculative and 
remains to be confirmed by replication  (Section 1.4.7). Insights into the 
cause of KC at the level of each individual KC cornea, together with data on 
shared altered pathways in all the KC corneas, provide a useful tool to 
bridge the gap in understanding between causes and effects, and may help 
to unravel some of the complexities of KC at the level of defective pathways.    
 
To our knowledge, this is the first study to establish an RNA-seq based gene 
profile for the normal anterior corneal tissue. It is also the first study to 
perform RNA-seq in the analysis of primary and secondary alterations in KC 
corneas, and to combine WES and RNA-seq analysis from the same KC 
patients to extract variants from the WES profile in genes that are 
significantly differentially expressed in KC corneas.   
 
RNA-seq technology is now the best tool to study transcriptomics in healthy 
and diseased tissues. However as with any other technique it has a number 
of limitations at the technical and analytical levels (Wang et al., 2009). The 
first limitation of all, resides in comparing fresh KC corneas, collected on the 
spot, to healthy corneas taken from cadavers up to 28 days after death 
(Sections 4.3.1.1 and 4.3.2), which will mean loss of many short half-life 
RNA species. However, this will always be an issue while working with 
human corneal tissues, since the procedure of enucleation is standard. The 
technical limitations start when the RNA is sheared for fragmentation 
purposes, which leads to depleted ends. The cDNA synthesis, amplification 
and sequencing steps can lead to non-uniform coverage of certain 
transcripts (i.e. PCR artefacts), introducing bias in the overrepresentation of 
some transcripts compared to others (Ozsolak and Milos, 2011, Yendrek et 
al., 2012, Kratz and Carninci, 2014). In addition, during the library 
construction, the cDNA synthesis and RNA manipulations potentially 
introduce further errors and artefacts, including the possibility of dissociation 
of the nascent cDNA from the template and annealing to a similar template; 
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self-priming arising from RNA secondary structure; and the low fidelity and 
lack of proofreading of the RNA transcriptase when compared to other 
polymerases.  
 
As for the bioinformatic analytical limitations, they reside mainly in the 
alignment of small reads to the whole genome, since these reads can often 
be non-uniquely aligned to several similar locations in the genome (Ozsolak 
and Milos, 2011). RNA-seq technologies that lead to the generation of longer 
read fragments, such as the PacBio platform, are a way to overcome this 
limitation. Mapping reads that span splice junctions also present a 
challenging task since for complex transcriptomes alternative splicing events 
are prominent (Kim et al., 2013). Length bias must usually be corrected for in 
RNA-seq analysis, since a bias is introduced during the fragmentation and 
RNA size selection steps, which might lead to an overrepresentation of 
longer transcripts (Trapnell et al., 2012). 
 
5.1.2.3 Combining results of RNA-seq and WES in families 
The power of this research resides in combining all the approaches followed 
so far in the course of this study. The combined analysis focused on genes 
that are expressed in corneas, significantly differentially expressed in 
individual KC corneas compared to pooled WT corneas, and that have 
potentially pathogenic variants in the corresponding WES data. The resulting 
list consists of WES variants from all the individual KC corneas that appear 
to be functional (missense, splicing and Indels) and have MAF < 2%. The list 
of WES identified variants in differentially expressed genes from every KC 
cornea was then compared to the PLINK/SEQ lists of genes enriched for 
variants in KC cases in Chapter 3, in order to look for genes in common. 
Subsequently, all of the genes highlighted by both the PLINK/SEQ  and 
differentially expressed genes with “functional” WES variants analyses, were 
checked for in the families described in Chapter 3, to look for variants that 
segregate in the families, in genes that are common to all lists. The result is 
a list of genes harbouring functional variants that segregate in families, 
appear enriched in variants on PLINK/SEQ analysis, are significantly 
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differentially expressed in individual KC corneas compared to pooled WT, 
and that harbour changes in the WES data of the corresponding individual 
KC corneas. The corresponding list is called “combined list”. 
 
To further filter and prioritize genes that might be directly related to the 
primary defect in KC, the previously generated list of genes or “combined 
list”, was subject to two further filtering steps. Only the genes that appeared 
in at least two families were included, and only the genes that appeared to 
be down-regulated in all the individual KC corneas were kept in the final list. 
This last step risks excluding mutations that cause KC through up-regulation 
of transcription. However, given that nonsense mutations are likely to be 
subject to nonsense-mediated decay, and that mutations that reduce or 
abolish function are more common as a cause of disease than increased 
function mutations, it seems reasonable to suppose that most mutations 
affecting transcription will manifest as downregulation. This strategy led to a 
narrowing down of the list of genes highlighted to 5 genes: FLNB (Filamin B, 
beta), ITGB4 (Integrin beta 4), KIAA0100,	LAMA5	(Laminin subunit alpha 5)	
and	PCDH1 (Protocadherin 1) (Table 5-2).		The differential expression levels 
of Table 5-2 genes in the individual KC corneas compared to pooled WT 
corneas, are displayed in Table 5-3.  
 
The strategy followed in this section served to prioritize the list of genes in 
the WES families data, according to their occurrence in PLINK/SEQ as well 
as to their downregulation in KC corneas compared to WT. This strategy 
does not assume that the missense variants of Table 5-2 are causal for the 
down-regulation of the genes presented in Table 5-3. Instead, it serves to 
highlight the overlap between the WES families’ data and the differential 
expression analysis of KC/WT corneas. However, in the future, searching for 
splice variants and mutations in promoter regions of the downregulated 
genes would be the orthodox way to check for the direct effect of these 
particular mutations on the expression of candidate genes. 
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Table 5-2: Genetic variants segregating in KC families, in genes shown to be downregulated in individual KC corneas. This 
table reports the different variants in FLNB, ITGB4, KIAA0100, LAMA5 and PCDH1 in different KC families’ WES data.  
Gene	 Family	 CADD	
Phred	
Amino	Acid	Change	 snp138	 Esp6500si	 1000g	 Exac03	 Status	
FLNB	
(3p14.3)	
F13	 35	 exon14:c.C2095T:p.R699W	 rs200554477	 0.000077	 0.000399	 0.000173	 het	
F7	 25	 exon22:c.G3785C:p.G1262A	 rs111330368	 0.004229	 0.002396	 0.005461	 het	
F13	 23.8	 exon26:c.T4447C:p.F1483L	 rs142631042	 .	 0.000998	 0.0008167	 het	
F13,	SC1,	SC2,	SC3	 20.1	 exon41:c.A6899C:p.H2300P	 rs202222289	 .	 .	 0.003068	 het	
F11	 9.944	 exon38:c.A6313G:p.M2105V	 .	 .	 .	 .	 het	
ITGB4	
(17q25.1)	
F11	 34	 exon20:c.G2477A:p.R826H	 rs200694443	 .	 0.000199	 0.0002389	 het	
SC1	 31	 exon6:c.C670T:p.R224W	 .	 .	 .	 0.0000082	 het	
KIAA0100	
(17q11.2)	
F13,	F9	 25.3	 exon35:c.C6037G:p.L2013V	 rs201896448	 0.000384	 .	 0.0003789	 het	
SC3	 22.3	 exon16:c.C2474T:p.S825L	 .	 .	 0.000199	 0.000313	 het	
LAMA5	
(20q13.33)	
F9,	F12,	F13	 28.9	 exon32:c.G4037A:p.C1346Y	 rs371144423	 0.000077	 .	 0.0000663	 het/hom/het	
F8	 25.4	 exon28:c.G3467A:p.R1156Q	 rs143551466	 0.000154	 0.000399	 0.00047	 het	
SC2	 25.1	 exon29:c.G3587T:p.S1196I	 .	 .	 .	 .	 het	
F8,	KF	 23.8	 exon53:c.G7052A:p.R2351Q	 rs147290767	 0.002335	 0.009584	 0.008156	 het	
F9,	F12	 13.41	 exon80:c.G10995A:p.M3665I	 .	 .	 .	 .	 het/hom	
KF	 8.749	 exon53:c.G7138A:p.G2380S	 rs150998056	 0.001161	 0.006190	 0.003745	 het	
PCDH1	
(5q31.3)	
F10	 25.2	 exon2:c.G829A:p.G277S	 .	 .	 .	 0.0000247	 het	
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Table 5-3: LogFC and FDR values of FLNB, ITGB4, KIA0100, LAMA5 and PCDH1 in all the six individual KC corneas. This 
table represents the result output of EdgeR, with logFC being the log of the fold change and FDR the corrected p-value.  
KC	cornea	 MA18	 MA26	 MA46	 MA47	 MA52	 MA58	
Gene	 logFC	 FDR	value	 logFC	 FDR	value	 logFC	 FDR	value	 logFC	 FDR	value	 logFC	 FDR	value	 logFC	 FDR	value	
FLNB	 -1.637	 0.0044	 -	 -	 -1.505	 0.00921	 -1.715	 0.00284	 -1.559	 0.0065	 -	 -	
ITGB4	 -3.575	 2.84E-09	 -3.625	 1.58E-09	 -3.635	 1.53E-09	 -3.435	 9.68E-09	 -3.542	 3.22E-09	 -3.728	 8.30E-10	
KIAA0100	 -1.327	 0.02895	 -1.332	 0.02724	 -1.617	 0.006782	 -1.319	 0.03030	 -1.412	 0.01846	 -	 -	
LAMA5	 -2.703	 1.10E-05	 -2.678	 1.19E-05	 -3.312	 1.52E-07	 -2.753	 7.99E-06	 -2.765	 6.80E-06	 -2.391	 8.73E-05	
PCDH1	 -4.184	 1.99E-11	 -4.100	 3.26E-11	 -4.409	 2.95E-12	 -4.028	 8.26E-11	 -4.235	 1.15E-11	 -3.828	 4.59E-10	
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FLNB is an actin binding protein (actin binding protein 278), mRNA splice 
variants of which control the organization of cytoskeleton actin and 
specifically bind to integrin (beta) subunits (van der Flier et al., 2002). FLNB 
has been reported to be involved in keratinocyte development, epithelial cell 
morphogenesis and skeletal muscle tissue development 
(http://www.ncbi.nlm.nih.gov/gene/2317). More precisely, FLNB has been 
reported in the literature to be involved in the cytoskeletal anchoring at 
plasma membrane (Xu et al., 1998) and signal transduction (Leedman et al., 
1993).	 Moreover, FLNB is involved in the MAPK signalling pathway, 
suggesting a role in processing cellular environmental information, and in the 
cell community of the focal adhesion pathway (http://www.genome.jp/dbget-
bin/www_bget?hsa:2317). 
	
The FLNB locus has been shown to be associated in meta-analysis GWAS 
to Primary Open-Angle Glaucoma (POAG) (Springelkamp et al., 2015). 
Association between POAG and KC has been established in the literature 
(Goel et al., 2015). In the families WES data of this project, missense 
heterozygous mutations of FLNB have been found (Table 5-2) in six families 
(F7, F11, F13, SC1, SC2 and SC3). Four variants (c.C2095T:p.R699W; 
c.G3785C:p.G1262A; c.T4447C:p.F1483L and exon41:c.A6899C:p.H2300P)	
in FLNB have CADD Phred scores > 20, in exons 14, 22, 26 and 41 
respectively. 
 
ITGB4 is a none-covalently associated transmembrane glycoprotein 
receptor, which tends to bind to the alpha 6 integrin subunit. It is involved in 
the formation of stable cell adhesions and in G-protein coupled receptor 
binding (Ni et al., 2014). ITGB4 is a receptor for the laminins and particularly 
for Laminin-5, an essential component of basement membranes. In 
keratinocytes the ITGB4 and laminin-5 play an important role in cell 
migration and cell-cell adhesion (Geuijen and Sonnenberg, 2002, 
Hintermann et al., 2005). Involved in the integrin mediated signalling 
pathway, ITGB4 is equally involved in amelogenesis (Schumann et al., 
2013), autophagy (Li et al., 2013a), cell adhesion (Suzuki and Naitoh, 1990), 
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cell motility (Hamill et al., 2009), cell matrix adhesion (Schumann et al., 
2013), hemidesmosome assembly (Koster et al., 2003, Schumann et al., 
2013), mesodermal cell differentiation (Brafman et al., 2013), nail and skin 
development (Schumann et al., 2013) and response to wound healing 
(Hamill et al., 2009).  
 
According to KEGG (Section 2.14), ITGB4 is involved in the PI3K-akt 
(phosphatidylinositol 3' kinase) cell signalling pathway and in the ECM-
receptor pathway. Moreover, it plays a role in the regulation of the actin 
skeleton pathway in cell motility, as well as in the focal adhesion pathway 
(http://www.genome.jp/dbget-bin/www_bget?hsa:3691). Two heterozygous 
ITGB4 variants (c.G2477A:p.R826H; c.C670T:p.R224W) were identified in 
two families in this project’s cohort (F11, SC1), these having CADD Phred 
scores > 30. 
 
KIAA0100 is a protein coding gene the function of which is still not well 
understood. By  in-silico modelling, KIAA0100 has been proposed to be a 
component in the extracellular region 
(http://www.ncbi.nlm.nih.gov/gene/9703) involved in membrane trafficking 
(Gene Ontology). Nothing else is yet known about this gene or protein. In 
this project, two heterozygous variants (c.C2474T:p.S825L and 
c.C6037G:p.L2013V;) were identified in exons 16 and 35 respectively of 
KIAA0100, segregating in three different families belonging to the KC cohort 
of this study (F9, F13, SC3) and having CADD Phred scores > 20. 
 
LAMA5 is a non-collageneous component of the basement membrane. It 
functions in integrin binding and is a structural molecule (Doi et al., 2002). 
According to the literature, LAMA5 is involved in cell differentiation, 
migration, proliferation and recognition (Doi et al., 2002). Additionally, it is 
involved in angiogenesis, cytoskeleton organization, embryo development, 
endothelial cell differentiation, focal adhesion assembly and the integrin-
mediated signalling pathway (Doi et al., 2002). From the inferred electronic 
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annotation, LAMA5 has been thought to play a role in cilium assembly, 
establishment of protein localization to plasma membrane and regulation of 
cell adhesion and cell migration (http://www.ncbi.nlm.nih.gov/gene/3911). 
According to KEGG, LAMA5 is involved in the PI3K-Akt cell signalling, ECM-
receptor and focal adhesion pathways (http://www.genome.jp/dbget-
bin/www_bget?hsa:3911). Moreover, according to WikiPathways and the 
REACTOME (Section 2.14), LAMA5 is involved in the inflammatory 
response pathway (http://www.wikipathways.org/index.php/Pathway:WP453) 
as well as in the extracellular matrix degradation pathway 
(http://www.reactome.org/content/detail/1474228). In this study, two 
homozygous variants (c.G4037A:p.C1346Y; c.G10995A:p.M3665I) were 
identified in LAMA5 in one family (F12) in exons 32 and 80 respectively, with 
corresponding CADD Phred scores of 28.9 and 13.41. In addition, five 
heterozygous LAMA5 variants (c.G4037A:p.C1346Y; c.G3467A:p.R1156Q; 
c.G3587T:p.S1196I; c.G7052A:p.R2351Q and c.G7138A:p.G2380S) were 
identified in the families WES component of this study in five families (F8, 
F9, F13, KF, SC2), with CADD scores of > 20.  
 
PCDH1  is a calcium ion binding, protocadherin membrane protein found at 
cell-cell boundaries. It is involved in the process of cell-cell signalling and 
nervous system development (Sano et al., 1993). According to KEGG, 
PCDH1 is a member of the beta integrin and cadherin protein families, and 
is involved in centrosome formation and ciliogenesis 
(http://www.genome.jp/dbget-bin/www_bget?hsa:56141). In this study, 
PCDH1 mutations presented in two families (F10, KF), these being variants 
(c.G829A:p.G277S and c.A3688T:p.T1230S) in exons 2 and 5, having 
respective CADD Phred scores of 25.2 and 11.92. 
 
The data presented highlight the possible involvement of these five genes, 
FLNB, ITGB4, KIAA0100, LAMA5, PCDH1, and corresponding variant 
proteins in KC pathogenesis. The fact that these genes appear to be 
highlighted in all three sets of analysis conducted in this study (WES data of 
KC families, PLINK/SEQ  data and differential RNA-seq expression data), 
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make them strong candidate genes in which variants may contribute to the 
susceptibility to KC development. While it is known that some of the genes 
reported in this section and their corresponding proteins (ITGB4, LAMA5) 
are normally involved in keratinocyte formation and function (Geuijen and 
Sonnenberg, 2002, Hintermann et al., 2005), the present study has 
highlighted that they may also be involved in KC pathogenesis.  
 
The literature associated with three of the five genes suggests that defects in 
the focal adhesion pathway (FLNB, ITGB4, LAMA5), as well as the MAPK 
signalling, PI3-akt signalling and ECM-receptor pathways, may therefore be 
involved in KC pathogenesis. However, many of the keratoconus pathways 
implicated by other researchers do not overlap with the pathways that have 
been highlighted in this study.  
 
The lack of overlap between the five most strongly supported candidate 
genes identified by this study and those reported literature could imply that 
the reports of pathways associated with KC in the literature, which are often 
speculative and based on un-replicated studies (Section 1.4.7), are largely 
incorrect. Alternatively, much of the data reported in this study might be 
artefactual. However, the combined approach conducted in this project, 
using results from different sets of data, attempts to minimise the amount of 
noise generated by the different analyses. Hence further analysis of the 
candidate genes reported in this project are warranted. Only confirmation of 
the results of this project by replicating the outcomes in larger datasets can 
confirm these findings and elucidate the potential role of sequence variation 
in these proteins in KC development.  
 
The combination of the RNA-seq data and the WES data in this section 
focused mainly on the downregulated genes. However this data may 
highlight more genes in the upregulated category, and indeed other strong 
candidates excluded at various stages of filtering. These analyses were not 
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completed due to time restrictions. Another next objective for this project will 
therefore be to explore all the aspects of this data more rigorously. 
 
5.2 Future directions and concluding remarks  
5.2.1 Summary of key findings 
Four years were spent in developing and carrying out the work of this 
project, during which families were collected, WES data and RNA-seq data 
were generated and analysis strategies were developed. The project started 
with the aim of searching for recessive alleles of large effect by autozygosity 
mapping in consanguineous, and to some extent endogamous, populations. 
However during years one and two it became evident that, if such alleles 
exist, they are relatively rare in this cohort at least, and no one gene is a 
common site for a significant proportion of them.  
 
The family approach yielded long lists of potential pathogenic variants 
segregating in the families. Subsequently, the data generated in the family 
approach was checked for association in an underpowered association 
analysis which also generated long lists of genes apparently enriched in 
variants in KC cases from the families studied. However, no one gene was 
consistently affected in either analyses. These findings therefore do not 
support the initial hypothesis of this study that “one or a few recessive KC 
alleles will be enriched in endogamous consanguineous populations, but 
rather suggest that KC is indeed a genetically highly complex disorder and 
that a small family cohort is not sufficiently powerful to identify the few alleles 
of large effect, found in multiple different genes, that might exist (Chapter 3). 
It was therefore necessary to switch approaches half way through the study 
to a more complex association based approach, combined with 
transcriptome differential analyses, to identify candidate KC susceptibility 
genes. Although large amounts of data were generated, the time restriction 
led to the under-exploration of all aspects of the data.  
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The RNA-seq analysis first profiled the transcriptome of the normal anterior 
human cornea in addition to identifying a number of putative new cornea-
specific transcripts. Moreover, the RNA-seq analysis generated long lists of 
differentially expressed genes both in single and pooled KC corneas against 
the pooled WT corneas. Differential expression in pooled KC vs WT corneas  
serves as a tool to overview the secondary consequences of KC, while 
examination of the differentially expressed gene lists in individual corneas, 
as well as detecting secondary changes, is more likely to highlight primary 
causative changes.  
 
Furthermore, through the combination of WES and RNA-seq datasets, this 
study yielded a list of 5 genes implicated by both approaches, namely FLNB, 
ITGB4, KIAA0100, LAMA5 and PCDH1 (Section 5.1.2.3). The fact that these 
5 genes encode structural proteins, thought to be involved in maintaining 
tissue structure and shape as well as cell-cell adhesion, is consistent with 
their involvement in KC pathogenesis and highlights them as strong KC 
candidates (Section 5.1.2.3). However, further validation of the highlighted 
variants is required. This can be obtained by Sanger sequencing in families 
to confirm and segregate variants. In addition, these genes should now be 
screened for these and other variants in a large cohort of sporadic KC 
cases, in order to obtain further proof of the involvement of these genes in 
KC in the general population.  
 
Interestingly, this is the first study to highlight genes implicated in KC 
pathogenesis by combining WES and RNA-seq data. This data - if confirmed 
by further validation tests - will in effect have been replicated within this 
study since it is highlighted by multiple different analyses. However, 
replication in other data sets is required in order to corroborate a conclusion 
on the involvement of the corresponding genes in KC pathogenesis. 
 
Moreover, since there is a fine line between considering a result as real or 
as an artefact due to the amount of noise generated by any applied method 
(especially bioinformatics), replication is essential in order to achieve robust 
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results. With this in mind, the 43 KC candidate genes described in the 
literature were checked for variants in this study and 13 of these were found 
to carry highlighted variants. Although this result is subject to confirmation by 
further analyses, the fact that 10 of the 13 genes (COL4A1, COL8A2, FLG, 
MPDZ, NEIL1, PARP1, RAB3GAP1, RXRA, XRCC1, ZNF469) contain 
potentially pathogenic variants with CADD scores of greater than 15 again 
suggests that these 10 are strong candidates for involvement in KC 
pathogenesis, warranting further investigation. However, the 30 candidate 
genes that did not contain segregating variants in this cohort are unlikely to 
have a role in KC development in these patients, though this does not 
exclude their involvement in other KC cases and families. 
 
Nonetheless, this project is still an ongoing project where all the data 
generated during the course of four years, in addition to new data, will be 
more fully investigated for the purpose of finding new insights into the 
genetic basis of KC.  
 
5.2.2 Retrospective insights 
Notwithstanding the decades of study into the genetics of KC, its aetiology 
remains a challenge that researchers are still trying to unravel. This may in 
part be due to the diagnostic as well as genetic complexity of KC. In order 
for researchers to achieve a better understanding of KC, the diagnostic 
components of this disease must first be addressed by researchers. It is 
important to differentiate between secondary KC associated with other 
diseases and primary KC. This strategy has the potential to determine 
whether other diseases that are associated with secondary KC involve 
genes/proteins that contribute directly to genetic predisposition for KC, or 
whether these associations are caused by secondary consequences such as 
eye rubbing. Once this differentiation is established, the figure for prevalence 
of KC can be more accurately established. In addition, the pathways 
involved in diseases associated with secondary KC may give clues as to 
pathways involved in primary KC. It is also necessary to define the different 
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phenotypes involved in KC manifestations, and categorise the patients 
according to the different sub-types and the forme-fruste of the disease. 
Once that categorisation is clear, any genetic variants involved may be 
easier to detect in well-defined homogeneous cohorts of patients with each 
subtype. Accordingly, and looking retrospectively at this project, better 
categorising of KC phenotype during patients’ recruitment might have 
increased the power to identify genetic variants contributing to susceptibility 
to the different KC types.  
 
As for the family study, in order to address its lack of power in the search of 
rare alleles of major effect, a larger and more powerful cohort might 
potentially have increased the chances of positive findings. This large cohort 
would have been more powerful if all patients belong in origin to one 
ethnicity, where all the patients and the ethnically matched controls have 
undergone thorough phenotyping. Furthermore, given the weakness of the 
family study, the emphasis might have been more productively directed 
towards sampling a large cohort of KC cases rather than sampling families. 
 
To strengthen the RNA-seq study, a larger number of KC corneas would 
have been at the core of the analysis. In addition, the technical batch effect 
generated by the design of the RNA-seq experiment would have been 
avoided by ensuring a better experimental design. Moreover, the WES 
analysis would have been done in parallel to the RNA-seq analysis, avoiding 
the time lag between producing the two sets of data. 
	
5.2.3 Future directions 
The next task in this project is to validate the results generated so far, in the 
families and in a larger cohort of familial and sporadic patients, by Sanger or 
multiplex sequencing. For these purposes a sample of 250 Leeds KC 
patients has already been obtained, and a further 2000 KC patient DNAs are 
available through collaboration with colleagues at Moorfields Eye Hospital.  
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In addition, only protein coding genes and coding variants were explored in 
WES data. However, microRNA genetic variations have been associated 
with KC (Lechner et al., 2013b) as well as non-coding variants being 
associated with eye diseases (Braun et al., 2013). Thus in the future, the 
search for KC associated variants will be inclusive of all the variants 
identified in the lists, applying less stringent filtering (including UTRs and 
synonymous variants). Similarly when combining the genomic WES data 
and the RNA-seq data in individual KC corneas, all the coding and non-
coding variants in the WES data will be checked for a corresponding effect in 
the RNA-seq data, since functional elements reside in non-coding regions 
and intronic variations could result in pre-mRNA splicing (Baralle and 
Baralle, 2005, Lomelin et al., 2010, Ward and Cooper, 2010). However, 
expanding the search to non-coding variants in genomic sequence will vastly 
increase the complexity of the analysis required and is therefore a huge 
challenge 
 
In the near future, Whole Genome Sequencing (WGS) will be considered as 
an alternative replacement for WES technology, especially with the 
continuous improvement in software analysis to handle large data, reducing 
time consumption and cost. The switch to WGS in this project will allow not 
only the wider coverage of genomic sequence, increasing the possibility to 
detect KC causative variants, but it will also be a useful and global tool to 
explore copy number variations (CNVs) in case these also contribute to KC 
causation. CNVs have been studied in KC but only in mitochondria (Hao et 
al., 2015b), thus this has yet to be investigated further.  
 
Since the main purpose is to look for KC causative variants, the collection of 
more sporadic KC patients in addition to families belonging to endogamous 
and consanguineous ethnicities will be a continuous task for this project. In 
the process of collecting families, forme-fruste patients ought to be identified 
and looked at separately. Studying the forme-fruste KC patients will be key 
to finding the molecular pathogenesis and will help characterize the main 
genetic components that lead to the development of the disease. Obtaining 
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data from further families and cases and the better characterisation of forme-
fruste KC in those families and cases will greatly increase the power of 
genetic studies.  
 
In order to increase the power of the transcriptomic data, KC and WT cornea 
collection will also be an ongoing process. Although the RNA-seq data 
generated in this project was focussed on mRNA transcripts, in the future 
the analysis will be broadened to study microRNAs and other non-coding 
RNAs.  
 
From the analytical point of view, the focus of the RNA-seq analysis in this 
project was mainly directed towards the primary transcripts of protein coding 
genes. In the future of this project, another aspect of the analysis that will be 
further advanced is in the identification of novel isoforms and splice variants. 
Once a clear specification of elements involved in KC pathogenesis is 
confirmed, functional analysis is the next step to be achieved.  
 
Collectively, in the era of collaboration between research groups, the WES 
data generated in this study can also serve as a relatively small dataset that 
can be included with other similar studies of WES data in order to run a 
more appropriately powered GWAS on KC patients and thus possibly 
highlight rare and common susceptibility alleles for KC.   
 
5.2.4 Implications for KC research and patients 
In addition to the scientific interest, a better understanding of the 
pathophysiology of KC could also have clinical implications. It could help 
clarify the diagnosis, allowing better characterization of forme-fruste KC, and 
distinguishing this from severe astigmatism through screening of patients for 
mutations in genes known to be implicated in KC. Thus diagnosis will be 
strengthened through a blood test, analysed alongside the corneal 
topographies.  
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A better understanding of the pathophysiology of the disease could have 
substantial implications for KC treatment, opening up new therapies far from 
the conventional treatment approaches that are used currently. Molecular 
characterising of the different KC subtypes could also facilitate a 
personalised approach to treatment, improving patient outcomes. It could in 
some cases clarify whether KC in any given patient is syndromic, which 
might have wider implications for treatment beyond the eye. For example 
this approach could clarify whether KC is an inflammatory disorder in some 
cases.  
 
In the future treatment of KC, for cases where the molecular pathogenesis is 
determined, slowing down the progression of KC and minimizing the need 
for corneal grafting ought to be a priority. In the light of personalised 
medicine, the well phenotyped groups of patients based on genotype, might 
have customised treatments that are proven to work best in their subtype of 
KC, hence improving outcomes for KC treatment. Advances in therapeutic 
strategies, drug specifications and gene therapy might make this a feasible 
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1. WES commands 
1.1 Alignment 
Reference file (fasta format) indexing 
  $ bwa index -p  hg_19.bwaidx –a bwtsw hg_19.fasta 
Sample fastq files alignment to the reference file  
$ bwa aln –t 4 hg_19.fa R1-sequence.fq > R1-sequence.sai 
$ bwa aln –t 4 hg_19.fa R2-sequence.fq > R2-sequence.sai 
- 293 - 
 
$ bwa sampe –r “@RG\tID:ID\tSM:ID\tPL:Illumina\tPU:HiSeq” 
hg_19.fa R1-sequence.sai R2-sequence.sai R1-sequence.fq R2-
sequence.fq > output.sam 
 
Sorting and indexing of the output.sam file according to the reference file 
using samtools.  
Create a reference index file 
$ samtools faidx hg_19.fa 
Index the output.sam to the reference index and sort 
$ samtools view –bt hg_19.fa.fai output.sam > output.bam 
$ samtools sort output.bam output-sort 
$ samtools index output-sort.bam 
 
 
1.2 Local realignment 
Local realignments around indels using GATK.  
List of dubious alignments generation 
$ java –Xmx50g –jar GenomeAnalysisTK.jar –T 
RealignerTargetCreator –R hg_19.fasta –I output-sort.bam –known 
hg19_indels.vcf –log output.intervals.log –o output.intervals 
 
Realignment over the dubious regions 
$ java – Xmx50g –jar GenomeAnalysisTK.jar –T IndelRealigner –R 
hg19.fasta –I output-sort.bam –targetIntervals output.intervals –log 
output.realn.log –o output-sort.realn.bam 
 
1.3 Remove duplicates 
Removal of duplicate reads using Picard tools 






Re-indexing of the file without the duplicates using samtools 
$ samtools index output-sort.realn.dedup.bam 
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1.4 Variant calling 
Calling variants of the output-sort.realn.dedup.bam is done using GATK: 
$ java –Xmx30g –jar GenomeAnalysisTK.jar –T UnifiedGenotyper –
R hg_19.fa –I output-sort.realn.dedup.bam –D dbsnp.vcf –L 
intervals.interval_list –nt 8 –stand_call_conf 50.0 –stand_emit_conf 
10.0 –dcov 200 –l INFO –A AlleleBalance –A DepthOfCoverage –A 
FisherStrand –log output.variants.log –o output.variants.SNP.vcf -
mbq 15 -glm SNP 
 
$ java –Xmx30g –jar GenomeAnalysisTK.jar –T UnifiedGenotyper –
R hg_19.fa –I output-sort.realn.dedup.bam –D dbsnp.vcf –L 
intervals.interval_list –nt 8 –stand_call_conf 50.0 –stand_emit_conf 
10.0 –dcov 200 –l INFO –A AlleleBalance –A DepthOfCoverage –A 
FisherStrand –log output.variants.log –o output.variants.INDEL.vcf -
mbq 15 -glm INDEL 
 
1.5 Variant recalibration 







hg_19.dbsnp.vcf –an QD –an HaplotypeScore –an MQRankSum –an 
ReadPosRankSum –an FS –an MQ –-maxGaussians 6 –nt 8 -mode 
BOTH –log output.recal.log –recalFile output.recal.recal –tranchesFile 
output.recal.tranches –rscriptFile output.plot.R 
 
Apply recalibration: 
$ java –Xmx30g –jar GATK.jar –T ApplyRecalibration –R hg_19.fa –
input output.variants.SNP.vcf –recalFile output.recal.recal –
tranchesFile output.recal.tranches –ts_filter_level 99.0 –log 
output.apply_recal.log –o output.variants.recal.SNP.vcf 
 
Combine variants: 
$ java –Xmx30g –jar GATK.jar –T CombineVariants –R hg_19.fa --
variant output.variants.recal.SNP.vcf --variant 
output.variants.INDEL.vcf –o combined.vcf 
 
1.6 Annotate 
Convert the combined.vcf to a file compatible with ANNOVAR. 
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$ Perl convert2annovar.pl combine.vcf –format vcf4 –withzyg -
includeinfo –o combine.annovar.vcf 
 
Annotating the combined.vcf file using ANNOVAR 




,exac03,cadd,clinvar_20140929,avsift -otherinfo -remove -operation 
g,g,g,r,r,r,f,f,f,f,f,f,f,f -nastring . –outfile combine.annovar.annotated -
argument "-splicing_threshold 5",,,,,,,,,,,,, 
 
1.7 Depth of coverage 
$java -Xmx30g -jar GenomeAnalysisTK.jar -T DepthOfCoverage -R 
hg_19.fasta -mbq 17 -mmq 10 -I Sample.fastq -o SamplesStats.txt -L 
V5-Capturekit_Regions.bed -ct 5 -ct 10 -ct 15 -ct 20 
 
2. Highlight-similarities – perl script 
The below script is developed specifically for this study. 
# highlight-similarities-xlsx 
# Copyright (C) 2014 Qais Yousef 
# highlight-similarities-xlsx is free software: you can redistribute it and/or 
modify it under the terms of the GNU General Public License as published 
by the Free Software Foundation, either version 2 of the License, or (at your 
option) any later version. 
# highlight-similarities-xlsx is distributed in the hope that it will be useful, but 
WITHOUT ANY WARRANTY; without even the implied warranty of 
MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See 
the GNU General Public License for more details. You should have received 
a copy of the GNU General Public License along with highlight-similarities-








# auto flush the output after every print 
$| = 1; 
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# ignore some annoying warnings from Spreadsheet::XLSX 
$SIG{'__WARN__'} = sub { warn $_[0] unless (caller eq 
"Spreadsheet::XLSX"); }; 
 
my $destname = shift @ARGV; 
my $sourcename = shift @ARGV 
 or die "invocation: $0 <destination file> <source1 file> <source2 file> 
.. <sourceN file>"; 
 
print "Opening <$sourcename> (this might take a while if the file is large)..."; 
my $source_book = Spreadsheet::XLSX->new($sourcename) 
 or die "Could not open source Excel file $sourcename: $!"; 
my $dest_book = Excel::Writer::XLSX->new($destname) 
 or die "Could not open source Excel file $destname: $!"; 
 




foreach my $arg (0 .. $#ARGV) 
{ 
 $cmpname[$arg] = shift @ARGV 
  or die "invocation: $0 <destination file> <source1 file> 
<source2 file> .. <sourceN file>"; 
 if (!-e $cmpname[$arg]) 
 { 




my $matches = 0; 
my $format = $dest_book->add_format(); 
$format->set_bg_color('yellow'); 
 
# which colums to compare? 
my $cell0 = 1; 
my $cell1 = 4; 
my $cell2 = 6; 
 
# final result 
my @result = (); 
 
# copy the source_sheet to dest_book 
my $dest_sheet = $dest_book->add_worksheet(); 
my $source_sheet = $source_book->{Worksheet}[0]; 
foreach my $src_row_index ($source_sheet->{MinRow} .. $source_sheet-
>{MaxRow}) 
{ 
 next unless defined $source_sheet->{MaxRow}; 
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 next unless $source_sheet->{MinRow} <= $source_sheet-
>{MaxRow}; 
 
 foreach my $src_col_index ($source_sheet->{MinCol} .. 
$source_sheet->{MaxCol}) 
 { 
  next unless defined $source_sheet->{MaxCol}; 
  next unless $source_sheet->{MinCol} <= $source_sheet-
>{MaxCol}; 
 
  my $source_cell = $source_sheet-
>{Cells}[$src_row_index][$src_col_index]; 





print "[2K\rComparing <$sourcename> ", $source_sheet->{MaxRow}+1, " 
rows\nwith:\n"; 
 
print "Opening <$cmpname[0]> (this might take a while if the file is large)..."; 
$cmp_book = Spreadsheet::XLSX->new($cmpname[0]) 
 or die "Could not open source Excel file $cmpname[0]: $!"; 
$cmp_sheet = $cmp_book->{Worksheet}[0]; 
print "[2K\r - <$cmpname[0]>\t", $cmp_sheet->{MaxRow}+1, " rows\n"; 
 
foreach my $src_row_index ($source_sheet->{MinRow} .. $source_sheet-
>{MaxRow}) 
{ 
 foreach my $cmp_row_index ($cmp_sheet->{MinRow} .. $cmp_sheet-
>{MaxRow}) 
 { 
  my $source_cell0 = $source_sheet-
>{Cells}[$src_row_index][$cell0]; 
  my $cmp_cell0 = $cmp_sheet-
>{Cells}[$cmp_row_index][$cell0]; 
  my $source_cell1 = $source_sheet-
>{Cells}[$src_row_index][$cell1]; 
  my $cmp_cell1 = $cmp_sheet-
>{Cells}[$cmp_row_index][$cell1]; 
  my $source_cell2 = $source_sheet-
>{Cells}[$src_row_index][$cell2]; 
  my $cmp_cell2 = $cmp_sheet-
>{Cells}[$cmp_row_index][$cell2]; 
  if ($source_cell0 && $cmp_cell0 && 
   $source_cell1 && $cmp_cell1 && 
   $source_cell2 && $cmp_cell2 && 
   $source_cell0->Value eq $cmp_cell0->Value && 
   $source_cell1->Value eq $cmp_cell1->Value && 
   $source_cell2->Value eq $cmp_cell2->Value) 
  { 
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   push(@result, $src_row_index); 
   last; 
  } # end of source_cell check 
 } # foreach cmp_row_index 
 if ($source_sheet->{MaxRow}) 
 { 
  print floor($src_row_index/$source_sheet->{MaxRow}*100), 
"%\r"; 
 } 
} # foreach src_row_index 
 
# compare with the result of the files using the result variable 
if ($#cmpname > 0) 
{ 
 foreach my $i (1 .. $#cmpname) 
 { 
  print "Opening <$cmpname[$i]> (this might take a while if the 
file is large)..."; 
  $cmp_book = Spreadsheet::XLSX->new($cmpname[$i]) 
   or die "Could not open source Excel file $cmpname[$i]: 
$!"; 
  $cmp_sheet = $cmp_book->{Worksheet}[0]; 
  print "[2K\r - <$cmpname[$i]>\t", $cmp_sheet->{MaxRow}+1, " 
rows\n"; 
 
  foreach my $j (0 .. $#result) 
  { 
   my $src_row_index = $result[$j]; 
   if ($src_row_index < 0) 
   { 
    next; 
   } 
 
   my $found = 0; 
 
   foreach my $cmp_row_index ($cmp_sheet->{MinRow} .. 
$cmp_sheet->{MaxRow}) 
   { 
    my $source_cell0 = $source_sheet 
>{Cells}[$src_row_index][$cell0]; 
    my $cmp_cell0 = $cmp_sheet-
>{Cells}[$cmp_row_index][$cell0]; 
    my $source_cell1 = $source_sheet-
>{Cells}[$src_row_index][$cell1]; 
    my $cmp_cell1 = $cmp_sheet-
>{Cells}[$cmp_row_index][$cell1]; 
    my $source_cell2 = $source_sheet-
>{Cells}[$src_row_index][$cell2]; 
    my $cmp_cell2 = $cmp_sheet-
>{Cells}[$cmp_row_index][$cell2]; 
    if ($source_cell0 && $cmp_cell0 && 
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     $source_cell1 && $cmp_cell1 && 
     $source_cell2 && $cmp_cell2 && 
     $source_cell0->Value eq $cmp_cell0-
>Value && 
     $source_cell1->Value eq $cmp_cell1-
>Value && 
     $source_cell2->Value eq $cmp_cell2-
>Value) 
    { 
     $found = 1; 
     last; 
    } # end of source_cell check 
   } # foreach cmp_row_index 
   if ($source_sheet->{MaxRow}) 
   { 
    print floor($src_row_index/$source_sheet-
>{MaxRow}*100), "%\r"; 
   } 
   if (!$found) 
   { 
    $result[$j] = -1; 
   } 
  } # foreach src_row_index 
 } # foreach cmp_sheet_number 
} 
 
# Finally highlight the rseult in the output 
foreach my $i (0 .. $#result) 
{ 
 if ($result[$i] >= 0) 
 { 
  $matches += 1; 




print  $matches, " matches found\n"; 





3. RNA-seq commands 
3.1 Prepare the fastq files 
Trimming the ends of RNA-seq reads using Cut-adapt. 
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$ cutadapt -q20 -aGATCGGAAGAGCG –o output-trimmed.fastq.gz 
input.fastq.gz > log.txt 
 
3.2 Align the RNA-seq reads 
Tophat alignment: 
Index the reference file (GRCh38p2) and align according to the indexed file 
$ tophat index GRCh38p2.fasta 
$ tophat --library-type fr-firststrand -p 8 --no-coverage-search 
GRCh38p2/ Sample-R1.fastq Sample-R2.fastq -o Sample/ 
 
RUM alignment: 
Indexed hg19 is downloaded from online RUM library  
$ Perl rum_runner align -i /indexes/hg19 --name Sample -o Sample/ --
chunks 12  Sample-R1.fastq Sample-R2.fastq 
 
3.3 Cufflinks pipeline 
Assemble the RNA reads with the guidance of a gtf file: 
$ /cufflinks/cufflinks -p16 –g GRCh38p2.gtf –o /tophat/Sample-
accepted_hits.bam 
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Merge the gtf files of all the samples with the reference gtf file using 
Cuffmerge: 
$ cufflinks/cuffmerge -p 16 -o output-merged/ -g GRCh38p2.gtf -s 
GRCh38p2.fa assemblies.txt 
 
Perform the differential expression analysis using Cuffdiff: 
$ cufflinks/cuffdiff -p16 –o output-cuffdiff/ -L KC,WT 








For transcriptome profile generation of the WT anterior human cornea: 







Merge the gtf files of all the WT samples with the reference gtf file using 
Cuffmerge: 
$ cufflinks/cuffmerge -p 16 -o output-mergedWT/ -g GRCh38p2.gtf -s 
GRCh38p2.fa assembliesWT.txt 
Generate normalised reads for all the WT RNA reads: 




05/accepted_hits.bam --output-format cuffdiff 
 
Visualize using CummeRbund: 




































3.4 EdgeR pipeline 
Count the reads using the featureCounts option of subread software:  











Differential analysis using EdgeR is done on R platform.  If using for the first 
time, packages need to be installed. 
Generate a .txt file containing all the conditions “Conditions.txt”: 
Sample Condition Label 
MA18  KC  KC01 
MA26  KC  KC02 
MA46  KC  KC03 
MA47  KC  KC04 
MA52  KC  KC05 
MA58  KC  KC06 
WT28  Control WT01 
WT35  Control WT02 
WT51  Control WT03 
WT67  Control WT04 
WT82  Control WT05 
 













Import “Conditions.txt” file: 
> targets <- readTargets(“Conditions.txt”) 
> targets 
 
Import the Table of counts “Counts.txt” generated by Subreads to EdgeR: 




Convert raw data into a DGEList: 
> y <- DGEList(counts=rawdata[,6:16], group=targets$Condition, 
genes=data.frame(Length=rawdata[,5])) 
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> colnames(y) <- targets$Label 
 
Count the number of genes: 
> dim(y) 
 
Add gene annotation using annotation.gtf file: 
> anno <- read.delim(file=” GRCh38p2.gtf”) 
> head(anno) 
 
Match the ENSG number in the data to the ENSG number, Gene Symbol 
and Feature info 
> m <- match(rownames(y), anno[,9]) 
> y$genes <- anno[m, c(9,13,11)]  
> colnames(y$genes) <- c(“GeneID”, “Symbol”, “Feature”) 
> head(y$genes) 
 
Calculate Normalisation factors for each of the samples: 
>  y <- calcNormFactors(y) 
> y$samples 
 
Plot an MDS plot to show how consistent the replicates are with each other: 
> plotMDS(y) 
 
Calculate the BCV (square root of common dispersion) for the dataset 
averaged over all genes: 
> y <- estimateCommonDisp(y, verbose=TRUE) 
 
Estimate gene specific dispersions and plot the estimated dispersions: 
> y <- estimateTagwiseDisp(y) 
> plotBCV(y) 
 
Compute exact gene wise tests for differential expression between 
conditions: 
> et <- exactTest(y) 
 
Check out the top 10 results: 
> top <- topTags(et) 
> top 
 
Generate a summary of the number of DE genes in the data: 
> summary(de <- decideTestsDGE(et)) 
 
Plot a smear graph to show over DE gene expression: 
> detags <- rownames(y)[as.logical(de)] 
> plotSmear (et, de.tags=detags) 
> abline(h=c(-1,1), col=”blue”) 
 
The blue lines indicate a 2-fold change. 
 
Write DE.genes to a table: 
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> DE.genes <- as.data.frame(topTags(et, n=insert no. of DE genes 
here+1and -1 genes numbers)) 
 
Write to excel: 
> library(“xlsx”) 
> write.xlsx(DE.genes, file = “DE.genes.xls”) 
 
4. PLINK/SEQ commands 
4.1 Prepare the vcf file 
Calling variants of the output-sort.realn.dedup.bam is done using GATK: 
$ java –Xmx30g –jar GenomeAnalysisTK.jar –T UnifiedGenotyper –
R hg_19.fa –I output1-sort.realn.dedup.bam –I output2-
sort.realn.dedup.bam … –I outputn-sort.realn.dedup.bam –D 
dbsnp.vcf –L intervals.interval_list –nt 8 –stand_call_conf 50.0 –
stand_emit_conf 10.0 –dcov 200 –l INFO –A AlleleBalance –A 
DepthOfCoverage –A FisherStrand –log outputPlinkSeq.variants.log –
o outputPlinkSeq.variants.SNP.vcf -mbq 15 -glm SNP 
 
$ java –Xmx30g –jar GenomeAnalysisTK.jar –T UnifiedGenotyper –
R hg_19.fa –I output1-sort.realn.dedup.bam –I output2-
sort.realn.dedup.bam … –I outputn-sort.realn.dedup.bam –D 
dbsnp.vcf –L intervals.interval_list –nt 8 –stand_call_conf 50.0 –
stand_emit_conf 10.0 –dcov 200 –l INFO –A AlleleBalance –A 
DepthOfCoverage –A FisherStrand –log outputPlinkSeq.variants.log –
o outputPlinkSeq.variants.INDEL.vcf -mbq 15 -glm INDEL 
 







hg_19.dbsnp.vcf –an QD –an HaplotypeScore –an MQRankSum –an 
ReadPosRankSum –an FS –an MQ –-maxGaussians 6 –nt 8 -mode 
BOTH –log outputPlinkSeq.recal.log –recalFile 
outputPlinkSeq.recal.recal –tranchesFile 
outputPlinkSeq.recal.tranches –rscriptFile outputPlinkSeq.plot.R 
 
Apply recalibration: 
$ java –Xmx30g –jar GATK.jar –T ApplyRecalibration –R hg_19.fa –
input outputPlinkSeq.variants.raw.vcf –recalFile 
outputPlinkSeq.recal.recal –tranchesFile 
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outputPlinkSeq.recal.tranches –ts_filter_level 99.0 –log 
outputPlinkSeq.apply_recal.log –o outputPlinkSeq.variants.recal.vcf 
 
Combine variants: 
$ java –Xmx30g –jar GATK.jar –T CombineVariants –R hg_19.fa --
variant outputPlinkSeq.variants.SNP.vcf --variant 
outputPlinkSeq.variants.INDEL.vcf –o combinedPlinkSeq.vcf 
 
Remove chr from the contig lines: 
$ sed s/##contig=\<ID=chr/##contig=\<ID=/ combined.vcf > 
combined.chrcontig.vcf 
 
$ Bgzip combined.chrcontig.vcf 
$ Tabix –p VCF combined.chrcontig.vcf.gz 
Liftover variants using the GATK to convert the vcf file from hg19 to b37 to 
be able to use dbsnp 141.b37: 
$ java -Xmx4g -jar GATK.jar -T LiftoverVariants -V 
combinedPlinkSeq.vcf -o combinedPlinkSeq.converted.vcf -R 
hg_19.fasta -chain liftover_chains/hg19tob37.chain -dict 
/b37/human_g1k_v37.dict 
 
$ Bgzip combinedPlinkSeq.converted.vcf 
$ Tabix –p combinedPlinkSeq.converted.vcf 
Remove all the variants with MAF > 2% in dbSNP141 and below: 
$ perl annotateSnps.pl -i combinedPlinkSeq.converted.vcf.gz -o 
combinedPlinkSeq.converted.vcf.dbSNP2.vcf -f 2 --progress -forks 8 -
d /b37/dbSnp141.b37.vcf.gz 
 
Remove all the variants with MAF > 2% in EVS (esp6500si): 
$ perl filterOnEvsMaf.pl -i 
combinedPlinkSeq.converted.vcf.dbSNP2.vcf -o 
combinedPlinkSeq.converted.vcf.dbSNP2.EVS2.vcf -f 2 -p -forks 8 -d 
EVS/files/ 
 
Annotate VCF file using: TrasnlateVCF.pl (Dave’s) 
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Filter out all the non functional variants:  
$ Perl filter_by_anno.pl 
combinedPlinkSeq.converted.vcf.dbSNP2.EVS2.annotated.vcf 
The output file is called PlinkSeq.vcf 
 
4.2 Run PLINK/SEQ 
Create project 
$ pseq EnrichementProject new-project --resources PlinkSeq/hg19 
 
Load vcf into project 
$ pseq EnrichementProject load-vcf -- PlinkSeq.vcf  
 
Load phenotype information 
$ pseq EnrichementProject load-pheno --file EnrichementProject.phe 
 
Perform enrichment per gene: 
$ pseq EnrichementProject assoc --phenotype kc --mask 
loc.group=refseq > EnrichementProject-Association.txt 
 
Perform enrichment per variant: 
$ pseq EnrichementProject v-assoc --phenotype kc  
 
4.3 Post PLINK/SEQ the vcf changes 
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Open the vcf file on excel in order to check the variants and filter out all the 
variants with p-value < 0.05 then use it in this step and an input file in order 
to convert it back to a vcf file: 
$ perl gwas_to_vcf.pl -i PlinkSeq-Variant.xlsx -o PlinkSeq-Variant.xlsx 
 
Add info to the SNPs in the file: 
$ perl annotateSnps.pl -d hg19/dbSnp141.hg19liftover.vcf.gz -i 
PlinkSeq-Variant-snp2.vcf -o PlinkSeq-Variant.vcf --progress 
 
Annotate functional information by using VEP (Variant Effect Predictor): 
$ perl variant_effect_predictor.pl --offline --everything --dir 
variant_effect_predictor_76/ensembl-tools-release-
76/scripts/variant_effect_predictor/vep_cache/  --assembly GRCh37  -
-vcf -i PlinkSeq-Variant-snp2.vcf -o vep.PlinkSeq-Variant-snp2.vcf 
 
convert back from .vcf to .xlsx formats: 
$ perl vcf_to_gwas.pl -i vep.PlinkSeq-Variant-snp2.vcf -v --fields 
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5. Coverage Statistics per sample 
sample_id	 total	 mean	 %_bases_above_5	 %_bases_above_10	 %_bases_above_15	 %_bases_above_20	
10-1	 3176830071	 63.04	 97.7	 96	 93.3	 89.4	
2_1	 3440255711	 68.27	 97.7	 96.3	 94.2	 91	
2-3	 3399997683	 67.47	 97.8	 96.5	 94.4	 91.3	
12_1	 2633409626	 52.26	 92.8	 88	 82.4	 76.4	
10-1	 4297713470	 85.29	 97.8	 96.5	 94.5	 91.9	
13-3	 1708370434	 33.9	 91.3	 86.4	 79.9	 72.1	
2_5	 3080542049	 61.13	 97.8	 96.1	 93.4	 89.4	
11_3	 3678424737	 73	 94.2	 91.3	 87.8	 83.8	
13-1	 1648396247	 32.71	 91	 85.9	 79.2	 71.2	
9-1	 3265253057	 64.8	 97.5	 96	 93.6	 90.1	
11_4	 3014746101	 59.83	 93.7	 89.8	 85.2	 80.1	
KF54	 4924475810	 97.73	 98	 97.4	 96.4	 95	
KF52	 4402986990	 87.38	 97.9	 97	 95.7	 93.9	
KF53	 4789108194	 95.04	 98.1	 97.4	 96.3	 94.7	
KF50	 5541449339	 109.97	 98.1	 97.5	 96.7	 95.7	
KF51	 4490698135	 89.12	 98	 97.2	 96.1	 94.4	
6-1	 4418144022	 87.68	 98	 97.1	 95.8	 94	
8-1	 4519915855	 89.7	 98	 97.1	 95.7	 93.9	
8-2	 3609948124	 71.64	 97.7	 96.5	 94.6	 91.8	
6-10	 8830126388	 175.23	 98.2	 98	 97.5	 97.1	
6-3	 3532484205	 70.1	 97.7	 96.4	 94.4	 91.5	
7-1	 3317951079	 65.84	 97.7	 96.1	 93.3	 89.6	
IL	 1883409306	 37.38	 91.5	 87.1	 81.5	 74.6	
ASD433	 4181485035	 82.98	 98	 97	 95.6	 93.5	
ASD434	 3261048630	 64.72	 97.8	 96.4	 94.1	 90.7	
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RP79	 3530172618	 70.06	 95.3	 93.5	 91.4	 88.6	
B1	 1553327374	 30.83	 89.1	 79.3	 68.9	 58.8	
SC1	 3409526344	 67.66	 93.8	 90.1	 85.7	 80.7	
SC2	 2748579236	 54.55	 93.4	 89.3	 84.3	 78.7	
SC3	 3764586050	 74.71	 94.1	 91.2	 87.6	 83.5	
B2	 1356163327	 26.91	 90.5	 83.6	 74.2	 63.3	
FL	 774774852	 15.38	 86	 68.7	 48.8	 31.1	
YL82	 4143528276	 82.23	 98	 97	 95.5	 93.3	
ML81	 3276060921	 65.01	 97.8	 96.3	 93.8	 90.3	
AM	 4150478090	 82.37	 97.8	 96.7	 95	 92.7	
 
6. Compound heterozygous full lists of Chapter 3- Section 3.2.4 
SC1 Compound heterozygous variants full list: 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AAChange.refGene	
34	 ABI3BP	 nonsynonymous	 3q12.2	 .	 0.000199681	 rs199998539	 0.000455	 ABI3BP:NM_015429:exon2:c.G167A:p.R56H	
23.1	 ABI3BP	 nonsynonymous	 3q12.2	 0.002419	 0.00778754	 rs141302553	 0.005041	 ABI3BP:NM_015429:exon27:c.G2305C:p.V769L	
25.4	 AGAP1	 nonsynonymous	 2q37.2	 .	 .	 .	 0.002459	 AGAP1:NM_014914:exon12:c.G1390C:p.D464H	
24.2	 AGAP1	 nonsynonymous	 2q37.2	 .	 .	 .	 0.0008237	 AGAP1:NM_014914:exon12:c.T1402C:p.S468P	
23.4	 APOB	 nonsynonymous	 2p24.1	 .	 .	 .	 .	 APOB:NM_000384:exon26:c.G6313T:p.D2105Y	
19.98	 APOB	 nonsynonymous	 2p24.1	 0.002615	 0.0061901	 rs72653095	 0.004374	 APOB:NM_000384:exon26:c.C8462T:p.P2821L	
14.64	 APOB	 nonsynonymous	 2p24.1	 .	 .	 .	 0.00008236	 APOB:NM_000384:exon26:c.C8719T:p.R2907C	
22.6	 C2CD2	 nonsynonymous	 21q22.3	 0.000615	 0.00339457	 rs140022230	 0.003286	 C2CD2:NM_199050:exon10:c.G937A:p.V313I	
17.16	 C2CD2	 nonsynonymous	 21q22.3	 .	 .	 rs201984634	 0.0002387	 C2CD2:NM_015500:exon1:c.C236G:p.A79G	
29.1	 C2CD5	 nonsynonymous	 12p12.1	 .	 0.000199681	 rs142327845	 0.000453	 C2CD5:NM_001286174:exon8:c.G982T:p.G328W	
22.7	 C2CD5	 nonsynonymous	 12p12.1	 .	 0.000199681	 rs147669786	 0.000453	 C2CD5:NM_001286174:exon8:c.G983T:p.G328V	
25.3	 COL18A1	 nonsynonymous	 21q22.3	 0.012614	 0.0175719	 rs61736805	 0.007476	 COL18A1:NM_030582:exon42:c.G4354T:p.V1452L	
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13.14	 COL18A1	 nonsynonymous	 21q22.3	 .	 .	 .	 .	 COL18A1:NM_030582:exon34:c.C3371G:p.P1124R	
25.4	 CXCR1	 nonsynonymous	 2q35	 0.022682	 0.0229633	 rs16858808	 0.027	 CXCR1:NM_000634:exon2:c.C1003T:p.R335C	
21.8	 CXCR1	 nonsynonymous	 2q35	 .	 0.00579073	 rs142978743	 0.003599	 CXCR1:NM_000634:exon2:c.A847T:p.I283F	
29.7	 DMXL1	 frameshift	
deletion	




5q23.1	 .	 .	 .	 .	 DMXL1:NM_001290321:exon18:c.4262delC:p.S1421fs	
19.39	 DMXL1	 nonsynonymous	 5q23.1	 .	 .	 .	 .	 DMXL1:NM_001290321:exon11:c.G1327T:p.G443C	
24.6	 DNAH6	 nonsynonymous	 2p11.2	 .	 .	 .	 0.0001209	 DNAH6:NM_001370:exon16:c.C2572T:p.R858C	
14.2	 DNAH6	 nonsynonymous	 2p11.2	 .	 .	 .	 0.0002803	 DNAH6:NM_001370:exon36:c.A5851G:p.I1951V	
26.2	 E4F1	 nonsynonymous	 16p13.3	 .	 .	 .	 0.00004123	 E4F1:NM_001288776:exon10:c.G1469A:p.R490H	
21.8	 E4F1	 nonsynonymous	 16p13.3	 0.000077	 0.0071885	 rs145769654	 0.002949	 E4F1:NM_001288776:exon8:c.G1141A:p.V381I	
17.98	 ENAH	 nonsynonymous	 1q42.12	 .	 .	 .	 .	 ENAH:NM_001008493:exon5:c.C661A:p.R221S	
15.18	 ENAH	 nonsynonymous	 1q42.12	 .	 .	 .	 .	 ENAH:NM_001008493:exon5:c.G651T:p.E217D	
31	 FAM186B	 nonsynonymous	 12q13.12	 0.001076	 0.00259585	 rs141974060	 0.003089	 FAM186B:NM_032130:exon2:c.G321C:p.W107C	
24.8	 FAM186B	 nonsynonymous	 12q13.12	 0.001153	 0.00259585	 rs144854212	 0.003122	 FAM186B:NM_032130:exon7:c.G2556C:p.E852D	
15.12	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.G2344C:p.E782Q	
14.53	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.A2345C:p.E782A	
10.89	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.A2333C:p.Q778P	
21.4	 FBXO7	 nonsynonymous	 22q12.3	 .	 0.00119808	 .	 0.0004365	 FBXO7:NM_012179:exon2:c.A155G:p.Y52C	
13.27	 FBXO7	 nonsynonymous	 22q12.3	 .	 .	 .	 0.000008236	 FBXO7:NM_012179:exon2:c.T260C:p.I87T	
29.7	 FES	 nonsynonymous	 15q26.1	 .	 .	 .	 0.0002418	 FES:NM_001143783:exon14:c.A1778G:p.E593G	
28.1	 FES	 nonsynonymous	 15q26.1	 .	 .	 .	 0.000008239	 FES:NM_001143784:exon2:c.G263A:p.R88Q	
17.89	 FLG	 nonsynonymous	 1q21.3	 0.01753	 0.0249601	 rs35621145	 0.023	 FLG:NM_002016:exon3:c.C9808T:p.R3270C	
12.11	 FLG	 nonsynonymous	 1q21.3	 0.017607	 0.0247604	 rs71626704	 0.023	 FLG:NM_002016:exon3:c.C6045A:p.D2015E	
15.29	 FNDC1	 nonsynonymous	 6q25.3	 .	 .	 .	 .	 FNDC1:NM_032532:exon14:c.G4442C:p.R1481P	
13.15	 FNDC1	 nonsynonymous	 6q25.3	 .	 .	 rs200598839	 .	 FNDC1:NM_032532:exon14:c.C4436G:p.T1479S	
22.9	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 rs201635586	 .	 GPRIN1:NM_052899:exon2:c.A698T:p.E233V	
19.14	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 rs199714570	 .	 GPRIN1:NM_052899:exon2:c.G707T:p.G236V	
13.71	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 .	 .	 GPRIN1:NM_052899:exon2:c.T713C:p.L238S	
23.5	 HCLS1	 nonsynonymous	 3q13.33	 .	 .	 .	 .	 HCLS1:NM_001292041:exon11:c.T1021C:p.Y341H	
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23.3	 HCLS1	 nonsynonymous	 3q13.33	 .	 .	 .	 .	 HCLS1:NM_001292041:exon11:c.A1015C:p.N339H	
16.09	 HCLS1	 nonsynonymous	 3q13.33	 .	 .	 .	 .	 HCLS1:NM_001292041:exon11:c.C1020G:p.D340E	
15.94	 HCLS1	 nonsynonymous	 3q13.33	 .	 .	 .	 .	 HCLS1:NM_001292041:exon11:c.A1016C:p.N339T	
25.8	 HDGFRP2	 nonsynonymous	 19p13.3	 .	 .	 .	 .	 HDGFRP2:NM_001001520:exon15:c.G1744C:p.G582R	
24.7	 HDGFRP2	 nonsynonymous	 19p13.3	 .	 .	 .	 .	 HDGFRP2:NM_001001520:exon15:c.G1750A:p.E584K	
23.8	 HDGFRP2	 nonsynonymous	 19p13.3	 .	 .	 .	 .	 HDGFRP2:NM_001001520:exon15:c.G1745A:p.G582E	
22	 HDGFRP2	 nonsynonymous	 19p13.3	 .	 .	 .	 .	 HDGFRP2:NM_001001520:exon15:c.T1739C:p.L580P	
20.2	 HDGFRP2	 nonsynonymous	 19p13.3	 .	 .	 .	 .	 HDGFRP2:NM_001001520:exon15:c.G1741C:p.A581P	
18.54	 HDGFRP2	 nonsynonymous	 19p13.3	 .	 .	 rs200976909	 .	 HDGFRP2:NM_001001520:exon15:c.C1738G:p.L580V	
21.3	 KMT2D	 nonsynonymous	 12q13.12	 0.003701	 0.0259585	 rs3741626	 0.012	 KMT2D:NM_003482:exon31:c.C7144T:p.P2382S	
18.39	 KMT2D	 nonsynonymous	 12q13.12	 .	 0.00319489	 .	 0.001091	 KMT2D:NM_003482:exon24:c.G5477T:p.G1826V	
23.7	 KNDC1	 nonsynonymous	 10q26.3	 0.020734	 0.0131789	 rs11101618	 0.02	 KNDC1:NM_152643:exon4:c.G382T:p.A128S	
13.44	 KNDC1	 nonsynonymous	 10q26.3	 0.02202	 0.0131789	 rs11101620	 0.022	 KNDC1:NM_152643:exon4:c.G467A:p.R156Q	
11.15	 KNDC1	 nonsynonymous	 10q26.3	 0.021706	 0.0131789	 rs11101619	 0.022	 KNDC1:NM_152643:exon4:c.A463G:p.S155G	
10.92	 KNDC1	 nonsynonymous	 10q26.3	 0.022989	 0.0133786	 rs41317288	 0.024	 KNDC1:NM_152643:exon11:c.G1808A:p.C603Y	
13.42	 KRTAP10-
6	
nonsynonymous	 21q22.3	 .	 .	 .	 0.00001712	 KRTAP10-6:NM_198688:exon1:c.C149G:p.A50G	
12.51	 KRTAP10-
6	
nonsynonymous	 21q22.3	 .	 .	 .	 .	 KRTAP10-6:NM_198688:exon1:c.G148A:p.A50T	
12.05	 LCE4A	 nonsynonymous	 1q21.3	 .	 .	 rs118176527	 .	 LCE4A:NM_178356:exon1:c.A161G:p.E54G	
11.85	 LCE4A	 nonsynonymous	 1q21.3	 .	 .	 .	 .	 LCE4A:NM_178356:exon1:c.G166T:p.G56C	
40	 LOR	 stopgain	 1q21.3	 .	 .	 .	 .	 LOR:NM_000427:exon2:c.G592T:p.G198X	
10.87	 LOR	 nonsynonymous	 1q21.3	 .	 .	 .	 .	 LOR:NM_000427:exon2:c.T565G:p.Y189D	
18.57	 MAP1S	 nonsynonymous	 19p13.11	 .	 .	 rs199703392	 0.001036	 MAP1S:NM_018174:exon5:c.C1405G:p.R469G	
14.98	 MAP1S	 nonsynonymous	 19p13.11	 .	 .	 rs201564716	 0.0007222	 MAP1S:NM_018174:exon5:c.C1400G:p.P467R	
24.8	 MRGPRD	 nonsynonymous	 11q13.3	 0.003542	 0.00399361	 rs146025023	 0.001161	 MRGPRD:NM_198923:exon1:c.C616T:p.R206W	
23.2	 MRGPRD	 nonsynonymous	 11q13.3	 .	 .	 .	 0.0001977	 MRGPRD:NM_198923:exon1:c.G641A:p.R214Q	
12.94	 MRPL19	 nonsynonymous	 2p12	 .	 .	 .	 0.00007513	 MRPL19:NM_014763:exon1:c.T77C:p.L26P	
12.58	 MRPL19	 nonsynonymous	 2p12	 0.006561	 0.00698882	 rs41382847	 0.006452	 MRPL19:NM_014763:exon3:c.G313A:p.V105I	
11.71	 MUC5B	 nonsynonymous	 11p15.5	 0.023567	 0.0117812	 rs55657020	 0.027	 MUC5B:NM_002458:exon41:c.G16306A:p.V5436M	
11	 MUC5B	 nonsynonymous	 11p15.5	 0.025274	 0.0147764	 rs56220864	 0.021	 MUC5B:NM_002458:exon41:c.G16422C:p.E5474D	
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23.2	 NLRX1	 nonsynonymous	 11q23.3	 .	 0.0163738	 rs200846476	 0.00832	 NLRX1:NM_001282143:exon7:c.C2035G:p.L679V	
12.58	 NLRX1	 nonsynonymous	 11q23.3	 .	 .	 .	 0.00004942	 NLRX1:NM_001282143:exon6:c.G1129A:p.V377I	
11.96	 NLRX1	 nonsynonymous	 11q23.3	 .	 0.000998403	 rs151306288	 0.000338	 NLRX1:NM_001282143:exon7:c.G2228A:p.R743H	
25.2	 OBSL1	 nonsynonymous	 2q35	 .	 0.000399361	 rs369705959	 0.0003222	 OBSL1:NM_001173408:exon5:c.G1850A:p.R617H	
21.6	 OBSL1	 nonsynonymous	 2q35	 .	 .	 .	 0.00604	 OBSL1:NM_001173431:exon11:c.A3730C:p.T1244P	
27	 OPLAH	 nonsynonymous	 8q24.3	 0.01469	 0.00638978	 rs10107332	 0.014	 OPLAH:NM_017570:exon13:c.G1750T:p.G584C	
21.2	 OPLAH	 nonsynonymous	 8q24.3	 .	 .	 .	 0.00002496	 OPLAH:NM_017570:exon10:c.C1331T:p.P444L	
26.6	 OR52N1	 nonsynonymous	 11p15.4	 .	 .	 .	 .	 OR52N1:NM_001001913:exon1:c.G769C:p.A257P	
26.3	 OR52N1	 nonsynonymous	 11p15.4	 .	 .	 rs201810252	 .	 OR52N1:NM_001001913:exon1:c.C767A:p.P256Q	
17.24	 OVGP1	 nonsynonymous	 1p13.2	 .	 .	 .	 .	 OVGP1:NM_002557:exon11:c.G1594C:p.V532L	
13.21	 OVGP1	 nonsynonymous	 1p13.2	 .	 .	 rs74322126	 .	 OVGP1:NM_002557:exon11:c.A1565C:p.K522T	
10.96	 OVGP1	 nonsynonymous	 1p13.2	 .	 .	 .	 .	 OVGP1:NM_002557:exon11:c.T1587G:p.H529Q	
24.8	 PCM1	 nonsynonymous	 8p22	 .	 .	 .	 0.00002483	 PCM1:NM_006197:exon18:c.A2656G:p.T886A	
12.81	 PCM1	 nonsynonymous	 8p22	 .	 0.0071885	 rs373403157	 0.003683	 PCM1:NM_006197:exon5:c.C467T:p.A156V	
25.6	 RECQL4	 nonsynonymous	 8q24.3	 .	 0.000199681	 .	 0.0002572	 RECQL4:NM_004260:exon9:c.C1561T:p.R521W	
24.4	 RECQL4	 nonsynonymous	 8q24.3	 0.000159	 0.00279553	 rs369852601	 0.001683	 RECQL4:NM_004260:exon10:c.C1625T:p.S542F	
25.6	 SDK1	 nonsynonymous	 7p22.2	 0.000077	 .	 rs374147324	 0.00005766	 SDK1:NM_152744:exon16:c.T2324C:p.I775T	
24.7	 SDK1	 nonsynonymous	 7p22.2	 0.000242	 0.00958466	 rs117504728	 0.002929	 SDK1:NM_152744:exon45:c.C6563A:p.T2188K	
23.4	 SDK1	 nonsynonymous	 7p22.2	 0.016454	 0.0179712	 rs61735696	 0.018	 SDK1:NM_152744:exon21:c.C3080T:p.T1027M	
35	 SLC5A4	 nonsynonymous	 22q12.3	 0.010303	 0.0113818	 rs62239049	 0.012	 SLC5A4:NM_014227:exon9:c.G1007A:p.R336H	
31	 SLC5A4	 nonsynonymous	 22q12.3	 0.010764	 0.0113818	 rs62239058	 0.012	 SLC5A4:NM_014227:exon5:c.G415T:p.E139X	
33	 SPATA20	 nonsynonymous	 17q21.33	 .	 .	 .	 0.00008776	 SPATA20:NM_001258372:exon11:c.C1487A:p.P496H	
29.7	 SPATA20	 nonsynonymous	 17q21.33	 .	 .	 .	 0.00006033	 SPATA20:NM_001258372:exon11:c.C1486A:p.P496T	
40	 TIAM2	 stopgain	 6q25.3	 0.016767	 0.028754	 rs116268446	 0.014	 TIAM2:NM_001010927:exon13:c.T1343A:p.L448X	
24.1	 TIAM2	 nonsynonymous	 6q25.3	 0.016456	 0.028754	 rs114239511	 0.014	 TIAM2:NM_001010927:exon13:c.G1340C:p.S447T	
26.8	 TMTC2	 nonsynonymous	 12q21.31	 .	 .	 rs200268500	 0.013	 TMTC2:NM_152588:exon2:c.C415G:p.R139G	
21.7	 TMTC2	 nonsynonymous	 12q21.31	 0.000692	 0.000798722	 rs117020331	 0.000906	 TMTC2:NM_152588:exon6:c.C1730T:p.T577M	
26.5	 TTN	 nonsynonymous	 2q31.2	 .	 0.000599042	 .	 0.0002315	 TTN:NM_003319:exon177:c.G70223A:p.R23408H	
23.8	 TTN	 nonsynonymous	 2q31.2	 .	 0.00199681	 rs369707906	 0.0008361	 TTN:NM_003319:exon154:c.G49727A:p.R16576H	
21	 TTN	 nonsynonymous	 2q31.2	 0.000081	 0.00199681	 rs368914555	 0.0008436	 TTN:NM_003319:exon154:c.C47839T:p.R15947W	
18.85	 TTN	 nonsynonymous	 2q31.2	 .	 0.00139776	 .	 0.0003395	 TTN:NM_003319:exon154:c.A47354G:p.D15785G	
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16.45	 TTN	 nonsynonymous	 2q31.2	 .	 0.00199681	 rs375627540	 0.000803	 TTN:NM_133378:exon72:c.G18068A:p.G6023D	
26.3	 USP43	 nonsynonymous	 17p13.1	 0.000744	 0.000998403	 rs191605843	 0.001804	 USP43:NM_001267576:exon15:c.C3196T:p.R1066C	
12.24	 USP43	 nonsynonymous	 17p13.1	 .	 .	 rs75472522	 0.008175	 USP43:NM_001267576:exon14:c.G2200C:p.G734R	
28.9	 VWA8	 nonsynonymous	 13q14.11	 .	 0.00399361	 rs200850191	 0.00135	 VWA8:NM_015058:exon43:c.A5351C:p.Q1784P	
23	 VWA8	 nonsynonymous	 13q14.11	 .	 0.00399361	 rs201654359	 0.00135	 VWA8:NM_015058:exon43:c.C5350A:p.Q1784K	
24.9	 ZNF880	 nonsynonymous	 19q13.41	 .	 .	 rs12975097	 0.023	 ZNF880:NM_001145434:exon4:c.G1238T:p.C413F	
17.36	 ZNF880	 nonsynonymous	 19q13.41	 .	 .	 rs76053634	 0.005047	 ZNF880:NM_001145434:exon4:c.A1217G:p.Q406R	
 
 
SC2 Compound heterozygous variants full list: 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
21.8	 ADCY8	 nonsynonymous	 8q24.22	 0.022085	 0.0179712	 rs2228949	 0.02	 ADCY8:NM_001115:exon1:c.G238A:p.A80T	
17.85	 ADCY8	 nonsynonymous	 8q24.22	 .	 .	 rs201402635	 0.002825	 ADCY8:NM_001115:exon3:c.G1120C:p.V374L	
25.4	 AGAP1	 nonsynonymous	 2q37.2	 .	 .	 .	 0.002459	 AGAP1:NM_014914:exon12:c.G1390C:p.D464H	
24.2	 AGAP1	 nonsynonymous	 2q37.2	 .	 .	 .	 0.0008237	 AGAP1:NM_014914:exon12:c.T1402C:p.S468P	
24.4	 C17orf96	 nonsynonymous	 17q12	 .	 0.00119808	 .	 0.002137	 C17orf96:NM_001130677:exon1:c.A326T:p.D109V	
20.2	 C17orf96	 nonsynonymous	 17q12	 .	 0.00119808	 .	 0.002174	 C17orf96:NM_001130677:exon1:c.G318T:p.E106D	
25.2	 CAPN5	 nonsynonymous	 11q13.5	 .	 .	 rs201256547	 0.005429	 CAPN5:NM_004055:exon2:c.T95C:p.F32S	
22.1	 CAPN5	 nonsynonymous	 11q13.5	 .	 0.000399361	 .	 0.00003295	 CAPN5:NM_004055:exon10:c.G1369A:p.V457I	
20.6	 CD24	 frameshift	
insertion	
Yq11.222	 .	 .	 .	 .	 CD24:NM_001291737:exon1:c.68_69insTTTTA:p.Q23fs	
20.3	 CD24	 nonsynonymous	 Yq11.222	 .	 .	 .	 0.022	 CD24:NM_001291737:exon1:c.C65T:p.T22M	
19.96	 CD24	 stopgain	 Yq11.222	 .	 .	 .	 .	 CD24:NM_001291737:exon1:c.C67T:p.Q23X	
14.32	 COL6A3	 nonsynonymous	 2q37.3	 0.001153	 0.0265575	 rs77181645	 0.023	 COL6A3:NM_057164:exon4:c.G1267T:p.A423S	
13.37	 COL6A3	 nonsynonymous	 2q37.3	 0.001153	 0.0265575	 rs113155945	 0.023	 COL6A3:NM_057164:exon4:c.G1198A:p.A400T	
24.1	 DENND2A	 nonsynonymous	 7q34	 .	 0.00698882	 rs374255633	 0.004011	 DENND2A:NM_015689:exon1:c.C890G:p.P297R	
20.8	 DENND2A	 nonsynonymous	 7q34	 .	 0.00698882	 rs200642129	 0.003995	 DENND2A:NM_015689:exon1:c.C54G:p.S18R	
29.1	 DIEXF	 nonsynonymous	 1q32.2	 .	 0.000599042	 .	 0.0002553	 DIEXF:NM_014388:exon7:c.G1135T:p.D379Y	
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18.17	 DIEXF	 nonsynonymous	 1q32.2	 .	 0.000599042	 .	 0.0002718	 DIEXF:NM_014388:exon4:c.G463A:p.E155K	
24.4	 DMKN	 nonsynonymous	 19q13.12	 .	 .	 .	 0.00000823
6	
DMKN:NM_001126056:exon2:c.T551C:p.F184S	
14.43	 DMKN	 nonsynonymous	 19q13.12	 .	 .	 rs148799704	 .	 DMKN:NM_001126057:exon5:c.G839A:p.G280D	
15.16	 FAM170A	 nonsynonymous	 5q23.1	 .	 0.00259585	 rs199769553	 0.001464	 FAM170A:NM_001163991:exon2:c.C167G:p.S56C	
10.53	 FAM170A	 nonsynonymous	 5q23.1	 .	 0.00259585	 rs201150712	 0.001464	 FAM170A:NM_001163991:exon2:c.C119T:p.A40V	
15.71	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.G2346C:p.E782D	
15.12	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.G2344C:p.E782Q	
10.89	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.A2333C:p.Q778P	
15.1	 FLG	 nonsynonymous	 1q21.3	 .	 0.000199681	 .	 0.0003295	 FLG:NM_002016:exon3:c.G5332T:p.A1778S	
12.02	 FLG	 nonsynonymous	 1q21.3	 0.001384	 0.00199681	 rs150251062	 0.001911	 FLG:NM_002016:exon3:c.G3896A:p.R1299Q	
32	 GPR124	 nonsynonymous	 8p11.23	 0.000615	 .	 rs200841231	 0.0007335	 GPR124:NM_032777:exon9:c.C1204T:p.R402W	
24.5	 GPR124	 nonsynonymous	 8p11.23	 0.000077	 0.00579073	 rs200624144	 0.002908	 GPR124:NM_032777:exon12:c.C1648T:p.P550S	
22.9	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 rs201635586	 .	 GPRIN1:NM_052899:exon2:c.A698T:p.E233V	
19.14	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 rs199714570	 .	 GPRIN1:NM_052899:exon2:c.G707T:p.G236V	
13.71	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 .	 .	 GPRIN1:NM_052899:exon2:c.T713C:p.L238S	
18.1	 IPP	 nonsynonymous	 1p34.1	 .	 0.000199681	 .	 0.0002224	 IPP:NM_001145349:exon4:c.G802C:p.E268Q	
11.25	 IPP	 nonsynonymous	 1p34.1	 .	 0.000199681	 .	 0.0002224	 IPP:NM_001145349:exon4:c.G788A:p.C263Y	
15.94	 KCNN3	 nonsynonymous	 1q21.3	 .	 .	 .	 0.025	 KCNN3:NM_001204087:exon1:c.T197A:p.L66H	
11.71	 KCNN3	 nonsynonymous	 1q21.3	 .	 .	 .	 0.023	 KCNN3:NM_001204087:exon1:c.C191A:p.P64Q	
28	 KIAA0226	 nonsynonymous	 3q29	 .	 .	 rs80094312	 0.027	 KIAA0226:NM_014687:exon13:c.G1954T:p.V652F	
24.8	 KIAA0226	 nonsynonymous	 3q29	 .	 .	 .	 0.0001574	 KIAA0226:NM_014687:exon20:c.C2828G:p.A943G	
32	 L3MBTL2	 nonsynonymous	 22q13.2	 .	 .	 .	 0.007265	 L3MBTL2:NM_031488:exon6:c.G697C:p.A233P	
23.9	 L3MBTL2	 nonsynonymous	 22q13.2	 .	 .	 rs200870155	 0.026	 L3MBTL2:NM_031488:exon8:c.T905G:p.V302G	
23	 MTUS2	 nonsynonymous	 13q12.3	 0.028401	 0.0155751	 rs61999321	 0.026	 MTUS2:NM_001033602:exon5:c.C2870T:p.T957M	
16.08	 MTUS2	 nonsynonymous	 13q12.3	 0.00008	 0.00179712	 rs376426921	 0.0004836	 MTUS2:NM_015233:exon3:c.C316G:p.R106G	
31	 MYO1E	 nonsynonymous	 15q22.2	 0.001388	 0.00179712	 rs147579391	 0.002413	 MYO1E:NM_004998:exon27:c.C3146A:p.P1049H	
25	 MYO1E	 nonsynonymous	 15q22.2	 0.001157	 0.00199681	 rs141565214	 0.002496	 MYO1E:NM_004998:exon7:c.A554G:p.D185G	
24.1	 MYOCD	 nonsynonymous	 17p12	 .	 0.00159744	 rs369225309	 0.002557	 MYOCD:NM_001146312:exon11:c.G2074A:p.D692N	
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19.18	 MYOCD	 nonsynonymous	 17p12	 .	 0.00159744	 rs374404083	 0.002216	 MYOCD:NM_153604:exon11:c.A2081G:p.D694G	
10.14	 MYOCD	 nonsynonymous	 17p12	 .	 0.00239617	 rs193131989	 0.002034	 MYOCD:NM_153604:exon13:c.C2376A:p.S792R	
32	 NEB	 nonsynonymous	 2q23.3	 .	 .	 .	 .	 NEB:NM_004543:exon89:c.G13328T:p.S4443I	
29.5	 NEB	 nonsynonymous	 2q23.3	 .	 .	 rs370790324	 0.00000827
6	
NEB:NM_001164507:exon47:c.G6025C:p.D2009H	
22.9	 NEB	 nonsynonymous	 2q23.3	 .	 .	 rs375377794	 .	 NEB:NM_001164508:exon143:c.A21317G:p.K7106R	
24.9	 NFKBIZ	 splicing	 3q12.3	 .	 .	 .	 .	 NM_001005474:exon11:c.1635+1G&gt;C	
23.5	 NFKBIZ	 nonsynonymous	 3q12.3	 .	 .	 .	 .	 NFKBIZ:NM_031419:exon10:c.C1931G:p.A644G	
19.97	 NFKBIZ	 nonsynonymous	 3q12.3	 .	 .	 .	 .	 NFKBIZ:NM_031419:exon10:c.G1930A:p.A644T	
10.79	 NFKBIZ	 splicing	 3q12.3	 .	 .	 .	 .	 NM_001005474:exon11:c.1635+2-&gt;TTAATAACC	
23.2	 NLRX1	 nonsynonymous	 11q23.3	 .	 0.0163738	 rs200846476	 0.00832	 NLRX1:NM_001282143:exon7:c.C2035G:p.L679V	
12.58	 NLRX1	 nonsynonymous	 11q23.3	 .	 .	 .	 0.00004942	 NLRX1:NM_001282143:exon6:c.G1129A:p.V377I	
17.24	 OVGP1	 nonsynonymous	 1p13.2	 .	 .	 .	 .	 OVGP1:NM_002557:exon11:c.G1594C:p.V532L	
13.21	 OVGP1	 nonsynonymous	 1p13.2	 .	 .	 rs74322126	 .	 OVGP1:NM_002557:exon11:c.A1565C:p.K522T	
25	 P2RY4	 nonsynonymous	 Xq13.1	 .	 .	 rs202027224	 0.002463	 P2RY4:NM_002565:exon1:c.G674C:p.R225P	
23.5	 P2RY4	 nonsynonymous	 Xq13.1	 .	 .	 .	 0.0003464	 P2RY4:NM_002565:exon1:c.G677C:p.R226P	
17.86	 RHOT2	 nonsynonymous	 16p13.3	 .	 0.00559105	 rs117897697	 0.001481	 RHOT2:NM_138769:exon13:c.G1060A:p.G354S	
12.16	 RHOT2	 nonframeshift	
deletion	
16p13.3	 .	 0.00559105	 rs145581089	 0.001483	 RHOT2:NM_138769:exon18:c.1689_1691del:p.563_564
del	
27.8	 RNF213	 nonsynonymous	 17q25.3	 .	 0.000199681	 rs202143169	 0.0002636	 RNF213:NM_001256071:exon29:c.G7583A:p.R2528Q	
24.6	 RNF213	 nonsynonymous	 17q25.3	 0.001	 0.000399361	 rs141301945	 0.000626	 RNF213:NM_001256071:exon57:c.C13913T:p.T4638I	
19.68	 SACS	 nonsynonymous	 13q12.12	 0.000154	 0.000798722	 rs376680832	 0.0008813	 SACS:NM_001278055:exon8:c.T5020C:p.C1674R	
11.49	 SACS	 nonsynonymous	 13q12.12	 0.000461	 0.000199681	 rs149638449	 0.0006095	 SACS:NM_001278055:exon6:c.G1444A:p.A482T	
23.3	 SCMH1	 nonsynonymous	 1p34.2	 .	 .	 .	 .	 SCMH1:NM_001172222:exon6:c.T854C:p.I285T	
15.8	 SCMH1	 nonsynonymous	 1p34.2	 .	 0.000998403	 .	 0.0009637	 SCMH1:NM_001172221:exon13:c.A1496G:p.D499G	
29	 SDK1	 nonsynonymous	 7p22.2	 0.008535	 0.0125799	 rs34775958	 0.00775	 SDK1:NM_152744:exon6:c.C950T:p.A317V	
13.08	 SDK1	 nonsynonymous	 7p22.2	 0.002153	 0.00878594	 rs117824452	 0.006244	 SDK1:NM_152744:exon7:c.C1100T:p.P367L	
24.4	 SLFN5	 nonsynonymous	 17q12	 0.008227	 0.0251597	 rs117695297	 0.017	 SLFN5:NM_144975:exon5:c.C1963G:p.R655G	
13.19	 SLFN5	 nonsynonymous	 17q12	 .	 0.00259585	 .	 0.001787	 SLFN5:NM_144975:exon5:c.G2138A:p.R713H	
26.9	 SORBS1	 nonsynonymous	 10q24.1	 0.000077	 .	 rs372968425	 0.00000823 SORBS1:NM_001034954:exon28:c.G3292T:p.G1098W	
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6	
24.4	 SORBS1	 nonsynonymous	 10q24.1	 .	 0.00159744	 .	 0.00104	 SORBS1:NM_001034954:exon28:c.C3095G:p.S1032C	
16.9	 SSPO	 frameshift	
deletion	
7q36.1	 .	 .	 .	 0.0003453	 SSPO:NM_198455:exon69:c.9782delG:p.W3261fs	
13.01	 SSPO	 nonsynonymous	 7q36.1	 0.014379	 0.00858626	 rs189214453	 0.017	 SSPO:NM_198455:exon50:c.G7442A:p.R2481Q	
13.88	 TRAK1	 nonframeshift	
insertion	




3p22.1	 .	 .	 .	 .	 TRAK1:NM_001265609:exon13:c.1841_1842insGGAGG
A:p.T614delinsTEE	
23.1	 TTN	 nonsynonymous	 2q31.2	 0.017343	 0.00938498	 rs72648987	 0.016	 TTN:NM_133378:exon87:c.C22204T:p.R7402C	
19.93	 TTN	 nonsynonymous	 2q31.2	 0.015037	 0.00738818	 rs56307213	 0.015	 TTN:NM_003319:exon154:c.G52588C:p.D17530H	
19	 TTN	 nonsynonymous	 2q31.2	 0.02046	 0.0105831	 rs72650006	 0.019	 TTN:NM_133378:exon102:c.A26080T:p.T8694S	
25.2	 UNC13D	 nonsynonymous	 17q25.1	 .	 .	 .	 0.00002471	 UNC13D:NM_199242:exon13:c.G1076T:p.R359L	
21.6	 UNC13D	 nonsynonymous	 17q25.1	 0.016146	 0.0155751	 rs9904366	 0.016	 UNC13D:NM_199242:exon3:c.G175A:p.A59T	
16.45	 YBX3	 nonsynonymous	 12p13.2	 .	 0.000199681	 .	 .	 YBX3:NM_001145426:exon1:c.G208C:p.A70P	
10.38	 YBX3	 nonsynonymous	 12p13.2	 .	 .	 .	 .	 YBX3:NM_001145426:exon1:c.C200A:p.T67N	
 
 
SC3 Compound heterozygous variants full list: 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
32	 ATG2B	 nonsynonymous	 14q32.2	 0.00025	 0.00299521	 rs78100888	 0.001696	 ATG2B:NM_018036:exon2:c.G320A:p.R107H	
16.34	 ATG2B	 nonsynonymous	 14q32.2	 0.000231	 0.000599042	 rs146341899	 0.0007907	 ATG2B:NM_018036:exon30:c.G4397T:p.G1466V	
14.12	 CASP6	 nonsynonymous	 4q25	 .	 .	 .	 .	 CASP6:NM_001226:exon1:c.C22G:p.R8G	
13.98	 CASP6	 nonsynonymous	 4q25	 .	 .	 .	 .	 CASP6:NM_001226:exon1:c.G17A:p.G6E	
11.51	 CASP6	 frameshift	
insertion	
4q25	 .	 .	 .	 .	 CASP6:NM_001226:exon1:c.16_17insC:p.G6fs	
28.6	 COG1	 nonsynonymous	 17q25.1	 0.013247	 0.00479233	 rs142719529	 0.011	 COG1:NM_018714:exon1:c.G58C:p.A20P	
25.5	 COG1	 nonsynonymous	 17q25.1	 .	 .	 rs201454609	 0.00256	 COG1:NM_018714:exon2:c.G547C:p.A183P	
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24	 DST	 nonsynonymous	 6p12.1	 .	 0.000599042	 rs200345187	 0.0004633	 DST:NM_015548:exon43:c.A8784C:p.Q2928H	
10.93	 DST	 nonsynonymous	 6p12.1	 .	 .	 .	 .	 DST:NM_015548:exon84:c.G15424A:p.G5142S	
23.8	 EDEM3	 splicing	 1q25.3	 0.000879	 0.0119808	 rs200358232	 0.005758	 NM_025191:exon18:c.1846-5-&gt;T	
15.42	 EDEM3	 nonsynonymous	 1q25.3	 .	 0.0119808	 rs193034365	 0.005701	 EDEM3:NM_025191:exon1:c.A60C:p.R20S	
24.2	 EPPK1	 nonsynonymous	 8q24.3	 0.013834	 0.00738818	 rs116925616	 0.014	 EPPK1:NM_031308:exon2:c.C3196T:p.R1066C	
14.12	 EPPK1	 nonsynonymous	 8q24.3	 .	 .	 rs191805316	 0.0001246	 EPPK1:NM_031308:exon2:c.G6644C:p.R2215P	
21	 FAM71E2	 frameshift	
insertion	
19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.2336_2337insCTGG
GACCCC:p.P779fs	
14.88	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.T2338A:p.W780R	
10.89	 FAM71E2	 nonsynonymous	 19q13.42	 .	 .	 .	 .	 FAM71E2:NM_001145402:exon9:c.A2333C:p.Q778P	
34	 FANCM	 nonsynonymous	 14q21.2	 .	 .	 .	 0.00002471	 FANCM:NM_020937:exon10:c.G1706A:p.R569H	
23.2	 FANCM	 nonsynonymous	 14q21.2	 .	 .	 .	 0.00009884	 FANCM:NM_020937:exon13:c.A2258G:p.D753G	
24.4	 GPAM	 nonsynonymous	 10q25.2	 .	 .	 rs199856746	 0.00924	 GPAM:NM_001244949:exon15:c.G1469T:p.C490F	
23.3	 GPAM	 frameshift	
insertion	
10q25.2	 .	 .	 .	 .	 GPAM:NM_001244949:exon15:c.1469_1470insTTTTT:p.
C490fs	
22.9	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 rs201635586	 .	 GPRIN1:NM_052899:exon2:c.A698T:p.E233V	
19.14	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 rs199714570	 .	 GPRIN1:NM_052899:exon2:c.G707T:p.G236V	
13.71	 GPRIN1	 nonsynonymous	 5q35.2	 .	 .	 .	 .	 GPRIN1:NM_052899:exon2:c.T713C:p.L238S	
24.7	 ITPR1	 nonsynonymous	 3p26.1	 .	 0.00119808	 .	 0.0007689	 ITPR1:NM_001168272:exon29:c.G3565A:p.V1189M	
15.83	 ITPR1	 nonsynonymous	 3p26.1	 .	 .	 .	 0.007936	 ITPR1:NM_001168272:exon28:c.G3458A:p.G1153E	
24.2	 KCNE1L	 nonsynonymous	 Xq23	 .	 .	 .	 0.00008777	 KCNE1L:NM_012282:exon1:c.G88T:p.G30C	
22.9	 KCNE1L	 nonsynonymous	 Xq23	 .	 .	 rs200894798	 0.009642	 KCNE1L:NM_012282:exon1:c.G87T:p.L29F	
16.51	 MUC6	 nonsynonymous	 11p15.5	 .	 .	 rs75538227	 0.003782	 MUC6:NM_005961:exon31:c.C5765T:p.T1922I	
15.35	 MUC6	 nonsynonymous	 11p15.5	 .	 .	 .	 0.0002386	 MUC6:NM_005961:exon7:c.G854C:p.G285A	
24.9	 NFKBIZ	 splicing	 3q12.3	 .	 .	 .	 .	 NM_001005474:exon11:c.1635+1G&gt;C,NM_031419:e
xon10:c.1935+1G&gt;C	
23.5	 NFKBIZ	 nonsynonymous	 3q12.3	 .	 .	 .	 .	 NFKBIZ:NM_031419:exon10:c.C1931G:p.A644G	
19.97	 NFKBIZ	 nonsynonymous	 3q12.3	 .	 .	 .	 .	 NFKBIZ:NM_031419:exon10:c.G1930A:p.A644T	
24.2	 OR9A2	 nonsynonymous	 7q34	 .	 0.000199681	 rs56540628	 0.00014	 OR9A2:NM_001001658:exon1:c.G349A:p.D117N	
18.78	 OR9A2	 nonframeshift	
deletion	
7q34	 .	 .	 .	 0.00001647	 OR9A2:NM_001001658:exon1:c.70_72del:p.24_24del	
25	 P2RY4	 nonsynonymous	 Xq13.1	 .	 .	 rs202027224	 0.002463	 P2RY4:NM_002565:exon1:c.G674C:p.R225P	
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23.5	 P2RY4	 nonsynonymous	 Xq13.1	 .	 .	 .	 0.0003464	 P2RY4:NM_002565:exon1:c.G677C:p.R226P	
29.1	 SCNN1A	 nonsynonymous	 12p13.31	 0.017453	 0.0133786	 rs5742912	 0.018	 SCNN1A:NM_001159576:exon9:c.T1654C:p.W552R	
26.9	 SCNN1A	 nonsynonymous	 12p13.31	 .	 .	 rs201553658	 0.0009566	 SCNN1A:NM_001159576:exon3:c.G1018C:p.A340P	
26.8	 TMTC2	 nonsynonymous	 12q21.31	 .	 .	 rs200268500	 0.013	 TMTC2:NM_152588:exon2:c.C415G:p.R139G	
26.4	 TMTC2	 nonsynonymous	 12q21.31	 .	 .	 .	 0.001648	 TMTC2:NM_152588:exon2:c.T410G:p.V137G	
18.07	 TTN	 nonsynonymous	 2q31.2	 .	 0.000998403	 rs141142920	 0.0003542	 TTN:NM_003319:exon27:c.G6221T:p.R2074L	
15.77	 TTN	 nonsynonymous	 2q31.2	 .	 0.000998403	 rs372782502	 0.0003641	 TTN:NM_003319:exon154:c.T42902C:p.V14301A	
14.26	 TTN	 nonsynonymous	 2q31.2	 0.006707	 0.00439297	 rs72648927	 0.007397	 TTN:NM_133378:exon48:c.C11252G:p.P3751R	
24.5	 UTP23	 nonsynonymous	 8q24.11	 .	 .	 .	 .	 UTP23:NM_032334:exon1:c.T65G:p.V22G	
23.9	 UTP23	 nonsynonymous	 8q24.11	 .	 .	 .	 0.00001934	 UTP23:NM_032334:exon1:c.C67G:p.R23G	
 
 
F9 Compound heterozygous variants full list: 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
24.6	 CUL9	 nonsynonymous	 6p21.1	 0.000077	 .	 rs149800737	 0.00002471	 CUL9:NM_015089:exon12:c.C2882T:p.A961V	
23.9	 CUL9	 nonsynonymous	 6p21.1	 .	 .	 .	 .	 CUL9:NM_015089:exon12:c.G2881T:p.A961S	
17.01	 CUL9	 nonsynonymous	 6p21.1	 0.006612	 0.00219649	 rs145911635	 0.006383	 CUL9:NM_015089:exon7:c.G1849A:p.E617K	
33	 DCAF15	 frameshift	
insertion	
19p13.12	 .	 .	 .	 .	 DCAF15:NM_138353:exon9:c.1440dupG:p.E480fs	
15.78	 DCAF15	 nonsynonymous	 19p13.12	 .	 .	 .	 .	 DCAF15:NM_138353:exon9:c.G1438C:p.E480Q	
40	 DYNC2H1	 stopgain	 11q22.3	 .	 .	 .	 .	 DYNC2H1:NM_001080463:exon26:c.C4018T:p.Q1340X	
22.7	 DYNC2H1	 nonsynonymous	 11q22.3	 0.011624	 0.00439297	 rs144717489	 0.013	 DYNC2H1:NM_001377:exon89:c.G12865C:p.G4289R	
24.6	 HEXDC	 nonsynonymous	 17q25.3	 0.003336	 0.00539137	 rs140743740	 0.001441	 HEXDC:NM_173620:exon12:c.G1454A:p.C485Y	
22.7	 HEXDC	 nonsynonymous	 17q25.3	 0.003179	 0.00539137	 rs150076334	 0.001425	 HEXDC:NM_173620:exon12:c.C1526A:p.A509E	
36	 IGSF10	 stopgain	 3q25.1	 0.002768	 0.00279553	 rs79363433	 0.002627	 IGSF10:NM_178822:exon4:c.G4804T:p.E1602X	
35	 IGSF10	 stopgain	 3q25.1	 .	 .	 .	 .	 IGSF10:NM_178822:exon2:c.G220T:p.E74X	
25	 IGSF10	 nonsynonymous	 3q25.1	 0.007996	 0.0121805	 rs3732775	 0.01	 IGSF10:NM_001178145:exon2:c.A1507T:p.R503W	
28.9	 LAMA5	 nonsynonymous	 20q13.33	 0.000077	 .	 rs371144423	 0.00006636	 LAMA5:NM_005560:exon32:c.G4037A:p.C1346Y	
13.41	 LAMA5	 nonsynonymous	 20q13.33	 .	 .	 .	 .	 LAMA5:NM_005560:exon80:c.G10995A:p.M3665I	
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25.9	 LTBP1	 nonsynonymous	 2p22.3	 .	 .	 .	 .	 LTBP1:NM_000627:exon20:c.T2692A:p.S898T	
24.2	 LTBP1	 nonsynonymous	 2p22.3	 0.004844	 0.00239617	 rs141080282	 0.004596	 LTBP1:NM_001166264:exon21:c.G2885A:p.R962Q	
22.9	 MUC16	 nonsynonymous	 19p13.2	 0.021355	 0.0131789	 rs114676657	 0.022	 MUC16:NM_024690:exon36:c.G38821A:p.E12941K	
19.34	 MUC16	 nonsynonymous	 19p13.2	 0.004124	 0.00559105	 rs114920126	 0.002628	 MUC16:NM_024690:exon70:c.G41972A:p.R13991Q	
28.3	 NEB	 nonsynonymous	 2q23.3	 0.000583	 0.000199681	 rs111517514	 0.000447	 NEB:NM_004543:exon104:c.T15023C:p.L5008P	
20.3	 NEB	 nonsynonymous	 2q23.3	 0.013294	 0.00878594	 rs149025191	 0.009322	 NEB:NM_004543:exon71:c.G10383C:p.M3461I	
24.9	 NOD2	 nonsynonymous	 16q12.1	 .	 0.000399361	 .	 0.0001647	 NOD2:NM_001293557:exon3:c.C1540T:p.R514W	
23.2	 NOD2	 nonsynonymous	 16q12.1	 0.000385	 0.000199681	 rs5743276	 0.0003542	 NOD2:NM_001293557:exon3:c.C1969T:p.R657W	
21	 PAQR6	 nonsynonymous	 1q22	 0.007689	 0.00539137	 rs34514408	 0.007333	 PAQR6:NM_001272109:exon4:c.G4T:p.A2S	
16.77	 PAQR6	 nonsynonymous	 1q22	 0.007843	 0.00539137	 rs62001925	 0.007392	 PAQR6:NM_001272109:exon4:c.C44T:p.S15L	
18.12	 PCDHGB1	 nonsynonymous	 5q31.3	 0.029647	 0.0235623	 rs77250251	 0.028	 PCDHGB1:NM_018922:exon1:c.A1195G:p.K399E	
10.98	 PCDHGB1	 nonsynonymous	 5q31.3	 0.029952	 0.0235623	 rs62378414	 0.028	 PCDHGB1:NM_018922:exon1:c.G557T:p.S186I	
26.1	 PCNT	 nonsynonymous	 21q22.3	 0.006075	 0.00459265	 rs35881595	 0.00277	 PCNT:NM_006031:exon39:c.T8924C:p.L2975P	
23.3	 PCNT	 nonsynonymous	 21q22.3	 0.006766	 0.00459265	 rs35848602	 0.002817	 PCNT:NM_006031:exon31:c.C6986G:p.P2329R	
28.4	 POLR3B	 nonsynonymous	 12q23.3	 .	 .	 .	 0.001602	 POLR3B:NM_001160708:exon13:c.C940T:p.L314F	
25.1	 POLR3B	 nonsynonymous	 12q23.3	 .	 .	 .	 0.0003229	 POLR3B:NM_001160708:exon13:c.A933T:p.L311F	
15.77	 RPGR	 nonsynonymous	 Xp11.4	 .	 .	 .	 0.0004837	 RPGR:NM_001034853:exon15:c.A2801G:p.E934G	
12.23	 RPGR	 nonsynonymous	 Xp11.4	 .	 .	 .	 .	 RPGR:NM_001034853:exon15:c.G2795A:p.G932E	
17.44	 SHROOM3	 nonsynonymous	 4q21.1	 0.012225	 0.00658946	 rs76656494	 0.012	 SHROOM3:NM_020859:exon5:c.A1691C:p.E564A	
13.84	 SHROOM3	 nonsynonymous	 4q21.1	 .	 .	 .	 0.00005026	 SHROOM3:NM_020859:exon5:c.G2651T:p.R884L	
13.36	 SHROOM3	 nonsynonymous	 4q21.1	 0.005297	 0.00399361	 rs147732653	 0.006311	 SHROOM3:NM_020859:exon5:c.C3035A:p.T1012N	
15.83	 SPINT2	 nonsynonymous	 19q13.2	 0.001538	 0.000798722	 rs143567268	 0.001631	 SPINT2:NM_001166103:exon6:c.G544A:p.G182R	
14.54	 SPINT2	 nonsynonymous	 19q13.2	 0.024527	 0.0177716	 rs11548457	 0.028	 SPINT2:NM_001166103:exon6:c.G427C:p.V143L	
16.49	 SSH1	 nonsynonymous	 12q24.11	 0.000077	 0.00898562	 rs117900986	 0.00229	 SSH1:NM_001161331:exon13:c.A1895G:p.N632S	
15.93	 SSH1	 nonsynonymous	 12q24.11	 .	 .	 .	 .	 SSH1:NM_018984:exon15:c.C1901G:p.A634G	
16.09	 SSPO	 nonsynonymous	 7q36.1	 0.029224	 0.0161741	 rs117048984	 0.017	 SSPO:NM_198455:exon2:c.A230G:p.Y77C	
14.51	 SSPO	 nonsynonymous	 7q36.1	 0.021425	 0.0249601	 rs73727627	 0.009719	 SSPO:NM_198455:exon63:c.C9187T:p.R3063C	
12.42	 SSPO	 nonsynonymous	 7q36.1	 0.018129	 0.0285543	 rs58369703	 0.012	 SSPO:NM_198455:exon91:c.G13139C:p.R4380P	
10.31	 SSPO	 nonsynonymous	 7q36.1	 0.016326	 0.0249601	 rs55857423	 0.00791	 SSPO:NM_198455:exon91:c.G13195A:p.A4399T	
24	 TAS2R31	 nonsynonymous	 12p13.2	 0.014555	 0.014377	 rs139069360	 0.015	 TAS2R31:NM_176885:exon1:c.G843T:p.W281C	
21	 TAS2R31	 nonsynonymous	 12p13.2	 0.01161	 0.0101837	 rs116926686	 0.014	 TAS2R31:NM_176885:exon1:c.A711T:p.L237F	
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22.9	 TTN	 nonsynonymous	 2q31.2	 0.000082	 .	 rs375422359	 0.00001655	 TTN:NM_003319:exon154:c.G55303A:p.E18435K	
22.2	 TTN	 nonsynonymous	 2q31.2	 0.015796	 0.0231629	 rs55675869	 0.028	 TTN:NM_003319:exon184:c.G72901A:p.V24301I	
15.09	 TTN	 nonsynonymous	 2q31.2	 0.015783	 0.0223642	 rs3813245	 0.026	 TTN:NM_003319:exon154:c.T49525C:p.Y16509H	
15	 TTN	 nonsynonymous	 2q31.2	 0.015959	 0.0223642	 rs3731745	 0.026	 TTN:NM_003319:exon154:c.T52070C:p.I17357T	
14.22	 TTN	 nonsynonymous	 2q31.2	 0.015579	 0.0223642	 rs72648257	 0.026	 TTN:NM_003319:exon170:c.A67852G:p.S22618G	
13.59	 TTN	 nonsynonymous	 2q31.2	 0.015659	 0.0295527	 rs2303832	 0.029	 TTN:NM_003319:exon105:c.A25928T:p.K8643I	
10.65	 TTN	 nonsynonymous	 2q31.2	 0.015832	 0.0223642	 rs3813246	 0.026	 TTN:NM_003319:exon154:c.A50084G:p.N16695S	
10.46	 TTN	 nonsynonymous	 2q31.2	 .	 .	 .	 .	 TTN:NM_133379:exon46:c.T10975G:p.F3659V	
12.58	 ZNF469	 nonframeshift	
deletion	
16q24.2	 .	 0.00179712	 .	 0.003504	 ZNF469:NM_001127464:exon2:c.9010_9024del:p.3004
_3008del	
12.24	 ZNF469	 nonsynonymous	 16q24.2	 .	 .	 .	 .	 ZNF469:NM_001127464:exon1:c.A3062C:p.E1021A	
 
F11 Compound heterozygous variants full list: 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
12.36	 CNBD1	 nonframeshift	
deletion	
8q21.3	 0.013658	 0.00519169	 rs201174674	 0.009674	 CNBD1:NM_173538:exon9:c.1116_1118del:p.372
_373del	
15.72	 CNBD1	 nonsynonymous	 8q21.3	 0.021681	 0.0215655	 rs16894901	 0.006598	 CNBD1:NM_173538:exon3:c.C205A:p.Q69K	
26.2	 CYP1A1	 nonsynonymous	 15q24.1	 0.001155	 0.000798722	 rs4987133	 0.001252	 CYP1A1:NM_000499:exon3:c.T857C:p.I286T	
26.2	 CYP1A1	 nonsynonymous	 15q24.1	 0.001155	 0.000599042	 rs61747605	 0.001186	 CYP1A1:NM_000499:exon2:c.C712T:p.P238S	
24.2	 DNAH2	 nonsynonymous	 17p13.1	 0.021913	 0.0127796	 rs79350244	 0.023	 DNAH2:NM_020877:exon78:c.A12184C:p.I4062L	
19.64	 DNAH2	 nonsynonymous	 17p13.1	 0.021759	 0.0127796	 rs117465420	 0.023	 DNAH2:NM_020877:exon79:c.A12303T:p.L4101F	
15.76	 DNAH2	 nonsynonymous	 17p13.1	 0.008304	 0.00319489	 rs117487916	 0.008475	 DNAH2:NM_020877:exon37:c.G5986A:p.D1996N	
32	 EPPK1	 nonsynonymous	 8q24.3	 0.006663	 0.00359425	 rs140364895	 0.006588	 EPPK1:NM_031308:exon2:c.C1234T:p.R412W	
14.12	 EPPK1	 nonsynonymous	 8q24.3	 .	 .	 rs191805316	 0.0001246	 EPPK1:NM_031308:exon2:c.G6644C:p.R2215P	
24.2	 FLG	 nonsynonymous	 1q21.3	 0.017684	 0.0249601	 rs36006086	 0.023	 FLG:NM_002016:exon3:c.C5671T:p.R1891W	
22.3	 FLG	 nonsynonymous	 1q21.3	 0.004306	 0.00479233	 rs12750571	 0.004958	 FLG:NM_002016:exon3:c.C4309T:p.R1437C	
17.89	 FLG	 nonsynonymous	 1q21.3	 0.01753	 0.0249601	 rs35621145	 0.023	 FLG:NM_002016:exon3:c.C9808T:p.R3270C	
12.76	 FLG	 nonsynonymous	 1q21.3	 0.017684	 0.0249601	 rs12750081	 0.023	 FLG:NM_002016:exon3:c.C4568T:p.T1523I	
12.11	 FLG	 nonsynonymous	 1q21.3	 0.017607	 0.0247604	 rs71626704	 0.023	 FLG:NM_002016:exon3:c.C6045A:p.D2015E	
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24.9	 NFKBIZ	 splicing	 3q12.3	 .	 .	 .	 .	 NM_001005474:exon11:c.1635+1G&amp;amp;gt;
C	
23.5	 NFKBIZ	 nonsynonymous	 3q12.3	 .	 .	 .	 .	 NFKBIZ:NM_031419:exon10:c.C1931G:p.A644G	
19.97	 NFKBIZ	 nonsynonymous	 3q12.3	 .	 .	 .	 .	 NFKBIZ:NM_031419:exon10:c.G1930A:p.A644T	
29.2	 OR8D4	 frameshift	
insertion	
11q24.1	 0.017891	 0.0231629	 rs201238608	 0.005518	 OR8D4:NM_001005197:exon1:c.304dupT:p.L101f
s	
23	 OR8D4	 nonsynonymous	 11q24.1	 0.01669	 0.0227636	 rs79430449	 0.005222	 OR8D4:NM_001005197:exon1:c.G716A:p.S239N	
21.1	 RIMS2	 nonsynonymous	 8q22.3	 0.003423	 0.00199681	 rs182266368	 0.004304	 RIMS2:NM_014677:exon15:c.G2479A:p.D827N	
16.12	 RIMS2	 nonsynonymous	 8q22.3	 .	 .	 .	 .	 RIMS2:NM_001282881:exon1:c.T17G:p.L6W	
28.4	 TCTN3	 nonsynonymous	 10q24.1	 .	 .	 .	 .	 TCTN3:NM_001143973:exon2:c.C368G:p.P123R	
11.38	 TCTN3	 nonsynonymous	 10q24.1	 0.004921	 0.00359425	 rs141088838	 0.007182	 TCTN3:NM_015631:exon9:c.G1030A:p.G344R	
27.1	 USH2A	 nonsynonymous	 1q41	 0.021529	 0.00758786	 rs41277212	 0.022	 USH2A:NM_206933:exon35:c.A6713C:p.E2238A	
26.5	 USH2A	 nonsynonymous	 1q41	 .	 .	 .	 0.0000082
37	
USH2A:NM_007123:exon13:c.G2384A:p.C795Y	
27.3	 XIRP2	 nonsynonymous	 2q24.3	 0.002507	 0.00439297	 rs143400009	 0.006258	 XIRP2:NM_001199144:exon7:c.T748C:p.S250P	
23.2	 XIRP2	 nonsynonymous	 2q24.3	 0.017556	 0.0235623	 rs16853333	 0.022	 XIRP2:NM_001199144:exon7:c.G9464A:p.G3155E	
 
 
F12 Compound heterozygous variants full list: 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
11.73	 ABCA13	 nonframeshift	
deletion	
7p12.3	 0.012644	 0.00579073	 rs200644776	 0.01	 ABCA13:NM_152701:exon18:c.7911_7913del:p.2637_
2638del	
36	 AFF1	 stopgain	 4q21.3	 .	 .	 .	 .	 AFF1:NM_005935:exon3:c.C1031G:p.S344X	
35	 ANGEL1	 frameshift	
deletion	
14q24.3	 .	 .	 .	 .	 ANGEL1:NM_015305:exon5:c.1091delT:p.V364fs	
16.85	 ANGPT1	 splicing	 8q23.1	 .	 .	 rs149628829	 0.007953	 NM_001146:exon6:c.809-4-&amp;gt;T	
37	 ARL6IP4	 stopgain	 12q24.31	 .	 .	 .	 0.0008843	 ARL6IP4:NM_001002251:exon1:c.G472T:p.E158X	
13.3	 CBL	 nonframeshift	
insertion	
11q23.3	 .	 0.00559105	 .	 0.0005325	 CBL:NM_005188:exon1:c.105_106insCAC:p.P35delinsP
H	




Yq11.222	 .	 .	 .	 .	 CD24:NM_001291737:exon1:c.68_69insTTTTA:p.Q23fs	
36	 CEP290	 frameshift	
deletion	








4q24	 .	 .	 .	 0.0007379	 CXXC4:NM_025212:exon2:c.495_496insGGC:p.S166de
linsGS	
35	 DNAH17	 nonsynonymous	 17q25.3	 .	 .	 .	 .	 DNAH17:NM_173628:exon66:c.G10675A:p.E3559K	
26.2	 DPYSL4	 .	 10q26.3	 0.00137	 0.00359425	 .	 0.0005386	 .	
21.7	 EFNA3	 nonframeshift	
deletion	
1q22	 0.013709	 0.014976	 rs199552063	 0.017	 EFNA3:NM_004952:exon2:c.208_219del:p.70_73del	
39	 EML6	 stopgain	 2p16.1	 .	 .	 .	 .	 EML6:NM_001039753:exon5:c.G531A:p.W177X	
16.97	 FAM111B	 frameshift	
deletion	
11q12.1	 0.020451	 0.0185703	 rs199851144	 0.026	 FAM111B:NM_001142704:exon2:c.302delT:p.V101fs	
23.4	 FAM71E2	 frameshift	
insertion	








12q13.13	 0.000247	 .	 .	 0.0001734	 FIGNL2:NM_001013690:exon2:c.67_69del:p.23_23del	
35	 GCAT	 nonsynonymous	 22q13.1	 0.007458	 0.00439297	 rs17856459	 0.00864	 GCAT:NM_001171690:exon9:c.C1237T:p.R413W	
17.1	 GTF2F1	 nonframeshift	
deletion	
19p13.3	 0.005112	 .	 .	 0.0007083	 GTF2F1:NM_002096:exon7:c.751_753del:p.251_251d
el	
11.49	 GUSB	 splicing	 7q11.21	 .	 .	 .	 0.015	 NM_001293104:exon12:c.1220-5T&amp;gt;-	
11.18	 HORMAD1	 splicing	 1q21.3	 .	 .	 rs367543855	 0.0005871	 NM_032132:exon13:c.872-5T&amp;gt;-	
10.02	 HRC	 nonframeshift	
insertion	










2q35	 .	 0.00319489	 .	 0.008202	 LOC100996693:NM_001286811:exon2:c.380_385del:p
.127_129del	
35	 LRGUK	 nonsynonymous		 7q33	 0.003844	 0.00159744	 rs61749957	 0.00411	 LRGUK:NM_144648:exon10:c.C1196T:p.P399L	
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35	 MAP3K5	 nonsynonymous		 6q23.3	 .	 0.000199681	 rs114243010	 0.00008236	 MAP3K5:NM_005923:exon17:c.G2300A:p.R767H	
12.67	 NCL	 nonframeshift	
deletion	
2q37.1	 .	 0.00539137	 .	 0.005898	 NCL:NM_005381:exon4:c.783_785del:p.261_262del	
35	 NFASC	 	
nonsynonymous	
1q32.1	 0.000077	 0.000199681	 rs184631101	 0.00008236	 NFASC:NM_001160331:exon11:c.C1378T:p.R460W	
15.27	 NRG2	 nonframeshift	
deletion	
5q31.2	 .	 .	 .	 0.00008997	 NRG2:NM_001184935:exon8:c.2150_2158del:p.717_7
20del	
35	 NYNRIN	 stopgain	 14q12	 .	 .	 .	 .	 NYNRIN:NM_025081:exon4:c.C1810T:p.Q604X	
35	 PCK2	 frameshift	
insertion	
14q11.2	 .	 .	 .	 .	 PCK2:NM_001291556:exon10:c.1468dupA:p.P489fs	
37	 PGPEP1	 stopgain	 19p13.11	 .	 .	 .	 .	 PGPEP1:NM_001300927:exon2:c.C85T:p.Q29X	
11.09	 PPM1F	 nonframeshift	
deletion	




9q21.2	 0.014067	 0.0131789	 rs144828766	 0.004293	 PRUNE2:NM_015225:exon8:c.5871_5882del:p.1957_1
961del	
35	 PYGL	 nonsynonymous	 14q22.1	 .	 .	 .	 .	 PYGL:NM_001163940:exon5:c.C625T:p.R209C	
22.2	 TLDC2	 nonframeshift	
deletion	
20q11.23	 0.002636	 0.00139776	 .	 0.0008319	 TLDC2:NM_080628:exon4:c.417_419del:p.139_140del	
26.6	 ZC2HC1C	 frameshift	
insertion	
14q24.3	 0.003254	 0.000998403	 .	 0.002442	 ZC2HC1C:NM_024643:exon2:c.983dupG:p.R328fs	
10.99	 ZIC5	 nonframeshift	
deletion	
13q32.3	 .	 .	 .	 0.006557	 ZIC5:NM_033132:exon1:c.1260_1262del:p.420_421de
l	
35	 ZNF445	 stopgain	 3p21.31	 .	 .	 .	 .	 ZNF445:NM_181489:exon3:c.C58T:p.R20X	
12.58	 ZNF469	 nonframeshift	
deletion	
16q24.2	 .	 0.00179712	 .	 0.003504	 ZNF469:NM_001127464:exon2:c.9010_9024del:p.300
4_3008del	
 
7. Heterozygous full lists of Chapter 3- Section 3.2.5 (CADD Phred scores ≥ 30) 
AR1F heterozygous variants full list: 
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CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
35	 CLYBL	 stopgain	 13q32.3	 0.020529	 0.0219649	 rs41281112	 0.027	 CLYBL:NM_206808:exon6:c.C775T:p.R259X	
34	 DOCK5	 nonsynonymous	 8p21.2	 0.000231	 0.000798722	 rs148483229	 0.0001154	 DOCK5:NM_024940:exon30:c.G3056A:p.R1019H	
30	 FERMT3	 nonsynonymous	 11q13.1	 0.000233	 0.00638978	 rs373999037	 0.003478	 FERMT3:NM_031471:exon12:c.G1393A:p.E465K	
 
 
SC1 heterozygous variants full list: 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
40	 LOR	 stopgain	 1q21.3	 .	 .	 .	 .	 LOR:NM_000427:exon2:c.G592T:p.G198X	
40	 TIAM2	 stopgain	 6q25.3	 0.016767	 0.028754	 rs116268446	 0.014	 TIAM2:NM_001010927:exon13:c.T1343A:p.L448X	
39	 C15orf65	 stopgain	 15q21.3	 .	 .	 rs201241267	 0.014	 C15orf65:NM_001198784:exon2:c.C263A:p.S88X	
37	 CHIT1	 stopgain	 1q32.1	 .	 .	 rs201320385	 .	 CHIT1:NM_001256125:exon9:c.G1016A:p.W339X	
36	 ZNF790	 stopgain	 19q13.12	 .	 .	 .	 0.00004118	 ZNF790:NM_001242800:exon5:c.C1483T:p.R495X	
35	 ZKSCAN7	 frameshift	
deletion	




5q23.1	 .	 .	 .	 .	 DMXL1:NM_001290321:exon18:c.4262delC:p.S1421fs	
35	 TMEM222	 nonsynonymous		 1p36.11	 0.009303	 0.0081869	 rs150461998	 0.009398	 TMEM222:NM_032125:exon6:c.C622T:p.R208W	
35	 SCN10A	 nonsynonymous		 3p22.2	 0.000077	 0.00199681	 rs369399424	 0.0009884	 SCN10A:NM_001293307:exon24:c.G4085A:p.R1362Q	
35	 C3orf67	 nonsynonymous		 3p14.2	 0.000769	 0.000599042	 rs139831294	 0.0001812	 C3orf67:NM_198463:exon16:c.G1609A:p.E537K	
35	 CSRP3	 nonsynonymous		 11p15.1	 .	 0.000199681	 .	 0.0001483	 CSRP3:NM_003476:exon7:c.G538T:p.G180C	
35	 ITGB7	 nonsynonymous		 12q13.13	 .	 .	 .	 0.000008236	 ITGB7:NM_000889:exon15:c.C2263T:p.R755C	
35	 PLEKHH1	 nonsynonymous		 14q24.1	 .	 0.000199681	 .	 0.0001737	 PLEKHH1:NM_020715:exon13:c.C1852T:p.R618W	
35	 ZNF544	 stopgain	 19q13.43	 0.007996	 0.00898562	 rs79258645	 0.015	 ZNF544:NM_014480:exon7:c.C1843T:p.R615X	
35	 TGM2	 stopgain	 20q11.23	 .	 .	 .	 0.0001565	 TGM2:NM_004613:exon9:c.G1303T:p.E435X	
35	 PLA2G3	 stopgain	 22q12.2	 .	 .	 rs201767666	 0.00003295	 PLA2G3:NM_015715:exon1:c.C436T:p.R146X	
35	 SLC5A4	 nonsynonymous		 22q12.3	 0.010303	 0.0113818	 rs62239049	 0.012	 SLC5A4:NM_014227:exon9:c.G1007A:p.R336H	
34	 MMS19	 frameshift	
insertion	
10q24.1	 .	 .	 .	 .	 MMS19:NM_001289403:exon23:c.2248_2249insTCTG
GGC:p.P750fs	




17q21.2	 .	 .	 .	 .	 TOP2A:NM_001067:exon3:c.231dupT:p.V78fs	
34	 PTPRU	 nonsynonymous		 1p35.3	 .	 .	 .	 0.0003709	 PTPRU:NM_001195001:exon27:c.G3917C:p.R1306P	
34	 ABI3BP	 nonsynonymous		 3q12.2	 .	 0.000199681	 rs199998539	 0.000455	 ABI3BP:NM_015429:exon2:c.G167A:p.R56H	
34	 MRPS30	 nonsynonymous		 5p12	 0.008996	 0.00519169	 rs35601455	 0.011	 MRPS30:NM_016640:exon1:c.C305T:p.A102V	
34	 MYL10	 nonsynonymous		 7q22.1	 0.000923	 0.00279553	 rs146674429	 0.00126	 MYL10:NM_138403:exon2:c.C94T:p.R32W	
34	 NPDC1	 nonsynonymous		 9q34.3	 .	 .	 .	 0.00001946	 NPDC1:NM_015392:exon7:c.G736A:p.A246T	
34	 SPPL3	 nonsynonymous		 12q24.31	 .	 .	 .	 0.00008242	 SPPL3:NM_139015:exon7:c.G545C:p.R182P	
34	 ABCD4	 nonsynonymous		 14q24.3	 .	 .	 rs77210030	 0.0005518	 ABCD4:NM_005050:exon13:c.T1373C:p.F458S	
34	 FUK	 nonsynonymous		 16q22.1	 0.000402	 0.000599042	 rs186275161	 0.0003663	 FUK:NM_145059:exon16:c.G1874A:p.R625Q	
34	 CCL5	 nonsynonymous		 17q12	 .	 0.000798722	 rs200852773	 0.0009801	 CCL5:NM_002985:exon3:c.G200A:p.R67Q	
34	 MRPS7	 nonsynonymous		 17q25.1	 .	 .	 .	 0.00004118	 MRPS7:NM_015971:exon5:c.C538G:p.R180G	
34	 UPB1	 nonsynonymous		 22q11.23	 .	 .	 .	 .	 UPB1:NM_016327:exon7:c.C827T:p.A276V	
33	 PRIMPOL	 frameshift	
deletion	
4q35.1	 .	 .	 .	 0.0006177	 PRIMPOL:NM_001300767:exon13:c.1039_1039del:p.E3
47fs	
33	 HSPG2	 nonsynonymous		 1p36.12	 .	 .	 .	 0.00006595	 HSPG2:NM_001291860:exon26:c.G3349A:p.G1117S	
33	 GPX7	 nonsynonymous		 1p32.3	 .	 .	 .	 0.00001647	 GPX7:NM_015696:exon2:c.C316T:p.R106C	
33	 GHRL	 stopgain	 3p25.3	 .	 .	 .	 0.00001647	 GHRL:NM_001134941:exon2:c.G50A:p.W17X	
33	 ABCC5	 nonsynonymous		 3q27.1	 .	 .	 .	 .	 ABCC5:NM_005688:exon23:c.G3394A:p.A1132T	
33	 CPED1	 nonsynonymous		 7q31.31	 .	 .	 .	 .	 CPED1:NM_001105533:exon16:c.G2161A:p.G721R	
33	 KDELC2	 nonsynonymous		 11q22.3	 0.016593	 0.00898562	 rs74911261	 0.016	 KDELC2:NM_153705:exon3:c.C431T:p.P144L	
33	 VPS18	 nonsynonymous		 15q15.1	 .	 .	 .	 .	 VPS18:NM_020857:exon4:c.C1162T:p.R388C	
33	 MYLK3	 nonsynonymous		 16q11.2	 .	 .	 rs200890698	 0.017	 MYLK3:NM_182493:exon11:c.C2129T:p.S710F	
33	 SPATA20	 nonsynonymous		 17q21.33	 .	 .	 .	 0.00008776	 SPATA20:NM_001258372:exon11:c.C1487A:p.P496H	
33	 GPATCH1	 nonsynonymous		 19q13.11	 0.000154	 .	 rs374963833	 0.00006589	 GPATCH1:NM_018025:exon16:c.C2242T:p.R748C	
33	 VPS16	 nonsynonymous		 20p13	 .	 0.00139776	 rs199753911	 0.00159	 VPS16:NM_080413:exon16:c.C1495T:p.R499C	
32	 REV1	 nonsynonymous		 2q11.2	 .	 0.00139776	 rs199850949	 0.0006507	 REV1:NM_001037872:exon17:c.T2774C:p.L925P	
32	 NXPE3	 nonsynonymous		 3q12.3	 0.000231	 0.000199681	 rs140128269	 0.000173	 NXPE3:NM_001134456:exon8:c.C1448T:p.T483M	
32	 WFS1	 nonsynonymous		 4p16.1	 0.004767	 0.00379393	 rs35932623	 0.004789	 WFS1:NM_001145853:exon8:c.C2452T:p.R818C	
32	 RGS7BP	 nonsynonymous		 5q12.3	 .	 .	 .	 0.0004779	 RGS7BP:NM_001029875:exon1:c.G32C:p.R11P	
32	 TMEM194A	 nonsynonymous		 12q13.3	 .	 .	 .	 .	 TMEM194A:NM_001130963:exon1:c.G11A:p.G4E	
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32	 ACTR10	 nonsynonymous		 14q23.1	 .	 .	 rs76669080	 0.001371	 ACTR10:NM_018477:exon1:c.A35G:p.E12G	
32	 PIF1	 nonsynonymous		 15q22.31	 .	 .	 .	 0.01	 PIF1:NM_001286496:exon4:c.G778C:p.A260P	
32	 LPIN3	 nonsynonymous		 20q12	 0.029064	 0.0299521	 rs41277016	 0.026	 LPIN3:NM_001301860:exon2:c.C181T:p.R61W	
32	 NOL12	 nonsynonymous		 22q13.1	 .	 .	 rs373277967	 0.00003295	 NOL12:NM_024313:exon6:c.C583T:p.R195C	
32	 L3MBTL2	 nonsynonymous		 22q13.2	 .	 .	 .	 0.007265	 L3MBTL2:NM_031488:exon6:c.G697C:p.A233P	
31	 NUP210	 nonsynonymous		 3p25.1	 .	 .	 .	 0.000008243	 NUP210:NM_024923:exon2:c.C178T:p.R60W	
31	 PPID	 nonsynonymous		 4q32.1	 0.02891	 0.0277556	 rs2070631	 0.026	 PPID:NM_005038:exon2:c.C145T:p.R49C	
31	 KIAA1244	 nonsynonymous		 6q23.3	 .	 .	 rs372977543	 0.011	 KIAA1244:NM_020340:exon34:c.T6506G:p.V2169G	
31	 CNTRL	 nonsynonymous		 9q33.2	 0.000231	 0.00119808	 rs138015820	 0.001046	 CNTRL:NM_007018:exon7:c.G1069A:p.A357T	
31	 RELT	 nonsynonymous		 11q13.4	 0.006777	 0.0103834	 rs141813904	 0.009275	 RELT:NM_032871:exon8:c.C767T:p.T256M	
31	 FAM186B	 nonsynonymous		 12q13.12	 0.001076	 0.00259585	 rs141974060	 0.003089	 FAM186B:NM_032130:exon2:c.G321C:p.W107C	
31	 NCOR2	 nonsynonymous		 12q24.31	 .	 .	 rs112797765	 .	 NCOR2:NM_001077261:exon38:c.G5488A:p.G1830R	
31	 FBN1	 nonsynonymous		 15q21.1	 .	 .	 .	 0.000008237	 FBN1:NM_000138:exon46:c.C5548T:p.R1850C	
31	 ITGB4	 nonsynonymous		 17q25.1	 .	 .	 .	 0.000008237	 ITGB4:NM_001005619:exon6:c.C670T:p.R224W	
31	 TMEM259	 nonsynonymous		 19p13.3	 .	 .	 rs199888865	 0.0008705	 TMEM259:NM_001033026:exon9:c.G1159C:p.A387P	
31	 SLC5A4	 stopgain	 22q12.3	 0.010764	 0.0113818	 rs62239058	 0.012	 SLC5A4:NM_014227:exon5:c.G415T:p.E139X	
30	 ZNF76	 nonsynonymous		 6p21.31	 0.012456	 0.00638978	 rs33959228	 0.016	 ZNF76:NM_001292032:exon9:c.C814T:p.R272C	
 
 
SC2 heterozygous variants full list (>20): 
CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
39	 C15orf65	 stopgain	 15q21.3	 .	 .	 rs201241267	 0.014	 C15orf65:NM_001198784:exon2:c.C263A:p.S88X	
39	 MAP3K10	 stopgain	 19q13.2	 .	 .	 .	 0.0008072	 MAP3K10:NM_002446:exon4:c.G1072T:p.E358X	
35	 TRIM45	 frameshift	
deletion	




10q25.2	 .	 .	 .	 .	 GPAM:NM_001244949:exon15:c.1468_1469insTTTT
TTT:p.C490fs	
35	 BBS7	 nonsynonymous	 4q27	 0.000077	 0.000798722	 rs372685495	 0.0004201	 BBS7:NM_018190:exon13:c.G1337A:p.R446Q	
35	 RNF10	 nonsynonymous	 12q24.31	 .	 .	 .	 0.00003295	 RNF10:NM_014868:exon5:c.C646T:p.R216C	
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35	 KIAA1683	 stopgain	 19p13.11	 0.000438	 0.000399361	 rs200745939	 0.002004	 KIAA1683:NM_001145304:exon3:c.C3004T:p.Q1002
X	
35	 CLCN6	 nonsynonymous	 1p36.22	 0.000077	 .	 rs368875103	 0.00004942	 CLCN6:NM_001256959:exon10:c.C817T:p.R273C	
35	 LAMA1	 nonsynonymous	 18p11.31	 0.00123	 0.00279553	 rs142063208	 0.002405	 LAMA1:NM_005559:exon50:c.C7141T:p.R2381C	
34	 PLD4	 frameshift	
deletion	
14q32.33	 .	 0.000798722	 .	 0.000853	 PLD4:NM_138790:exon8:c.937_944del:p.C313fs	
34	 SPATA20	 frameshift	
insertion	
17q21.33	 .	 .	 rs149572077	 .	 SPATA20:NM_001258372:exon11:c.1488_1489insA
AAAA:p.P496fs	
34	 TMEM79	 nonsynonymous	 1q22	 .	 0.000399361	 rs181268580	 0.00002471	 TMEM79:NM_032323:exon3:c.C841T:p.R281W	
34	 LHPP	 nonsynonymous	 10q26.13	 0.000077	 0.000199681	 rs372122309	 0.00002472	 LHPP:NM_022126:exon6:c.G664A:p.G222S	
34	 SPPL3	 nonsynonymous	 12q24.31	 .	 .	 .	 0.00008242	 SPPL3:NM_139015:exon7:c.G545C:p.R182P	
34	 FBLN7	 nonsynonymous	 2q13	 .	 0.000199681	 rs199980872	 0.00003295	 FBLN7:NM_001128165:exon7:c.G1034A:p.R345Q	
34	 CLYBL	 nonsynonymous	 13q32.3	 .	 .	 .	 0.00009884	 CLYBL:NM_206808:exon2:c.G217A:p.D73N	
34	 PAG1	 nonsynonymous	 8q21.13	 .	 0.00139776	 .	 0.001211	 PAG1:NM_018440:exon7:c.G796A:p.D266N	
34	 PDE8B	 nonsynonymous	 5q13.3	 .	 0.00239617	 .	 0.0009307	 PDE8B:NM_001029851:exon15:c.G1630A:p.D544N	
34	 SLC9A5	 nonsynonymous	 16q22.1	 .	 .	 .	 0.013	 SLC9A5:NM_004594:exon15:c.G2180C:p.R727P	
34	 INADL	 nonsynonymous	 1p31.3	 0.011379	 0.00499201	 rs41289428	 0.009843	 INADL:NM_176877:exon35:c.G4495A:p.E1499K	
34	 XPO1	 nonsynonymous	 2p15	 .	 .	 rs79074863	 0.012	 XPO1:NM_003400:exon16:c.G1754T:p.C585F	
34	 CYLD	 nonsynonymous	 16q12.1	 .	 .	 rs200154154	 0.00934	 CYLD:NM_001042355:exon17:c.C2597A:p.T866K	
34	 PLA2G4D	 nonsynonymous	 15q15.1	 0.007613	 0.00838658	 rs56985825	 0.004176	 PLA2G4D:NM_178034:exon12:c.C997T:p.R333W	
34	 GJD4	 stopgain	 10p11.21	 0.000169	 0.00339457	 rs370286081	 0.001934	 GJD4:NM_153368:exon2:c.C946T:p.R316X	
34	 EPHA8	 nonsynonymous	 1p36.12	 0.000077	 0.00199681	 rs146856523	 0.001548	 EPHA8:NM_020526:exon15:c.G2636A:p.R879Q	
33	 NPHP3	 nonsynonymous	 3q22.1	 0.000769	 0.00419329	 rs142663818	 0.001771	 NPHP3:NM_153240:exon2:c.C449T:p.A150V	
33	 SNCAIP	 nonsynonymous	 5q23.2	 0.010918	 0.00638978	 rs140850272	 0.008953	 SNCAIP:NM_001242935:exon8:c.G1319A:p.R440H	
33	 BIVM-
ERCC5,ERCC5	
nonsynonymous	 13q33.1	 .	 0.000998403	 .	 0.0002553	 ERCC5:NM_000123:exon12:c.C2600T:p.P867L	
33	 PON3	 nonsynonymous	 7q21.3	 0.002307	 0.00159744	 rs139856535	 0.002792	 PON3:NM_000940:exon9:c.G971A:p.G324D	
33	 RUNX3	 nonsynonymous	 1p36.11	 .	 .	 .	 0.00001647	 RUNX3:NM_004350:exon4:c.G590A:p.R197H	
33	 FGL1	 nonsynonymous	 8p22	 0.011994	 0.00938498	 rs2653414	 0.015	 FGL1:NM_004467:exon7:c.G767T:p.W256L	
33	 CCZ1	 nonsynonymous	 7p22.1	 .	 .	 .	 0.0001079	 CCZ1:NM_015622:exon7:c.C533T:p.T178M	
32	 CACNA1B	 frameshift	
insertion	
9q34.3	 .	 .	 .	 .	 CACNA1B:NM_000718:exon1:c.284_285insTCCATTC
GAGTAT:p.P95fs	
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32	 NFASC	 nonsynonymous	 1q32.1	 0.005151	 0.0061901	 rs3795564	 0.009406	 NFASC:NM_001160331:exon4:c.C458T:p.T153M	
32	 SERPINI1	 nonsynonymous	 3q26.1	 .	 .	 .	 .	 SERPINI1:NM_001122752:exon2:c.C89T:p.S30L	
32	 CRTC2	 nonsynonymous	 1q21.3	 .	 0.00159744	 rs199770709	 0.001112	 CRTC2:NM_181715:exon6:c.G602A:p.R201H	
32	 NEB	 nonsynonymous	 2q23.3	 .	 .	 .	 .	 NEB:NM_004543:exon89:c.G13328T:p.S4443I	
32	 KPNA7	 nonsynonymous	 7q22.1	 .	 0.00219649	 rs202200015	 0.002697	 KPNA7:NM_001145715:exon4:c.C536T:p.A179V	
32	 SGCE	 nonsynonymous	 7q21.3	 .	 0.000798722	 .	 0.0003625	 SGCE:NM_001301139:exon3:c.G287A:p.R96H	
32	 HEXA	 nonsynonymous	 15q23	 .	 .	 rs121907956	 0.00007413	 HEXA:NM_000520:exon13:c.G1496A:p.R499H	
32	 RGS7BP	 nonsynonymous	 5q12.3	 .	 .	 .	 0.0004779	 RGS7BP:NM_001029875:exon1:c.G32C:p.R11P	
32	 AMBRA1	 nonsynonymous	 11p11.2	 .	 .	 .	 0.000008236	 AMBRA1:NM_001267782:exon7:c.G707A:p.R236Q	
32	 EPSTI1	 nonsynonymous	 13q14.11	 .	 .	 .	 .	 EPSTI1:NM_001002264:exon6:c.G502A:p.E168K	
32	 MYBL2	 nonsynonymous	 20q13.12	 .	 .	 rs199623276	 0.00485	 MYBL2:NM_002466:exon3:c.G172C:p.A58P	
32	 L3MBTL2	 nonsynonymous	 22q13.2	 .	 .	 .	 0.007265	 L3MBTL2:NM_031488:exon6:c.G697C:p.A233P	
32	 GPR124	 nonsynonymous	 8p11.23	 0.000615	 .	 rs200841231	 0.0007335	 GPR124:NM_032777:exon9:c.C1204T:p.R402W	
32	 DCAF12	 nonsynonymous	 9p13.3	 0.000231	 0.00399361	 rs149115505	 0.002183	 DCAF12:NM_015397:exon7:c.C908T:p.A303V	
32	 SEPSECS	 nonsynonymous	 4p15.2	 .	 .	 .	 .	 SEPSECS:NM_016955:exon5:c.C671T:p.T224I	
32	 SH3BP2	 nonsynonymous	 4p16.3	 0.003152	 0.00419329	 rs148761331	 0.004761	 SH3BP2:NM_001122681:exon11:c.C1429T:p.R477W	
31	 SAMD9L	 nonsynonymous	 7q21.2	 .	 0.00279553	 .	 0.0008484	 SAMD9L:NM_152703:exon5:c.G695A:p.R232H	
31	 TBX18	 nonsynonymous	 6q14.3	 .	 0.0139776	 rs200742037	 0.008105	 TBX18:NM_001080508:exon5:c.G868A:p.G290R	
31	 CCDC125	 nonsynonymous	 5q13.2	 0.000384	 0.000599042	 rs115866581	 0.00008237	 CCDC125:NM_001297696:exon5:c.C479T:p.T160M	
31	 BEAN1	 stopgain	 16q21	 .	 .	 .	 0.00003758	 BEAN1:NM_001136106:exon4:c.C247T:p.R83X	
31	 MYO1E	 nonsynonymous	 15q22.2	 0.001388	 0.00179712	 rs147579391	 0.002413	 MYO1E:NM_004998:exon27:c.C3146A:p.P1049H	
31	 TNS3	 nonsynonymous	 7p12.3	 .	 0.000199681	 .	 0.0001738	 TNS3:NM_022748:exon23:c.G3538C:p.E1180Q	
31	 PIP5K1C	 nonsynonymous	 19p13.3	 .	 .	 .	 0.00001647	 PIP5K1C:NM_001195733:exon11:c.G1334A:p.R445
Q	
31	 TMEM259	 nonsynonymous	 19p13.3	 .	 .	 rs199888865	 0.0008705	 TMEM259:NM_001033026:exon9:c.G1159C:p.A387
P	
30	 SMAD6	 nonsynonymous	 15q22.31	 0.002465	 0.00279553	 rs188799901	 0.002231	 SMAD6:NM_005585:exon1:c.G61A:p.D21N	
8. Pubmatrix results  
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Pubmatrix results of all the heterozygous variants occurring in at least two families belonging to 2 different ethnicities 
PubMatrix Keratoconus Cornea Oxidative Stress Collagen Eye Inflammation Proteinase Apoptosis Epithelial cells Keratocytes 
ABCC4 0 1 9 7 11 20 4 24 105 0 
ABCD4 0 0 0 0 0 0 0 2 6 0 
AHNAK 0 0 2 3 1 4 3 4 21 0 
AHNAK2 0 0 0 0 0 1 0 0 0 0 
ATM 0 12 401 40 106 243 255 1646 884 0 
BCLAF1 0 0 0 0 1 1 5 23 12 0 
CELA1 0 0 0 0 0 1 3 1 2 0 
COL6A3 0 2 1 102 1 6 5 6 6 0 
CROCC 0 0 0 0 7 0 0 0 6 0 
DNAH1 0 0 0 1 0 0 0 0 0 0 
DNAH10 0 0 0 0 0 0 0 0 0 0 
DNAH17 0 0 0 0 0 0 0 0 0 0 
DNAJB7 0 0 0 0 0 1 0 0 0 0 
DSPP 0 0 1 86 2 9 34 12 44 0 
DST 2 23 48 508 80 72 42 34 178 0 
EPPK1 0 0 0 0 1 1 0 0 0 0 
FAM186B 0 0 0 0 0 0 0 0 0 0 
FAM188B 0 0 0 0 0 0 0 0 0 0 
FAM71E2 0 0 0 0 0 0 0 0 0 0 
FES 2 3 35 12 51 48 42 32 77 0 
FKRP 0 0 0 4 51 4 5 4 1 0 
FLG 1 6 6 6 14 40 18 15 62 1 
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FLNB 0 0 0 2 1 0 1 2 2 0 
GPAM 0 0 3 0 0 8 1 5 9 0 
HCLS1 0 0 0 2 1 2 8 20 9 0 
HRCT1 0 0 0 0 0 0 0 0 0 0 
IGFN1 0 0 0 0 0 1 0 0 0 0 
KIAA1683 0 0 0 0 0 0 0 0 0 0 
KNDC1 0 0 0 0 0 0 0 0 1 0 
KRTAP5-7 0 0 0 0 0 0 0 0 0 0 
LAMA5 0 0 0 3 0 2 1 4 11 0 
LAMC1 0 0 1 6 7 2 2 7 12 0 
LTBP1 0 0 0 15 5 3 18 4 26 1 
MAP1A 0 1 2 1 6 0 5 5 11 0 
MUC16 0 37 5 2 56 18 20 17 100 0 
MUC17 0 0 0 1 2 3 0 2 17 0 
MUC4 0 38 3 7 71 40 21 43 218 0 
MUC6 0 1 1 2 10 33 41 7 141 0 
NCOR2 0 0 3 0 3 14 10 24 72 0 
NEB 0 0 9 9 6 20 15 18 129 0 
NFASC 0 0 0 2 6 4 2 0 12 0 
NFKBIZ 0 3 0 1 5 31 2 6 28 0 
NOM1 0 0 0 2 0 0 5 1 2 0 
OBSCN 0 0 0 0 0 0 0 2 3 0 
OVGP1 0 0 1 0 0 1 3 2 18 0 
P2RY4 0 0 0 0 0 0 0 0 1 0 
PCDHGB1 0 0 0 0 0 0 0 0 0 0 
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PKHD1L1 0 0 0 0 0 0 0 0 0 0 
PLEKHA4 0 0 0 0 0 0 0 0 0 0 
PRX 0 3 313 8 12 24 25 101 84 1 
PSMB10 0 1 1 0 5 7 70 6 10 0 
RBMXL3 0 0 0 0 0 0 0 0 0 0 
RPGR 0 1 0 0 239 0 0 5 9 0 
SACS 0 22 38 102 280 181 68 67 419 2 
SHROOM3 0 0 0 1 5 1 0 0 12 0 
SPATA20 0 0 0 0 0 0 0 0 1 0 
SSPO 0 0 0 0 0 0 0 0 0 0 
SVEP1 0 0 0 0 0 3 1 1 1 0 
SYNE1 0 1 0 1 4 1 1 3 12 0 
TTN 0 0 7 20 2 7 47 14 27 0 
UBXN11 0 0 0 0 0 0 1 0 1 0 
USH2A 0 0 0 1 60 0 1 0 8 0 
XPO4 0 0 0 0 0 0 0 0 4 0 
ZNF469 11 23 0 9 16 0 0 0 0 0 
ZNF880 0 0 0 0 0 0 0 0 0 0 
 
9. ZNF469 primers 
Product size Forward Melting Temperature 
304 CTCCCCACCCACTACCAG 
CCAGGAGCAGGCCACAGA 
58.27    
61.32    




59.16    
58.67    
250 GAGAATCCACTGCACATCGG 
CTGTCTCCTTCTGCCTGGC 
58.71    


















10. PLINK/SEQ results 
Gene enrichment results: 
LOCUS	 POS	 ALIAS	 NVAR	 TEST	 P	 ALIAS	 I	 Symbol	 DESC	
NM_024011	 chr1:1635973..1647893	 CDK11A	 3	 BURDEN	 0.0386905	 CDK11A	 0.00298507	 CDK11A	 23/60	
NM_033529	 chr1:1635973..1647893	 .	 3	 BURDEN	 0.0511811	 .	 0.00395257	 .	 23/60	
NM_002923	 chr1:192778206..192778269	 RGS2	 2	 BURDEN	 0.0356164	 RGS2	 0.0741758	 RGS2	 2/0	
NM_006085	 chr1:220236272..220240666	 BPNT1	 2	 BURDEN	 0.00566802	 BPNT1	 0.0141758	 BPNT1	 4/0	
NM_003679	 chr1:241725615..241755283	 KMO	 4	 BURDEN	 0.0599078	 KMO	 0.00925926	 KMO	 3/1	
NM_001004686	 chr1:248201939..248202474	 OR2L2	 4	 BURDEN	 0.0383481	 OR2L2	 0.00591716	 OR2L2	 4/4	
NM_014023	 chr10:1132232..1151117	 WDR37	 4	 BURDEN	 0.0577778	 WDR37	 0.0178571	 WDR37	 4/4	
NM_022761	 chr11:111753245..111753246	 C11orf1	 2	 BURDEN	 0.0118343	 C11orf1	 0.0296108	 C11orf1	 3/1	
NM_003986	 chr11:27076985..27076985	 BBOX1	 1	 BURDEN	 0.0346667	 BBOX1	 0.0106952	 BBOX1	 4/3	
NM_001003750	 chr11:55861103..55861523	 OR8I2	 2	 BURDEN	 0.0351351	 OR8I2	 0.0704607	 OR8I2	 2/0	
NM_001004458	 chr11:57982524..57982635	 OR1S1	 3	 BURDEN	 0.0572687	 OR1S1	 0.0132743	 OR1S1	 2/1	
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NM_001005167	 chr11:5862797..5862797	 OR52E6	 1	 BURDEN	 0.0439189	 OR52E6	 0.00677966	 OR52E6	 3/3	
NM_024099	 chr11:62432404..62434492	 C11orf48	 9	 BURDEN	 0.0333333	 C11orf48	 0.00257069	 C11orf48	 19/36	
NM_001043229	 chr11:62433781..62434492	 METTL12	 6	 BURDEN	 0.0093147	 METTL12	 0.00133156	 METTL12	 19/32	
NM_005959	 chr11:92702929..92715404	 MTNR1B	 3	 BURDEN	 0.0402477	 MTNR1B	 0.00310559	 MTNR1B	 3/2	
NM_001097643	 chr12:11285909..11286841	 TAS2R30	 7	 BURDEN	 0.0577778	 TAS2R30	 0.00892857	 TAS2R30	 1/10	
NM_001759	 chr12:4388038..4409107	 CCND2	 2	 BURDEN	 0.0277228	 CCND2	 0.0555556	 CCND2	 2/0	
NM_173086	 chr12:52863031..52867520	 KRT6C	 4	 BURDEN	 0.0173697	 KRT6C	 0.00372671	 KRT6C	 4/2	
NM_031290	 chr13:52439662..52440202	 CCDC70	 2	 BURDEN	 0.0287474	 CCDC70	 0.0596708	 CCDC70	 2/0	
NM_001004479	 chr14:20711524..20711858	 OR11H4	 3	 BURDEN	 0.0496183	 OR11H4	 0.00766284	 OR11H4	 3/2	
NM_001012264	 chr14:21502431..21502431	 RNASE13	 1	 BURDEN	 0.000649984	 RNASE13	 9.29E-05	 RNASE13	 6/1	
NM_001193635	 chr14:24459428..24464283	 DHRS4L2	 3	 BURDEN	 0.0530612	 DHRS4L2	 0.0204918	 DHRS4L2	 3/3	
NM_003813	 chr14:70924643..70925559	 ADAM21	 6	 BURDEN	 0.0575221	 ADAM21	 0.0222222	 ADAM21	 4/3	
NM_003814	 chr14:70989377..70990774	 ADAM20	 3	 BURDEN	 0.0490566	 ADAM20	 0.00757576	 ADAM20	 2/1	
NM_001001413	 chr15:22742709..22743398	 GOLGA6L1	 14	 BURDEN	 0.013766	 GOLGA6L1	 0.000984252	 GOLGA6L1	 31/50	
NM_024793	 chr16:3569909..3580663	 CLUAP1	 2	 BURDEN	 0.0368272	 CLUAP1	 0.0539773	 CLUAP1	 2/0	
NM_002153	 chr16:82069137..82131943	 HSD17B2	 4	 BURDEN	 0.0245614	 HSD17B2	 0.00351494	 HSD17B2	 3/1	
NM_033184	 chr17:39221816..39221816	 KRTAP2-4	 1	 BURDEN	 0.0345745	 KRTAP2-4	 0.00266667	 KRTAP2-4	 4/3	
NM_033188	 chr17:39305619..39305910	 KRTAP4-5	 9	 BURDEN	 0.0117155	 KRTAP4-5	 0.000837521	 KRTAP4-5	 52/77	
NM_145041	 chr17:41365129..41368562	 TMEM106A	 4	 BURDEN	 0.0401235	 TMEM106A	 0.0123839	 TMEM106A	 4/2	
NM_014804	 chr17:6493855..6524149	 KIAA0753	 5	 BURDEN	 0.0572687	 KIAA0753	 0.00442478	 KIAA0753	 3/2	
NM_001146036	 chr18:43328350..43329744	 .	 2	 BURDEN	 0.0342105	 .	 0.0633245	 .	 2/0	
NM_015865	 chr18:43328350..43329744	 SLC14A1	 2	 BURDEN	 0.0341207	 SLC14A1	 0.0657895	 SLC14A1	 2/0	
NM_001080821	 chr19:12501584..12502493	 ZNF799	 6	 BURDEN	 0.0101229	 ZNF799	 0.00144718	 ZNF799	 9/8	
NM_001145404	 chr19:19905458..19916911	 ZNF506	 4	 BURDEN	 0.0440678	 ZNF506	 0.0102041	 ZNF506	 4/2	
NM_001099269	 chr19:19905458..19916911	 .	 4	 BURDEN	 0.0306346	 .	 0.0131579	 .	 4/2	
NM_199285	 chr19:42814708..42814812	 PRR19	 2	 BURDEN	 0.0181818	 PRR19	 0.00390117	 PRR19	 3/1	
NM_002783	 chr19:43430027..43433676	 PSG7	 4	 BURDEN	 0.00656969	 PSG7	 0.0112676	 PSG7	 4/1	
NM_001206650	 chr19:43430027..43433676	 .	 4	 BURDEN	 0.00645161	 .	 0.0119871	 .	 4/1	
NM_003445	 chr19:44500677..44501296	 ZNF155	 4	 BURDEN	 0.0341463	 ZNF155	 0.00488998	 ZNF155	 3/1	
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NM_198089	 chr19:44500677..44501296	 .	 4	 BURDEN	 0.0254083	 .	 0.00545455	 .	 3/1	
NM_002257	 chr19:51322450..51323581	 KLK1	 2	 BURDEN	 0.0398773	 KLK1	 0.0523077	 KLK1	 2/0	
NM_033341	 chr19:53793083..53793083	 BIRC8	 1	 BURDEN	 0.0212766	 BIRC8	 0.0410959	 BIRC8	 2/0	
NM_001004301	 chr19:53993629..53995115	 ZNF813	 5	 BURDEN	 0.0431894	 ZNF813	 0.0133333	 ZNF813	 4/4	
NM_018328	 chr2:149220153..149247720	 MBD5	 12	 BURDEN	 0.01566	 MBD5	 0.00223964	 MBD5	 7/7	
NM_015702	 chr2:150427649..150438708	 MMADHC	 3	 BURDEN	 0.0490566	 MMADHC	 0.00378788	 MMADHC	 3/2	
NM_001127391	 chr2:202172256..202216069	 .	 8	 BURDEN	 0.0153173	 .	 0.00219058	 .	 5/4	
NM_139163	 chr2:202172256..202216069	 ALS2CR12	 8	 BURDEN	 0.0185185	 ALS2CR12	 0.00264901	 ALS2CR12	 5/4	
NM_018848	 chr20:10389422..10393680	 .	 2	 BURDEN	 0.0290456	 .	 0.00623701	 .	 3/1	
NM_170784	 chr20:10389422..10393680	 MKKS	 2	 BURDEN	 0.0290456	 MKKS	 0.00623701	 MKKS	 3/1	
NM_020157	 chr20:16729640..16730591	 OTOR	 2	 BURDEN	 0.0295359	 OTOR	 0.0486258	 OTOR	 2/0	
NM_001037732	 chr20:168558..168664	 DEFB128	 2	 BURDEN	 0.0183246	 DEFB128	 0.00393185	 DEFB128	 3/1	
NM_015511	 chr20:34827827..34843656	 C20orf4	 6	 BURDEN	 0.0336788	 C20orf4	 0.00779221	 C20orf4	 4/3	
NM_172201	 chr21:35742799..35742947	 KCNE2	 2	 BURDEN	 0.00562023	 KCNE2	 0.0128514	 KCNE2	 3/0	
NM_145641	 chr22:36537775..36537775	 APOL3	 1	 BURDEN	 0.047619	 APOL3	 0.00735294	 APOL3	 4/3	
NM_145642	 chr22:36537775..36537775	 .	 1	 BURDEN	 0.040625	 .	 0.00940439	 .	 4/3	
NM_145640	 chr22:36537775..36556836	 .	 3	 BURDEN	 0.0565217	 .	 0.0131004	 .	 4/4	
NM_173472	 chr3:10146243..10146243	 C3orf24	 1	 BURDEN	 0.00910865	 C3orf24	 0.0143229	 C3orf24	 3/0	
NM_001164839	 chr3:10146243..10146243	 .	 1	 BURDEN	 0.00872274	 .	 0.015586	 .	 3/0	
NM_001134941	 chr3:10331519..10331815	 .	 2	 BURDEN	 0.00507063	 .	 0.0112319	 .	 3/0	
NM_001134946	 chr3:10331519..10331815	 .	 2	 BURDEN	 0.00483425	 .	 0.0117444	 .	 3/0	
NM_016362	 chr3:10331519..10331815	 GHRL	 2	 BURDEN	 0.00920447	 GHRL	 0.0164474	 GHRL	 3/0	
NM_001134944	 chr3:10331519..10331815	 .	 2	 BURDEN	 0.0104556	 .	 0.0171898	 .	 3/0	
NM_001134945	 chr3:10331519..10331815	 .	 2	 BURDEN	 0.0100937	 .	 0.017316	 .	 3/0	
NM_001184720	 chr3:148711967..148727061	 .	 4	 BURDEN	 0.00775623	 .	 0.000554324	 .	 4/1	
NM_004130	 chr3:148711967..148727061	 GYG1	 4	 BURDEN	 0.00800457	 GYG1	 0.000572082	 GYG1	 4/1	
NM_001184721	 chr3:148711967..148744773	 .	 5	 BURDEN	 0.0169492	 .	 0.00363636	 .	 4/2	
NM_001178146	 chr3:151154509..151155879	 .	 6	 BURDEN	 0.013712	 .	 0.00196078	 .	 4/2	
NM_001178145	 chr3:151154509..151156366	 .	 7	 BURDEN	 0.0335917	 .	 0.00259067	 .	 4/2	
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NM_018029	 chr3:73111624..73111747	 EBLN2	 2	 BURDEN	 0.015891	 EBLN2	 0.00227273	 EBLN2	 4/2	
NM_018309	 chr3:99998531..100037987	 TBC1D23	 3	 BURDEN	 0.0555556	 TBC1D23	 0.103004	 TBC1D23	 3/2	
NM_001199198	 chr3:99998531..100037987	 .	 3	 BURDEN	 0.0485075	 .	 0.104869	 .	 3/2	
NM_000253	 chr4:100503136..100543977	 MTTP	 6	 BURDEN	 0.0562771	 MTTP	 0.00869565	 MTTP	 8/12	
NM_183075	 chr4:108852804..108866739	 CYP2U1	 3	 BURDEN	 0.0192308	 CYP2U1	 0.00275103	 CYP2U1	 3/1	
NM_006583	 chr4:110754408..110757197	 RRH	 2	 BURDEN	 0.0401235	 RRH	 0.00928793	 RRH	 3/1	
NM_003263	 chr4:38799283..38800360	 TLR1	 3	 BURDEN	 0.0332542	 TLR1	 0.0619048	 TLR1	 2/0	
NM_006068	 chr4:38828828..38830124	 TLR6	 3	 BURDEN	 0.0171149	 TLR6	 0.00611995	 TLR6	 5/4	
NM_032927	 chr4:4239589..4247938	 TMEM128	 2	 BURDEN	 0.0100874	 TMEM128	 0.00201884	 TMEM128	 4/2	
NM_001038603	 chr5:68715712..68728852	 .	 4	 BURDEN	 0.0290456	 .	 0.002079	 .	 3/1	
NM_001244734	 chr5:68715712..68728852	 .	 4	 BURDEN	 0.0290456	 .	 0.002079	 .	 3/1	
NM_030908	 chr6:132022285..132022286	 OR2A4	 2	 BURDEN	 0.0494297	 OR2A4	 0.00381679	 OR2A4	 7/5	
NM_012328	 chr7:108212243..108213739	 DNAJB9	 2	 BURDEN	 0.0204082	 DNAJB9	 0.0525547	 DNAJB9	 2/0	
NM_001005281	 chr7:143701257..143701257	 OR6B1	 1	 BURDEN	 0.046595	 OR6B1	 0.0791367	 OR6B1	 2/0	
NM_001005480	 chr7:143807139..143807598	 OR2A2	 2	 BURDEN	 0.025974	 OR2A2	 0.0557621	 OR2A2	 2/0	
NM_003014	 chr7:37947150..37953987	 SFRP4	 2	 BURDEN	 0.0577778	 SFRP4	 0.0178571	 SFRP4	 3/1	
NM_006908	 chr7:6438337..6438337	 .	 1	 BURDEN	 0.006941	 .	 0.0143849	 .	 3/0	
NM_018890	 chr7:6438337..6438337	 RAC1	 1	 BURDEN	 0.00842866	 RAC1	 0.0156627	 RAC1	 3/0	
NM_052937	 chr8:52732961..52733242	 PCMTD1	 14	 BURDEN	 0.00427742	 PCMTD1	 0.000305623	 PCMTD1	 101/20
5	
NM_184086	 chr8:67062103..67062103	 .	 1	 BURDEN	 0.0194715	 .	 0.0389972	 .	 2/0	
NM_033058	 chr8:67062103..67062103	 .	 1	 BURDEN	 0.0244328	 .	 0.041958	 .	 2/0	
NM_184085	 chr8:67062103..67062103	 TRIM55	 1	 BURDEN	 0.0190217	 TRIM55	 0.0421769	 TRIM55	 2/0	
NM_184087	 chr8:67062103..67062103	 .	 1	 BURDEN	 0.0189702	 .	 0.0434193	 .	 2/0	
NM_144650	 chr8:67344758..67380507	 ADHFE1	 8	 BURDEN	 0.0208644	 ADHFE1	 0.00149254	 ADHFE1	 8/9	
NM_001080526	 chr8:82370643..82371545	 FABP9	 6	 BURDEN	 0.0139303	 FABP9	 0.0059761	 FABP9	 6/3	
NM_014581	 chr9:136083528..136083528	 OBP2B	 1	 BURDEN	 0.000173531	 OBP2B	 4.96E-05	 OBP2B	 10/6	
NM_001256693	 chr9:36651842..36651842	 .	 1	 BURDEN	 0.00619469	 .	 0.0146082	 .	 3/0	
NM_018465	 chr9:5361143..5361758	 C9orf46	 2	 BURDEN	 0.0408805	 C9orf46	 0.00630915	 C9orf46	 3/2	
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NM_001098412	 chrX:49189238..49189246	 GAGE13	 4	 BURDEN	 0.0408805	 GAGE13	 0.022082	 GAGE13	 5/3	
NM_001127200_
dup1	
chrX:49189238..49189246	 .	 4	 BURDEN	 0.0436242	 .	 0.023569	 .	 5/3	
NM_007268	 chrX:65242157..65253634	 VSIG4	 6	 BURDEN	 0.0445205	 VSIG4	 0.00687285	 VSIG4	 7/8	
NM_001100431	 chrX:65242157..65253634	 .	 6	 BURDEN	 0.0522088	 .	 0.00806452	 .	 7/8	
NM_001184831	 chrX:65253454..65253634	 .	 4	 BURDEN	 0.0445205	 .	 0.00687285	 .	 6/7	
NM_001184830	 chrX:65253454..65253634	 .	 4	 BURDEN	 0.0467626	 .	 0.00722022	 .	 6/7	
NM_000044	 chrX:66765155..66766412	 AR	 10	 BURDEN	 0.027027	 AR	 0.00193424	 AR	 22/42	
 
 
Variant enrichment results: 
VAR	 REF	 ALT	 P	 OR	 ID	 symbol	 consequence	
chr15:82934933	 T	 C	 2.63408E-06	 126.818	 .	 GOLGA6L18	 missense_variant	
chr3:195508787	 G	 T	 1.93718E-05	 33.3333	 .	 MUC4	 missense_variant	
chr2:240981681	 G	 C	 2.82076e-05	 66	 rs201306820	 PRR21	 missense_variant	
chr9:135946801	 C	 A	 3.64897E-05	 477	 .	 CEL	 missense_variant	
chr15:20740399	 T	 C	 0.00004567	 69.16	 .	 GOLGA6L6	 missense_variant	
chr1:12907385	 G	 A	 0.000137135	 9.72222	 rs150590256	 HNRNPCL1	 missense_variant	
chr4:38828828	 G	 A	 0.000155248	 46.3827	 rs386599647;rs5743820	 TLR6	 missense_variant	
chr14:106053342	 T	 A	 0.000231739	 65	 rs202028307	 IGHA2	 missense_variant	
chr15:33192236	 G	 T	 0.000251257	 8.4857099999999992	 rs75033201	 FMN1	 missense_variant	
chr3:195508790	 T	 C	 0.000277934	 9.37037	 .	 MUC4	 missense_variant	
chr6:56044835	 C	 A	 0.000409741	 37.3951	 rs199696799	 COL21A1	 missense_variant	
chr14:19378395	 A	 G	 0.000515808	 11	 rs201551285	 OR11H12	 missense_variant	
chr3:195508789	 C	 T	 0.000574645	 9.85714	 .	 MUC4	 missense_variant	
chr19:53384111	 A	 C	 0.000700508	 38.3012	 .	 ZNF320	 missense_variant	
chr19:53384114	 T	 A	 0.000700508	 38.3012	 .	 ZNF320	 missense_variant	
chr3:195514825	 G	 A	 0.000839195	 40.0968	 rs200800552	 MUC4	 missense_variant	
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chr3:195514846	 A	 G	 0.000853006	 39.2857	 rs200225290	 MUC4	 missense_variant	
chr14:21502431	 G	 A	 0.000884237	 21.45	 rs113995906	 RNASE13	 missense_variant	
chr19:16630967	 T	 G	 0.00142853	 7.0540500000000002	 .	 CHERP	 missense_variant	
chrX:8433535	 A	 C	 0.00161576	 10.1429	 rs201965035	 VCX3B	 missense_variant	
chr16:22546163	 A	 C	 0.00185599	 99	 .	 NPIPB5	 missense_variant	
chr16:22546169	 C	 G	 0.00185599	 99	 rs370469653	 NPIPB5	 missense_variant	
chrX:49189238	 C	 T	 0.0020202	 153	 .	 GAGE13	 missense_variant	
chr15:34823738	 G	 A	 0.00202224	 42.6	 rs200544945	 GOLGA8B	 missense_variant	
chr1:12907358	 T	 C	 0.002179	 8.4359	 rs74587302	 HNRNPCL1	 missense_variant	
chr1:12907380	 C	 A	 0.002179	 8.4359	 rs141207681	 HNRNPCL1	 missense_variant	
chr3:37370562	 A	 G	 0.00269321	 32.1111	 .	 GOLGA4	 missense_variant	
chr3:43389767	 G	 T	 0.00286217	 5.6918899999999999	 rs73831264	 SNRK	 missense_variant	
chr1:12907400	 G	 A	 0.002878	 10.65	 rs149302457	 HNRNPCL1	 missense_variant	
chr21:38568265	 C	 A	 0.002878	 10.65	 rs78583828	 TTC3	 stop_gained	
chr5:54591272	 G	 T	 0.00310225	 30.6	 rs76212559	 DHX29	 missense_variant	
chrX:117959307	 G	 A	 0.00310225	 30.6	 rs190906444	 ZCCHC12	 missense_variant	
chr22:19711964	 C	 T	 0.00316581	 31.1053	 .	 GP1BB	 stop_gained	
chr20:60904915	 C	 T	 0.00323748	 30.176500000000001	 rs371144423	 LAMA5	 missense_variant	
chr1:12907350	 C	 T	 0.00330257	 5.85263	 rs2359486	 HNRNPCL1	 missense_variant	
chr11:119181832	 C	 G	 0.00342681	 17.439	 rs370970803	 MCAM	 missense_variant	
chr12:3129932	 C	 T	 0.00342681	 17.439	 rs71583736	 TEAD4	 missense_variant	
chr7:100645525	 A	 C	 0.00370918	 10.5455	 rs140153344	 MUC12	 missense_variant	
chr8:52733003	 C	 T	 0.00454955	 4.1666699999999999	 rs79195845	 PCMTD1	 missense_variant	
chr17:79414763	 C	 A	 0.0046348	 26.7882	 rs374971809	 RP11-
1055B8.7	
missense_variant	
chr2:62066566	 G	 T	 0.00484355	 5.89474	 rs200331923	 FAM161A	 missense_variant	
chr2:152404248	 A	 G	 0.00485881	 26.3647	 rs111517514	 NEB	 missense_variant	
chr4:88036182	 C	 A	 0.00492001	 4.21143	 rs201122599	 AFF1	 missense_variant	
chr1:201180388	 G	 A	 0.00495237	 15.7317	 .	 IGFN1	 missense_variant	
chr3:195393086	 G	 A	 0.0052305	 35.2545	 rs201125791	 SDHAP2	 splice_donor_variant&nc_tran
script_variant	
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chr5:74450118	 T	 C	 0.00534894	 25.5176	 .	 ANKRD31	 missense_variant	
chr19:17731515	 G	 T	 0.00534894	 25.5176	 rs201764059	 UNC13A	 missense_variant	
chr17:41352520	 A	 C	 0.00552985	 15.2439	 .	 NBR1	 missense_variant	
chr1:206566903	 G	 A	 0.00605368	 5.17895	 rs2987927	 SRGAP2	 missense_variant&splice_regio
n_variant	
chr4:170476887	 G	 T	 0.00618972	 14.7561	 rs201059497	 NEK1	 missense_variant	
chr4:1388497..1388499	 TCA	 T	 0.00620063	 3.8	 .	 CRIPAK	 frameshift_variant&feature_tr
uncation	
chr2:179595427	 A	 C	 0.00652948	 23.823499999999999	 .	 TTN	 missense_variant	
chr16:23718102	 T	 G	 0.00672439	 4.77193	 .	 ERN2	 missense_variant	
chr17:16675944	 C	 A	 0.00726744	 31.127700000000001	 rs201462518	 CCDC144A	 missense_variant	
chr19:36002386	 C	 T	 0.00772493	 5.30303	 rs117522133	 DMKN	 missense_variant	
chrX:49189241	 A	 C	 0.00824176	 37.799999999999997	 .	 GAGE13	 missense_variant	
chr7:100807151	 G	 C	 0.00869543	 9.0909099999999992	 .	 VGF	 missense_variant	
chr16:22546136	 T	 C	 0.00887354	 31	 .	 NPIPB5	 missense_variant	
chr3:195513413	 G	 A	 0.00903632	 4.75789	 rs7374593	 MUC4	 missense_variant	
chr6:32549481	 C	 T	 0.00985746	 4.12088	 .	 HLA-DRB1	 missense_variant	
chr3:195506185	 G	 A	 0.00991377	 6.69231	 rs149026852	 MUC4	 missense_variant	
  
































Variants in KC candidate genes detected in Leeds cohort families: 
Family	 CADD	 Gene	 Exonic	Function	 cytoBand	 esp6500si	 1000g2014	 snp138	 exac03	 AA	Change	
F2	 23.8	 FLG	 nonsynonymous 1q21.3	 0.10772	 0.28774	 rs12405278	 0.229	 FLG:NM_002016:exon3:c.C5095T:p.R1699C	
F2	 22.6	 FLG	 nonsynonymous 1q21.3	 0.077095	 .	 rs75448155	 0.191	 FLG:NM_002016:exon3:c.G10903A:p.D3635N	
F2	 22.6	 FLG	 nonsynonymous 1q21.3	 0.139243	 0.327676	 rs74129461	 0.256	 FLG:NM_002016:exon3:c.G2263A:p.E755K	
F2	 22.5	 IL1A	 nonsynonymous 2q13	 0.261648	 0.217452	 rs17561	 0.272	 IL1A:NM_000575:exon5:c.G340T:p.A114S	
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F2	 20.7	 FLG	 nonsynonymous 1q21.3	 0.10772	 0.287141	 rs11204978	 0.229	 FLG:NM_002016:exon3:c.C4445A:p.S1482Y	
F2	 20.3	 COL4A3	 nonsynonymous 2q36.3	 0.063256	 0.100639	 rs34505188	 0.091	 COL4A3:NM_000091:exon21:c.G1223A:p.R408H	
F2	 17.66	 FLG	 nonsynonymous 1q21.3	 0.118714	 0.296725	 rs12407807	 0.232	 FLG:NM_002016:exon3:c.G5051A:p.R1684H	
F2	 15.37	 FLG	 nonsynonymous 1q21.3	 0.107676	 0.28774	 rs11586631	 0.229	 FLG:NM_002016:exon3:c.G4079A:p.R1360H	
F2	 15.37	 FLG	 nonsynonymous 1q21.3	 0.155774	 0.340655	 rs41267154	 0.26	 FLG:NM_002016:exon3:c.G995T:p.G332V	
F2	 14.66	 FLG	 nonsynonymous 1q21.3	 0.099721	 .	 rs71625202	 0.206	 FLG:NM_002016:exon3:c.G7097C:p.S2366T	
F2	 13.01	 FLG	 nonsynonymous 1q21.3	 0.084081	 .	 rs11582087	 0.188	 FLG:NM_002016:exon3:c.A8506C:p.S2836R	
F2	 11.35	 FLG	 nonsynonymous 1q21.3	 0.10795	 0.28754	 rs12407748	 0.229	 FLG:NM_002016:exon3:c.G5672A:p.R1891Q	
F2	 10.76	 FLG	 nonsynonymous 1q21.3	 0.107873	 0.286941	 rs77422831	 0.229	 FLG:NM_002016:exon3:c.G11213A:p.R3738H	
F2	 10.19	 FLG	 nonsynonymous 1q21.3	 0.107753	 0.28754	 rs12405241	 0.229	 FLG:NM_002016:exon3:c.C5414T:p.A1805V	
F2	 10.05	 FLG	 nonsynonymous 1q21.3	 0.209519	 .	 rs7522925	 0.221	 FLG:NM_002016:exon3:c.C6323T:p.A2108V	
F2	 9.817	 COL4A2	 synonymous	 13q34	 0.241984	 0.186302	 rs4773199	 0.198	 COL4A2:NM_001846:exon43:c.G4089A:p.A1363A	
F2	 8.403	 FLG	 nonsynonymous	 1q21.3	 0.331462	 0.514177	 rs2065955	 0.299	 FLG:NM_002016:exon3:c.G10307C:p.G3436A	
F2	 8.221	 COL27A1	 synonymous		 9q32	 0.198524	 0.234225	 rs1687410	 0.157	 COL27A1:NM_032888:exon43:c.A4083G:p.G1361G	
F2	 7.041	 FLG	 synonymous		 1q21.3	 0.180231	 0.396366	 rs57672167	 0.269	 FLG:NM_002016:exon3:c.G8673T:p.V2891V	
F2	 6.882	 FLG	 nonsynonymous	 1q21.3	 0.107796	 0.287141	 rs11588170	 0.229	 FLG:NM_002016:exon3:c.G1330A:p.G444R	
F2	 6.855	 FLG	 synonymous		 1q21.3	 0.251771	 0.469649	 rs9436066	 0.299	 FLG:NM_002016:exon3:c.G9645T:p.V3215V	
F2	 6.267	 FLG	 synonymous		 1q21.3	 0.108027	 0.28754	 rs2065956	 0.229	 FLG:NM_002016:exon3:c.G10017A:p.Q3339Q	
F2	 4.804	 FLG	 nonsynonymous	 1q21.3	 0.197846	 .	 rs7546186	 0.219	 FLG:NM_002016:exon3:c.G6134C:p.S2045T	
F2	 3.844	 FLG	 synonymous	 1q21.3	 0.057488	 .	 rs57670307	 0.182	 FLG:NM_002016:exon3:c.C8343T:p.D2781D	
F2	 3.616	 COL4A3	 synonymous	 2q36.3	 0.068087	 0.105232	 rs34019152	 0.092	 COL4A3:NM_000091:exon23:c.G1452A:p.G484G	
F2	 1.414	 FLG	 nonsynonymous 1q21.3	 0.270567	 0.464058	 rs2011331	 0.295	 FLG:NM_002016:exon3:c.A1360G:p.T454A	
F2	 1.143	 FLG	 nonsynonymous 1q21.3	 0.109565	 0.290535	 rs72697000	 0.234	 FLG:NM_002016:exon3:c.G10590T:p.R3530S	
F2	 1.027	 FLG	 nonsynonymous 1q21.3	 0.281154	 0.47484	 rs3126072	 0.297	 FLG:NM_002016:exon3:c.G7633A:p.G2545R	
F2	 0.93	 FLG	 synonymous	 1q21.3	 .	 0.453474	 rs6664985	 0.278	 FLG:NM_002016:exon3:c.C6990T:p.H2330H	
F2	 0.819	 FLG	 nonsynonymous 1q21.3	 0.198601	 .	 rs7512857	 0.218	 FLG:NM_002016:exon3:c.T6058G:p.S2020A	
F2	 0.384	 FLG	 nonsynonymous 1q21.3	 0.089428	 .	 rs80221306	 0.208	 FLG:NM_002016:exon3:c.A8807G:p.D2936G	
F2	 0.264	 FLG	 synonymous	 1q21.3	 0.26984	 0.463658	 rs2184954	 0.294	 FLG:NM_002016:exon3:c.T6498C:p.S2166S	
F2	 0.147	 FLG	 synonymous	 1q21.3	 0.333385	 0.522564	 rs3126067	 0.301	 FLG:NM_002016:exon3:c.T10473C:p.N3491N	
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F2	 0.138	 FLG	 synonymous	 1q21.3	 0.262729	 0.473642	 rs3091276	 0.284	 FLG:NM_002016:exon3:c.T10194C:p.S3398S	
F2	 0.135	 FLG	 synonymous	 1q21.3	 0.282177	 0.473243	 rs3120653	 0.298	 FLG:NM_002016:exon3:c.T2508C:p.D836D	
F2	 0.113	 FLG	 synonymous	 1q21.3	 0.263611	 0.463059	 rs66831674	 0.294	 FLG:NM_002016:exon3:c.T3387C:p.S1129S	
F2	 0.085	 FLG	 nonsynonymous	 1q21.3	 .	 .	 rs78974621	 0.235	 FLG:NM_002016:exon3:c.A6626G:p.H2209R	
F2	 0.046	 FLG	 synonymous	 1q21.3	 0.194449	 0.327676	 rs7512554	 0.221	 FLG:NM_002016:exon3:c.T6354C:p.H2118H	
F2	 0.034	 FLG	 nonsynonymous	 1q21.3	 0.143626	 .	 rs66954353	 0.237	 FLG:NM_002016:exon3:c.A6574C:p.K2192Q	
F2	 0.025	 FLG	 synonymous	 1q21.3	 0.255077	 0.447085	 rs3126066	 0.278	 FLG:NM_002016:exon3:c.T10491C:p.D3497D	
F2	 0.017	 FLG	 nonsynonymous	 1q21.3	 0.154475	 0.330471	 rs71625201	 0.258	 FLG:NM_002016:exon3:c.G7192C:p.E2398Q	
F2	 0.016	 FLG	 synonymous	 1q21.3	 0.203829	 0.367212	 rs2338554	 0.241	 FLG:NM_002016:exon3:c.T6603C:p.D2201D	
F2	 0.011	 FLG	 nonsynonymous 1q21.3	 .	 0.25639	 rs7518080	 0.193	 FLG:NM_002016:exon3:c.G10691A:p.R3564H	
F2	 0.006	 FLG	 nonsynonymous 1q21.3	 0.15426	 0.343051	 rs71625200	 0.261	 FLG:NM_002016:exon3:c.A7330G:p.K2444E	
F2	 0.006	 FLG	 nonsynonymous 1q21.3	 .	 0.539736	 rs2184953	 0.317	 FLG:NM_002016:exon3:c.T6580C:p.Y2194H	
F2	 0.004	 FLG	 synonymous	 1q21.3	 0.156005	 0.341054	 rs6681433	 0.261	 FLG:NM_002016:exon3:c.A9966G:p.Q3322Q	
F2	 0.004	 FLG	 synonymous	 1q21.3	 0.172305	 0.328075	 rs80353812	 0.22	 FLG:NM_002016:exon3:c.T6072C:p.H2024H	
F2	 0.002	 FLG	 nonsynonymous 1q21.3	 0.195294	 0.327676	 rs7512553	 0.221	 FLG:NM_002016:exon3:c.T6355C:p.Y2119H	
F2	 0.002	 FLG	 nonsynonymous 1q21.3	 0.15713	 0.343051	 rs11581433	 0.261	 FLG:NM_002016:exon3:c.A4126G:p.R1376G	
F2	 0.001	 FLG	 nonsynonymous 1q21.3	 0.269799	 0.46226	 rs3126074	 0.294	 FLG:NM_002016:exon3:c.C7521G:p.H2507Q	
F2	 0.001	 FLG	 nonsynonymous 1q21.3	 0.15762	 0.342452	 rs55650366	 0.261	 FLG:NM_002016:exon3:c.T7442C:p.L2481S	
F2	 0.001	 FLG	 nonsynonymous 1q21.3	 0.101799	 .	 rs78179835	 0.208	 FLG:NM_002016:exon3:c.G6891C:p.E2297D	
F2	 0.001	 FLG	 nonsynonymous 1q21.3	 .	 0.34385	 rs74129452	 0.237	 FLG:NM_002016:exon3:c.A6462C:p.Q2154H	
F2	 0.001	 FLG	 nonsynonymous 1q21.3	 0.346917	 0.538139	 rs3126079	 0.317	 FLG:NM_002016:exon3:c.C5883A:p.H1961Q	
F2	 0.001	 FLG	 nonsynonymous 1q21.3	 0.310165	 0.534145	 rs58001094	 0.306	 FLG:NM_002016:exon3:c.C3500G:p.A1167G	
F2	 0.001	 FLG	 nonsynonymous 1q21.3	 0.158312	 0.344649	 rs11584340	 0.261	 FLG:NM_002016:exon3:c.C1432T:p.P478S	
F2	 0.001	 COL4A3	 nonsynonymous 2q36.3	 0.073534	 0.111422	 rs11677877	 0.094	 COL4A3:NM_000091:exon22:c.A1352G:p.H451R	
F7	 6.039	 MUTYH	 nonsynonymous 1p34.1	 0.254115	 0.313498	 rs3219489	 0.268	 MUTYH:NM_001048171:exon12:c.G972C:p.Q324H	
F7	 8.811	 COL4A2	 nonsynonymous 13q34	 0.231056	 0.190895	 rs9583500	 0.171	 COL4A2:NM_001846:exon28:c.C2152T:p.P718S	
F7	 32	 XRCC1	 nonsynonymous 19q13.31	 0.061664	 0.123802	 rs1799782	 0.093	 XRCC1:NM_006297:exon6:c.C580T:p.R194W	
F8	 34	 DOCK9	 nonsynonymous 13q32.3	 0.071235	 0.0788738	 rs117633128	 0.07	 DOCK9:NM_001130049:exon1:c.C52T:p.R18W	
F8	 32	 PARP1	 nonsynonymous 1q42.12	 0.123328	 0.196885	 rs1136410	 0.202	 PARP1:NM_001618:exon17:c.T2285C:p.V762A	
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F8	 32	 MPDZ	 nonsynonymous 9p23	 .	 .	 .	 0.00001	 MPDZ:NM_001261406:exon22:c.C3203A:p.A1068D	
F8	 25.1	 COL4A4	 nonsynonymous 2q36.3	 0.034696	 0.0205671	 rs1800516	 0.028	 COL4A4:NM_000092:exon23:c.G1634C:p.G545A	
F8	 24.3	 FLG	 nonsynonymous 1q21.3	 0.027953	 .	 rs77166567	 0.141	 FLG:NM_002016:exon3:c.G7015A:p.D2339N	
F8	 23	 COL4A3	 nonsynonymous 2q36.3	 0.16577	 0.115815	 rs55703767	 0.167	 COL4A3:NM_000091:exon17:c.G976T:p.D326Y	
F8	 17.73	 ZNF469	 nonsynonymous	 16q24.2	 0.055848	 0.0435304	 rs3812954	 0.041	 ZNF469:NM_001127464:exon2:c.A8246T:p.D2749V	
F8	 16.83	 COL5A1	 synonymous		 9q34.3	 0.081578	 0.101837	 rs41306391	 0.044	 COL5A1:NM_000093:exon7:c.C1092T:p.P364P	
F8	 15.08	 COL4A1	 nonsynonymous	 13q34	 0.000154	 0.0001996	 rs201964644	 0.00024	 COL4A1:NM_001845:exon32:c.C2624G:p.P875R	
F8	 12.45	 NUB1	 synonymous		 7q36.1	 0.000818	 0.0003993	 rs182317005	 0.00019	 NUB1:NM_001243351:exon13:c.C1521T:p.T507T	
F8	 11.22	 COL4A2	 synonymous		 13q34	 0.087228	 0.100839	 rs391859	 0.1	 COL4A2:NM_001846:exon47:c.G4617A:p.A1539A	
F8	 9.907	 COL4A4	 splicing	 2q36.3	 0.074102	 0.103035	 rs3769641	 0.087	 NM_000092:exon30:c.2384-5T&amp;amp;gt;C	
F8	 6.039	 MUTYH	 nonsynonymous	 1p34.1	 0.254115	 0.313498	 rs3219489	 0.268	 MUTYH:NM_001048171:exon12:c.G972C:p.Q324H	
F8	 3.614	 COL8A2	 synonymous		 1p34.3	 0.003537	 0.0017971	 rs149090218	 0.00303	 COL8A2:NM_001294347:exon4:c.C1551T:p.T517T	
F8	 3.252	 ZNF469	 nonsynonymous	 16q24.2	 .	 0.028754	 rs3812951	 0.016	 ZNF469:NM_001127464:exon2:c.G10891A:p.G3631
R	
F8	 0.93	 FLG	 synonymous		 1q21.3	 .	 0.453474	 rs6664985	 0.278	 FLG:NM_002016:exon3:c.C6990T:p.H2330H	
F8	 0.085	 FLG	 nonsynonymous	 1q21.3	 .	 .	 rs78974621	 0.235	 FLG:NM_002016:exon3:c.A6626G:p.H2209R	
F8	 0.039	 COL4A1	 synonymous		 13q34	 0.252499	 0.20647	 rs995224	 0.258	 COL4A1:NM_001845:exon21:c.T1257C:p.P419P	
F9	 28.7	 MPDZ	 nonsynonymous	 9p23	 0.000165	 0.0005990	 rs149265684	 0.00028	 MPDZ:NM_001261406:exon14:c.C1739G:p.S580C	
F9	 24.1	 ZNF469	 nonframeshift	
deletion	
16q24.2	 .	 0.0017971	 .	 0.00350	 ZNF469:NM_001127464:exon2:c.9010_9024del:p.3
004_3008del	
F9	 23.8	 FLG	 nonsynonymous 1q21.3	 0.10772	 0.28774	 rs12405278	 0.229	 FLG:NM_002016:exon3:c.C5095T:p.R1699C	
F9	 22.6	 FLG	 nonsynonymous 1q21.3	 0.077095	 .	 rs75448155	 0.191	 FLG:NM_002016:exon3:c.G10903A:p.D3635N	
F9	 22.6	 FLG	 nonsynonymous 1q21.3	 0.139243	 0.327676	 rs74129461	 0.256	 FLG:NM_002016:exon3:c.G2263A:p.E755K	
F9	 22.5	 IL1A	 nonsynonymous 2q13	 0.261648	 0.217452	 rs17561	 0.272	 IL1A:NM_000575:exon5:c.G340T:p.A114S	
F9	 20.7	 FLG	 nonsynonymous 1q21.3	 0.10772	 0.287141	 rs11204978	 0.229	 FLG:NM_002016:exon3:c.C4445A:p.S1482Y	
F9	 20.3	 COL4A3	 nonsynonymous 2q36.3	 0.063256	 0.100639	 rs34505188	 0.091	 COL4A3:NM_000091:exon21:c.G1223A:p.R408H	
F9	 19.32	 MPDZ	 nonsynonymous 9p23	 0.029927	 0.0135783	 rs34605667	 0.033	 MPDZ:NM_001261407:exon41:c.G5537A:p.R1846K	
F9	 17.66	 FLG	 nonsynonymous 1q21.3	 0.118714	 0.296725	 rs12407807	 0.232	 FLG:NM_002016:exon3:c.G5051A:p.R1684H	
F9	 15.37	 FLG	 nonsynonymous 1q21.3	 0.107676	 0.28774	 rs11586631	 0.229	 FLG:NM_002016:exon3:c.G4079A:p.R1360H	
F9	 15.37	 FLG	 nonsynonymous 1q21.3	 0.155774	 0.340655	 rs41267154	 0.26	 FLG:NM_002016:exon3:c.G995T:p.G332V	
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F9	 14.66	 FLG	 nonsynonymous 1q21.3	 0.099721	 .	 rs71625202	 0.206	 FLG:NM_002016:exon3:c.G7097C:p.S2366T	
F9	 13.89	 COL4A2	 synonymous		 13q34	 0.262849	 0.238618	 rs76425569	 0.231	 COL4A2:NM_001846:exon19:c.G1095A:p.P365P	
F9	 13.5	 ZNF469	 nonsynonymous 16q24.2	 .	 .	 .	 .	 ZNF469:NM_001127464:exon1:c.A3062C:p.E1021A	
F9	 13.01	 FLG	 nonsynonymous 1q21.3	 0.084081	 .	 rs11582087	 0.188	 FLG:NM_002016:exon3:c.A8506C:p.S2836R	
F9	 12.89	 COL4A2	 synonymous		 13q34	 0.284764	 0.246805	 rs74941798	 0.295	 COL4A2:NM_001846:exon19:c.C1179T:p.I393I	
F9	 12.45	 ZNF469	 nonsynonymous	 16q24.2	 .	 0.028754	 rs3812951	 0.016	 ZNF469:NM_001127464:exon2:c.G10891A:p.G3631
R	
F9	 12.41	 COL5A1	 synonymous		 9q34.3	 0.425188	 0.408147	 rs2228560	 0.375	 COL5A1:NM_000093:exon58:c.G4482C:p.P1494P	
F9	 12.24	 ZNF469	 synonymous		 16q24.2	 .	 .	 .	 .	 ZNF469:NM_001127464:exon1:c.G2808T:p.A936A	
F9	 12.19	 LOX	 nonsynonymous 5q23.2	 0.175339	 0.156749	 rs1800449	 0.17	 LOX:NM_002317:exon1:c.G473A:p.R158Q	
F9	 11.35	 FLG	 nonsynonymous 1q21.3	 0.10795	 0.28754	 rs12407748	 0.229	 FLG:NM_002016:exon3:c.G5672A:p.R1891Q	
F9	 11.22	 COL4A2	 synonymous		 13q34	 0.087228	 0.100839	 rs391859	 0.1	 COL4A2:NM_001846:exon47:c.G4617A:p.A1539A	
F9	 11.04	 PARP1	 synonymous		 1q42.12	 0.147701	 0.218251	 rs1805404	 0.208	 PARP1:NM_001618:exon2:c.C243T:p.D81D	
F9	 10.76	 FLG	 nonsynonymous 1q21.3	 0.107873	 0.286941	 rs77422831	 0.229	 FLG:NM_002016:exon3:c.G11213A:p.R3738H	
F9	 10.23	 ZNF469	 nonsynonymous 16q24.2	 .	 0.0471246	 rs113937803	 0.019	 ZNF469:NM_001127464:exon1:c.G1285A:p.A429T	
F9	 10.22	 FLG	 nonsynonymous 1q21.3	 0.060298	 .	 rs2184952	 0.085	 FLG:NM_002016:exon3:c.G8548A:p.G2850S	
F9	 10.19	 FLG	 nonsynonymous 1q21.3	 0.107753	 0.28754	 rs12405241	 0.229	 FLG:NM_002016:exon3:c.C5414T:p.A1805V	
F9	 10.05	 FLG	 nonsynonymous 1q21.3	 0.209519	 .	 rs7522925	 0.221	 FLG:NM_002016:exon3:c.C6323T:p.A2108V	
F9	 9.922	 ZEB1	 synonymous		 10p11.22	 0.064278	 0.0858626	 rs7918614	 0.032	 ZEB1:NM_001128128:exon2:c.C141T:p.D47D	
F9	 9.85	 COL4A2	 Splicing	 13q34	 0.192017	 0.190895	 rs3803228	 0.175	 NM_001846:exon32:c.2759-5T&amp;gt;C	
F9	 9.817	 COL4A2	 synonymous		 13q34	 0.241984	 0.186302	 rs4773199	 0.198	 COL4A2:NM_001846:exon43:c.G4089A:p.A1363A	
F9	 9.066	 ZNF469	 nonsynonymous 16q24.2	 0.025843	 0.0365415	 rs3812955	 0.016	 ZNF469:NM_001127464:exon2:c.G8128A:p.A2710T	
F9	 8.403	 FLG	 nonsynonymous 1q21.3	 0.331462	 0.514177	 rs2065955	 0.299	 FLG:NM_002016:exon3:c.G10307C:p.G3436A	
F9	 8.221	 COL27A1	 synonymous		 9q32	 0.198524	 0.234225	 rs1687410	 0.157	 COL27A1:NM_032888:exon43:c.A4083G:p.G1361G	
F9	 8.181	 ZNF469	 synonymous		 16q24.2	 .	 .	 .	 0.00003	 ZNF469:NM_001127464:exon2:c.G4836A:p.A1612A	
F9	 8.17	 ZNF469	 synonymous		 16q24.2	 0.022996	 0.0339457	 rs74032865	 0.017	 ZNF469:NM_001127464:exon2:c.C4350T:p.S1450S	
F9	 7.45	 ZNF469	 synonymous		 16q24.2	 .	 0.0163738	 rs117310292	 0.011	 ZNF469:NM_001127464:exon2:c.G4842A:p.S1614S	
F9	 7.041	 FLG	 synonymous		 1q21.3	 0.180231	 0.396366	 rs57672167	 0.269	 FLG:NM_002016:exon3:c.G8673T:p.V2891V	
F9	 6.916	 IL1RN	 synonymous		 2q13	 0.333154	 0.35004	 rs315952	 0.308	 IL1RN:NM_173842:exon4:c.T390C:p.S130S	
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F9	 6.882	 FLG	 nonsynonymous	 1q21.3	 0.107796	 0.287141	 rs11588170	 0.229	 FLG:NM_002016:exon3:c.G1330A:p.G444R	
F9	 6.855	 FLG	 synonymous		 1q21.3	 0.251771	 0.469649	 rs9436066	 0.299	 FLG:NM_002016:exon3:c.G9645T:p.V3215V	
F9	 6.267	 FLG	 synonymous		 1q21.3	 0.108027	 0.28754	 rs2065956	 0.229	 FLG:NM_002016:exon3:c.G10017A:p.Q3339Q	
F9	 4.804	 FLG	 nonsynonymous	 1q21.3	 0.197846	 .	 rs7546186	 0.219	 FLG:NM_002016:exon3:c.G6134C:p.S2045T	
F9	 3.616	 COL4A3	 synonymous		 2q36.3	 0.068087	 0.105232	 rs34019152	 0.092	 COL4A3:NM_000091:exon23:c.G1452A:p.G484G	
F9	 3.252	 ZNF469	 nonsynonymous	 16q24.2	 .	 .	 .	 .	 ZNF469:NM_001127464:exon2:c.C8342T:p.P2781L	
F9	 2.925	 ZNF469	 synonymous		 16q24.2	 .	 0.113618	 rs61472141	 0.045	 ZNF469:NM_001127464:exon2:c.G6378A:p.P2126P	
F9	 1.976	 FLG	 nonsynonymous 1q21.3	 .	 0.313498	 rs113544881	 0.215	 FLG:NM_002016:exon3:c.T5828A:p.L1943H	
F9	 1.414	 FLG	 nonsynonymous 1q21.3	 0.270567	 0.464058	 rs2011331	 0.295	 FLG:NM_002016:exon3:c.A1360G:p.T454A	
F9	 1.296	 HGF	 synonymous		 7q21.11	 0.104061	 0.103435	 rs5745635	 0.042	 HGF:NM_000601:exon3:c.A333G:p.E111E	
F9	 1.143	 FLG	 nonsynonymous 1q21.3	 0.109565	 0.290535	 rs72697000	 0.234	 FLG:NM_002016:exon3:c.G10590T:p.R3530S	
F9	 1.027	 FLG	 nonsynonymous 1q21.3	 0.281154	 0.47484	 rs3126072	 0.297	 FLG:NM_002016:exon3:c.G7633A:p.G2545R	
F9	 0.819	 FLG	 nonsynonymous 1q21.3	 0.198601	 .	 rs7512857	 0.218	 FLG:NM_002016:exon3:c.T6058G:p.S2020A	
F9	 0.449	 FLG	 nonsynonymous 1q21.3	 .	 .	 rs80059102	 0.22	 FLG:NM_002016:exon3:c.T5839G:p.W1947G	
F9	 0.268	 FLG	 nonsynonymous 1q21.3	 .	 0.206669	 rs7540123	 0.187	 FLG:NM_002016:exon3:c.C10702G:p.Q3568E	
F9	 0.264	 FLG	 synonymous		 1q21.3	 0.26984	 0.463658	 rs2184954	 0.294	 FLG:NM_002016:exon3:c.T6498C:p.S2166S	
F9	 0.147	 FLG	 synonymous		 1q21.3	 0.333385	 0.522564	 rs3126067	 0.301	 FLG:NM_002016:exon3:c.T10473C:p.N3491N	
F9	 0.138	 FLG	 synonymous		 1q21.3	 0.262729	 0.473642	 rs3091276	 0.284	 FLG:NM_002016:exon3:c.T10194C:p.S3398S	
F9	 0.135	 FLG	 synonymous		 1q21.3	 0.282177	 0.473243	 rs3120653	 0.298	 FLG:NM_002016:exon3:c.T2508C:p.D836D	
F9	 0.113	 FLG	 synonymous		 1q21.3	 0.263611	 0.463059	 rs66831674	 0.294	 FLG:NM_002016:exon3:c.T3387C:p.S1129S	
F9	 0.097	 FLG	 synonymous		 1q21.3	 .	 .	 rs201652079	 0.00017	 FLG:NM_002016:exon3:c.T7842C:p.A2614A	
F9	 0.097	 XRCC1	 nonsynonymous 19q13.31	 0.011379	 0.0213658	 rs2307177	 0.012	 XRCC1:NM_006297:exon16:c.A1727C:p.N576T	
F9	 0.085	 FLG	 nonsynonymous 1q21.3	 .	 .	 rs78974621	 0.235	 FLG:NM_002016:exon3:c.A6626G:p.H2209R	
F9	 0.046	 FLG	 synonymous		 1q21.3	 0.194449	 0.327676	 rs7512554	 0.221	 FLG:NM_002016:exon3:c.T6354C:p.H2118H	
F9	 0.039	 COL4A1	 synonymous		 13q34	 0.252499	 0.20647	 rs995224	 0.258	 COL4A1:NM_001845:exon21:c.T1257C:p.P419P	
F9	 0.034	 FLG	 nonsynonymous	 1q21.3	 0.143626	 .	 rs66954353	 0.237	 FLG:NM_002016:exon3:c.A6574C:p.K2192Q	
F9	 0.025	 FLG	 synonymous		 1q21.3	 0.255077	 0.447085	 rs3126066	 0.278	 FLG:NM_002016:exon3:c.T10491C:p.D3497D	
F9	 0.017	 FLG	 nonsynonymous	 1q21.3	 0.154475	 0.330471	 rs71625201	 0.258	 FLG:NM_002016:exon3:c.G7192C:p.E2398Q	
F9	 0.016	 FLG	 synonymous		 1q21.3	 0.203829	 0.367212	 rs2338554	 0.241	 FLG:NM_002016:exon3:c.T6603C:p.D2201D	
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F9	 0.011	 FLG	 nonsynonymous 1q21.3	 .	 0.25639	 rs7518080	 0.193	 FLG:NM_002016:exon3:c.G10691A:p.R3564H	
F9	 0.006	 FLG	 nonsynonymous 1q21.3	 0.15426	 0.343051	 rs71625200	 0.261	 FLG:NM_002016:exon3:c.A7330G:p.K2444E	
F9	 0.006	 FLG	 nonsynonymous 1q21.3	 .	 0.539736	 rs2184953	 0.317	 FLG:NM_002016:exon3:c.T6580C:p.Y2194H	
F9	 0.004	 FLG	 synonymous		 1q21.3	 0.156005	 0.341054	 rs6681433	 0.261	 FLG:NM_002016:exon3:c.A9966G:p.Q3322Q	
F9	 0.004	 FLG	 synonymous		 1q21.3	 0.172305	 0.328075	 rs80353812	 0.22	 FLG:NM_002016:exon3:c.T6072C:p.H2024H	
F9	 0.002	 FLG	 nonsynonymous 1q21.3	 0.195294	 0.327676	 rs7512553	 0.221	 FLG:NM_002016:exon3:c.T6355C:p.Y2119H	
F9	 0.002	 FLG	 nonsynonymous 1q21.3	 0.15713	 0.343051	 rs11581433	 0.261	 FLG:NM_002016:exon3:c.A4126G:p.R1376G	
F9	 0.002	 POLG	 nonframeshift	
deletion	




F9	 0.001	 FLG	 nonsynonymous 1q21.3	 .	 0.206669	 rs7532285	 0.187	 FLG:NM_002016:exon3:c.A10703G:p.Q3568R	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 .	 .	 .	 0.00010
71	
FLG:NM_002016:exon3:c.C10087T:p.P3363S	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 .	 0.0027955	 rs138143041	 0.00016	 FLG:NM_002016:exon3:c.T7687C:p.W2563R	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 0.269799	 0.46226	 rs3126074	 0.294	 FLG:NM_002016:exon3:c.C7521G:p.H2507Q	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 0.15762	 0.342452	 rs55650366	 0.261	 FLG:NM_002016:exon3:c.T7442C:p.L2481S	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 0.101799	 .	 rs78179835	 0.208	 FLG:NM_002016:exon3:c.G6891C:p.E2297D	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 .	 0.34385	 rs74129452	 0.237	 FLG:NM_002016:exon3:c.A6462C:p.Q2154H	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 0.346917	 0.538139	 rs3126079	 0.317	 FLG:NM_002016:exon3:c.C5883A:p.H1961Q	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 0.310165	 0.534145	 rs58001094	 0.306	 FLG:NM_002016:exon3:c.C3500G:p.A1167G	
F9	 0.001	 FLG	 nonsynonymous 1q21.3	 0.158312	 0.344649	 rs11584340	 0.261	 FLG:NM_002016:exon3:c.C1432T:p.P478S	
F9	 0.001	 COL4A3	 nonsynonymous 2q36.3	 0.073534	 0.111422	 rs11677877	 0.094	 COL4A3:NM_000091:exon22:c.A1352G:p.H451R	
F9	 	 XRCC1	 nonsynonymous	 19q13.31	 0.042776	 0.0670927	 rs25489	 0.066	 XRCC1:NM_006297:exon9:c.G839A:p.R280H	
F9	 	 XRCC1	 synonymous		 19q13.31	 0.42032	 0.321286	 rs915927	 0.335	 XRCC1:NM_006297:exon7:c.A618G:p.P206P	
F10	 28.2	 CDH11	 nonsynonymous 16q21	 0.260111	 0.18151	 rs35195	 0.273	 CDH11:NM_001797:exon6:c.C764T:p.T255M	
F10	 23.8	 FLG	 nonsynonymous 1q21.3	 0.10772	 0.28774	 rs12405278	 0.229	 FLG:NM_002016:exon3:c.C5095T:p.R1699C	
F10	 22.6	 FLG	 nonsynonymous 1q21.3	 0.077095	 .	 rs75448155	 0.191	 FLG:NM_002016:exon3:c.G10903A:p.D3635N	
F10	 22.6	 FLG	 nonsynonymous 1q21.3	 .	 .	 .	 0.00000
8236	
FLG:NM_002016:exon3:c.G3095C:p.R1032T	
F10	 22.6	 FLG	 nonsynonymous 1q21.3	 0.139243	 0.327676	 rs74129461	 0.256	 FLG:NM_002016:exon3:c.G2263A:p.E755K	
F10	 20.7	 FLG	 nonsynonymous 1q21.3	 0.10772	 0.287141	 rs11204978	 0.229	 FLG:NM_002016:exon3:c.C4445A:p.S1482Y	
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F10	 20.3	 COL4A3	 nonsynonymous 2q36.3	 0.063256	 0.100639	 rs34505188	 0.091	 COL4A3:NM_000091:exon21:c.G1223A:p.R408H	
F10	 19.86	 CDH11	 synonymous		 16q21	 0.322159	 0.223642	 rs28216	 0.33	 CDH11:NM_001797:exon7:c.G945A:p.S315S	
F10	 17.73	 ZNF469	 nonsynonymous 16q24.2	 0.055848	 0.0435304	 rs3812954	 0.041	 ZNF469:NM_001127464:exon2:c.A8246T:p.D2749V	
F10	 17.66	 FLG	 nonsynonymous 1q21.3	 0.118714	 0.296725	 rs12407807	 0.232	 FLG:NM_002016:exon3:c.G5051A:p.R1684H	
F10	 17.48	 RXRA	 nonsynonymous 9q34.2	 0.000077	 .	 rs137938878	 0.00011	 RXRA:NM_001291921:exon2:c.G10A:p.V4I	
F10	 15.37	 FLG	 nonsynonymous 1q21.3	 0.107676	 0.28774	 rs11586631	 0.229	 FLG:NM_002016:exon3:c.G4079A:p.R1360H	
F10	 15.37	 FLG	 nonsynonymous 1q21.3	 0.155774	 0.340655	 rs41267154	 0.26	 FLG:NM_002016:exon3:c.G995T:p.G332V	
F10	 14.66	 FLG	 nonsynonymous 1q21.3	 0.099721	 .	 rs71625202	 0.206	 FLG:NM_002016:exon3:c.G7097C:p.S2366T	
F10	 14.3	 DOCK9	 synonymous		 13q32.3	 0.13827	 0.167532	 rs12428661	 0.181	 DOCK9:NM_001130049:exon5:c.C477T:p.V159V	
F10	 13.01	 FLG	 nonsynonymous 1q21.3	 0.084081	 .	 rs11582087	 0.188	 FLG:NM_002016:exon3:c.A8506C:p.S2836R	
F10	 12.72	 COL4A2	 nonsynonymous 13q34	 0.103497	 0.103834	 rs3803230	 0.106	 COL4A2:NM_001846:exon27:c.G2048C:p.G683A	
F10	 12.45	 XRCC1	 nonsynonymous 19q13.31	 0.042776	 0.0670927	 rs25489	 0.066	 XRCC1:NM_006297:exon9:c.G839A:p.R280H	
F10	 12.41	 COL5A1	 synonymous		 9q34.3	 0.425188	 0.408147	 rs2228560	 0.375	 COL5A1:NM_000093:exon58:c.G4482C:p.P1494P	
F10	 11.35	 FLG	 nonsynonymous 1q21.3	 0.10795	 0.28754	 rs12407748	 0.229	 FLG:NM_002016:exon3:c.G5672A:p.R1891Q	
F10	 10.76	 FLG	 nonsynonymous 1q21.3	 0.107873	 0.286941	 rs77422831	 0.229	 FLG:NM_002016:exon3:c.G11213A:p.R3738H	
F10	 10.51	 DOCK9	 Synonymous	 13q32.3	 0.004942	 0.0037939	 rs41279128	 0.00443	 DOCK9:uc001vns.2:exon15:c.C1686T:p.C562C	
F10	 10.22	 FLG	 nonsynonymous 1q21.3	 0.060298	 .	 rs2184952	 0.085	 FLG:NM_002016:exon3:c.G8548A:p.G2850S	
F10	 10.19	 FLG	 nonsynonymous 1q21.3	 0.107753	 0.28754	 rs12405241	 0.229	 FLG:NM_002016:exon3:c.C5414T:p.A1805V	
F10	 10.05	 FLG	 nonsynonymous 1q21.3	 0.209519	 .	 rs7522925	 0.221	 FLG:NM_002016:exon3:c.C6323T:p.A2108V	
F10	 10.05	 CDH11	 synonymous		 16q21	 0.081206	 0.0625	 rs35182	 0.092	 CDH11:NM_001797:exon3:c.C99T:p.P33P	
F10	 9.923	 NUB1	 synonymous		 7q36.1	 0.485389	 0.384385	 rs386956	 0.52	 NUB1:NM_001243351:exon9:c.C912T:p.Y304Y	
F10	 8.403	 FLG	 nonsynonymous	 1q21.3	 0.331462	 0.514177	 rs2065955	 0.299	 FLG:NM_002016:exon3:c.G10307C:p.G3436A	
F10	 8.119	 ZNF469	 synonymous		 16q24.2	 .	 0.0003993	 rs150435442	 0.00066	 ZNF469:NM_001127464:exon1:c.G2841A:p.R947R	
F10	 7.596	 FOXO1	 nonsynonymous	 13q14.11	 .	 .	 .	 .	 FOXO1:NM_002015:exon1:c.C251T:p.P84L	
F10	 7.482	 MPDZ	 synonymous		 9p23	 0.0049	 0.0013977	 rs34704118	 0.00459	 MPDZ:NM_001261406:exon19:c.A2580G:p.L860L	
F10	 7.041	 FLG	 synonymous		 1q21.3	 0.180231	 0.396366	 rs57672167	 0.269	 FLG:NM_002016:exon3:c.G8673T:p.V2891V	
F10	 6.882	 FLG	 nonsynonymous		 1q21.3	 0.107796	 0.287141	 rs11588170	 0.229	 FLG:NM_002016:exon3:c.G1330A:p.G444R	
F10	 6.855	 FLG	 synonymous		 1q21.3	 0.251771	 0.469649	 rs9436066	 0.299	 FLG:NM_002016:exon3:c.G9645T:p.V3215V	
F10	 6.267	 FLG	 synonymous		 1q21.3	 0.108027	 0.28754	 rs2065956	 0.229	 FLG:NM_002016:exon3:c.G10017A:p.Q3339Q	
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F10	 4.804	 FLG	 nonsynonymous		 1q21.3	 0.197846	 .	 rs7546186	 0.219	 FLG:NM_002016:exon3:c.G6134C:p.S2045T	
F10	 3.844	 FLG	 synonymous		 1q21.3	 0.057488	 .	 rs57670307	 0.182	 FLG:NM_002016:exon3:c.C8343T:p.D2781D	
F10	 3.616	 COL4A3	 synonymous		 2q36.3	 0.068087	 0.105232	 rs34019152	 0.092	 COL4A3:NM_000091:exon23:c.G1452A:p.G484G	
F10	 1.552	 NUB1	 synonymous		 7q36.1	 0.406845	 0.332867	 rs2159158	 0.397	 NUB1:NM_001243351:exon15:c.A1905G:p.A635A	
F10	 1.414	 FLG	 nonsynonymous		 1q21.3	 0.270567	 0.464058	 rs2011331	 0.295	 FLG:NM_002016:exon3:c.A1360G:p.T454A	
F10	 1.143	 FLG	 nonsynonymous		 1q21.3	 0.109565	 0.290535	 rs72697000	 0.234	 FLG:NM_002016:exon3:c.G10590T:p.R3530S	
F10	 1.027	 FLG	 nonsynonymous		 1q21.3	 0.281154	 0.47484	 rs3126072	 0.297	 FLG:NM_002016:exon3:c.G7633A:p.G2545R	
F10	 0.93	 FLG	 synonymous		 1q21.3	 .	 0.453474	 rs6664985	 0.278	 FLG:NM_002016:exon3:c.C6990T:p.H2330H	
F10	 0.819	 FLG	 nonsynonymous		 1q21.3	 0.198601	 .	 rs7512857	 0.218	 FLG:NM_002016:exon3:c.T6058G:p.S2020A	
F10	 0.424	 DOCK9	 synonymous		 13q32.3	 0.19774	 0.205871	 rs2296984	 0.202	 DOCK9:uc001vns.2:exon12:c.A1197C:p.A399A	
F10	 0.264	 FLG	 synonymous		 1q21.3	 0.26984	 0.463658	 rs2184954	 0.294	 FLG:NM_002016:exon3:c.T6498C:p.S2166S	
F10	 0.147	 FLG	 synonymous		 1q21.3	 0.333385	 0.522564	 rs3126067	 0.301	 FLG:NM_002016:exon3:c.T10473C:p.N3491N	
F10	 0.138	 FLG	 synonymous		 1q21.3	 0.262729	 0.473642	 rs3091276	 0.284	 FLG:NM_002016:exon3:c.T10194C:p.S3398S	
F10	 0.135	 FLG	 synonymous		 1q21.3	 0.282177	 0.473243	 rs3120653	 0.298	 FLG:NM_002016:exon3:c.T2508C:p.D836D	
F10	 0.113	 FLG	 synonymous		 1q21.3	 0.263611	 0.463059	 rs66831674	 0.294	 FLG:NM_002016:exon3:c.T3387C:p.S1129S	
F10	 0.097	 XRCC1	 synonymous		 19q13.31	 0.42032	 0.321286	 rs915927	 0.335	 XRCC1:NM_006297:exon7:c.A618G:p.P206P	
F10	 0.085	 FLG	 nonsynonymous		 1q21.3	 .	 .	 rs78974621	 0.235	 FLG:NM_002016:exon3:c.A6626G:p.H2209R	
F10	 0.046	 FLG	 synonymous		 1q21.3	 0.194449	 0.327676	 rs7512554	 0.221	 FLG:NM_002016:exon3:c.T6354C:p.H2118H	
F10	 0.034	 FLG	 nonsynonymous		 1q21.3	 0.143626	 .	 rs66954353	 0.237	 FLG:NM_002016:exon3:c.A6574C:p.K2192Q	
F10	 0.025	 FLG	 synonymous		 1q21.3	 0.255077	 0.447085	 rs3126066	 0.278	 FLG:NM_002016:exon3:c.T10491C:p.D3497D	
F10	 0.017	 FLG	 nonsynonymous		 1q21.3	 0.154475	 0.330471	 rs71625201	 0.258	 FLG:NM_002016:exon3:c.G7192C:p.E2398Q	
F10	 0.016	 FLG	 synonymous		 1q21.3	 0.203829	 0.367212	 rs2338554	 0.241	 FLG:NM_002016:exon3:c.T6603C:p.D2201D	
F10	 0.011	 FLG	 nonsynonymous		 1q21.3	 .	 0.25639	 rs7518080	 0.193	 FLG:NM_002016:exon3:c.G10691A:p.R3564H	
F10	 0.006	 FLG	 nonsynonymous		 1q21.3	 0.15426	 0.343051	 rs71625200	 0.261	 FLG:NM_002016:exon3:c.A7330G:p.K2444E	
F10	 0.006	 FLG	 nonsynonymous		 1q21.3	 .	 0.539736	 rs2184953	 0.317	 FLG:NM_002016:exon3:c.T6580C:p.Y2194H	
F10	 0.004	 FLG	 synonymous		 1q21.3	 0.156005	 0.341054	 rs6681433	 0.261	 FLG:NM_002016:exon3:c.A9966G:p.Q3322Q	
F10	 0.004	 FLG	 synonymous		 1q21.3	 0.172305	 0.328075	 rs80353812	 0.22	 FLG:NM_002016:exon3:c.T6072C:p.H2024H	
F10	 0.002	 FLG	 nonsynonymous		 1q21.3	 0.195294	 0.327676	 rs7512553	 0.221	 FLG:NM_002016:exon3:c.T6355C:p.Y2119H	
F10	 0.002	 FLG	 nonsynonymous		 1q21.3	 0.15713	 0.343051	 rs11581433	 0.261	 FLG:NM_002016:exon3:c.A4126G:p.R1376G	
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F10	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.269799	 0.46226	 rs3126074	 0.294	 FLG:NM_002016:exon3:c.C7521G:p.H2507Q	
F10	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.15762	 0.342452	 rs55650366	 0.261	 FLG:NM_002016:exon3:c.T7442C:p.L2481S	
F10	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.101799	 .	 rs78179835	 0.208	 FLG:NM_002016:exon3:c.G6891C:p.E2297D	
F10	 0.001	 FLG	 nonsynonymous		 1q21.3	 .	 0.34385	 rs74129452	 0.237	 FLG:NM_002016:exon3:c.A6462C:p.Q2154H	
F10	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.346917	 0.538139	 rs3126079	 0.317	 FLG:NM_002016:exon3:c.C5883A:p.H1961Q	
F10	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.310165	 0.534145	 rs58001094	 0.306	 FLG:NM_002016:exon3:c.C3500G:p.A1167G	
F10	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.158312	 0.344649	 rs11584340	 0.261	 FLG:NM_002016:exon3:c.C1432T:p.P478S	
F10	 0.001	 COL4A3	 nonsynonymous		 2q36.3	 0.073534	 0.111422	 rs11677877	 0.094	 COL4A3:NM_000091:exon22:c.A1352G:p.H451R	
F11	 28.4	 COL4A1	 nonsynonymous		 13q34	 0.000231	 0.0001996	 rs141395813	 0.00010	 COL4A1:NM_001845:exon45:c.G3997A:p.D1333N	
F11	 24.2	 FLG	 nonsynonymous		 1q21.3	 0.017684	 0.0249601	 rs36006086	 0.023	 FLG:NM_002016:exon3:c.C5671T:p.R1891W	
F11	 23.7	 ZNF469	 nonsynonymous		 16q24.2	 .	 0.0027955	 rs75288466	 0.00411	 ZNF469:NM_001127464:exon2:c.G10277A:p.R3426
Q	
F11	 23	 COL4A3	 nonsynonymous		 2q36.3	 0.16577	 0.115815	 rs55703767	 0.167	 COL4A3:NM_000091:exon17:c.G976T:p.D326Y	
F11	 22.6	 FLG	 nonsynonymous		 1q21.3	 0.139243	 0.327676	 rs74129461	 0.256	 FLG:NM_002016:exon3:c.G2263A:p.E755K	
F11	 22.5	 IL1A	 nonsynonymous		 2q13	 0.261648	 0.217452	 rs17561	 0.272	 IL1A:NM_000575:exon5:c.G340T:p.A114S	
F11	 22.3	 FLG	 nonsynonymous		 1q21.3	 0.004306	 0.0047923	 rs12750571	 0.00495	 FLG:NM_002016:exon3:c.C4309T:p.R1437C	
F11	 18.89	 COL8A2	 nonsynonymous		 1p34.3	 0.000616	 0.0005990	 rs142307403	 0.00075	 COL8A2:NM_001294347:exon4:c.G1504A:p.G502S	
F11	 17.89	 FLG	 nonsynonymous		 1q21.3	 0.01753	 0.0249601	 rs35621145	 0.023	 FLG:NM_002016:exon3:c.C9808T:p.R3270C	
F11	 15.37	 FLG	 nonsynonymous		 1q21.3	 0.155774	 0.340655	 rs41267154	 0.26	 FLG:NM_002016:exon3:c.G995T:p.G332V	
F11	 14.38	 COL5A1	 synonymous		 9q34.3	 0.031601	 0.0415335	 rs78511105	 0.041	 COL5A1:NM_000093:exon36:c.C2892T:p.G964G	
F11	 13.89	 COL4A2	 synonymous		 13q34	 0.262849	 0.238618	 rs76425569	 0.231	 COL4A2:NM_001846:exon19:c.G1095A:p.P365P	
F11	 13.84	 COL27A1	 synonymous		 9q32	 0.080194	 0.0796725	 rs13290696	 0.093	 COL27A1:NM_032888:exon8:c.G2148T:p.P716P	
F11	 12.89	 COL4A2	 synonymous		 13q34	 0.284764	 0.246805	 rs74941798	 0.295	 COL4A2:NM_001846:exon19:c.C1179T:p.I393I	
F11	 12.76	 FLG	 nonsynonymous		 1q21.3	 0.017684	 0.0249601	 rs12750081	 0.023	 FLG:NM_002016:exon3:c.C4568T:p.T1523I	
F11	 12.72	 COL4A2	 nonsynonymous		 13q34	 0.103497	 0.103834	 rs3803230	 0.106	 COL4A2:NM_001846:exon27:c.G2048C:p.G683A	
F11	 12.41	 COL5A1	 synonymous		 9q34.3	 0.425188	 0.408147	 rs2228560	 0.375	 COL5A1:NM_000093:exon58:c.G4482C:p.P1494P	
F11	 12.11	 FLG	 nonsynonymous		 1q21.3	 0.017607	 0.0247604	 rs71626704	 0.023	 FLG:NM_002016:exon3:c.C6045A:p.D2015E	
F11	 10.4	 MPDZ	 synonymous		 9p23	 0.318029	 0.393171	 rs2274856	 0.286	 MPDZ:NM_001261406:exon20:c.G2754A:p.S918S	
F11	 9.923	 NUB1	 synonymous		 7q36.1	 0.485389	 0.384385	 rs386956	 0.52	 NUB1:NM_001243351:exon9:c.C912T:p.Y304Y	
- 350 - 
 
F11	 9.85	 COL4A2	 splicing	 13q34	 0.192017	 0.190895	 rs3803228	 0.175	 NM_001846:exon32:c.2759-5T&amp;amp;gt;C	
F11	 8.831	 VSX2	 synonymous		 14q24.3	 0.033133	 0.0195687	 rs62006815	 0.031	 VSX2:NM_182894:exon5:c.G831A:p.L277L	
F11	 7.041	 FLG	 synonymous		 1q21.3	 0.180231	 0.396366	 rs57672167	 0.269	 FLG:NM_002016:exon3:c.G8673T:p.V2891V	
F11	 6.916	 IL1RN	 synonymous		 2q13	 0.333154	 0.35004	 rs315952	 0.308	 IL1RN:NM_173842:exon4:c.T390C:p.S130S	
F11	 6.855	 FLG	 synonymous		 1q21.3	 0.251771	 0.469649	 rs9436066	 0.299	 FLG:NM_002016:exon3:c.G9645T:p.V3215V	
F11	 1.678	 FLG	 nonsynonymous		 1q21.3	 0.017684	 0.0249601	 rs62623409	 0.023	 FLG:NM_002016:exon3:c.C5617A:p.Q1873K	
F11	 1.552	 NUB1	 synonymous		 7q36.1	 0.406845	 0.332867	 rs2159158	 0.397	 NUB1:NM_001243351:exon15:c.A1905G:p.A635A	
F11	 1.414	 FLG	 nonsynonymous		 1q21.3	 0.270567	 0.464058	 rs2011331	 0.295	 FLG:NM_002016:exon3:c.A1360G:p.T454A	
F11	 1.027	 FLG	 nonsynonymous		 1q21.3	 0.281154	 0.47484	 rs3126072	 0.297	 FLG:NM_002016:exon3:c.G7633A:p.G2545R	
F11	 0.384	 FLG	 nonsynonymous		 1q21.3	 0.089428	 .	 rs80221306	 0.208	 FLG:NM_002016:exon3:c.A8807G:p.D2936G	
F11	 0.264	 FLG	 synonymous		 1q21.3	 0.26984	 0.463658	 rs2184954	 0.294	 FLG:NM_002016:exon3:c.T6498C:p.S2166S	
F11	 0.034	 FLG	 nonsynonymous		 1q21.3	 0.143626	 .	 rs66954353	 0.237	 FLG:NM_002016:exon3:c.A6574C:p.K2192Q	
F11	 0.012	 FLG	 synonymous		 1q21.3	 0.017607	 0.0249601	 rs12732920	 0.023	 FLG:NM_002016:exon3:c.T4410C:p.H1470H	
F11	 0.006	 FLG	 nonsynonymous		 1q21.3	 .	 0.539736	 rs2184953	 0.317	 FLG:NM_002016:exon3:c.T6580C:p.Y2194H	
F11	 0.004	 FLG	 synonymous		 1q21.3	 0.156005	 0.341054	 rs6681433	 0.261	 FLG:NM_002016:exon3:c.A9966G:p.Q3322Q	
F11	 0.002	 FLG	 nonsynonymous		 1q21.3	 0.15713	 0.343051	 rs11581433	 0.261	 FLG:NM_002016:exon3:c.A4126G:p.R1376G	
F11	 0.002	 FLG	 nonsynonymous		 1q21.3	 0.017684	 0.0249601	 rs7512779	 0.023	 FLG:NM_002016:exon3:c.C2181A:p.H727Q	
F11	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.269799	 0.46226	 rs3126074	 0.294	 FLG:NM_002016:exon3:c.C7521G:p.H2507Q	
F11	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.15762	 0.342452	 rs55650366	 0.261	 FLG:NM_002016:exon3:c.T7442C:p.L2481S	
F11	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.346917	 0.538139	 rs3126079	 0.317	 FLG:NM_002016:exon3:c.C5883A:p.H1961Q	
F11	 0.001	 FLG	 nonsynonymous		 1q21.3	 .	 0.0339457	 rs12756586	 0.025	 FLG:NM_002016:exon3:c.C2938G:p.H980D	
F11	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.158312	 0.344649	 rs11584340	 0.261	 FLG:NM_002016:exon3:c.C1432T:p.P478S	
F11	 	 VSX1	 splicing	 20p11.21	 .	 0.230831	 rs11431377	 0.221	 NM_014588:exon6:c.809-5-&amp;amp;gt;T	
F12	 17.52	 MUTYH	 nonsynonymous		 1p34.1	 0.050054	 0.0203674	 rs3219484	 0.049	 MUTYH:NM_001048171:exon2:c.G64A:p.V22M	
F12	 10.76	 FLG	 nonsynonymous		 1q21.3	 0.107873	 0.286941	 rs77422831	 0.229	 FLG:NM_002016:exon3:c.G11213A:p.R3738H	
F12	 1.143	 FLG	 nonsynonymous		 1q21.3	 0.109565	 0.290535	 rs72697000	 0.234	 FLG:NM_002016:exon3:c.G10590T:p.R3530S	
F12	 0.025	 FLG	 synonymous		 1q21.3	 0.255077	 0.447085	 rs3126066	 0.278	 FLG:NM_002016:exon3:c.T10491C:p.D3497D	
F12	 0.147	 FLG	 synonymous		 1q21.3	 0.333385	 0.522564	 rs3126067	 0.301	 FLG:NM_002016:exon3:c.T10473C:p.N3491N	
F12	 6.267	 FLG	 synonymous		 1q21.3	 0.108027	 0.28754	 rs2065956	 0.229	 FLG:NM_002016:exon3:c.G10017A:p.Q3339Q	
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F12	 0.004	 FLG	 synonymous		 1q21.3	 0.156005	 0.341054	 rs6681433	 0.261	 FLG:NM_002016:exon3:c.A9966G:p.Q3322Q	
F12	 6.855	 FLG	 synonymous		 1q21.3	 0.251771	 0.469649	 rs9436066	 0.299	 FLG:NM_002016:exon3:c.G9645T:p.V3215V	
F12	 0.384	 FLG	 nonsynonymous		 1q21.3	 0.089428	 .	 rs80221306	 0.208	 FLG:NM_002016:exon3:c.A8807G:p.D2936G	
F12	 7.041	 FLG	 synonymous		 1q21.3	 0.180231	 0.396366	 rs57672167	 0.269	 FLG:NM_002016:exon3:c.G8673T:p.V2891V	
F12	 0.097	 FLG	 synonymous		 1q21.3	 .	 .	 rs201652079	 0.00017	 FLG:NM_002016:exon3:c.T7842C:p.A2614A	
F12	 0.001	 FLG	 nonsynonymous		 1q21.3	 .	 0.0027955	 rs138143041	 0.00016	 FLG:NM_002016:exon3:c.T7687C:p.W2563R	
F12	 1.027	 FLG	 nonsynonymous		 1q21.3	 0.281154	 0.47484	 rs3126072	 0.297	 FLG:NM_002016:exon3:c.G7633A:p.G2545R	
F12	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.269799	 0.46226	 rs3126074	 0.294	 FLG:NM_002016:exon3:c.C7521G:p.H2507Q	
F12	 0.006	 FLG	 nonsynonymous		 1q21.3	 0.15426	 0.343051	 rs71625200	 0.261	 FLG:NM_002016:exon3:c.A7330G:p.K2444E	
F12	 0.006	 FLG	 nonsynonymous		 1q21.3	 .	 0.539736	 rs2184953	 0.317	 FLG:NM_002016:exon3:c.T6580C:p.Y2194H	
F12	 0.264	 FLG	 synonymous		 1q21.3	 0.26984	 0.463658	 rs2184954	 0.294	 FLG:NM_002016:exon3:c.T6498C:p.S2166S	
F12	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.346917	 0.538139	 rs3126079	 0.317	 FLG:NM_002016:exon3:c.C5883A:p.H1961Q	
F12	 11.35	 FLG	 nonsynonymous		 1q21.3	 0.10795	 0.28754	 rs12407748	 0.229	 FLG:NM_002016:exon3:c.G5672A:p.R1891Q	
F12	 10.19	 FLG	 nonsynonymous		 1q21.3	 0.107753	 0.28754	 rs12405241	 0.229	 FLG:NM_002016:exon3:c.C5414T:p.A1805V	
F12	 23.8	 FLG	 nonsynonymous		 1q21.3	 0.10772	 0.28774	 rs12405278	 0.229	 FLG:NM_002016:exon3:c.C5095T:p.R1699C	
F12	 17.66	 FLG	 nonsynonymous		 1q21.3	 0.118714	 0.296725	 rs12407807	 0.232	 FLG:NM_002016:exon3:c.G5051A:p.R1684H	
F12	 20.7	 FLG	 nonsynonymous		 1q21.3	 0.10772	 0.287141	 rs11204978	 0.229	 FLG:NM_002016:exon3:c.C4445A:p.S1482Y	
F12	 15.37	 FLG	 nonsynonymous		 1q21.3	 0.107676	 0.28774	 rs11586631	 0.229	 FLG:NM_002016:exon3:c.G4079A:p.R1360H	
F12	 0.135	 FLG	 synonymous		 1q21.3	 0.282177	 0.473243	 rs3120653	 0.298	 FLG:NM_002016:exon3:c.T2508C:p.D836D	
F12	 22.6	 FLG	 nonsynonymous		 1q21.3	 0.139243	 0.327676	 rs74129461	 0.256	 FLG:NM_002016:exon3:c.G2263A:p.E755K	
F12	 0.001	 FLG	 nonsynonymous		 1q21.3	 0.158312	 0.344649	 rs11584340	 0.261	 FLG:NM_002016:exon3:c.C1432T:p.P478S	
F12	 1.414	 FLG	 nonsynonymous		 1q21.3	 0.270567	 0.464058	 rs2011331	 0.295	 FLG:NM_002016:exon3:c.A1360G:p.T454A	
F12	 6.882	 FLG	 nonsynonymous		 1q21.3	 0.107796	 0.287141	 rs11588170	 0.229	 FLG:NM_002016:exon3:c.G1330A:p.G444R	
F12	 15.37	 FLG	 nonsynonymous		 1q21.3	 0.155774	 0.340655	 rs41267154	 0.26	 FLG:NM_002016:exon3:c.G995T:p.G332V	
F12	 23	 PARP1	 nonsynonymous		 1q42.12	 0.000077	 0.0001996	 rs200470832	 0.00004	 PARP1:NM_001618:exon6:c.G727A:p.D243N	
F12	 22.5	 IL1A	 nonsynonymous		 2q13	 0.261648	 0.217452	 rs17561	 0.272	 IL1A:NM_000575:exon5:c.G340T:p.A114S	
F12	 6.916	 IL1RN	 synonymous		 2q13	 0.333154	 0.35004	 rs315952	 0.308	 IL1RN:NM_173842:exon4:c.T390C:p.S130S	
F12	 20.3	 COL4A3	 nonsynonymous		 2q36.3	 0.063256	 0.100639	 rs34505188	 0.091	 COL4A3:NM_000091:exon21:c.G1223A:p.R408H	
F12	 0.001	 COL4A3	 nonsynonymous		 2q36.3	 0.073534	 0.111422	 rs11677877	 0.094	 COL4A3:NM_000091:exon22:c.A1352G:p.H451R	
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F12	 3.616	 COL4A3	 synonymous		 2q36.3	 0.068087	 0.105232	 rs34019152	 0.092	 COL4A3:NM_000091:exon23:c.G1452A:p.G484G	
F12	 12.19	 LOX	 nonsynonymous		 5q23.2	 0.175339	 0.156749	 rs1800449	 0.17	 LOX:NM_002317:exon1:c.G473A:p.R158Q	
F12	 8.103	 SPARC	 synonymous		 5q33.1	 0.190912	 0.197684	 rs2304052	 0.11	 SPARC:NM_003118:exon3:c.A66G:p.E22E	
F12	 22.4	 HGF	 nonsynonymous		 7q21.11	 0.050284	 0.0197684	 rs5745687	 0.045	 HGF:NM_000601:exon8:c.G910A:p.E304K	
F12	 1.296	 HGF	 synonymous		 7q21.11	 0.104061	 0.103435	 rs5745635	 0.042	 HGF:NM_000601:exon3:c.A333G:p.E111E	
F12	 9.923	 NUB1	 synonymous		 7q36.1	 0.485389	 0.384385	 rs386956	 0.52	 NUB1:NM_001243351:exon9:c.C912T:p.Y304Y,NUB
1:NM_016118:exon9:c.C912T:p.Y304Y	
F12	 15.01	 RXRA	 synonymous		 9q34.2	 0.012917	 0.0075878	 rs1805348	 0.012	 RXRA:NM_001291921:exon9:c.G1080A:p.A360A	
F12	 24.9	 COL5A1	 nonsynonymous		 9q34.3	 0.031601	 0.0235623	 rs61735045	 0.035	 COL5A1:NM_000093:exon13:c.G1588A:p.G530S	
F12	 12.41	 COL5A1	 synonymous		 9q34.3	 0.425188	 0.408147	 rs2228560	 0.375	 COL5A1:NM_000093:exon58:c.G4482C:p.P1494P	
F12	 11.9	 STK24	 synonymous		 13q32.2	 0.000231	 0.0003993	 rs55640122	 0.00034	 STK24:NM_001286649:exon6:c.G852C:p.S284S	
F12	 14.3	 DOCK9	 synonymous	 13q32.3	 0.13827	 0.167532	 rs12428661	 0.181	 DOCK9:NM_001130049:exon5:c.C477T:p.V159V	
F12	 9.85	 COL4A2	 splicing	 13q34	 0.192017	 0.190895	 rs3803228	 0.175	 NM_001846:exon32:c.2759-5T&amp;gt;C	
F12	 6.676	 COL4A2	 splicing	 13q34	 0.035794	 0.117212	 rs2296849	 0.049	 NM_001846:exon38:c.3455-5C&amp;gt;G	
F12	 8.443	 COL4A2	 splicing	 13q34	 0.053195	 0.128395	 rs2274544	 0.091	 NM_001846:exon39:c.3634+4C&amp;gt;T	
F12	 	 POLG	 nonframeshift	
deletion	




F12	 19.86	 CDH11	 synonymous		 16q21	 0.322159	 0.223642	 rs28216	 0.33	 CDH11:NM_001797:exon7:c.G945A:p.S315S	
F12	 28.2	 CDH11	 nonsynonymous		 16q21	 0.260111	 0.18151	 rs35195	 0.273	 CDH11:NM_001797:exon6:c.C764T:p.T255M	
F12	 2.599	 BANP	 splicing	 16q24.2	 .	 .	 .	 .	 .	
F12	 10.23	 ZNF469	 synonymous		 16q24.2	 .	 .	 .	 .	 ZNF469:NM_001127464:exon1:c.G2808T:p.A936A	
F12	 8.17	 ZNF469	 synonymous		 16q24.2	 .	 .	 .	 0.00003	 ZNF469:NM_001127464:exon2:c.G4836A:p.A1612A	
F12	 9.066	 ZNF469	 nonsynonymous		 16q24.2	 .	 .	 .	 .	 ZNF469:NM_001127464:exon2:c.C8342T:p.P2781L	








F12	 10.27	 SLC4A11	 synonymous		 20p13	 0.093803	 0.0485224	 rs41281860	 0.091	 SLC4A11:NM_032034:exon13:c.C1659T:p.N553N	
F12	 10.54	 SLC4A11	 synonymous		 20p13	 0.090804	 0.0451278	 rs6084312	 0.085	 SLC4A11:NM_032034:exon11:c.G1389A:p.T463T	
F13	 28.2	 CDH11	 nonsynonymous		 16q21	 0.260111	 0.18151	 rs35195	 0.273	 CDH11:NM_001797:exon6:c.C764T:p.T255M	
F13	 24.9	 COL5A1	 nonsynonymous		 9q34.3	 0.031601	 0.0235623	 rs61735045	 0.035	 COL5A1:NM_000093:exon13:c.G1588A:p.G530S	
F13	 19.86	 CDH11	 synonymous		 16q21	 0.322159	 0.223642	 rs28216	 0.33	 CDH11:NM_001797:exon7:c.G945A:p.S315S	
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F13	 13.89	 COL4A2	 synonymous		 13q34	 0.262849	 0.238618	 rs76425569	 0.231	 COL4A2:NM_001846:exon19:c.G1095A:p.P365P	
F13	 12.89	 COL4A2	 synonymous		 13q34	 0.284764	 0.246805	 rs74941798	 0.295	 COL4A2:NM_001846:exon19:c.C1179T:p.I393I	
F13	 12.87	 SLC4A11	 nonsynonymous		 20p13	 .	 0.0640974	 rs79057061	 0.031	 SLC4A11:NM_001174090:exon1:c.A148G:p.R50G	
F13	 12.41	 COL5A1	 synonymous		 9q34.3	 0.425188	 0.408147	 rs2228560	 0.375	 COL5A1:NM_000093:exon58:c.G4482C:p.P1494P	
F13	 12.19	 LOX	 nonsynonymous		 5q23.2	 0.175339	 0.156749	 rs1800449	 0.17	 LOX:NM_002317:exon1:c.G473A:p.R158Q	
F13	 11.27	 ZNF469	 nonsynonymous		 16q24.2	 0.056338	 0.0894569	 rs141218390	 0.075	 ZNF469:NM_001127464:exon2:c.C7424A:p.A2475E	
F13	 10.27	 SLC4A11	 synonymous		 20p13	 0.093803	 0.0485224	 rs41281860	 0.091	 SLC4A11:NM_032034:exon13:c.C1659T:p.N553N	
F13	 1.652	 ZNF469	 synonymous		 16q24.2	 .	 0.0942492	 rs12919507	 0.079	 ZNF469:NM_001127464:exon2:c.G6468T:p.T2156T	
F13	 0.097	 XRCC1	 synonymous		 19q13.31	 0.42032	 0.321286	 rs915927	 0.335	 XRCC1:NM_006297:exon7:c.A618G:p.P206P	
F13	 0.039	 COL4A1	 synonymous		 13q34	 0.252499	 0.20647	 rs995224	 0.258	 COL4A1:NM_001845:exon21:c.T1257C:p.P419P	
KF	 22.6	 FLG	 nonsynonymous		 1q21.3	 0.077095	 .	 rs75448155	 0.191	 FLG:NM_002016:exon3:c.G10903A:p.D3635N	
KF	 14.99	 COL5A1	 synonymous		 9q34.3	 .	 .	 .	 .	 COL5A1:NM_000093:exon54:c.C4191T:p.P1397P	
KF	 14.66	 FLG	 nonsynonymous		 1q21.3	 0.099721	 .	 rs71625202	 0.206	 FLG:NM_002016:exon3:c.G7097C:p.S2366T	
KF	 9.808	 FLG	 nonsynonymous		 1q21.3	 0.000077	 .	 rs376237195	 0.00001	 FLG:NM_002016:exon3:c.G5212A:p.G1738R	
KF	 8.403	 FLG	 nonsynonymous		 1q21.3	 0.331462	 0.514177	 rs2065955	 0.299	 FLG:NM_002016:exon3:c.G10307C:p.G3436A	
KF	 8.201	 HGF	 nonsynonymous	 7q21.11	 .	 0.0021964	 .	 0.00143	 HGF:NM_000601:exon16:c.G1765A:p.V589I	
KF	 0.93	 FLG	 synonymous	 1q21.3	 .	 0.453474	 rs6664985	 0.278	 FLG:NM_002016:exon3:c.C6990T:p.H2330H	
KF	 0.819	 FLG	 nonsynonymous 1q21.3	 0.198601	 .	 rs7512857	 0.218	 FLG:NM_002016:exon3:c.T6058G:p.S2020A	
KF	 0.017	 FLG	 nonsynonymous 1q21.3	 0.154475	 0.330471	 rs71625201	 0.258	 FLG:NM_002016:exon3:c.G7192C:p.E2398Q	
KF	 0.006	 FLG	 nonsynonymous 1q21.3	 0.15426	 0.343051	 rs71625200	 0.261	 FLG:NM_002016:exon3:c.A7330G:p.K2444E	
KF	 0.004	 FLG	 synonymous	 1q21.3	 0.172305	 0.328075	 rs80353812	 0.22	 FLG:NM_002016:exon3:c.T6072C:p.H2024H	
KF	 0.001	 FLG	 nonsynonymous 1q21.3	 0.15762	 0.342452	 rs55650366	 0.261	 FLG:NM_002016:exon3:c.T7442C:p.L2481S	
KF	 0.001	 FLG	 nonsynonymous 1q21.3	 0.101799	 .	 rs78179835	 0.208	 FLG:NM_002016:exon3:c.G6891C:p.E2297D	
KF	 0.001	 FLG	 nonsynonymous 1q21.3	 0.346917	 0.538139	 rs3126079	 0.317	 FLG:NM_002016:exon3:c.C5883A:p.H1961Q	
KF	 0.001	 FLG	 nonsynonymous 1q21.3	 0.068046	 0.0369409	 rs34806697	 0.067	 FLG:NM_002016:exon3:c.A5741G:p.Q1914R	
KF	 0.001	 FLG	 nonsynonymous 1q21.3	 0.310165	 0.534145	 rs58001094	 0.306	 FLG:NM_002016:exon3:c.C3500G:p.A1167G	
 
